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Abstract	  
Background:	   Idiopathic	   pulmonary	   fibrosis	   (IPF)	   is	   a	   progressive	   fibrotic	   lung	   disease	   of	  
unknown	  cause	  that	  leads	  to	  respiratory	  failure	  and	  death	  within	  five	  years	  of	  diagnosis.	  It	  is	  
thought	   to	   arise	   in	   genetically	   susceptible	   individuals	   as	   a	   consequence	   of	   an	   aberrant	  
wound-­‐healing	   response	   following	   repetitive	   alveolar	   injury.	   The	   exact	   triggers,	   which	  
initiate	   the	   fibrotic	   process,	   remain	   unknown.	   Overt	   respiratory	   infection	   and	  
immunosuppression	   carry	   a	   high	   mortality,	   while	   polymorphisms	   in	   genes	   related	   to	  
epithelial	   integrity	   and	   host	   defence	   predispose	   to	   IPF.	   There	   has	   however,	   been	   no	  
systematic	  search	  for	  potential	  infective	  sources	  of	  alveolar	  injury	  in	  IPF.	  
Methods:	  Patients	  diagnosed	  with	  IPF	  were	  prospectively	  enrolled,	  together	  with	  matched	  
controls,	   and	   followed	   up	   over	   a	   two-­‐year	   period.	   Subjects	   underwent	   bronchoalveolar	  
lavage	   (BAL)	   at	   recruitment	   and	   during	   any	   exacerbations	   allowing	   quantification	   of	  
bacterial	   load	   and	   identification	   of	   communities	   by	   16S	   rRNA	   qPCR	   and	   pyrosequencing	  
(Roche	  454).	  Longitudinal	  peripheral	  whole	  blood	  gene	  expression	  profiles	  were	  generated	  
(Affymetrix	  1.1ST	  Arrays)	  and	  MUC5B	  SNP	  genotyping	  performed.	  
Results:	   IPF	   patients	   have	   double	   the	   burden	   of	   bacteria	   in	   BAL	   compared	   to	   controls.	  
Baseline	   bacterial	   burden	   predicted	   the	   rate	   of	   decline	   in	   lung	   volume,	   risk	   of	   death	   and	  
associated	   independently	   with	   the	   rs35705950	   polymorphism	   of	   the	   MUC5B	   gene.	  
Haemophilus,	   Streptococcus,	   Neisseria	   and	   Veillonella	   spp.	   were	   more	   abundant	   in	   cases	  
than	  controls.	  During	  an	  exacerbation	  of	  IPF	  there	  is	  an	  increase	  in	  BAL	  bacterial	  burden	  and	  
changes	  in	  the	  microbiome	  from	  baseline.	  Peripheral	  whole	  blood	  gene	  expression	  profiling	  
has	   given	   potential	   mechanistic	   insights	   in	   to	   the	   pathogenesis	   of	   IPF.	   A	   total	   of	   1,358	  
transcript	   clusters,	   differentially	   expressed	   between	   cases	   and	   controls,	   were	   identified.	  
Apoptosis,	  oxidative	  stress,	  angiogenesis,	  cellular	  inflammation	  and	  antimicrobial	  processes	  
were	   all	   implicated.	   Novel	   potential	   interactions	   with	   well	   established	   putative	   fibrotic	  
pathways	   were	   identified	   and	   for	   the	   first	   time	   longitudinal	   expression	   changes	   in	   IPF	  
subjects	  were	  demonstrated.	  
Conclusions:	   IPF	   is	   characterized	   by	   an	   increased	   bacterial	   burden	   in	   BAL	   that	   predicts	  
decline	  in	  lung	  function	  and	  death.	  Bacterial	  burden	  and	  the	  microbiota	  both	  change	  during	  
an	   exacerbation,	   despite	   current	   guidelines	   dictating	   they	   are	   non-­‐infective	   events.	   The	  
association	  demonstrated	  between	  bacterial	  load	  and	  MUC5B	  genotype	  suggests	  there	  may	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be	   a	   direct	   relationship	   between	   host	   immunity	   and	   the	   respiratory	   microbiome.	   IPF	  
patients	  have	  a	  characteristic	  peripheral	  blood	  transcriptome.	  Longitudinal	  expression	  and	  
WCGNA	   analysis	   not	   only	   identified	   genes	   associated	   with	   IPF	   and	   survival	   but	   also	  
confirmed	   previously	   suggested	   potential	   prognostic	   biomarkers	   including	   Lymphocyte-­‐specific	  protein	  tyrosine	  kinase	  (LCK).	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Abbreviations	  16S	  rRNA	   16S	  ribosomal	  RNA	  6MWT	  	   6	  minute	  walk	  testing	  AE-­‐IPF	  	   Acute	  Exacerbations	  of	  IPF	  AIP	   	   Acute	  Interstitial	  Pneumonia	  ARDS	   	   Acute	  Respiratory	  Distress	  Syndrome	  BAL	   	   Bronchoscopic	  Alveolar	  Lavage	  BMI	   	   Body	  Mass	  Index	  bp	   	   Base	  pairs	  BSA	   	   Bovine	  serum	  albumin	  cDNA	   	   complementary	  DNA	  ComBat	  	   Combining	  Batches	  of	  gene	  expression	  microarray	  data	  COP	   	   Cryptogenic	  Organizing	  Pneumonia	  COPD	   	   Chronic	  Obstructive	  Pulmonary	  Disease	  CPI	   	   Composite	  Physiologic	  Index	  CRP	   	   Clinical,	  Radiological	  and	  Physiological	  DAD	   	   Diffuse	  Alveolar	  Damage	  DAVID	  	   Database	  for	  Annotation,	  Visualisation,	  and	  Integrated	  Discovery	  DIP	   	   Desquamative	  Interstitial	  Pneumonia	  DLCO	   	   Carbon	  monoxide	  diffusing	  capacity	  DNA	   	   Deoxyribonucleic	  acid	  EBV	   	   Epstein–Barr	  virus	  EFA	   	   Exploratory	  Factor	  Analysis	  	  emPCR	  	   Emulsification	  PCR	  FDR	   	   False	  Discovery	  Rate	  FEV1	   	   Forced	  Expiratory	  Volume	  in	  1	  second	  FGF	   	   Fibroblast	  growth	  factor	  FIP	   	   Familial	  Interstitial	  Pneumonias	  FVC	   	   Forced	  Vital	  Capacity	  GO	   	   Gene	  Ontology	  GORD	   	   Gastro-­‐oesophageal	  reflux	  disease	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GWAS	   	   Genome-­‐Wide	  Association	  Study	  HHVs	   	   Human	  Herpes	  Viruses	  HP	   	   Hypersensitivity	  Pneumonitis	  	  HRCT	   	   High-­‐Resolution	  Computerised	  Tomography	  IIP	   	   Idiopathic	  Interstitial	  Pneumonias	  	  ILD	   	   Interstitial	  lung	  disease	  IPF	   	   Idiopathic	  Pulmonary	  Fibrosis	  	  LIMMA	   Linear	  Models	  for	  Microarray	  Data	  MDT	   	   Multidisciplinary	  team	  ml	   	   Millilitres	  NMDS	   	   Nonmetric	  Multidimensional	  Scaling	  NRI	   	   Net	  Relatedness	  Index	  NSIP	   	   Non-­‐specific	  Interstitial	  Pneumonia	  NTI	   	   Nearest	  Taxon	  Index	  OTUs	   	   Operational	  Taxonomic	  Units	  PaCO2	  	   Partial	  Pressure	  of	  Carbon	  dioxide	  in	  Arterial	  Blood	  	  PaO2	   	   Partial	  Pressure	  of	  Oxygen	  in	  Arterial	  Blood	  	  PBMC	   	   Peripheral	  Blood	  Mononuclear	  Cell	  PCA	   	   Principal	  component	  analysis	  PCoA	  	   	   Principal	  Coordinate	  Analysis	  PCR	   	   Polymerase	  Chain	  Reaction	  PDGF	   	   Platelet	  Derived	  Growth	  Factor	  PFT	   	   Pulmonary	  Function	  Tests	  PLCH	   	   Pulmonary	  Langerhans	  Cell	  Histiocytosis	  PVCA	   	   Principal	  Variance	  Component	  Analysis	  QIIME	  	   Quantitative	  Insights	  Into	  Microbial	  Ecology	  QoL	   	   Quality	  of	  Life	  Score	  qPCR	  	   	   Real-­‐time	  quantitative	  PCR	  RB-­‐ILD	   Respiratory	  Bronchiolitis	  Interstitial	  Lung	  Disease	  RIN	   	   RNA	  Integrity	  Number	  RLE	   	   Relative	  Log	  Expression	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RMA	   	   Robust	  Multi-­‐array	  Averaging	  RNA	   	   Ribonucleic	  acid	  RNA-­‐Seq	   RNA-­‐Sequencing	  rpm	   	   Revolutions	  per	  minute	  RSV	   	   Respiratory	  Syncytial	  Virus	  SAM	   	   Significance	  of	  microarray	  SaO2	   	   Oxygen	  Saturation	  SNP	   	   Single	  nucleotide	  polymorphisms	  TBE	   	   Tris-­‐Borate-­‐EDTA	  buffer	  TFS	   	   Transplant-­‐Free	  Survival	  TLC	   	   Total	  Lung	  Capacity	  TTV	   	   Transfusion	  Transmitted	  Virus	  UIP	   	   Usual	  Interstitial	  Pneumonia	  VEGF	   	   Vascular	  endothelial	  growth	  factor	  WGCNA	   Weighted	  Gene	  Co-­‐expression	  Network	  Analysis	  μg	   	   Microgram	  μl	   	   Microlitre	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Chapter	  1:	  Introduction	  
1.1 Interstitial	  Lung	  Disease	  Interstitial	  lung	  diseases	  (ILDs),	  also	  known	  as	  diffuse	  parenchymal	  lung	  diseases,	  are	  a	  heterogeneous	  group	  of	   conditions	  with	  differing	  aetiologies	  but	   similar	   radiographic,	  pathological,	   and	  clinical	   features.	  They	  can	  occur	   in	   response	   to	  a	  variety	  of	   triggers,	  both	  environmental	  and	   immune,	  and	  result	   in	  an	  exaggerated	  or	  unregulated	   fibrotic	  response	   within	   the	   lung	   interstitium.	   Although	   lung	   fibrosis	   is	   part	   of	   the	   natural	  response	   to	   some	   injuries	  or	   infections,	  when	   the	   scarring	  proceeds	  unchecked	   it	   can	  cause	   loss	   of	   alveolar	   structure,	   hindering	   gas	   exchange	   and	   ultimately	   causing	  respiratory	  failure.	  There	  are	  a	  multitude	  of	  recognised	  triggers	  of	  ILD,	  including	  reactions	  to	  drugs,	  organic	  and	  inorganic	  dusts	  and	  connective	  tissue	  disease.	  	  The	  aetiology	  of	  a	  large	  proportion	  of	  cases	  still	  remains	  unexplained	  and	  these	  are	  classified	  as	  the	  Idiopathic	  Interstitial	  Pneumonias	  (IIP)	  (Eickelberg	  and	  Selman	  2010).	  
	  
Figure	   1.1:	   Classification	   of	   interstitial	   lung	   diseases.	   Image	  reproduced	  with	  permission	  of	  the	  rights	  holder,	  Nature	  Publishing	  Group	  (du	  Bois	  2010).	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1.2 Idiopathic	  Interstitial	  Pneumonias	  IIPs	   can	   be	   distinguished	   from	   other	   forms	   of	   interstitial	   lung	   disease	   by	   clinical	  methods	   including	   history,	   physical	   examination,	   imaging,	   serology	   and	   pathology.	  Although	   grouped	   together	   and	   termed	   “idiopathic”	   due	   to	   the	   lack	   of	   an	   obvious	  aetiology,	  there	  are	  several	  clear	  clinical	  entities	  within	  the	  group	  which	  have	  important	  therapeutic	   and	   prognostic	   implications	   (Bradley	   et	   al.	   2008).	   The	   IIPs	   include	   the	  fibrotic	   conditions	   Idiopathic	   Pulmonary	   Fibrosis	   (IPF)	   and	   Idiopathic	   Non-­‐specific	  Interstitial	   Pneumonia	   (iNSIP);	   the	   smoking	   related	   conditions	   Respiratory	  Bronchiolitis	   Interstitial	   Lung	   Disease	   (RB-­‐ILD)	   and	   Desquamative	   Interstitial	  Pneumonia	  (DIP);	  and	  the	  acute/sub-­‐acute	  diseases	  Cryptogenic	  Organizing	  Pneumonia	  (COP)	  and	  Acute	  Interstitial	  Pneumonia	  (AIP).	  IPF	  is	  the	  commonest	  of	  all	  the	  idiopathic	  interstitial	  pneumonias	  and	  carries	  the	  worst	  prognosis.	  
1.3	   Idiopathic	  Pulmonary	  Fibrosis	  IPF	  affects	  between	  7	  and	  16	  people	  per	  100,000	  each	  year	  and	   its	   incidence	   is	  rising	  (Raghu	   et	   al.	   2006;	   Navaratnam	   et	   al.	   2011;	   Navaratnam	   et	   al.	   2012).	   In	   the	   UK	   IPF	  accounts	  for	  5000	  deaths	  every	  year,	  a	  figure	  far	  in	  excess	  of	  that	  of	  many	  cancers,	  and	  the	  5-­‐year	  survival	  is	  only	  20%	  (Navaratnam	  et	  al.	  2011).	  
1.3.1 Presentation,	  Symptoms	  and	  Diagnosis	  IPF	  most	  commonly	  affects	  men,	  and	  rarely	  presents	  before	  the	  age	  of	  50.	  Symptoms	  are	  usually	   insidious	   in	  onset	  and	   include	  exertional	  dyspnoea,	  dry	  cough	  and	  clubbing	  of	  the	  finger	  nail	  beds.	  These	  symptoms	  are	  not	  specific	  for	  IPF	  and	  can	  occur	  in	  other	  ILDs	  and	  a	  number	  of	  other	  non	  respiratory	  conditions	  (Gibb,	  Smith,	  and	  Miller	  2013).	  The	  diagnosis	  of	  IPF	  is	  therefore	  far	  from	  trivial	  and	  over	  recent	  years	  a	  multi-­‐disciplinary	  diagnostic	  approach	  has	  evolved.	  The	   ATS,	   ERS,	   JRS	   and	   ALAT	   joint	   statement	   defines	   IPF	   as	   a	   progressive	   fibrosing	  interstitial	  pneumonia	  of	  unknown	  cause,	   limited	  to	  the	   lungs,	  occurring	   in	  adults	  and	  associated	   with	   the	   histopathological	   and/or	   radiological	   pattern	   of	   usual	   interstitial	  pneumonia	  (UIP)	  (Raghu	  et	  al.	  2011).	  The	  suggested	  diagnostic	  pathway	  is	  outlined	  in	  Figure	  1.2	  and	  starts	  with	  careful	  exclusion	  of	  known	  causes	  of	   ILDs.	  This	   is	  achieved	  through	  a	  thorough	  history,	  examination	  and	  serological	  testing	  to	  identify	  predisposing	  domestic	  and	  occupational	  environmental	  exposures,	  medication	  usage	  and	  underlying	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medical	   conditions.	   A	   detailed	   family	   history	   is	   also	   necessary	   as	   some	   estimates	  suggest	  that	  up	  to	  10%	  of	  cases	  of	  IIP	  are	  familial	  (Talmadge	  E	  King,	  Pardo,	  and	  Selman	  2011).	  	  
	  
Figure	  1.2:	  Diagnostic	  algorithm	  for	  idiopathic	  pulmonary	  fibrosis.	  In	  the	  absence	  of	  an	  identifiable	  cause	  for	  ILD	  an	  HRCT	  demonstrating	  UIP	  pattern	  is	  diagnostic	  of	  IPF.	  In	   the	   absence	  of	   this	   IPF	   can	  be	  diagnosed	  by	   the	   combination	  of	   specific	  HRCT	  and	  histopathological	   patterns.	   The	   accuracy	   of	   diagnosis	   increases	  with	  multidisciplinary	  discussion	  (MDD)	  among	  ILD	  experts.	  Adapted	  from	  Raghu	  et	  al.,	  2011.	  If	  no	  underlying	  cause	  can	  be	   identified	   the	  patient	  may	  have	   IPF	  and	  evidence	  of	   the	  pathognomonic	  lesion	  of	  UIP	  is	  sought	  (Figure	  1.3).	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Figure	   1.3:	   A	   high-­‐resolution	   computerised	   tomography	   (HRCT)	   scan	  
demonstrating	   UIP.	   UIP	   is	   characterized	   on	   HRCT	   by	   the	   presence	   of	   reticular	  opacities,	  often	  associated	  with	  traction	  bronchiectasis.	  Honeycombing	  is	  common,	  and	  is	  critical	  for	  making	  a	  definite	  diagnosis.	  Honeycombing	  is	  seen	  here	  as	  clustered	  cystic	  airspaces	  in	  a	  characteristic	  basal	  and	  peripheral	  distribution.	  The	  weight	  of	  combined	  clinical,	  histopathological	  and	  radiological	  information	  is	  used	  by	   a	   multidisciplinary	   team	   to	   identify	   specific	   combinations	   of	   results	   that	   confirm,	  suggest	  or	  refute	  a	  diagnosis	  of	  IPF	  (Table	  1.1).	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HRCT	  Pattern	   Lung	  Biopsy	  Pattern	   IPF?	  UIP	   UIP	   Yes	  	   Probable	  UIP	   	  	   Possible	  UIP	   	  	   Non	  Classifiable	  Fibrosis	   	  	   Not	  UIP	   No	  Possible	  UIP	   UIP	   Yes	  	   Probable	  UIP	   	  	   Possible	  UIP	   Probable	  	   Non	  Classifiable	  Fibrosis	   	  	   Not	  UIP	   No	  Inconsistent	  with	  UIP	   UIP	   Possible	  	   Probable	  UIP	   No	  	   Possible	  UIP	   	  	   Non	  Classifiable	  Fibrosis	   	  	   Not	  UIP	   	  
Table	  1.1:	  Multi-­‐disciplinary	  guidelines	   for	  combining	  HRCT	  and	  Histopathology	  
in	   the	   diagnosis	   of	   IPF.	   Combinations	   that	   suggest	   definite,	   probable	   and	   possible	  diagnoses	   of	   IPF	   are	   highlighted.	   The	   accuracy	   of	   the	   diagnosis	   of	   IPF	   increases	  with	  multi-­‐disciplinary	  discussion	  (MDD).	  This	  is	  particularly	  relevant	  in	  cases	  in	  which	  the	  radiologic	  and	  histopathology	  patterns	  are	  discordant.	  Adapted	  from	  Raghu	  et	  al.,	  2011.	  
1.3.2	   Prognosis	  The	  median	  survival	  for	  patients	  with	  IPF	  is	  3	  to	  5	  years	  post	  diagnosis	  (Ley	  et	  al.	  2010)	  and	   until	   recently	   it	   was	   believed	   that	   all	   patients	   exhibited	   a	   gradual	   but	   relentless	  decline	   in	   lung	   function	   reflecting	   the	   development	   of	   progressive	   fibrosis	   (Toby	   M	  Maher	   2008).	   The	   clinical	   course	   of	   individual	   patients	   with	   IPF	   however	   is	   actually	  variable	   and	   unpredictable,	  with	   some	   experiencing	   long	   periods	   of	   relative	   stability,	  some	  a	  steady	  decline	  whilst	  others	  rapidly	  deteriorate	  (Figure	  1.4).	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Figure	  1.4:	  The	  potential	   clinical	   courses	  of	   idiopathic	  pulmonary	   fibrosis	   (IPF).	  The	  rate	  of	  decline	  may	  be	  rapid	  (A)	  or	  slow	  (C	  &	  D).	  Acute	  exacerbations	  (indicated	  by	  the	   black	   stars)	   can	   affect	   either	   course	   and	   here	   creates	   a	  mixed	   picture	   (curve	   B).	  Image	  reproduced	   with	  permission	   of	   the	   rights	   holder,	   American	   Thoracic	   Society,	  Copyright	  ©	  2014	  American	  Thoracic	  Society	  (Ley	  et	  al.	  2010).	  There	  is	  currently	  no	  way	  to	  accurately	  predict	  the	  clinical	  course	  of	  a	  patient	  diagnosed	  with	  IPF,	  but	  several	  factors	  have	  been	  identified	  that	  predict	  poor	  survival.	  At	  diagnosis	  the	  extent	  of	  fibrosis	  on	  HRCT	  (Lynch	  et	  al.	  2008)	  and	  the	  number	  of	  fibroblastic	  foci	  on	  biopsy	   (Nicholson	   2002)	   both	   correlate	   with	   survival.	   A	   low	   diffusion	   capacity	   for	  carbon	  monoxide	   (DLCO)	   (Collard	   et	   al.	   2003),	   increasing	   age	   (T	  E	  King,	   Tooze,	   et	   al.	  2001)	  and	  the	  presence	  of	  pulmonary	  hypertension	  at	  diagnosis	  (Mejía	  et	  al.	  2009)	  all	  predict	   an	   increased	   risk	   of	  mortality.	   Disease	   progression	   is	   suggested	   by	   a	   drop	   of	  over	   10%	   in	   Forced	   Vital	   Capacity	   (FVC),	   worsening	   fibrosis	   on	   serial	   imaging	   or	  increased	  dyspnoea,	  all	  of	  which	  predict	  an	  increased	  mortality	  (Raghu	  et	  al.	  2011).	  
1.3.3	   Acute	  Exacerbations	  Whichever	   course	   the	   disease	   takes	   it	   is	   often	   inter-­‐dispersed	   with	   periods	   of	  unheralded	   rapid	   deterioration,	   manifested	   as	   increasing	   dyspnoea,	   deterioration	   in	  pulmonary	  function	  tests	  and	  bilateral	  infiltrates	  on	  imaging	  (Figure	  1.5).	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Figure	  1.5:	  Imaging	  during	  an	  acute	  exacerbation	  of	  IPF	  (AE-­‐IPF).	  Scan	  A	  and	  B	  are	  from	   the	   same	   patient,	   but	   five	   weeks	   apart.	   The	   patient	   had	   clinically	   deteriorated,	  image	  B	  clearly	  demonstrates	  bilateral	  infiltrates,	  and	  with	  no	  obvious	  cause	  identified	  this	  was	  deemed	  an	  AE-­‐IPF.	  Pneumonia,	  heart	  failure	  and	  pulmonary	  thromboembolic	  disease	  are	  often	  the	  trigger,	  however,	   the	   cause	   for	   many	   remains	   unknown.	   These	   idiopathic	   episodes,	   termed	  acute	  exacerbations	  of	  IPF	  (AE-­‐IPF),	  have	  been	  formally	  defined	  as	  clinically	  significant	  deteriorations	  of	  unidentifiable	  cause	   in	  patients	  with	  underlying	   IPF	  within	   the	  prior	  30	  days	  (Collard	  et	  al.	  2007).	  The	  diagnostic	  criteria	  clearly	  distinguish	  exacerbations	  of	  IPF	  from	  exacerbations	  of	  other	  respiratory	  diseases.	   	  The	  latter	  are	  generally	  of	  acute	  onset	  and	  often	  have	  a	  well-­‐recognized	  trigger.	  Between	   4-­‐15%	   of	   individuals	   with	   IPF	   will	   experience	   an	   AE	   every	   year	   and	   these	  episodes	  confer	  a	  substantial	  morbidity	  and	  mortality	  (Raghu	  et	  al.	  2011;	  Collard	  et	  al.	  2007;	   Song	   et	   al.	   2011).	   Patients	   typically	   present	   with	   symptoms	   of	   worsening	  dyspnoea,	   cough	   and	   fever,	   which	   are	   insidious	   in	   onset	   (Collard	   et	   al.	   2007).	  Investigations	  focus	  on	  excluding	  known	  and	  treatable	  causes	  of	  deterioration	  such	  as	  infection,	   heart	   failure	   and	   pulmonary	   embolism.	   While	   the	   diagnostic	   criteria	  recommend	  invasive	  sampling	  to	  exclude	  infection,	  bronchoalveolar	  lavage	  is	  often	  not	  feasible	   as	   the	   risk	   to	   patients	   is	   too	   high.	   Consequently	   non-­‐invasive	   and	   serological	  testing	   are	   often	   replied	   upon.	   Radiologically	   there	  must	   be	   new	   bilateral	   pulmonary	  infiltrates	  (Akira	  et	  al.	  2008).	  Although	  rarely	  performed	  and	  unnecessary	  for	  diagnosis,	  surgical	   lung	   biopsy	   demonstrates	   that	   histologically	   acute	   exacerbations	   are	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characterised	   by	   the	   finding	   of	   diffuse	   alveolar	   damage	   (DAD)	   (Parambil,	  Myers,	   and	  Ryu	  2005).	  
1.3.4	   Pathogenesis	  The	   pathogenesis	   of	   IPF	   remains	   unknown.	   It	   was	   historically	   considered	   that	  inflammation	   preceded	   fibrosis,	   but	   the	   paucity	   of	   evidence	   of	   inflammation	   in	  histopathological	  samples	  from	  patients	  and	  the	  lack	  of	  efficacy	  of	  immunosuppressive	  therapy	  led	  to	  a	  shift	  in	  thinking.	  Current	  evidence	  suggests	  IPF	  develops	  in	  genetically	  susceptible	   individuals	   with	   dysfunctional	   alveolar	   epithelial	   repair	   mechanisms	  following	   repeated	   episodes	   of	   alveolar	   injury	   (Talmadge	   E	   King,	   Pardo,	   and	   Selman	  2011;	  T	  M	  Maher,	  Wells,	  and	  Laurent	  2007).	  A	  number	  of	  environmental	   triggers	  and	  infective	  agents	  have	  been	  suggested	  as	  plausible	  causative	  factors	  but	  as	  yet	  the	  initial	  stimulus	  remains	  unidentified	  (M	  Selman,	  King,	  and	  Pardo	  2001).	  In	   the	   presence	   of	   defective	   regenerative	   mechanisms,	   likely	   to	   be	   related	   to	  dysfunctional	   alveolar	   epithelial	   cells,	   repetitive	   injury	   results	   in	   myofibroblast	  recruitment	  and	  activation	  (Moises	  Selman	  et	  al.	  2006)	  and	  collagen	  deposition	  	  causing	  progressive	  accumulation	  of	  scar	  tissue	  (Strieter	  and	  Mehrad	  2009).	  This	  results	  in	  the	  classical	   radiological	   and	   histological	   patterns	   of	   UIP.	   Destruction	   of	   the	   lung	  architecture	   causes	   loss	   of	   alveolar	   structure,	   impairing	   gas	   exchange	   and	   ultimately	  resulting	  in	  respiratory	  failure.	  This	  presumptive	  model	  of	  development	  suggests	  a	  role	  in	   IPF	   for	   both	   host	   and	   environmental	   factors,	   with,	   in	   all	   likelihood,	   interactions	  between	  the	  two.	  
1.3.4.1 Genetic	  Factors:	  Why	  is	  there	  aberrant	  repair?	  Familial	  forms	  of	  IPF,	  where	  2	  or	  more	  members	  of	  a	  family	  are	  affected,	  provide	  strong	  evidence	  for	  an	  underlying	  genetic	  component	  to	  the	  disease.	  At	  present	  though	  familial	  forms	  only	  account	  for	  4%	  of	  all	  IPF	  cases	  (Lawson	  and	  Loyd	  2006).	  	  A	  larger	  group	  of	  heritable	  fibrotic	  lung	  diseases	  are	  the	  Familial	  Interstitial	  Pneumonias	  (FIP)	  where	  two	  or	  more	  family	  members	  have	  an	  idiopathic	  interstitial	  pneumonia,	  often	  including	  IPF	  (H.-­‐L.	   Lee	   et	   al.	   2005).	   	   Despite	   the	   autosomal	   dominant	   pattern	   of	   inheritance	   with	  variable	   penetrance	   seen	   in	   FIP,	   there	   is	   a	   large	   degree	   of	   phenotypic	   heterogeneity	  within	  families.	  Multiple	  pathological	  subtypes	  can	  occur	  within	  one	  family	  suggesting	  that	   the	  mutations	   are	   responsible	   for	   an	   underlying	   pathological	   process	  which	   can	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cause	   different	   IIP	   phenotypes,	   including	   IPF.	   Studies	   of	   FIP	   can	   therefore	   provide	   a	  greater	   understanding	   of	   the	   genetic	   factors	   behind	   the	   pathological	   processes	  occurring	  in	  IPF.	  FIP	  cases	  have	  been	  linked	  to	  variants	  in	  the	  genes	  encoding	  surfactant	  protein	   C	   (SFTPC),	   surfactant	   protein	   A2	   (SFTPA2),	   telomerase	   reverse	   transcriptase	  (hTERT),	   telomerase	   RNA	   component	   (TERC),	   ELMO	   domain	   containing	   2	   (ELMOD2)	  and	   most	   recently	   Mucin	   5B	   (MUC5B)	   gene.	   	   Although	   candidate	   gene	   studies	   in	  sporadic	  IPF	  have	  suggested	  an	  association	  with	  a	  number	  of	  other	  genetic	  mutations,	  their	   lack	   of	   validation	  means	   their	   role	   remains	   to	   be	   confirmed	   (Lawson	   and	   Loyd	  2006).	  
1.3.4.1.1 Mucin	  5B	  The	  strongest	  and	  most	  reproducible	  genetic	  association	  with	  IPF	  to	  date	  is	  that	  of	  the	  Mucin	  5B	  (MUC5B)	  gene.	  A	  genome-­‐wide	  linkage	  scan	  in	  82	  families	  with	  FIP	  identified	  an	  area	  of	  interest	  on	  Chromosome	  11,	  which	  encodes	  a	  number	  of	  the	  mucin	  proteins.	  	  This	   locus	   was	   mapped	   in	   more	   detail	   identifying	   a	   polymorphism	   in	   the	   promoter	  region	  of	  the	  MUC5B	  gene	  which	  is	  associated	  with	  the	  development	  of	  both	  IPF	  and	  FIP	  (Seibold	  et	  al.	  2011;	  Y.	  Zhang,	  Noth,	  and	  Society	  2011).	  The	  minor	  allele	  of	  rs35705950	  conferred	  a	  high	  odds	  ratio	  for	  idiopathic	  pulmonary	  fibrosis	  (9.0	  for	  heterozygotes	  and	  21.8	  for	  homozygotes)	  and	  was	  associated	  with	  increased	  expression	  of	  MUC5B	  in	  the	  lung,	  which	  accumulates	  within	  areas	  of	  honeycombing.	  This	  finding	  has	  now	  been	  robustly	  replicated	  (Stock	  et	  al.	  2013;	  Borie	  et	  al.	  2013;	  Peljto	  et	   al.	   2013)	   and	   the	   association	   with	  MUC5B	   was	   also	   the	   dominant	   finding	   in	   two	  recent	  genome-­‐wide	  association	  studies	  (Fingerlin	  et	  al.	  2013;	  Noth	  et	  al.	  2013).	  	  While	  the	   rs35705950	   polymorphism	   confers	   an	   increased	   risk	   of	   developing	   IPF	   it	  paradoxically	  confers	  a	  survival	  benefit	  amongst	  patients	  with	  IPF	  (Peljto	  et	  al.	  2013).	  At	  present	  it	  is	  not	  clear	  whether	  this	  polymorphism	  confers	  an	  increased	  risk	  of	  a	  less	  severe	  form	  of	  IPF	  or	  if	  these	  subjects	  present	  earlier	  in	  the	  course	  of	  disease	  causing	  a	  lead	  time	  bias	  during	  recruitment.	  	  The	   mucin	   glycoproteins	   are	   a	   major	   structural	   component	   of	   the	   mucus	   barrier,	  maintaining	   the	  hydration	  of	   the	  airway	  epithelium	  and	  crucially	  entrapping	  particles	  for	   removal	   by	   mucociliary	   clearance.	   In	   mice,	  Muc5b	   appears	   essential	   for	   normal	  macrophage	  function	  and	  effective	  mucociliary	  clearance	  of	  bacteria	  (Roy	  et	  al.	  2014).	  This	   has	   led	   to	   the	   hypothesis	   that	   excess	   production	   of	  MUC5B	   reduces	  mucociliary	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clearance	  of	  inhaled	  particles	  resulting	  in	  prolonged	  and	  repetitive	  exposure,	  triggering	  an	  exaggerated	  interstitial	  injury	  and	  eventually	  leading	  to	  the	  development	  of	  fibrosis.	  
1.3.4.1.2 Surfactant	  Proteins	  Multiple	  candidate	  gene	  studies	  have	  reported	  Surfactant	  protein	  C	  (SFTPC)	  mutations	  in	   FIP	   (van	  Moorsel	   et	   al.	   2010;	  Nogee	   et	   al.	   2001;	  Guillot	   et	   al.	   2009)	   and	   led	   to	   the	  subsequent	   identification	   of	   mutations	   in	   Surfactant	   protein	   A2	   (SFTPA2)	   also	  associated	   with	   FIP	   (Y.	   Wang	   et	   al.	   2009).	   Surfactant	   proteins	   are	   secreted	   into	   the	  alveolar	  space	  by	  Type	  II	  AECs,	  increasing	  alveolar	  compliance	  and	  playing	  a	  role	  in	  the	  lungs	   innate	   immune	   response	   to	   microbes	   and	   particulates	   in	   the	   lower	   airways.	  Mutations	   in	  both	   the	  SFTPC	   and	  SFTPA2	   genes	  have	  been	  shown	   to	  alter	   the	   tertiary	  structure	   of	   the	   proteins	   preventing	   their	   secretion	   into	   the	   alveolar	   space.	   This	  aberrant	   processing	   causes	   protein	   accumulation	   and	   triggers	   endoplasmic	   reticulum	  stress	  and	  ultimately	  apoptosis	  (Günther	  et	  al.	  1999).	  Although	  mutations	  in	  SFTPC	  may	  account	  for	  up	  to	  25%	  of	  FIP,	  in	  a	  study	  of	  more	  than	  90	  adults	  with	  sporadic	  IPF	  only	  one	  person	  carried	  an	  SFTPC	  mutation	  (Lawson,	  Loyd,	  and	  Degryse	  2011).	  Despite	  this,	  markers	  of	  endoplasmic	  reticulum	  stress	  and	  AEC	  apoptosis	  have	  been	  demonstrated	  in	  lung	   biopsies	   of	   sporadic	   IPF	   cases	   without	   known	   surfactant	   protein	   mutations,	  supporting	  a	  pathogenic	  role	  for	  ER	  stress	  in	  IPF.	  
1.3.4.1.3 Telomerase	  Genes	  The	  observation	  of	  an	  association	  with	  pulmonary	  fibrosis	  and	  Dyskeratosis	  congenita,	  an	  autosomal	  dominant	  disorder	  caused	  by	  mutations	  in	  the	  telomerase	  complex,	  led	  to	  the	   identification	   of	   mutations	   in	   the	   Telomerase	   reverse	   transcriptase	   (hTERT)	   and	  telomerase	   RNA	   component	   (TERC)	   genes	   in	   FIP	   (Armanios	   et	   al.	   2007).	   This	  association	  was	   confirmed	   in	   a	   recent	   GWAS	   (Fingerlin	   et	   al.	   2013).	   Telomerases	   are	  responsible	   for	   protecting	   the	   end	   terminals	   of	   chromosomes	  during	  DNA	   replication	  and	  cell	  division	  by	  maintaining	   telomere	   length.	   If	   telomeres	  shorten	  below	  a	  critical	  length	   then	   cell	   apoptosis	   is	   triggered.	   Studies	   have	   demonstrated	   shortening	   of	  telomeres	   in	   the	  alveolar	  epithelium	  and	  peripheral	  blood	   leukocytes	  of	   subjects	  with	  sporadic	  IPF	  (Lawson,	  Loyd,	  and	  Degryse	  2011).	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1.3.4.1.4 ELMOD2	  A	   linkage	   analysis	   on	   24	   FIP	   families	   from	   Finland	   identified	  ELMOD2	   as	   a	   potential	  candidate	  gene	  for	  FIP	  (Hodgson	  et	  al.	  2006).	  ELMOD2	  belongs	  to	  the	  group	  of	  proteins	  expressed	  by	  Type	   II	  AECs	  which	  are	  essential	   for	  phagocytosis	  of	  apoptotic	  cells	  and	  may	  be	  involved	  in	  the	  regulation	  of	  host	  responses	  to	  viral	  infections,	  however,	  its	  role	  in	  lung	  fibrosis	  remains	  far	  from	  clear	  (Pulkkinen	  et	  al.	  2010).	  
1.3.4.1.5 Gene	  Expression	  One	   of	   the	   earliest	   transcriptome	   studies	   in	   IPF	   demonstrated	   that	   gene	   expression	  profiles	   clearly	   distinguished	   normal	   lung	   from	   areas	   of	   usual	   interstitial	   pneumonia	  (UIP)	   (Zuo	   et	   al.	   2002).	   Following	   on	   from	   this	   Selman	   et	   al.	   compared	   the	   gene	  expression	   profiles	   of	   IPF,	   HP	   and	   NSIP	   demonstrating	   statistically	   significant	   gene	  expression	   signatures	   (Moises	   Selman	   et	   al.	   2006).	   This	   confirmed	   the	   lack	   of	   an	  inflammatory	   response	   in	   IPF	   and	   demonstrated	   up	   regulation	   of	   genes	   involved	   in	  tissue	   remodelling,	   production	   of	   extracellular	   matrix	   components	   as	   well	   as	  myofibroblast	  specific	  genes	  (Moises	  Selman	  et	  al.	  2006).	  The	  subgroup	  of	  IPF	  patients	  who	  display	  an	  accelerated	  clinical	  course	  posses	  a	   lung	  tissue	  expression	  profile	   that	  differs	   from	   those	   with	   more	   stable	   disease	   (Moisés	   Selman	   et	   al.	   2007).	   Clear	  differences	  can	  also	  be	  seen	  between	   the	  expression	  profiles	  of	   lung	   tissue	   in	  FIP	  and	  IPF	  (I.	  V	  Yang	  et	  al.	  2007)	  and	  between	  stable	  IPF	  and	  AE-­‐IPF	  (Konishi	  et	  al.	  2009).	  	  More	   recently	  work	   has	   concentrated	   on	   the	   analysis	   of	   peripheral	   blood	   expression	  profiles	  in	  the	  hunt	  for	  a	  peripheral	  signature	  for	  IPF.	  Yang	  and	  colleagues	  hypothesised	  that	  peripheral	  blood	   transcriptional	  profiles	   from	  patients	  with	   IPF	  could	  distinguish	  patients	  with	  IPF	  from	  controls,	  and	  mild	  from	  more	  advanced	  stages	  of	  the	  disease	  (I.	  V	  Yang	  et	  al.	  2012).	  Comparing	  mild	  IPF	  (n=16)	  to	  controls	  they	  demonstrated	  that	  1428	  genes	  were	  differentially	  expressed,	  while	  the	  comparison	  between	  severe	  (n=15)	  and	  controls	   demonstrated	   2790	   differentially	   expressed	   transcripts.	   Of	   these	   13	   genes	  were	  differentially	  expressed	  between	  mild	  and	  severe	  IPF.	  Herazo-­‐Maya	   and	   collegues	   similarly	   generated	   peripheral	   blood	   mononuclear	   cell	  (PBMC)	   gene	   expression	   profiles	   with	   the	   aim	   of	   identifying	   a	   signature	   that	   could	  predict	   outcomes	   in	   IPF	   (Herazo-­‐Maya	  et	   al.	   2013).	  Microarray	  analyses	   identified	  52	  genes	   associated	   with	   transplant-­‐free	   survival	   and	   this	   signature	   was	   validated	   in	   a	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second	   cohort.	   The	   authors	   suggest	   that	   a	   number	   of	   these	   may	   serve	   as	   useful	  biomarkers	  for	  IPF.	  
1.3.4.1.6 Epigenetics	  Epigenetic	   changes	   in	   gene	   expression	   are	   not	   accompanied	   by	   changes	   in	   DNA	  sequence	   and	   are	  mediated	   primarily	   by	   DNA	  methylation,	   MicroRNAs	   (miRNA)	   and	  histone	  modifications.	  DNA	  methylation	  is	  an	  important	  regulator	  of	  gene	  transcription	  and	  can	  either	  directly	  inhibit	  binding	  of	  transcription	  factors	  or	  cause	  conformational	  changes	   that	  prevent	   transcription.	   	   It	   is	  an	  essential	  process	  during	  development	  but	  aberrant	  methylation	   patterns	   have	   been	   demonstrated	   in	   a	   number	   of	  malignancies.	  Distinct	  differences	   in	  DNA	  methylation	  patterns	  between	  normal	   and	   IPF	   lungs	  have	  been	   identified	   (Rabinovich	   et	   al.	   2012;	   Sanders	   et	   al.	   2012),	   with	   the	   predominant	  observation	   being	   of	   hyper-­‐methylation	   in	   upstream	   promoter	   regions	  which	   altered	  the	  expression	  of	  several	  important	  genes	  (Cosgrove	  et	  al.	  2011).	  	  MicroRNAs	  are	  post-­‐transcriptional	  regulators	  that	  target	  messenger	  RNA	  transcripts	  to	  modulate	   gene	   function.	   They	   play	   a	   critical	   role	   in	  most	   basic	   cellular	   functions	   and	  have	  been	  implicated	  in	  a	  number	  of	  disease	  processes.	  miRNAs	  in	  IPF	  lungs	  may	  differ	  from	  those	   in	  healthy	   lungs	  by	  up	  to	  10%	  (Pandit,	  Milosevic,	  and	  Kaminski	  2011)	  and	  miRNA	  expression	  in	  IPF	  lung	  has	  also	  been	  correlated	  with	  disease	  severity	  (Oak	  et	  al.	  2011).	  
1.3.4.2 Environmental	  Factors:	  What	  initiates	  the	  cycle	  of	  aberrant	  repair?	  A	   history	   of	   smoking	   is	   associated	   with	   an	   increased	   risk	   of	   developing	   familial	   and	  sporadic	  IPF	  (KB	  Baumgartner	  	  CA	  Stidley,	  TV	  Colby	  and	  JA	  Waldron	  1997),	  providing	  a	  strong	   argument	   for	   a	   causative	   role	   of	   cigarette	   smoke.	   Although	   there	   is	   evidence	  suggesting	  that	  the	  association	  between	  smoking	  and	  IPF	   is	  dose-­‐dependent	  (Ekström	  et	  al.	  2014),	  IPF	  does	  occur	  in	  non-­‐smokers,	  so	  cigarette	  smoke	  alone	  cannot	  be	  the	  only	  trigger.	  Epidemiological	  studies	  have	  also	  implicated	  a	  number	  of	  other	  environmental	  (Taskar	  and	  Coultas	  2006)	  and	  occupational	  (Hubbard	  et	  al.	  1996;	  K.	  Iwai	  et	  al.	  1994)	  exposures	  which	  confer	  an	  increased	  risk	  of	  IPF.	  Nevertheless,	  despite	  evidence	  of	  higher	  levels	  of	  inorganic	  particles	  in	  the	  hilar	  lymph	  nodes	  of	  patients	  with	  IPF	  (Kitamura	  et	  al.	  2007),	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thought	   to	   originate	   from	   environmental	   exposure,	   their	   role	   in	   the	   disease	  pathogenesis	  remains	  unclear.	  Gastro-­‐oesophageal	  reflux	  disease	  (GORD)	  is	  commonly	  associated	  with	  IPF,	  with	  some	  studies	   suggesting	   it	   occurs	   in	   up	   to	   88%	   of	   patients	   (Joyce	   S	   Lee	   et	   al.	   2010).	  	  Aspiration	   pneumonitis	   and	   pneumonia	   are	   well-­‐recognised	   acute	   clinical	   conditions	  caused	  by	  aspiration.	  Chronic	  microaspiration	  has	  been	  associated	  with	  post	  transplant	  bronchiolitis	  obliterans	  and	  the	  development	  of	   fibrosis	   in	  mouse	  models	  (D’Ovidio	  et	  al.	   2005).	   It	   is	   not	   clear	   whether	   the	   introduction	   of	   components	   of	   refluxate	   or	  oesophageal	   organisms	   into	   the	   lungs	   trigger	   these	   injuries.	   Chronic	   reflux	   causes	  inflammation	   and	   changes	   to	   the	   oesophageal	   flora	   with	   Gram-­‐negative	   anaerobes	  dominating	   communities	  which	   are	   normally	   pre-­‐dominated	   by	   streptococcal	   species	  (L.	   Yang	   et	   al.	   2009).	   Silent	   micro-­‐aspiration	   in	   association	   with	   GORD	   therefore	  remains	  a	  very	  attractive	  candidate	  for	  the	  source	  of	  repetitive	  injury	  in	  IPF,	  especially	  as	  there	  are	  available	  medical	  and	  surgical	  treatment	  options	  (Joyce	  S	  Lee	  et	  al.	  2013).	  
1.3.4.3 Infection?	  Active	   infection	   in	   IPF	   is	   known	   to	   carry	   a	   high	  morbidity	   and	  mortality	   (Song	   et	   al.	  2011).	   In	   individuals	  with	   IPF	   immunosuppression	   is	   clearly	  deleterious	   (Raghu	  et	  al.	  2012)	  while	   treatment	  adherent	  subjects	   in	  a	   large	   trial	  of	   the	  use	  of	  prophylactic	  co-­‐trimoxazole	  in	  IPF	  experienced	  a	  reduction	  in	  overt	  infections	  and	  mortality	  (Shulgina	  et	  al.	  2013).	  Recent	  genetic	   studies	  have	  pointed	   to	  disordered	  host	  defence	  and	   thus	  susceptibility	  to	  infection,	  as	  an	  important	  contributor	  to	  disease	  progression	  in	  IPF	  (Y.	  Zhang,	  Noth,	  and	  Society	  2011;	  Peljto	  et	  al.	  2013;	  Seibold	  et	  al.	  2011).	   In	  mice,	  Muc5b	  appears	  essential	   for	  normal	  macrophage	   function	  and	  effective	  mucociliary	  clearance	  of	   bacteria	   (Roy	   et	   al.	   2014),	   supporting	   a	   potential	   role	   for	   infection	   as	   an	  environmental	  trigger	  in	  susceptible	  individuals	  (I.	  V	  Yang	  et	  al.	  2012).	  Viruses	  have	  long	  been	  suspected	  of	  playing	  a	  role	  in	  the	  pathogenesis	  of	  IPF,	  and	  there	  is	  growing	  evidence,	  obtained	  both	  from	  human	  tissue	  and	  animal	  models,	  to	  support	  a	  mechanistic	  role	  for	  airborne	  viruses	  in	  the	  initiation	  and	  progression	  of	  IPF.	  A	  number	  of	  small	  retrospective	  studies	  have	  demonstrated	  an	  association	  with	  the	  human	  herpes	  viruses	  (HHVs)	  family	  and	  IPF.	  The	  first	  study	  to	  suggest	  this	  association	  reported	  that	  12	  out	  of	  13	  IPF	  patients	  were	  seropositive	  for	  EBV	  compared	  to	  none	  of	  the	  12	  patients	  with	   another	   ILDs	   (Vergnon	   et	   al.	   1984).	   Since	   then	   several	   studies	   have	   replicated	  
	  	   33	  
these	  findings	  in	  lung	  tissue	  and	  lavage	  (Stewart	  et	  al.	  1999;	  Manika	  et	  al.	  2007).	  Whilst	  the	   Epstein–Barr	   virus	   (EBV)	   has	   been	   the	   most	   frequent	   of	   the	   HHVs	   studied	   in	  association	  with	   IPF,	  Tang	  et	  al.	  demonstrated	  past	   infection	  with	  at	   least	  one	  HHV	   in	  97%	  of	  patients	  with	  IPF	  compared	  to	  only	  36%	  of	  healthy	  controls	  (Tang	  et	  al.	  2003).	  	  Animal	  models	   support	   these	   association	   studies;	  mice	   latently	   infected	  with	  murine	  herpes	   virus	   prior	   to	   a	   fibrotic	   challenge	   develop	   an	   exaggerated	   fibrotic	   response	  compared	   to	  non-­‐infected	  animals	   (Stoolman	  et	  al.	  2011).	  Also	  a	   small	   study	  of	  open-­‐label	   ganciclovir	   in	   14	   subjects	   with	   severe	   IPF	   and	   positive	   EBV-­‐IgG	   serology	  demonstrated	  an	  improvement	  in	  lung	  function	  in	  9	  of	  subjects	  at	  8	  weeks	  (Egan	  et	  al.	  2011).	  Whilst	   there	   is	  some	  evidence	  to	  suggest	  a	  role	   for	  viruses	   in	   the	  pathogenesis	  of	   IPF,	  any	   role	   of	   bacteria	   is	   much	   less	   well	   established.	   Known	   pathogens	   including	  
Haemophilus,	  Streptococcus	  and	  Pseudomonas	  were	   identified	   in	  BAL	   cultures	   eight	   of	  22	  stable	  IPF	  patients	  used	  as	  controls	  in	  a	  study	  of	  Wegner’s	  granulomatosis	  (Richter	  et	   al.	   2009).	   Further	   evidence	   comes	   from	   a	   large	  multicentre,	   randomised,	   placebo-­‐controlled	   study	   that	   evaluated	   the	   prophylactic	   use	   of	   12	   months	   of	   septrin	   as	   a	  treatment	   for	   IPF	   (Shulgina	  et	  al.	  2013).	  Whilst	   it	   failed	   to	   reach	   its	  primary	  outcome	  and	   there	   were	   a	   large	   number	   of	   drop-­‐outs,	   post	   hoc	   analysis	   suggested	   that,	   in	  treatment	   adherent	   subjects,	   septrin	   led	   to	   a	   reduction	   in	   infections	   and	   mortality.	  Together	  with	  the	  high	  mortality	  associated	  with	  bacterial	  infections	  in	  IPF	  (Song	  et	  al.	  2011),	   this	   observation	   suggests	   bacteria	   may	   play	   a	   role	   in	   driving	   IPF	   disease	  progression	  (Molyneaux	  and	  Maher	  2013).	  The	   lack	   of	   interest	   in	   the	   role	   of	   bacteria	   in	   the	   pathogenesis	   of	   IPF	  probably	   stems	  from	  the	  longstanding,	  but	  incorrect,	  belief	  that	  the	  lower	  airways	  are	  sterile.	  Over	  the	  past	  decade	  advances	   in	  molecular	  microbiology	  have	  allowed	   the	   characterization	  of	  microbial	   communities	   that	   are	   not	   amenable	   to	   culture.	   Classical	   Culture	   based	  techniques	   suffer	   from	   a	   number	   of	   limitations,	   are	   very	   labour	   intensive	   and	   using	  standard	   conditions	   can	   culture	   only	   1%	   of	   bacteria	   (Relman	   1999).	   Molecular	   tools	  rely	   on	   genomic	   evolutionary	   relationships	   between	   bacteria	   and	   use	   nucleic	   acid	  sequence	   similarities	   in	   housekeeping	   genes,	   such	   as	   the	   highly	   conserved	   16S	   rRNA	  gene,	  to	  assign	  phylogeny.	  The	  need	  for	  culture	  prior	  to	  detection	  is	  therefore	  removed.	  The	   16S	   rRNA	   gene	   contains	   a	   number	   of	   hypervariable	   regions	   flanked	   by	   highly	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conserved	   regions	  which	   are	   consistent	   across	   the	   domain	  Bacteria.	   These	   conserved	  sequence	  regions	  within	  the	  16S	  rRNA	  gene	  can	  therefore	  be	  used	  to	  amplify	  sequences	  from	  any	  bacterial	  content	  of	  a	  sample,	  rather	  than	  just	  a	  single	  species,	  and	  importantly	  requires	  no	  a	  priori	  assumption	  as	  to	  which	  bacteria	  will	  be	  present.	  This	  constructs	  a	  picture	   of	   the	   complete	   microbial	   community	   in	   an	   environment	   (the	   microbiome),	  offering	   a	   more	   comprehensive	   analysis	   than	   classical	   culture-­‐based	   techniques.	  Initially	   these	   molecular	   culture	   independent	   techniques	   were	   used	   with	   denaturing	  and	   temperature	   gradient	   gel	   electrophoresis	   techniques	   to	   determine	   community	  structure	   and	   composition.	   To	   identify	   the	   bacterial	   members	   of	   these	   community’s	  clone	   libraries	   were	   constructed	   and	   sequenced	   (Rogers,	   Carroll,	   and	   Bruce	   2009).	  Although	   very	   informative	   these	   techniques	   are	   very	   labour	   intensive	   and	   subject	   to	  cloning	   biases,	   and	   have	   therefore	   now	   largely	   been	   replaced	   by	   high-­‐throughput	  sequencing	  of	  16S	  rRNA	  gene	  amplicons	  (Han	  et	  al.	  2012).	  	  Molecular	   culture	   independent	   techniques	   have	   demonstrated	   the	   existence	   of	   a	  respiratory	  microbiome	  in	  healthy	  non	  smokers,	  proving	  that	  the	   lungs	  are	  not	  sterile	  (Hilty	   et	   al.	   2010).	  Streptococcus,	  Prevotella,	  Fusobacteria,	   and	  Haemophilus	   have	   now	  been	   consistently	   identified	   in	   the	   airways	   of	   healthy	   subjects	   (Hilty	   et	   al.	   2010;	  Cardenas	   et	   al.	   2012;	   Y.	   J.	   Huang	   et	   al.	   2010;	   Charlson	   et	   al.	   2010).	   Recently	   distinct	  alterations	   from	   this	   healthy	   respiratory	   microbiome	   have	   been	   documented	   in	   a	  number	  of	  respiratory	  conditions	  (Molyneaux	  et	  al.	  2013;	  Cardenas	  et	  al.	  2012;	  Duff	  et	  al.	  2013;	  J.	  Zhao	  et	  al.	  2012)..	  Although	  a	  small	  study,	  principally	  looking	  at	  the	  potential	  role	   of	   chronic	   Pneumocystis	   jirovecii	   infection	   in	   IPF,	   demonstrated	   a	   number	   of	  uncultured	  bacteria	  in	  the	  BAL	  of	  IPF	  patients	  (Friaza	  et	  al.	  2010)	  these	  techniques	  have	  yet	  to	  be	  fully	  applied	  to	  IPF.	  While	   the	   combination	   of	   16S	   rRNA	   PCR	   with	   next-­‐generation	   sequencing	   has	  revolutionised	   the	   field	   of	   microbial	   ecology	   there	   are	   still	   limitations.	   The	   most	  significant	  are	  the	  biases	  introduced	  by	  primer	  design,	  which	  may	  select	  for	  or	  against	  particular	  bacteria	  (Sim	  et	  al.	  2012;	  Metzker	  2010).	  As	  with	  any	  PCR	  based	  technique	  it	  is	  also	  very	  susceptible	  to	  contamination,	  and	  multiple	  stringent	  controls	  are	  required.	  As	   the	   upper	   airways	   must,	   in	   general,	   be	   traversed	   to	   sample	   the	   respiratory	  microbiome	   there	   remains	   some	   concern	   that	   lung	   microbial	   signatures	   may	   be	  contaminated	  by	  microbiota	  of	  the	  upper	  respiratory	  tract.	  The	  respiratory	  microbiome	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is	   undoubtedly	   linked	   to	   the	   anatomically	   contiguous	   microbiomes	   of	   the	   upper	  respiratory	   tract,	   oropharynx	   and	   gut.	   Bacteria	   likely	   exist	   in	   a	   state	   of	   flux,	   passing	  freely	  between	  environments	  by	  inhalation,	  micro-­‐aspiration	  and	  coughing.	  Therefore	  it	  is	   unsurprising	   that	   the	  majority	   of	   the	   organisms	   in	   the	   lung	  microbiome	   have	   also	  been	   detected	   in	   the	  mouth	   and	   upper	   airways	   and	   that	   paired	   oral	   and	   respiratory	  samples	   from	   individuals	   cluster	   together	   (Charlson	   et	   al.	   2011).	   	   However,	   if	   the	  respiratory	   microbiome	   were	   simply	   due	   to	   upper	   airway	   carry	   over,	   consistent	  mirroring	  of	  the	  oral	  and	  lung	  microbiomes	  would	  be	  expected.	  This	  is,	  however,	  not	  the	  case.	  While	  there	  remain	  striking	  differences	  in	  the	  oral	  microbiome	  of	  healthy	  smokers	  and	   non	   smokers,	   this	   finding	   is	   not	   replicated	   when	   looking	   at	   the	   respiratory	  microbiome	  of	   these	  groups	   (Charlson	  et	   al.	  2010;	  Erb-­‐Downward	  et	  al.	  2011).	   In	   the	  largest	   study	   of	   the	   respiratory	   microbiome	   to	   date	   enrichment	   of	   distinct	   bacterial	  species	  from	  the	  oral	  cavity	  were	  seen	  in	  the	  lung	  microbiome	  (Morris	  et	  al.	  2013)	  while	  a	  number	  of	  unique	  taxa	  have	  been	  identified	  in	  the	  lower	  airways	  microbiota	  that	  are	  not	   present	   in	   the	   upper	   airways	   (Lozupone	   et	   al.	   2013).	   Even	   more	   reassuringly	  studies	   characterising	   the	   lung	   microbiota	   using	   surgical	   lung	   biopsy	   samples	   have	  demonstrated	   similar	   bacterial	   communities	   to	   BAL	   without	   traversing	   the	   upper	  airways	   and	   thereby	   eliminating	   potential	   carry-­‐over	   of	   upper	   respiratory	   tract	  organisms	  during	  sampling	  (S.	  Iwai	  et	  al.	  2012;	  Erb-­‐Downward	  et	  al.	  2011).	  
1.3.4.4 Acute	  Exacerbations?	  It	   is	   currently	  unclear	   if	   acute	  exacerbations	  of	   IPF	   (AE-­‐IPF)	   represent	  an	  accelerated	  phase	   or	   flare	   of	   the	   underlying	   fibroproliferative	   process	   or	   are	   due	   to	   unidentified	  infection	   or	   micro-­‐emboli	   (Toby	   M	   Maher	   2008).	   Histologically,	   AE-­‐IPF	   are	  characterised	  by	  the	  finding	  of	  diffuse	  alveolar	  damage	  (DAD).	  A	  number	  of	  insults	  have	  been	  shown	  to	  trigger	  the	  development	  of	  DAD,	  in	  particular	  thoracic	  surgery	  (Song	  et	  al.	   2011),	   pollution	   (Johannson	   et	   al.	   2014),	   aspiration	   (Joyce	   S	   Lee	   et	   al.	   2013)	   and	  drugs.	  The	  identification	  of	  such	  triggers	  however	  precludes	  the	  diagnosis	  of	  an	  AE-­‐IPF	  which	  must	  be	  truly	  cryptogenic.	  	  Given	   the	   lack	   of	   sensitivity	   encountered	   with	   current	   culture-­‐dependant	   clinical	  microbiology	  techniques	  and	  the	  limited	  repertoire	  of	  tools	  available	  to	  diagnose	  acute	  viral	   infections,	   it	   is	   plausible	   to	   hypothesise	   that	   many	   episodes	   of	   apparent	   acute	  exacerbations	  simply	  represent	  the	  sequelae	  of	  infection.	  Indeed	  there	  is	  some	  evidence	  
	  	   36	  
to	  support	  this.	  Seasonal	  patterns	  to	  AE-­‐IPF	  exist	  with	   increased	  exacerbations	  during	  the	   winter	   months	   (Olson	   et	   al.	   2009).	   In	   addition	   respiratory	   tract	   infections	   in	  individuals	  with	  IPF	  confer	  a	  mortality	  risk	  indistinguishable	  from	  that	  seen	  with	  acute	  exacerbations	   (Song	   et	   al.	   2011).	   Post	   mortem	   examination	   in	   such	   cases	   frequently	  discloses	  associated	  DAD.	  In	  animal	  models	  there	  is	  now	  good	  evidence	  to	  show	  that	  viral	  infection	  can	  exacerbate	  established	  fibrosis	  and	  in	  so	  doing	  give	  rise	  to	  a	  lesion	  resembling	  DAD	  (McMillan	  et	  al.	  2008).	   In	   humans	   however,	   the	   largest	   clinical	   study	   to	   date	   looking	   at	   the	   role	   of	  viruses	  in	  exacerbations	  was	  essentially	  negative.	  In	  a	  study	  of	  43	  individuals	  suffering	  an	   acute	   exacerbation	   of	   IPF,	  Wootton	   et	  al.	   failed	   to	   clearly	   identify	   a	   viral	   or	   other	  infectious	   trigger	   for	   the	   acute	   exacerbation	   in	   the	   vast	   majority	   of	   their	   subjects.	  During	  the	  acute	  exacerbations,	  all	  43	  IPF	  subjects	  had	  negative	  bacterial	  cultures	  and	  negative	   viral	   serology.	   Subsequent	   PCR	   analysis	   of	   BAL	   fluid	   identified	   four	   samples	  positive	  for	  rhinovirus,	  parainfluenza	  or	  coronavirus	  in	  the	  exacerbation	  cohort,	  and	  no	  evidence	   of	   detectable	   viruses	   in	   the	   40,	   stable,	   IPF	   patients	   (P=0.12).	   In	   addition	   to	  PCR,	  Wootton	  et	  al.	  went	  on	  to	  employ	  pan-­‐viral	  microarrays.	  These	  arrays	  identified,	  in	  the	  exacerbation	  cohort,	  additional	  evidence	  of	  HSV,	  EBV	  and	  interestingly	  12	  cases	  of	  transfusion	  transmitted	  virus	  (TTV)	  with	  no	  viruses	  being	  detected	  in	  the	  stable	  disease	  group.	   Deep	   sequencing	   of	   samples	   was	   also	   used	   to	   look	   for	   novel	   viruses	   not	  detectable	   by	   PCR	   or	   array	   based	   methods	   but	   this	   did	   not	   identify	   any	   additional	  viruses.	  Although	  TTV	  was	  not	  found	  in	  stable	  IPF	  patients,	  it	  was	  found	  with	  a	  similar	  incidence	   in	   a	   cohort	   of	   controls	   with	   acute	   lung	   injury	   (Wootton	   et	   al.	   2011).	   The	  authors	   therefore	   concluded	   that	   their	   findings	   may	   simply	   reflect	   the	   sequelae	   of	  severe	  underlying	  inflammation	  rather	  than	  proving	  a	  link	  between	  viral	  infection	  and	  acute	   exacerbations	   of	   IPF.	   Similarly	   a	   study	   of	   the	   gene	   transcription	   profile	   of	   the	  lungs	   taken	   from	  eight	   patients	  who	  died	   from	  an	   acute	   exacerbation	   of	   IPF	   failed	   to	  identify	   a	   signature	   that	  might	   be	   expected	   to	   be	   observed	   in	   the	   presence	   of	   a	   viral	  infection	  (Konishi	  et	  al.	  2009).	  
1.3.5 Treatment	  The	   last	   decade	   has	   seen	   important	   developments	   in	   the	   treatment	   of	   IPF,	   with	   a	  number	   of	   negative	   randomised	   controlled	   trials	   reshaping	   the	   treatment	   landscape.	  Previous	   therapeutic	  approaches	  based	  around	   immunosuppression	  have	  been	  shown	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to	   be	   harmful	   while	   compounds	   with	   anti-­‐fibrotic	   actions	   have	   been	   found	   to	   slow	  decline	  in	  lung	  function.	  Initial	  unsuccessful	   treatments	   for	   IPF	  were	   targeted	  at	   reducing	   inflammation,	  which	  was	   incorrectly	   felt	   to	   be	   the	   predominant	   underlying	   disease	   process.	   Large	   studies	  have	   however	   shown	   no	   benefits	   with	   corticosteroids	   and	   similar	   results	   were	   seen	  when	  studying	  the	  use	  of	  the	  immunosuppressive	  agents	  azathioprine,	  cyclosporin	  and	  cyclophosphamide	   (du	   Bois	   2010).	   Indeed	   far	   from	   demonstrating	   any	   benefit	  immunosuppression	   has	   actually	   proven	   to	   be	   harmful	   in	   IPF	   (Raghu	   et	   al.	   2012).	  Immunomodulatory	   drugs,	   including	   IFN-­‐γ,	   IFN-­‐β,	   Imatinib	   and	   Etanarcept	   have	   all	  been	  trialled	  and	  despite	  initial	  suggestions	  of	  benefits	  in	  small	  pilot	  studies	  none	  have	  gone	   on	   to	   shown	   any	   impact	   on	   disease	   progression	   or	   survival	   in	   larger	   studies	  (Woodcock	  and	  Maher	  2014).	  Even	  acetylcysteine,	  a	  mainstay	  of	  IPF	  treatment	  (Raghu	  et	  al.	  2012),	  has	  recently	  been	  shown	  to	  have	  no	  impact	  on	  the	  rate	  of	  decline	  in	  FVC	  in	  a	  large	  randomised	  control	  trial	  (Martinez	  et	  al.	  2014).	  Pirfenidone	   is	  a	  novel	  anti-­‐fibrotic	  agent	   that	  has	  become	  the	   first	  drug	  to	  be	   licensed	  specifically	   for	   the	   treatment	   of	   IPF.	   It	   possesses	   anti-­‐fibrotic,	   anti-­‐oxidant,	   and	   anti-­‐inflammatory	  effects	  (T	  M	  Maher	  2010).	   It	  has	  been	  licensed	  in	  Japan	  for	  a	  number	  of	  years,	  following	  two	  international	  studies	  suggesting	  it	  could	  slow	  the	  rate	  of	  decline	  in	  FVC.	  Subsequently	  two	  phase	  III	  RCTs	  of	  pirfenidone	  compared	  with	  placebo,	  CAPACITY	  (Clinical	   Studies	   Assessing	   Pirfenidone	   in	   IPF:	   Research	   of	   Efficacy	   and	   Safety	  Outcomes)	  1	  &	  2	  (Noble	  et	  al.	  2011).	  The	  primary	  end-­‐point	  for	  both	  trials	  was	  change	  in	  FVC	  after	  72	  weeks.	  CAPACITY	  1	  demonstrated	  a	  significant	  reduction	   in	  decline	   in	  FVC	   in	   the	   pirfenidone	   arm	   compared	   with	   placebo	   (−8%	   vs.	   −12.4%),	   however,	  CAPACITY	  2	  did	  not	  demonstrate	  any	  significant	  difference.	  The	  led	  to	  the	  ASCEND	  trial	  (Talmadge	  E	  King	  et	  al.	  2014).	  ASCEND	  demonstrated	  that	  after	  52	  weeks,	  half	  as	  many	  patients	   receiving	   pirfenidone	   had	   a	   significant	   decline	   in	   FVC	   compared	   to	   patients	  receiving	   the	   placebo.	   Although	   pirfenidone	   did	   not	   reduce	  mortality	   in	   the	   ASCEND	  trial,	  when	  the	  results	  of	  the	  ASCEND	  and	  CAPACITY	  trials	  were	  pooled,	  in	  a	  predefined	  analysis	  plan,	  patients	  taking	  pirfenidone	  had	  half	  the	  risk	  of	  death	  from	  all	  causes,	  and	  one-­‐third	   the	   risk	   of	   death	   from	   idiopathic	   pulmonary	   fibrosis.	   This	   supports	   the	  findings	  of	  a	  Cochrane	  meta-­‐analysis	  that	  suggests	  treatment	  with	  pirfenidone	  reduces	  the	  risk	  of	  disease	  progression	  by	  30%	  (Paolo	  Spagnolo	  et	  al.	  2010).	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Nintedanib	   (previously	  known	  as	  BIBF	  1120)	   is	   a	   tyrosine	  kinase	   receptor	  antagonist	  that	  inhibits	  a	  number	  of	  key	  profibrotic	  growth	  factors;	  platelet	  derived	  growth	  factor	  (PDGF),	  vascular	  endothelial	  growth	  factor	  (VEGF),	  and	  fibroblast	  growth	  factor	  (FGF)	  (Woodcock,	  Molyneaux,	  and	  Maher	  2013).	   Inhibition	  of	   these	  receptors	  has	  proved	   to	  be	  effective	  in	  experimental	  animal	  models	  of	  pulmonary	  fibrosis	  (Roth	  et	  al.	  2009).	  The	  Phase	   IIb	   TOMORROW	   trial	   demonstrated	   that	   treatment	   with	   nintedanib	   may	   slow	  decline	  in	  lung	  function,	  decrease	  the	  frequency	  of	  AE-­‐IPF,	  and	  even	  improve	  quality	  of	  life	   in	   patients	   with	   IPF	   (Richeldi	   et	   al.	   2011).	   Two	   large	   phase	   3	   randomized	   trials	  (INPULSIS-­‐1	   and	   INPULSIS-­‐2)	   followed	   on	   from	   this	   and	   have	   demonstrated	   that	  nintedanib	  reduces	  the	  decline	  of	  FVC	  by	  about	  100	  mL	  compared	  to	  placebo,	  and	  also	  prevents	   AE-­‐IPF	   (in	   one	   of	   the	   two	   trials)	   (Richeldi	   et	   al.	   2014).	   Nintedanib	   will	  undoubtedly	  be	  licenced	  for	  use	  in	  IPF	  and	  together	  with	  pirfenidone	  provides	  hope	  for	  the	  future	  for	  both	  patients	  and	  their	  doctors.	  There	   is	  very	   little	  evidence	  and	  even	  sparser	   trial	  data	  surrounding	   the	   treatment	  of	  AE-­‐IPF.	   Despite	   having	   excluded	   known	   causes	   of	   deterioration	   to	   make	   a	   formal	  diagnosis	   of	   an	   AE-­‐IPF	   the	   treatment	   remains	   largely	   empirical	   and	   centred	   around	  treating	  the	  very	  same	  triggers	  already	  excluded.	  Given	  the	  lack	  of	  sensitivity	  of	  current	  culture-­‐dependant	  clinical	  microbiology	  techniques	  almost	  all	  patients	  presenting	  with	  AE-­‐IPF	   initially	   receive	   empirical	   broad-­‐spectrum	   antibiotics	   targeting	   common	  respiratory	  pathogens.	  If	  there	  is	  no	  response	  to	  antibiotics	  then	  patients	  subsequently	  receive	  trials	  of	  high	  dose	  corticosteroids	  which	  are	  either	   tapered	  to	  a	   lower	  dose	  or	  discontinued	  based	  upon	  clinical	  response	  (Johannson	  and	  Collard	  2013).	  While	  this	  is	  occurring	   careful	   attention	   is	   paid	   to	   optimising	   fluid	   balance	   status	   and	   providing	  supplementary	  oxygen	  therapy.	  
1.4 Aims	  	  Idiopathic	  pulmonary	  fibrosis	  (IPF)	  is	  a	  progressive,	  and	  invariably	  fatal,	  disease	  that	  is	  believed	   to	   arise	   in	   genetically	   susceptible	   individuals	   following	   repetitive	   alveolar	  injury.	  This	  presumptive	  model	  suggests	  a	  role	  for	  both	  host	  and	  environmental	  factors	  and	   this	   thesis	   plans	   to	   explore	   this	   relationship.	   The	   aims	   of	   the	   project	   are	   to	   (i)	  characterize	   the	  respiratory	  microbiome	   in	  patients	  with	   IPF,	   (ii)	  establish	   if	  and	  how	  this	  changes	  during	  an	  exacerbation	  and	  (iii)	  explore	  the	  link	  between	  the	  microbiome	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and	   the	   host	   response	   by	   performing	   genotyping	   and	   longitudinal	   peripheral	   blood	  global	  gene	  expression.	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Chapter	  2:	  Materials	  and	  Methods	  This	  chapter	  provides	  detailed	  information	  on	  the	  laboratory	  procedures	  carried	  out	  for	  this	  thesis.	  The	  author	  carried	  out	  all	  the	  practical	  work	  unless	  otherwise	  stated.	  All	   incubations	   were	   carried	   out	   on	   a	   MJ	   Tetrad	   Thermocycler	   (Genetic	   Research	  Instrumentation)	   to	  ensure	  uniform	  incubation	  temperatures.	  Unless	  otherwise	  stated	  all	  centrifugations	  were	  carried	  out	  using	  a	  bench-­‐top	  microfuge	  (Eppendorf	  5424).	  All	   solutions	   and	   reagents	   for	   the	   DNA	   extraction,	   RNA	   extraction,	   16S	   rRNA	   gene	  amplification,	   pyrosequencing	   and	   gene	   expression	   analysis	   were	   provided	   by	   the	  manufacturers	  and	  prepared	  as	  per	  instructions.	  	  
2.1 Subject	  Recruitment	  The	  PRospective	   study	  Of	  Fibrosis	   In	  Lung	  Endpoints	   (PROFILE)	   study	   prospectively	  recruited	  patients	  with	  suspected	  but	  previously	  undiagnosed	  IPF	  from	  the	  Interstitial	  Lung	  Disease	  Unit	  at	  the	  Royal	  Brompton	  Hospital,	  London,	  England	  between	  November	  2010	  and	   January	  2013.	  At	   the	   time	  of	  diagnosis	   the	  patients	  underwent	  a	  number	  of	  baseline	  investigations	  and	  were	  subsequently	  followed	  up	  for	  up	  to	  36	  months	  with	  a	  series	   of	   examinations	   and	  measurements.	   	   This	   enabled	   disease	   progression	   in	   each	  individual	   patient	   to	   be	   tracked	   (Figure	   2.1).	   During	   this	   period,	   on	   the	   basis	   of	  experience	  gained	  in	  IPF	  trials,	  it	  was	  anticipated	  that	  6–10%	  of	  subjects	  per	  year	  would	  suffer	  an	  exacerbation	  of	  their	  disease	  (Talmadge	  E	  King	  et	  al.	  2011;	  Richeldi	  et	  al.	  2011;	  Noble	   et	   al.	   2011).	   In	   instances	  when	   this	   occurred,	   and	   if	   feasible,	   additional	   clinical	  investigation	   and	   biological	   sampling	  was	   undertaken.	  Written	   informed	   consent	  was	  obtained	   from	   all	   subjects	   and	   the	   study	  was	   approved	   by	   the	   Local	   Research	   Ethics	  Committee	   (Ref	  10/H0720/12).	  No	  a	  priori	  power	  calculation	  was	  carried	  out,	   as	   this	  work	   was	   a	   pilot	   study.	   The	   sample	   size	   was	   therefore	   based	   on	   feasibility	   in	   the	  available	  timeframe.	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Figure	  2.1:	  The	  PROFILE	  Study.	  The	  study	  is	  a	  longitudinal	  observational	  cohort	  study.	  Spirometry:	   Forced	  Expiratory	  Volume	   in	  1	   second	   (FEV1),	   and	  Forced	  Vital	   Capacity	  (FVC),	   Physiological	  measurements:	  DLCO,	   carbon	  monoxide	  diffusing	   capacity;	   PaO2,	  arterial	   oxygen	   concentrations;	   SaO2,	   oxygen	   saturation;	   QoL,	   quality	   of	   life	   score,	   St	  George’s	  and	  SF36	  questionnaires;	  6MWT,	  six	  minute	  walk	  test;	  HRCT,	  High-­‐Resolution	  Computerised	  Tomography;	  BAL,	  Bronchoscopic	  Alveolar	  Lavage.	  Control	   subjects,	   including	   healthy	   individuals	   (smokers	   and	   non-­‐smokers)	   and	  individuals	   with	   moderate	   (GOLD	   Stage	   II)	   Chronic	   Obstructive	   Pulmonary	   Disease	  (COPD),	  were	  recruited	  separately	  by	  Dr	  Joseph	  Footitt	  and	  Dr	  Patrick	  Mallia.	  Subjects	  were	  recruited	  through	  advertisements	  in	  local	  newspapers,	  respiratory	  clinics	  and	  on	  the	  internet.	  Recruitment	  of	  controls	  began	  before	  and	  continued	  during	  recruitment	  of	  IPF	   subjects.	   Approval	   was	   obtained	   from	   the	   Local	   Research	   Ethics	   Committee	   (Ref	  00/BA/459E	  and	  07/H0712/138)	  and	  written	  informed	  consent	  was	  obtained	  from	  all	  subjects.	  	   	  
	  	   42	  
2.1.1 IPF	  Subjects	  Inclusion	  criteria	  
• Aged	  over	  18	  years.	  
• A	   diagnosis	   of	   definite	   or	   probable	   IPF	   or	   definite	   or	   probable	   fibrotic	   Non-­‐specific	   Interstitial	   Pneumonia	   (NSIP)	   as	   defined	   by	   the	   2011	  ATS/ERS/JRS/ALAT	   consensus	   classification	   and	   made	   within	   the	   6	   months	  prior	  to	  recruitment	  into	  the	  study	  (Raghu	  et	  al.	  2011).	  Exclusion	  criteria	  	  
• Subjects	   with	   co-­‐existent	   conditions	   known	   to	   be	   associated	   with	   the	  development	  of	  fibrotic	  lung	  disease	  including:	  connective	  tissue	  disease,	  known	  drug	   induced	   lung	   disease,	   asbestosis	   or	   other	   asbestos	   related	   disease,	  granulomatous	  disease	  including	  sarcoidosis.	  
• Subjects	   with	   an	   auto-­‐immune	   profile	   considered	   diagnostic	   for	   a	   specific	  connective	  tissue	  disease	  even	  in	  the	  absence	  of	  systemic	  symptoms.	  
• Subjects	   with	   a	   history	   of	   self-­‐reported	   upper	   or	   lower	   respiratory	   tract	  infection,	  IPF	  acute	  exacerbation	  or	  antibiotic	  use	  in	  the	  prior	  three	  months.	  
• Subjects	  involved	  in	  clinical	  trials	  for	  therapeutic	  agents	  for	  IPF.	  
2.1.2 Healthy	  Control	  Subjects	  The	   inclusion	   and	   exclusion	   criteria	   for	   the	   healthy	   controls	   were	   identical	   for	   the	  smoking	   and	   non-­‐smoking	   controls,	   except	   the	   non-­‐smokers	   had	   no	   smoking	   history,	  while	  the	  smokers	  had	  a	  greater	  than	  20	  pack	  year	  history.	  	  Inclusion	  criteria	  
• Aged	  40	  years.	  
• No	  history	  or	  clinical	  diagnosis	  of	  COPD,	  asthma	  or	  allergic	  rhinitis.	  
• Post-­‐bronchodilator	  FEV1	  >80%	  predicted	  for	  age	  and	  height.	  
• Post-­‐bronchodilator	  FEV1/FVC	  ratio	  >70%.	  Exclusion	  criteria	  
• Subjects	  with	  a	  history	  of	  self-­‐reported	  upper	  or	  lower	  respiratory	  tract	  infection	  or	  antibiotic	  use	  in	  the	  prior	  three	  months.	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• Subjects	  with	  any	  clinically	  relevant	  or	  significant	  systemic	  disease.	  
2.1.3 COPD	  Control	  Subjects	  Inclusion	  criteria	  
• Aged	  over	  40	  years.	  
• Medical	  history	  or	  clinical	  diagnosis	  of	  COPD	  (GOLD	  Stage	  II).	  
• No	  history	  of	  asthma	  or	  allergic	  rhinitis.	  
• Cumulative	  smoking	  history	  of	  over	  20	  pack	  years.	  
• Post-­‐bronchodilator	  FEV1	  ≤80%	  and	  ≥50%	  predicted	  for	  age	  and	  height.	  
• Post-­‐bronchodilator	  FEV1/FVC	  ratio	  less	  than	  70%.	  
• β-­‐agonist	  reversibility	  of	  less	  than	  12%	  predicted	  FEV1	  and	  200ml.	  
• Absence	  of	  current	  or	  previous	  history	  of	  significant	  respiratory	  disease	  (except	  COPD).	  Exclusion	  criteria	  
• Subjects	  with	  a	  history	  of	  self-­‐reported	  upper	  or	  lower	  respiratory	  tract	  infection	  or	  antibiotic	  use	  in	  the	  prior	  three	  months.	  
• Subjects	  with	  any	  clinically	  relevant	  or	  significant	  systemic	  disease.	  
2.2 Subject	  Assessment	  and	  Sample	  Collection	  At	   baseline,	   as	   part	   of	   the	   standard	   clinical	   work-­‐up,	   a	   full	   history	   and	   clinical	  examination	  was	  performed	  on	  all	  patients.	  All	  patients	  underwent;	   full	   lung	   function	  testing,	  pulmonary	  exercise	   testing,	  6	  minute	  walk	   testing	   (6MWT)	  	  echocardiography	  and	   high	   resolution	   CT	   scanning.	   All	   patients	   had	   serological	   testing	   for	   common	  precipitins,	  an	  autoimmune	  profile,	  a	  coagulopathy	  screen	  and	  brain	  naturetic	  peptide	  measured.	  	  
2.2.1 Pulmonary	  Function	  Testing	  Full	   pulmonary	   function	   testing	   was	   performed	   within	   the	   Royal	   Brompton	   Hospital	  lung	   function	   laboratory	  at	  baseline	  and	  every	  six	  months.	   	  Testing	  was	  conducted	  by	  Association	   for	   Respiratory	   Technology	   and	   Physiology	   (ARTP)	   accredited	   NHS	   staff	  according	   to	   established	   protocols.	   Spirometry,	   DLCO,	   KCO,	   plethysmography	   and	  arterial	  blood	  gases	  were	  performed	  on	  all	  subjects.	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2.2.2 Fibre-­‐optic	  bronchoscopy	  with	  Bronchoscopic	  Alveolar	  Lavage	  (BAL)	  Prior	  to	  each	  bronchoscopy	  informed	  consent	  was	  obtained	  and	  adequate	  intravenous	  access	   and	   appropriate	   monitoring	   (SpO2	   and	   pulse)	   were	   present	   throughout.	  Following	   sedation	   with	   Midazolam	   and	   topical	   Xylocaine	   anaesthesia	   to	   the	  oropharynx,	   bronchoscopy	   was	   performed	   via	   the	   oral	   route.	   The	   vocal	   cords	   and	  bronchial	   tree	   were	   anaesthetized	   with	   topical	   2%	   Lidocaine	   and	   the	   bronchoscope	  wedged	  in	  the	  right	  middle	  lobe	  bronchus.	  Suction	  was	  stopped	  and	  under	  direct	  vision	  60	  ml	  of	  warm	  saline	  was	  slowly	  instilled	  from	  a	  syringe	  and	  then	  manually	  re-­‐aspirated	  by	   gently	   drawing	   back	   on	   the	   plunger	   of	   the	   60	  ml	   syringe.	   This	   process	   was	   then	  repeated	  a	  further	  3	  times	  (total	  volume	  instilled	  240	  ml).	  A	  further	  syringe	  was	  used	  to	  aspirate	  any	  remaining	  fluid.	  	  All	  return	  samples	  were	  pooled	  into	  a	  200	  ml	  falcon	  tube	  on	   ice.	   BAL	   was	   undertaken	   prior	   to	   visual	   inspection	   of	   the	   bronchial	   tree	   and	   in	  advance	  of	   any	  other	  planned	  bronchoscopic	  procedures.	  BAL	   fluid	  was	  examined	   for	  the	  presence	  of	  macrophages	   to	   confirm	  access	   of	   the	   alveolar	   compartment,	   and	   the	  absence	  of	  ciliated	  epithelium	  was	  used	  to	  exclude	  large	  airway	  contamination.	  Patients	   were	   monitored	   for	   2–4	   hours	   post	   bronchoscopy	   until	   they	   had	   recovered	  from	  sedation	  and	  the	  effects	  of	  the	  topical	  anaesthesia	  had	  worn	  off.	  To	   control	   for	   any	   potential	   contamination	   at	   the	   time	   of	   bronchoscopy,	   or	   during	  processing,	   negative	   control	   samples	   were	   collected	   by	   aspirating	   buffered	   saline	  through	   the	   bronchoscope	   suction	   channel	   prior	   to	   bronchoscopy.	   	   This	   was	   then	  processed	  in	  parallel	  with	  the	  patient	  BAL	  samples.	  
2.2.3 Sampling	  of	  Blood	  for	  DNA	  Samples	  of	  whole	  blood	  were	  collected	  into	  pre-­‐labelled	  EDTA	  vacutainers	  by	  standard	  venepuncture.	   Following	   collection	   the	   samples	   were	   inverted	   8-­‐10	   times	   and	   then	  stored	  at	  -­‐80oC	  prior	  to	  DNA	  extraction.	  
2.2.4 Sampling	  of	  Blood	  for	  RNA	  Two	  pre-­‐labelled	  2.5ml	  PAXgene	  Blood	  RNA	  tubes	  were	  collected	  from	  each	  patient	  by	  standard	   venepuncture.	   The	   PAXgene	  Blood	  RNA	   tubes	  were	   the	   last	   tubes	   drawn	   in	  any	   series	   and	   if	   a	   PAXgene	  Blood	  RNA	  Tube	  was	   the	   only	   tube	   to	   be	   drawn	   a	   small	  volume	  of	  blood	  was	  drawn	  into	  the	  supplied	  "Discard	  Tube"	  prior	  to	  collection	  of	  the	  main	  sample.	  After	  collection	  the	  PAXgene	  Blood	  RNA	  tubes	  were	  incubated	  for	  2	  hours	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at	  room	  temperature	   in	  order	  to	  ensure	  complete	  penetration	  of	   the	  PAXgene	  reagent	  into	  the	  blood	  cells.	  	  The	  tubes	  were	  then	  frozen	  at	  -­‐20oC	  for	  24	  hours	  before	  transfer	  to	  -­‐80oC	  for	  long	  term	  storage	  prior	  to	  RNA	  extraction.	  
2.3 Bacterial	  16S	  rRNA	  Gene	  Analysis	  	  
2.3.1 DNA	  Extraction	  DNA	  extraction	  optimisation	  experiments	  previously	  performed	  within	  the	  group	  (data	  unpublished)	   had	   determined	   that	   the	   MPBIO	   FastDNA®	   SPIN	   Kit	   for	   Soil	   produced	  consistently	  good	  yields	  of	  DNA	  of	  high	  quality	  for	  all	  sample	  types.	  	  This	  particularly	  kit	  also	  has	  the	  advantage	  of	  having	  a	  better	  safety	  profile	  than	  the	  phenol	  chloroform	  and	  spin	   kit	   protocols	   that	   had	   been	   trialled.	   For	   this	   study	   all	   DNA	   extractions	   were	  therefore	  performed	  using	  the	  MPBIO	  FastDNA®	  SPIN	  Kit	  for	  Soil.	  The	  Lysing	  Matrix	  E	  (LME)	   tubes	   used	   in	   the	   protocol	   contains	   a	   mixture	   of	   ceramic	   and	   silica	   particles	  designed	  to	  efficiently	  lyse	  organisms,	  ensuring	  a	  representative	  whole	  community	  DNA	  extraction.	  Two	  2	  ml	  aliquots	  of	  BAL	  fluid	  were	  centrifuged	  at	  20,000	  g	  for	  15	  minutes	  to	  pellet	  cell	  debris	   and	   bacteria.	   Each	   pellet	   was	   then	   re-­‐suspended	   in	   489	   μl	   Sodium	   Phosphate	  Buffer	  (MPBIO	   first	   lysis	  buffer	  solution)	  and	  transferred	  to	  a	  LME	  tube	  where	  122	  μl	  MT	  Buffer	  was	  added	  to	  protect	  nucleic	  acids	  upon	  cell	   lysis.	  Homogenisation	  and	  cell	  lysis	   then	   took	   place	   in	   the	   Precellys	   24	   bead-­‐beater	   (PeqLab,	   UK)	   6,000	   rpm	   for	   30	  seconds	  twice.	  The	  samples	  were	  then	  centrifuged	  at	  14,000	  g	  for	  15	  minutes	  to	  pellet	  cell	  debris.	  The	  supernatant	  was	  transferred	  to	  a	  new	  eppendorf	  and	  250	  μl	  of	  Protein	  Precipitation	  Solution	  added	  and	  the	  sample	  mixed	  by	  inverting	  10	  times.	  The	  protein	  released	   from	   the	   cell	   lysis	   step	  was	   precipitated	   by	   centrifugation	   at	   14,000	   g	   for	   5	  minutes	  and	  the	  supernatant	  transferred	  to	  a	  15ml	  tube.	  	  One	  ml	  of	  DNA	  Binding	  matrix	  suspension	  was	  added.	  The	  tube	  was	  inverted	  by	  hand	  for	  2	  minutes	  to	  allow	  binding	  of	  DNA	  and	  then	  placed	  in	  a	  rack	  for	  3	  minutes	  to	  allow	  settling	  of	  the	  bound	  silica	  matrix.	  Five	  hundred	  μl	  of	   the	   supernatant	  was	  discarded	  after	  which	   the	  DNA	  bound	  matrix	  was	   re-­‐suspended	   in	   the	   remaining	  supernatant.	  Eight	  hundred	  μl	  of	   the	  mixture	  was	  transferred	  to	  a	  SPIN™	  Filter	  and	  centrifuged	  at	  14,000	  g	  for	  1	  minute.	  The	  catch	  tube	  was	  emptied	  and	  the	  remaining	  mixture	  was	  added	  to	  the	  SPIN™	  Filter	  and	  centrifuged	  as	  before	  with	  discard	  of	  the	  flow	  through.	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To	   purify	   the	   sample	   500	   μl	   of	   prepared	   SEWS-­‐M	   solution	   was	   used	   to	   gently	   re-­‐suspend	  the	  pellet	  on	  top	  of	  the	  filter	  using	  the	  force	  of	  the	  liquid	  from	  the	  pipette	  tip.	  The	  column	  was	  then	  centrifuged	  at	  14,000	  g	  for	  1	  minute	  and	  the	  catch	  tube	  emptied	  and	  replaced.	  The	  spin	  column	  matrix	  was	  dried	  of	  residual	  wash	  solution	  with	  a	  second	  centrifugation	  at	  14,000	  g	  for	  2	  minutes	  and	  the	  catch	  tube	  again	  emptied	  and	  replaced.	  The	   SPIN™	   Filter	   was	   then	   air	   dried	   for	   1	   minute	   at	   room	   temperature	   before	   the	  addition	  of	   100	  μl	   of	  DNase/Pyrogen-­‐Free	  Water	   to	   re-­‐suspend	   the	  DNA	  pellet	   above	  the	   spin	   filter.	   The	   SPIN™	   Filter	   was	   then	   incubated	   at	   55˚C	   in	   a	   heat	   block	   prior	   to	  centrifugation	  at	  14,000	  g	  for	  1	  minute	  with	  collection	  of	  the	  eluted	  DNA	  into	  the	  clean	  eppendorf.	  The	  quantity	  of	  the	  extracted	  DNA	  was	  measured	  using	  a	  Thermo	  Scientific	  NanoDrop®	  and	  the	  DNA	  was	  stored	  at	  −80°C	  until	  further	  use.	  
2.3.2 Pyrosequencing	  of	  the	  V3-­‐V5	  Regions	  of	  Bacterial	  16S	  rRNA	  Gene	  To	  maximise	  the	  throughput	  capabilities	  of	  next	  generation	  sequencing	  systems	  (e.g.	  the	  Roche	  454	  platforms)	  multiple	  amplicons	  can	  be	  pooled	  and	  sequenced	   in	  one	  run	  by	  incorporating	   barcodes	   to	   uniquely	   label	   each	   sample.	   The	   Roche	   454	   Titanium	  pyrosequencing	   technology	   can	   be	   used	   on	   either	   the	   Roche	   GS	   Junior+,	   which	  generates	  up	  to	  70,000	  reads,	  or	   the	   larger	  GS	  FLX+	  system	  which	  can	  generate	  up	  to	  700,000	   reads	   per	   run.	   The	   GS	   Junior+	   can	   therefore	   multiplex	   40	   samples	   per	   run	  whilst	  the	  GS	  FLX+	  can	  process	  up	  to	  200	  samples.	  The	  author	  carried	  out	  all	  sample	  and	  library	  preparation	  as	  well	  as	  the	  sequencing	  on	  the	  Roche	  GS	  Junior+	  system	  with	  the	  exception	  of	  the	  library	  of	  samples	  in	  Chapter	  4.	  	  For	   that	   library	   the	   pyrosequencing	   was	   done	   on	   a	   GS	   FLX+	   system	   by	   the	   DNA	  Sequencing	   Facility	   at	   the	   University	   of	   Cambridge.	   	   All	   raw	   sequencing	   data	   was	  analysed	  by	  the	  author.	  
2.3.2.1	   PCR	  Amplification	  The	   16S	   rRNA	   gene	   was	   amplified	   using	   the	   reverse	   primer	   5′-­‐CCATCTCATCCCTGCGTGTCTCCGACTCAGNNNNNNNNNNNNCCGTCAATTCMTTTRAGT-­‐3′	  and	   the	   forward	   primer	   5′-­‐CCTATCCCCTGTGTGCCTTGGCAGTCTCAGCCTACGGGAGGCAGCAG-­‐3′.	   The	   reverse	  primers	  contain	  the	  A	  adaptor	  sequence	  for	  454	  sequencing	  (underlined),	  followed	  by	  a	  12	  nucleotide	  multiplex	  identifier	  barcode	  (represented	  as	  NNNNNNNNNNNN)	  used	  to	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tag	  each	  PCR	  product	  (Fierer	  et	  al.	  2008)	  and	  then	  the	  bacterial	  primer	  926R	  (italicized)	  (Muyzer	  et	  al.	  1995).	  The	  forward	  primer	  lacks	  the	  barcode	  but	  does	  contain	  an	  adaptor	  sequence	   (underlined)	   followed	  by	   the	   bacterial	   primer	   357F	   (italicized)	   (Muyzer,	   de	  Waal,	  and	  Uitterlinden	  1993).	  	  PCR	  reactions	  were	  prepared	  in	  a	  dedicated	  hood	  in	  which	  all	  surfaces	  and	  pipettes	  had	  been	   UV	   irradiated	   before	   use	   and	   cleaned	   with	   DNAZap	   to	   prevent	   contamination.	  Quadruplicate	  25	  µl	  PCR	  reactions	  were	  set	  up	  containing	  1µl	  of	  template,	  1	  µl	  Forward	  primer	  (10	  µM),	  1	  µl	  Reverse	  primer	  (10	  µM),	  0.5	  µl	  dNTP	  mix	  (10mM),	  1	  µl	  BSA	  (Sigma	  B8667	   20	  mg/ml),	   6.5	   µl	   Glycine	   betaine	   (1.3M),	   2.5	   µl	   FastStart	   10	   x	   Buffer,	   0.25	   µl	  FastStart	   HiFidelity	   Polymerase	   (5	   U/µl),	   11.25	   µl	   molecular	   biology	   grade	   water.	   A	  negative	   control	   was	   also	   included	   containing	   1	   µl	   of	   molecular	   biology	   grade	  water	  rather	  than	  template.	  Cycling	  conditions	  were	  one	  cycle	  of	  95°C	  for	  2	  minutes,	  then	  30	  cycles	  of	  94°C	  for	  20	  seconds,	  50°C	  for	  30	  seconds	  and	  72°C	  for	  5	  minutes.	  	  Replicate	   amplicons	  were	   pooled	   and	   5	   µl	   visualized	   on	   a	   2%	   agarose	   gel	   to	   confirm	  amplification	  and	  verify	  the	  negative	  PCR	  control.	  
2.3.2.2	   Agarose	  Gel	  Electrophoresis	  Gels	  were	  prepared	  using	  agarose	  (Sigma-­‐Aldrich)	  at	  a	  concentration	  of	  2%	  in	  1X	  Tris-­‐Borate-­‐EDTA	  buffer	  (TBE)	  (Sigma-­‐Aldrich).	  One	  µl	  of	  Gel	  Red	  (Biotium,	  Cambridge,	  UK)	  was	   added	   directly	   to	   the	   gel	   solution	   which	   was	   then	   poured	   into	   the	   gel-­‐casting	  platform	  around	  the	  comb	  and	  allowed	  to	  solidify	  at	  room	  temperature	  for	  30	  minutes.	  A	  100-­‐bp	  DNA	  ladder	  (New	  England	  Biolabs,	  UK)	  was	  used	  as	  a	  molecular	  size	  marker	  with	   each	   run	   and	   samples	  were	   electrophoresed	   in	   a	   1X	  TBE	  buffer	   at	   100	  V	   for	   40	  minutes.	  Gels	  were	  exposed	   to	  an	  ultraviolet	   transilluminator	   to	  visualize	  appropriate	  bands.	  
2.3.2.3	   Purification	  of	  Amplicons	  The	  pooled	  amplicons	  were	  bead	  purified	  using	  Agencourt®	  AMPure®	  XP	  purification	  kit	   protocol	   as	   per	   manufacturer	   instructions	   (Beckman	   Coulter).	   This	   allowed	   the	  efficient	   removal	   of	   unincorporated	   dNTPs,	   primers,	   primer	   dimers,	   salts	   and	   other	  contaminants.	   Additionally	   the	   ratio	   of	   Solid	   Phase	   Reversible	   Immobilisation	   (SPRI)	  beads	   to	   DNA	   was	   altered	   to	   0.7	   in	   order	   to	   preferentially	   recover	   and	   retain	   the	  amplified	  16S	  product.	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Prior	  to	  use	  the	  AMPure	  bead	  bottle	  was	  vortexed	  for	  20	  seconds,	  until	  the	  beads	  were	  completely	   resuspended.	   66.5	   μl	   of	   AMPure	   beads	  were	   added	   to	   each	  well	   (96-­‐well	  plate)	  containing	  the	  remaining	  95	  μl	  of	  pooled	  PCR	  product	  and	  mixed	  thoroughly	  by	  pipetting	  up	  and	  down	  at	  least	  12	  times	  to	  ensure	  homogeneity.	  The	  96-­‐well	  plate	  was	  then	  incubated	  for	  10	  minutes	  at	  room	  temperature,	  to	  bind	  the	  DNA	  to	  the	  beads.	  	  Next	  the	  plate	  was	  placed	  on	  the	  96-­‐well	  magnetic	  stand	  (Ambion	  #AM10027)	  and	  incubated	  for	  5	  minutes	  at	  room	  temperature	  or	  until	  all	  beads	  had	  been	  captured.	  With	  the	  plate	  still	  on	  the	  magnetic	  stand,	  the	  supernatant	  was	  carefully	  removed	  and	  discarded	   without	   disturbing	   the	   beads.	   The	   plate	   was	   removed	   from	   the	   magnetic	  stand	  and	  100	  μl	  of	  freshly	  prepared	  70%	  ethanol	  was	  added	  to	  each	  well,	  following	  by	  thorough	   pipetting	   to	   ensure	   the	   pellet	   was	   fully	   re-­‐suspended.	   The	   plate	   was	   then	  placed	  back	  on	   the	  magnetic	  stand	  and	   incubated	   for	  1	  minute,	   the	  supernatant	  again	  discarded	  and	  the	  100	  μl	  70%	  ethanol	  wash	  step	  repeated.	  Following	  this	  the	  plate	  was	  incubated	   on	   the	  magnetic	   stand	   for	   10	  minutes	   to	   completely	   dry	   the	   pellets,	  which	  were	   then	   re-­‐suspended	   by	   pipetting	   in	   50	   μl	   of	   1x	   TE,	   releasing	   the	   washed	   and	  purified	   DNA	   from	   the	   beads.	   The	   plate	   was	   then	   placed	   on	   the	  magnetic	   stand	   and	  incubated	   for	   a	   final	   2	  minutes	   following	  which	   the	   supernatant	   from	   each	  well	   was	  transferred	  into	  a	  fresh	  96-­‐well	  PCR	  plate.	  
2.3.2.4	   Quantification	  of	  Purified	  PCR	  Products	  The	  purified	  PCR	  products	  were	  quantified	  in	  order	  to	  allow	  equi-­‐molar	  pooling	  prior	  to	  pyrosequencing.	   Quantification	   was	   done	   by	   fluorometry	   using	   the	   Quant-­‐iT™	  PicoGreen®	   dsDNA	   Assay	   Kit	   (Invitrogen).	   A	   standard	   curve	   was	   generated	   by	  performing	   seven	   serial	   dilutions	   of	   the	   provided	   DNA	   standard	   in	   1x	   TE	   as	   per	   the	  manufacturer’s	  protocol	  (Table	  2.1).	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Tube	  #	   DNA	  Concentration	  Tube	  1	   100	  ng/well	  Tube	  2	   50	  ng/well	  Tube	  3	   25	  ng/well	  Tube	  4	   12.5	  ng/well	  Tube	  5	   6.25	  ng/well	  Tube	  6	   3.13	  ng/well	  Tube	  7	   1.56	  ng/well	  Tube	  8	   0	  ng/well	  
Table	   2.1:	   Quant-­‐iT™	   PicoGreen®	   dsDNA	   Assay	   Kit	   DNA	   standards.	   Seven	   serial	  dilutions	  are	  used	  to	  produce	  the	  standard	  curve	  for	  each	  reaction.	  The	   standard	   curve	   was	   generated	   in	   duplicate	   and	   100	   μl	   of	   each	   DNA	   standard	  dilution	   was	   then	   transferred	   to	   the	   wells	   of	   column	   11	   and	   12	   of	   a	   96-­‐well	   black	  fluorometer	  plate.	  The	  remaining	  80	  wells	  of	  the	  96-­‐well	  black	  fluorometer	  plate	  were	  filled	  with	  99	  μl	  of	  1x	  TE	  and	  then	  1	  μl	  of	  each	  amplicon	  was	  added	  to	  the	  appropriate	  wells	   of	   the	   fluorometer	  plates	   and	  mixed	  by	  pipetting	  up	  and	  down	  4	   times,	   using	   a	  multichannel	  pipette	  set	  to	  100	  μl.	  A	  1:200	  dilution	  of	  PicoGreen	  reagent	  was	   freshly	  prepared	  and	  100	  μl	  added	  to	  each	  well	  and	  again	  mixed	  as	  before.	  The	   samples	   were	   excited	   at	   480	   nm	   and	   the	   fluorescence	   emission	   intensity	   was	  measured	   at	   520	   nm	   using	   a	   spectrofluorometer.	   The	   average	   fluorescence	   emission	  intensity	  across	   the	   two	  standard	  curves	  at	  each	  DNA	  concentration	  was	   then	  plotted	  against	  DNA	  concentration	  to	  verify	  that	  the	  R2	  value	  of	  the	  standard	  curve	  was	  at	  least	  0.98	  and	  therefore	  reliable	  (Figure	  2.2).	  The	  concentration	  of	  the	  unknown	  samples	  was	  calculated	  using	  the	  gradient	  of	  the	  slope.	  If	  any	  sample	  readings	  exceeded	  the	  highest	  standard	  curve	  value,	  they	  were	  diluted	  and	  re-­‐quantified.	  	  Repeat	  measurements	  were	  performed	   in	   order	   to	   verify	   the	   concentration	   for	   any	   instances	   when	   a	   sample’s	  reading	  was	  <	  5	  ng/μl.	  	  If	  still	  <5	  ng/	  μl	  the	  PCR	  and	  purification	  steps	  were	  repeated.	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Figure	  2.2:	  Example	  standard	  curve.	  The	  concentration	  of	  unknown	  samples	  can	  be	  calculated	  using	  the	  standard	  curve	  slope	  equation.	  
2.3.2.5	   Pooling	  of	  Samples	  Quantified	  samples	  were	  then	  pooled	  in	  an	  equi-­‐molar	  fashion	  so	  that	  each	  sample	  was	  represented	   equally	   in	   the	   pool	   and	   to	   ensure	   no	   one	   sample	   was	   preferentially	  amplified	   in	   the	  emulsion	  PCR	  step.	  The	   spread	  of	   concentrations	  of	   the	  purified	  PCR	  products	   was	   visually	   inspected.	   For	   each	   pool	   a	   value	   in	   ng/μl	   was	   selected	   and	  appropriate	   volumes	   of	   each	   purified	   PCR	   product	   added	   to	   achieve	   this	   value.	   The	  value	  was	  picked	   to	   enable	   accurate	  pipetting	  volumes,	   all	   above	  1	  μl,	   and	   so	   that	  no	  more	  than	  10	  μl	  of	  any	  sample	  was	  added	  to	  the	  pool.	  The	  pool	  was	  then	  purified	  using	  the	  Agencourt®	  AMPure®	  XP	  purification	  kit	  protocol	  (Section	   2.1.1.2).	   Forty	   five	   μl	   of	   the	   pooled	   products	  were	   combined	  with	   31.5	   μl	   of	  AMPure	  beads,	  purified	  and	  eluted	  in	  45	  μl	  of	  TE,	  and	  then	  re-­‐purified	  in	  the	  exact	  same	  manner.	  The	  final	  elution	  was	  in	  10	  μl	  of	  TE.	  The	  purified	  pool	  was	  then	  re-­‐quantified,	  in	  duplicate,	   using	   the	   Quant-­‐iT™	   PicoGreen®	   dsDNA	   Assay	   Kit	   (Section	   2.1.1.3).	   An	  average	  of	   the	   two	  quantifications	  was	   then	  taken	  and	  this	  concentration	  was	  used	  to	  calculate	  the	  number	  of	  molecules/μl	  using	  the	  following	  equation.	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Molecules/μl= Sample	  concentration	  (ng/μl)	  x  6.022x10!"656.6x10!	  x	  569	  (amplicon	  length	  (basepairs)) .	  The	  pool	  was	  then	  diluted	  down	  to	  2	  x	  105	  molecules	  per	  µl	  and	  from	  this	  point	  onwards	  is	  referred	  to	  as	  the	  library.	  
2.3.2.6	   Emulsification	  PCR	  (emPCR)	  and	  Sequencing	  The	   Roche	   emPCR	   Amplification	   (Lib-­‐L)	   kit	   was	   used	   to	   isolate	   individual	   DNA	  molecules	   along	   with	   primer-­‐coated	   beads	   in	   aqueous	   droplets	   to	   allow	   clonal	  amplification	  of	  each	  DNA	  molecule	  by	  PCR	  to	  coat	  each	  bead.	  This	  was	  performed	  as	  per	  the	  manufacturer’s	  guidelines.	  Prior	  experience	  determined	  the	  optimum	  number	  of	  molecules	  of	   library	  DNA	  per	  Capture	  Bead	  to	  be	  0.35,	  as	   this	  yields	  bead	  enrichment	  between	  5%	  and	  20%,	  and	  generates	  satisfactory	  sequencing	  results	  (Molyneaux	  et	  al.	  2013).	  The	  following	  equation	  	  
Volume	  of	  library	  =	   0.35	  (Desired	  molecules	  per	  bead)	  x	  10,000,000	  (total	  beads)2x10!(Library	  concentration) 	  was	  used	  to	  establish	  that	  17.5	  µl	  of	  Library	  was	  required.	  The	   Library	   was	   combined	   with	   capture	   beads	   and	   enzyme	   mix	   and	   suspended	   in	  emulsification	  oil	  prior	  to	  undergoing	  PCR.	  The	  thermo-­‐cycling	  conditions	  were	  altered	  from	   the	   original	   manufacturer’s	   recommendations	   in	   order	   to	   ensure	   a	   longer	   read	  length.	  Cycling	  conditions	  were	  therefore	  one	  cycle	  of	  94°C	  for	  4	  minutes	  and	  then	  50	  cycles	  of	  94°C	  for	  30	  seconds,	  60°C	  for	  10	  minutes,	  followed	  by	  a	  2	  hour	  10°C	  hold.	  The	   beads	   were	   recovered	   using	   a	   Vacuum-­‐Assisted	   Emulsion	   Breaking	   Set	   Up	   and	  sequentially	   washed	   in	   isopropanol,	   enhancing	   buffer	   and	   ethanol.	   Bead	   enrichment	  then	   occurred	   following	  which	   the	   GS	   Junior	   Bead	   Counter	  was	   used	   to	   evaluate	   the	  amount	   of	   enriched	   beads.	   The	   recommended	   input	   bead	   number	   for	   a	   GS	   Junior	  sequencing	  run	  is	  500,000	  enriched	  beads.	  The	   Roche	   GS	   Junior	   Titanium	   Sequencing	   kit	   was	   then	   used	   to	   load	   the	   500,000	  enriched	   beads	   onto	   the	   PicoTiterPlate	   (PTP)	   and	   prepare	   the	   Roche	   454	   GS	   Junior	  Instrument.	  The	  Roche	  454	  GS	  Junior	  Instrument	  was	  prepared	  for	  pyrosequencing	  by	  washing	   the	   instrument’s	   fluidics	   with	   the	   supplied	   Pre-­‐wash	   buffer,	   removing	   the	  previous	   runs	   PTP	   cartridge,	   changing	   the	   sipper	   tubes	   and	   finally	   priming	   the	  instrument	  with	  the	  sequencing	  reagents	  and	  buffers.	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The	  barcode	   identifiers	   of	   the	   emPCR	  kit,	   sequencing	  kit	   and	  PTP	  plate	  were	   entered	  into	  the	  GS	  Junior	  Instrument	  Procedure	  window.	  Full	  processing	  for	  amplicons	  and	  200	  hundred-­‐nucleotide	  cycles	  were	  selected	  to	  achieve	  read	  lengths	  of	  over	  500bp.	  
2.3.2.7	   Quality	  Control	  (QC)	  The	   GS	   Run	   Browser	   (Roche)	   was	   used	   to	   process	   the	   raw	   image	   and	   automatically	  perform	  a	  number	  of	  QC	  steps.	  The	  Browser	  first	  counts	  the	  number	  of	  raw	  wells	  that	  appear	  as	  a	  bright	  spot	  on	  the	  background	  of	  the	  Pico-­‐Titer-­‐Plate	  (PTP)	  (Figure	  2.3).	  	  
	  
Figure	  2.3	  The	  GS	  run	  browser	  view	  of	  a	  PTP.	  The	  whole	  plate	  is	  pictured	  on	  the	  left	  hand	  side,	  with	  a	  magnified	  view	  on	  the	  right	  where	  individual	  wells	  can	  be	  seen.	  Green	  dots	  represent	  passed	  filter	  wells,	  while	  red	  dots	  represent	  failed	  wells.	  The	  raw	  well	  count	   indicates	  the	  total	  number	  of	  reads	  and	  should	  be	  250,000.	  Reads	  which	  do	  not	  start	  with	  a	  valid	  4-­‐base	  sequence	  corresponding	  to	  either	  a	  Library	  read	  (TCAG)	  or	   a	  Control	  DNA	   read	   (CATG)	   are	  discarded.	  The	  number	  of	   reads	  discarded	  should	   not	   exceed	   10%	   of	   the	   raw	   well	   count	   if	   they	   do	   then	   the	   run	   should	   be	  discarded.	  The	  flowgrams	  are	  interrogated	  next	  and	  reads	  which	  have	  ambiguous	  flows:	  too	  many	  nucleotide	  incorporations,	  signal	  contamination	  from	  a	  neighbouring	  well	  or	  a	  low	   signal-­‐to-­‐noise	   ratio	   well;	   are	   excluded	   (mixed	   filter).	   Three	   consecutive	   flows	  without	  an	  incorporation	  is	  recorded	  as	  a	  dot	  and	  reads	  which	  have	  over	  5%	  dots	  are	  also	  rejected	  (dot	   filter).	  Dot	  and	  Mixed	  filter	  reads	  suggest	  technical	  problems	  within	  the	  raw	  flowgram	  and	  this	  number	  should	  be	  <20%	  of	  the	  total	  number	  of	  passed	  filter	  wells.	  The	  signal	  intensity	  degrades	  over	  the	  course	  of	  a	  pyrosequening	  run,	  resulting	  in	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lower	   quality	   signal	   intensity	   towards	   the	   3’	   end.	   Consequently	   after	   the	   read	  rejection/QC	  steps	  above	  low	  quality	  reads	  are	  trimmed	  from	  the	  3’	  end	  and	  primer	  and	  adaptor	  sequences	  are	  removed.	  At	  this	  point	  further	  reads	  are	  then	  rejected	  if	  they	  are	  far	  shorter	  than	  expected	  fragment	  length.	  	  Following	  these	  stringent	  filtering	  algorithms	  ensure	  better	  results	  and	  at	  the	  end	  of	  the	  process	  between	  50,000	  and	  80,000	  high	  quality	  reads	  will	  remain	  (Table	  2.2).	  	  
Amplicon	  Benchmark	   Value	  
Total	  raw	  wells	   ≤250,000	  
Total	  Key	  Pass	   >90%	  
Mixed	  +	  Dots	   <20%	  
Trimmed/Too	  short	   30-­‐50%	  
Table	  2.2	  Predicted	  reads	  for	  an	  optimal	  454	  GS	  Junior	  sequencing	  run.	  Following	  stringent	  filtering	  between	  50	  and	  80,000	  of	  an	  initial	  250,000	  reads	  will	  remain.	  
2.3.2.8	   Data	  Analysis	  Prior	   to	   any	   further	   analysis	   a	   mapping	   file	   was	   generated	   containing	   all	   of	   the	  information	  about	  the	  samples	  necessary	  to	  perform	  the	  data	  analysis.	  The	  mapping	  file	  contained	   the	   names	   and	   barcode	   sequences	   used	   for	   each	   sample,	   the	   linker	   and	  primer	   sequence	   used	   for	   amplification	   and	   descriptive	   columns	   containing	   the	  metadata	  associated	  with	  each	  sample.	  The	  remaining	  (post	  QC)	  barcoded	  pyrosequence	  reads	  were	  imported	  into	  QIIME	  1.7.0	  	  (Caporaso,	   Kuczynski,	   et	   al.	   2010)	   where	   the	   mapping	   file	   was	   used	   to	   assign	   the	  multiplexed	  reads	  to	  samples	  based	  on	  their	  nucleotide	  barcode.	  Sequence	  reads	  were	  also	  removed	  at	  this	  stage	  if	  they	  contained	  ambiguous	  bases,	  contained	  mismatches	  in	  the	  primer	  sequences,	  homopolymer	  runs	  or	  a	  mean	  window	  quality	  score	  less	  than	  25.	  Pyrosequencing	   technology	   produces	   characteristic	   sequencing	   errors,	   mostly	  imprecise	   signals	   for	   longer	   homopolymers	   runs.	   Sequences	   containing	   these	   errors	  could	  be	  classified	  as	  an	  additional	  rare	  OTU,	  so	  a	  denoising	  procedure	  was	  to	  used	  to	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reduce	  sequencing	  errors	  (Quince	  et	  al.	  2009).	  Following	  this	  ChimeraSlayer	  was	  used	  to	  remove	  PCR	  generated	  artefacts	  (Haas	  et	  al.	  2011).	  The	  remaining	  high	  quality	  sequence	  reads	  were	  clustered	  into	  Operational	  Taxonomic	  Units	   (OTUs)	   at	   97%	   identity	   (Edgar	   2010).	   At	   this	   level	   of	   sequence	   similarity	   each	  resulting	   cluster	   approximates	   to	   classical	   bacterial	   taxonomy.	   As	   each	   OTU	   may	   be	  made	  up	  of	  many	  related	  sequences,	  a	  representative	  sequence	  from	  each	  OTU	  is	  picked	  for	  downstream	  analysis.	  This	  representative	  sequence	  was	  then	  aligned	  to	  full	   length	  16S	   rRNA	   sequences	   (Caporaso,	   Bittinger,	   et	   al.	   2010)	   and	   assigned	   a	   taxonomic	  identity	   with	   the	   Ribosomal	   Database	   Project	   classifier	   (Q.	   Wang	   et	   al.	   2007).	   Next	  phylogenetic	  trees	  were	  constructed	  using	  FastTree2	  (Price,	  Dehal,	  and	  Arkin	  2010).	  To	  allow	   comparisons	   of	   diversity	   between	   samples	   (β-­‐diversity)	   and	   for	   Principal	  Coordinate	  Analysis	  (PCoA)	  the	  data	  was	  rarefied.	  Rarefaction	  is	  an	  ecological	  approach	  that	   allows	   standardization	   of	   data	   obtained	   from	   samples	   sequenced	   to	   differing	  depths.	  Metastats	   was	   used	   to	   perform	   non-­‐parametric	   t-­‐test	   comparisons	   of	   microbial	  communities	   between	   groups	   (White,	   Nagarajan,	   and	   Pop	   2009),	   with	   P-­‐values	  corrected	   for	   multiple	   hypotheses	   testing	   using	   the	   FDR	   approach	   of	   Benjamini	   and	  Hochberg	   (Benjamini,	   Yoav	   and	  Hochberg	  1995).	   Testing	  was	   restricted	   to	  OTUs	   that	  had	   a	   differing	  mean	   abundance	   between	   cases	   and	   controls	   of	  more	   than	   1%	  of	   the	  total.	   Shannon’s	   entropy	   (Shannon	   2001)	   (alpha	   diversity	   index)	   and	   weighted	   and	  unweighted	  UniFrac	  distances	   (Lozupone,	  Hamady,	   and	  Knight	  2006)	   (beta	  diversity)	  were	  calculated	  in	  QIIME.	  Representative	   sequences	   (most	   common)	   from	   each	   OTU	   of	   interest	   were	   aligned	  using	   the	   online	   SINA	   aligner	   (http://www.arb-­‐silva.de/aligner/)	   and	   then	   imported	  into	  the	  ARB	  phylogenetic	  package	  (http://www.arb-­‐home.de/)	  running	  on	  Biolinux	  6.0	  (http://nebc.nerc.ac.uk/tools/bio-­‐linux/bio-­‐linux-­‐6.0).	   Alignments	   were	   merged	   with	  the	   reference	   Silva	   alignment	   (SSURef_108)	   and	   the	   375	   bp	   region	   between	   the	  
Escherichia	  coli	   reference	  positions	   533	   and	  908	  used	   to	   generate	   phylogenetic	   trees.	  Phylogenetic	   trees	   of	   the	   OTU	   sequences	   and	   nearest	   neighbours	   were	   constructed	  using	  ARB's	  neighbour-­‐joining	  package	  with	  1,000	  bootstrap	  replicates	  and	  rooted	  with	  out-­‐groups	   from	  related	  bacterial	   families.	  This	  more	   intensive	  phylogenetic	  approach	  was	  performed	  to	  maximize	  the	  confidence	  of	  the	  identification	  of	  OTUs	  of	  interest.	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2.3.3 16s	  qPCR	  To	  assess	  the	  quantity	  of	  16S	  bacteria	  in	  each	  sample	  qPCR	  was	  performed.	  There	  are	  multiple	  Taqman	  and	  SyberGreen	  based	  assays	  to	  quantify	  the	  16S	  gene,	  but	  all	  amplify	  very	  small	  fragments,	  typically	  under	  200	  bp,	  using	  different	  primers	  to	  those	  used	  for	  pyrosequencing	  (Nadkarni	  et	  al.	  2002;	  S.	  Yang	  et	  al.	  2002;	  Zemanick	  et	  al.	  2010).	  Ideally	  quantification	   and	   sequencing	   would	   be	   performed	   using	   the	   same	   set	   of	   primers	  thereby	   ensuring	   what	   is	   quantified	   can	   actually	   be	   correlated	   to	   data	   generated	   by	  sequencing.	  The	  primers	  used	  for	  pyrosequencing	  produce	  a	  569	  bp	  fragment	  and	  span	  multiple	   hyper	   variable	   regions,	   so	   a	   more	   specific	   Taqman	   based	   system	   was	   not	  feasible.	   A	   SyberGreen	   based	   assay	   was	   therefore	   developed.	   A	   standard	   curve	   was	  generated	  using	  Pseudomonas	  aeruginosa	  01	  (PA01)	  strain	  DNA	  which	  has	  a	  known	  16S	  copy	  number	  and	  full	  genome	  sequence	  available.	  PCR	  conditions	  were	  optimised	  and	  validated	  prior	  to	  any	  quantification.	  
2.3.3.1	   Generation	  of	  a	  Standard	  Curve	  PA01	   strain	   DNA	   was	   amplified	   using	   the	   16S	   27F	   and	   1492R	   primers	   (Lane	   et	   al.	  1985).	  Triplicate	  PCR	  reactions	  were	  set	  up	  containing	  1	  µl	  of	   template,	  1	  µl	  Forward	  primer	  (10	  µM),	  1	  µl	  Reverse	  primer	  (10	  µM),	  0.5	  µl	  dNTP	  mix	  (10mM),	  1µl	  BSA	  (Sigma	  B8667	   20	  mg/ml),	   6.5	   µl	   Glycine	   betaine	   (1.3M),	   2.5	   µl	   FastStart	   10	   x	   Buffer,	   0.25	   µl	  FastStart	   HiFidelity	   Polymerase	   (5	   U/µl),	   11.25	   µl	   molecular	   biology	   grade	   water.	   A	  negative	  control	  was	  included	  containing	  1	  µl	  of	  molecular	  biology	  grade	  water	  rather	  than	  template.	  Cycling	  conditions	  were	  one	  cycle	  of	  95°C	  for	  2	  minutes,	  then	  30	  cycles	  of	  94°C	  for	  20s,	  50°C	  for	  30s	  and	  72°C	  for	  5	  minutes.	  The	   amplicons	  were	   pooled	   and	   run	   on	   a	   1%	   agarose	   gel	   (1g	   agarose	   per	   100ml	   1X	  Tris/Borate/EDTA	  (TBE)	  with	  1µl	  of	  Gel	  Red	  (10,0000x))	  to	  confirm	  amplification	  and	  verify	   the	   negative	   PCR	   control.	   The	   bands	   were	   excised	   and	   purified	   using	   the	  QIAquick®	  Gel	  extraction	  kit	  (Qiagen)	  as	  per	  the	  manufacturer’s	  protocols.	  The	  column	  purified	  PCR	  product	  was	  eluted	  in	  50µl	  of	  final	  elution	  buffer	  EB.	  The	   TOPO®	  TA	  Cloning®	  kit	   (Invitrogen)	  was	   then	   used	   to	   clonally	   amplify	   the	   PCR	  product.	  A	  master	  mix	  was	  prepared	  containing	  4	  µl	  of	  PCR	  product,	  1	  µl	  of	  salt	  solution	  and	  1	  µl	  of	  the	  II-­‐TOPO®	  Vector.	  This	  was	  incubated	  at	  room	  temperature	  for	  5	  minutes.	  One	  vial	   of	  One	  Shot®	  E.	   coli	   cells	  was	   thawed	  on	   ice	   and	  4	  µl	   of	   the	  mastermix	  was	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added,	  gently	  mixed	  and	  then	  incubated	  on	  ice	  for	  5	  minutes.	  Volumes	  of	  5,	  10,	  15	  and	  25	  µl	  of	  this	  mastermix	  were	  then	  plated	  onto	  four	  pre-­‐warmed	  LB	  plates	  containing	  X-­‐gal	   and	   50	   µl/ml	   of	   ampicillin.	   These	   were	   incubated	   at	   37oC	   overnight.	   Four	   white	  colonies	  were	  then	  picked	  and	  cultured	  in	  LB	  medium	  containing	  50	  µl/ml	  of	  ampicillin	  for	   another	   16	   hours	   at	   37oC.	   Plasmid	   DNA	   was	   isolated	   from	   the	   successfully	  transformed	  and	  cultured	  cells	  using	  the	  QIAprep®	  Spin	  Miniprep	  Kit	  (QIAgen)	  as	  per	  the	  manufacturer’s	  protocols.	  Quantity	  and	  quality	  of	  plasmid	  DNA	  was	  measured	  using	  the	  Thermo	  Scientific	  NanoDrop®	  (Table	  2.3).	  	  
	   ng/ul	   A260	   260/280	   260/230	  
Plasmid	  1	   423.57	   8.471	   2.02	   2.29	  
Plasmid	  2	   289.82	   5.796	   1.98	   2.23	  
Plasmid	  3	   382.05	   7.641	   1.94	   2.24	  
Plasmid	  4	   253.11	   5.062	   2	   2.25	  
Table	  2.3:	  Nanodrop	  results	  of	  the	  purified	  plasmid	  DNA.	  High	  yields	  of	  good	  quality	  DNA	  were	  obtained	  for	  all	  four	  plasmid	  preparations.	  The	  plasmid	  DNA	  was	  then	  Sanger	  sequenced	  at	  Eurofins	  Scientific,	  UK	  and	  the	  raw	  data	  returned	   for	   analysis.	   Using	   the	   recommended	   external	   Sp6	   Promoter	   (F)	   and	   T7	  promoter	  (R)	  for	  sequencing	  produces	  a	  large	  product	  of	  at	   least	  1542bp	  (Figure	  2.4).	  The	   quality	   of	   Sanger	   sequencing	   traces	   deteriorates	   after	   700-­‐900	   bases,	   so	   two	  internal	  primers,	  341F	  (Muyzer,	  de	  Waal,	  and	  Uitterlinden	  1993)	  and	  907R	  (Teske	  et	  al.	  1996),	   were	   also	   used	   to	   ensure	   an	   accurate	   sequence	   could	   be	   constructed	   by	   re-­‐assembling	  the	  contiguous	  sequences.	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Figure	   2.4:	   The	   pCR	   II-­‐TOPO®	  Vector.	  Demonstrating	   the	   insertion	   site	  of	   the	  PCR	  product	  and	  the	  location	  of	  the	  external	  promoter	  sequences	  Sp6	  (F)	  and	  T7	  (R)	  which	  were	  used	  for	  sequence	  verification.	  The	   aligned	   sequences	   had	   a	   length	   of	   1546bp	   and	   the	   consensus	   sequence	   aligned	  exactly	   to	   Pseudomonas	   aeruginosa	   PAO1,	   using	   the	   Pseudomonas	   Genome	   Database,	  with	  no	  mismatches.	  The	  purified	  PCR	  product	  was	  diluted	  down	   to	  a	  working	  concentration	  based	  on	   the	  nanodrop	   quantification	   (Table	   2.3)	   and	   quantified	   using	   the	   Quant-­‐iT™	   PicoGreen®	  dsDNA	  Assay	  Kit	   (Invitrogen)	   (Section	   2.1.1.3).	   Using	   the	   combined	   size	   of	   the	   insert	  (1546bp)	   and	   the	   size	   of	   the	   plasmid	   (3973bp)	   this	   then	   allowed	   calculation	   of	   the	  number	  of	  molecules/µl	  using	  the	  formula:-­‐	  
Molecules/μl= Sample	  concentration	  (ng/μl)	  x  6.022𝑥10!"656.6x10!	  x	  5519	  (amplicon	  length	  (basepairs)) .	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The	  working	  stock	  had	  2.4	  x	  1010	  copies	  of	  the	  16S	  gene	  per	  μl	  and	  from	  here	  two	  serial	  1/10	   dilutions	   were	   performed	   to	   produce	   a	   stock	   solution	   for	   the	   standard	   curve	  (Table	  2.4).	  Serial	  dilutions	  of	  the	  standard	  stock	  were	  made	  fresh	  each	  time.	  
Standard	   DNA	   Dilution	   molecules/µl	  1	   5μl	  Standard	   45μl	  Water	   2.40	  x	  108	  2	   5μl	  dilution	   45μl	  Water	   2.40	  x	  107	  3	   5μl	  dilution	   45μl	  Water	   2.40	  x	  106	  4	   5μl	  dilution	   45μl	  Water	   2.40	  x	  105	  5	   5μl	  dilution	   45μl	  Water	   2.40	  x	  104	  6	   5μl	  dilution	   45μl	  Water	   2.40	  x	  103	  
Table	  2.4	  Dilutions	  of	  working	  stock	  used	  to	  construct	  the	  qPCR	  standards.	  	  
2.3.3.2	   qPCR	  KAPA	  SYBR®	  FAST	  qPCR	  Kits	  (Kapa	  Biosystems,	  Woburn,	  MA)	  were	  used	  as	   the	  DNA	  polymerase	   has	   been	   engineered	   and	   optimized	   for	   qPCR	  with	   longer	   products	   (over	  500bp).	   The	   standard	   two	   step	   amplification	   process	   that	   the	   manufacturers	  recommend	  involves	  a	  combined	  annealing	  and	  extension	  phase	  at	  60oC.	  The	  357F	  and	  926R	  primers	  have	  an	  annealing	  temperature	  of	  50oC.	  A	  three	  step	  cycling	  protocol	  was	  therefore	  used.	  All	  optimisation	  was	  carried	  out	  using	  20	  μl	  reactions	  and	  this	  was	  then	  scaled	  down	  to	  a	  10	  μl	  total	  reaction	  volume.	  Initially	  1	  ul	  of	  each	  standard	  was	  added	  to	  the	   qPCR	   reaction	   but	   at	   the	   lower	   ladder	   concentrations	   the	   accuracy	   and	  reproducibility	   decreased	   significantly	   so	   the	   volume	   added	   to	   the	   reaction	   was	  increased	  to	  4.6μl,	  improving	  reproducibility	  and	  accuracy	  of	  standards.	  For	   the	   standard	   curve	   Triplicate	   10	   μl	   qPCRs	  were	   set	   up	   containing	   4.6	   μl	   of	   each	  standard,	  0.2	  μl	  of	  forward	  primer	  357F	  (10	  μM),	  0.2	  μl	  of	  reverse	  primer	  926R	  (10	  μM),	  5	  μl	  of	  KAPA	  SYBR	  FAST	  Universal	  2×	  qPCR	  master	  mix	  (Kapa	  Biosystems),	  and	  0.6	  μl	  of	  water.	   Identical	   triplicate	   10	  μl	   qPCRs	  were	   set	   up	   for	   each	   sample,	   but	   using	  1	   µl	   of	  sample	  and	  3.6	  µl	  of	  molecular	  biology	  grade	  water.	  Cycling	  conditions	  were:	  1	  cycle	  of	  95°C	  for	  3	  minutes;	  40	  cycles	  of	  94°C	  for	  20	  seconds;	  1	  cycle	  of	  50°C	  for	  30	  seconds;	  and	  1	   cycle	   of	   72°C	   for	   30	   seconds.	   	   Quantitative	   PCR	   reactions	   were	   performed	   on	   the	  Corbett	  rotor-­‐gene	  6000	  and	  analysed	  with	  Corbett	  rotor-­‐gene	  6.1	  software	  (Qiagen).	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The	   efficiency	   deduced	   from	   the	   slope	   of	   the	   standard	   curve	   (Vaerman,	   Saussoy,	   and	  Ingargiola	  2004)	  was	  93%	  with	  an	  amplification	  factor	  of	  1.93.	  Threshold	  cycle	  number	  (Ct)	   values	   are	   fractional	   cycle	   numbers	   where	   the	   amplification	   fluorescence	   levels	  reach	   a	   fixed	   threshold	   which	   is	   set	   at	   the	   same	   position	   for	   all	   reactions	   that	   are	  compared.	  A	   standard	  curve	  was	   then	  constructed	  by	  plotting	   the	   log	  of	   the	   standard	  copy	   numbers	   against	   the	   Ct	   values	   allowing	   Ct	   values	   of	   unknown	   samples	   to	   be	  converted	  to	  concentrations	  (Figure	  2.5).	  
	  
Figure	   2.5.	   Amplification	   plot	   of	   the	   standard	   curve.	   The	   reaction	   efficiency	  was	  93%.	  The	  six	  standards	  are	  in	  blue	  whilst	  the	  negative	  controls	  are	  shown	  in	  black.	  Non-­‐diluted	   samples	   were	   initially	   found	   to	   have	   Ct	   values	   less	   than	   5.	   Assays	   were	  therefore	  repeated	  using	  1	  in	  10	  dilutions	  of	  the	  samples	  (Figure	  2.6)	  with	  4.6	  μl	  of	  the	  dilutions	  used	  per	  reaction.	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Figure	  2.6:	  16S	  qPCR	  Assay.	  The	  reaction	  efficiency	  was	  93%.	  The	  six	  standards	  are	  in	  blue,	  while	  triplicates	  of	  three	  1	  in	  10	  dilutions	  of	  samples	  are	  in	  shown	  in	  red.	  After	  the	  qPCR,	  a	  dissociation	  curve	  (melting	  curve)	  was	  constructed	  in	  the	  range	  of	  65–95°C	  to	  check	  the	  quality	  of	  the	  qPCR	  (Figure	  2.7).	  	  
	  
Figure	   2.7:	   Melt	   Curve.	   The	   amplification	   of	   pure	   PA01	   strain	   sequence	   in	   the	  standards	   generates	   a	   smooth	   curve	   (blue),	   but	   the	   amplification	   of	   samples	   (green)	  generates	   a	   different	   melt	   curve	   due	   to	   the	   presence	   of	   multiple	   16S	   targets	   and	  therefore	  PCR	  products	  in	  the	  samples.	  There	  is	  no	  amplification	  of	  the	  negative	  control	  (black).	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The	   amplification	   of	   pure	   PA01	   strain	   sequence	   in	   the	   standards	   generates	   a	   smooth	  curve,	  but	  as	  anticipated,	  because	  there	  are	  multiple	  16S	  targets	  and	  therefore	  products	  present	   in	   the	  samples,	  amplification	  of	  samples	  generated	  a	  somewhat	  different	  melt	  curve.	   The	   amplified	   products	   were	   subsequently	   run	   on	   a	   2%	   agarose	   gel	   (Chapter	  2.1.1.2)	  to	  confirm	  amplification	  and	  verify	  that	  the	  negative	  control	  was	  truly	  negative	  (Figure	  2.8).	  
	  
Figure	   2.8:	   2%	  Agarose	   gel	   of	   the	   standard	   curve	   and	   negative	   controls.	  Lane	  1	  contains	  the	  gel	  ladder.	  Lanes	  2-­‐7	  contain	  the	  series	  of	  standards,	  most	  concentrated	  to	  least,	  and	  lane	  8	  contains	  the	  negative	  control.	  
2.4 DNA	  Extraction	  from	  Whole	  Blood	  The	   samples	   were	   defrosted	   at	   room	   temperature,	   thoroughly	   mixed	   and	   then	  transferred	  into	  a	  15	  ml	  Falcon	  tube	  containing	  9	  ml	  of	  Cell	  Lysis	  Solution.	  The	  tube	  was	  incubated	  at	  room	  temperature	  on	  a	  rocker	  (medium	  speed)	  to	  ensure	  efficient	  lysis	  of	  the	  red	  blood	  cells.	  The	  tubes	  were	  then	  centrifuged	  at	  2,000	  g	  for	  10	  minutes	  at	  room	  temperature	   to	   pellet	   the	   white	   blood	   cells.	   The	   supernatant	   was	   then	   carefully	  discarded	  (approximately	  50–100	  μl	  of	  supernatant	  was	  left	  to	  ensure	  the	  pellet	  was	  not	  disturbed).	  The	  tube	  was	  then	  vortexed	  vigorously	  until	  the	  white	  blood	  cells	  were	  re-­‐suspended	  after	  which	  3	  ml	  of	  Nuclei	  Lysis	  Solution	  was	  added	  to	  lyse	  the	  white	  blood	  cells	   and	   their	   nuclei.	   Incubation	   at	   37oC	   in	   a	   water	   bath	   for	   two	   hours	   ensured	  complete	  lysis	  after	  which	  15	  µl	  of	  RNase	  A	  was	  added	  with	  a	  further	  incubation	  of	  15	  minutes	   and	   then	   the	   tube	   was	   allowed	   to	   cool	   to	   room	   temperature.	   Next	   a	   salt-­‐
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precipitation	  was	  performed	  by	   the	   addition	  of	   3	  ml	   of	  Protein	  Precipitation	  Solution	  and	   vigorous	   vortexing	   for	   10-­‐20	   seconds.	   This	   results	   in	   the	  precipitation	  of	   protein	  whilst	   the	  high	  molecular	  weight	   genomic	  DNA	   remains	   in	   solution.	   Centrifugation	   at	  2,000	  g	  for	  10	  minutes	  resulted	  in	  pelleting	  of	  the	  precipitated	  protein	  after	  which	  the	  supernatant	   was	   transferred	   to	   a	   15	   ml	   centrifuge	   tube	   containing	   3	   ml	   room-­‐temperature	  isopropanol.	  Gentle	  mixing	  of	  the	  solution	  by	  inversion	  occurred	  until	  the	  white	   thread-­‐like	   strands	   of	   DNA	   formed	   a	   visible	   mass.	   The	   DNA	   was	   pelleted	   by	  centrifugation	   at	   2,000	   g	   for	   2	   minutes,	   the	   supernatant	   removed	   and	   3	   ml	   of	   70%	  ethanol	  added	  to	  wash	  the	  DNA.	  A	  further	  centrifugation	  at	  2,000	  g	  for	  2	  minutes	  was	  done	   and	   the	   ethanol	   carefully	   removed.	  The	  pellet	  was	   air	   dried	   for	  10	  minutes	   and	  then	  250	  µl	  of	  rehydration	  solution	  was	  added	  and	  the	  tube	  incubated	  overnight	  at	  4oC.	  
2.5 MUC5B	  Genotyping	  Genotypes	  of	  the	  MUC5B	  SNP	  rs35705950	  were	  determined	  using	  Taqman	  assays	  (Life	  Technologies).	  Reactions	  were	  carried	  out	  in	  384-­‐well	  plates,	  and	  fluorescence	  was	  read	  using	   an	   Applied	   Biosystems	   Viia7	   Sequence	   Detection	   System.	   Dr	   E.	   Murphy	   at	   the	  University	  of	  Colorado,	  USA,	  performed	  this	  work	  and	  raw	  data	  files	  were	  returned	  to	  Imperial	  College	  London	  for	  further	  analysis.	  
2.6 Gene	  Expression	  Analysis	  
2.6.1 RNA	  Isolation	  The	   PAXgeneTM	   Blood	   RNA	  Kit	   (QIAGEN)	  was	   used	   to	   isolate	   RNA	   from	  whole	   blood	  collected	   in	  PAXgene	  tubes.	  To	  maximise	   the	  yield	  and	  purity	  of	   the	  RNA	  the	  protocol	  was	  amended	  slightly	  in	  that	  during	  the	  final	  elution	  steps	  a	  second	  elution	  into	  a	  fresh	  tube	  was	  performed.	  This	  optimised	   the	  quality	  and	  concentration	  of	  RNA	   in	   the	   first	  sample.	   The	   first	   sample	   provided	   adequate	   amounts	   of	   high	   quality	   RNA	   to	   carry	  forwards	  to	  gene	  expression	  but	   if	  a	   further	  elution	   into	   the	  same	  collecting	   tube	  was	  done	   it	   decreased	   the	   quality	   and	   concentration	   of	   the	   RNA	   hence	   the	   protocol	  modification.	  This	   work	   was	   carried	   out	   in	   a	   designated	   pre-­‐amplification	   blood	   workspace.	   All	  surfaces	  were	  wiped	  with	  70%	  ethanol	  followed	  by	  RNase	  Zap	  (Sigma).	  RNA	  dedicated	  pipettes	   and	   pipette	   filter	   tips	  were	   used	   at	   all	   times	   to	   avoid	   contamination	   or	   RNA	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degradation.	   The	   PAXgene	   tubes	   were	   defrosted	   at	   room	   temperature	   and	   once	  completely	   thawed	   maintained	   for	   a	   further	   2	   hours	   at	   room	   temperature	   as	   per	  Qiagen’s	  recommendation.	  The	  PAXgene	  Blood	  RNA	  tubes	  were	  then	  centrifuged	  for	  10	  minutes	  at	  5,000	  g	  using	  a	  swing-­‐out	  rotor	  to	  pellet	   the	  nucleic	  acids.	  The	  supernatant	  was	  decanted	  and	  5	  ml	  of	  RNase-­‐free	  water	  was	   added	   and	   the	   pellet	   re-­‐suspended	   by	   vortexing.	   The	   PAXgene	  Blood	   RNA	   tubes	   were	   again	   centrifuged	   for	   10	   minutes	   at	   5,000	   g	   and	   the	   entire	  supernatant	   discarded.	   The	   pellet	   was	   then	   re-­‐suspended	   in	   360	   μl	   Buffer	   BR1	   by	  vortexing	  and	  transferred	  to	  a	  1.5	  ml	  eppendorf	  tube.	  Three	  hundred	  μl	  of	  Buffer	  BR2	  and	  40	  μl	  Proteinase	  K	  were	  added	  and	  after	  vortexing	  the	  tube	  was	   incubated	  for	  10	  minutes	  at	  55°C	  in	  a	  shaking	  incubator	  to	  allow	  protein	  digestion.	  The	  tubes	  were	  then	  centrifuged	  for	  3	  minutes	  at	  20,000	  g	  and	  the	  supernatant	  transferred	  to	  a	  fresh	  1.5	  ml	  eppendorf	  where	  350	  μl	  of	  100%	  ethanol	  was	  added.	  The	  sample	  was	  then	  applied,	   in	  700	  μl	  aliquots,	  to	  a	  PAXgene	  column	  sitting	  in	  a	  2	  ml	  processing	  tube,	  and	  centrifuged	  for	  1	  minute	  at	  8,000	  g,	  discarding	  the	  flow	  through	  each	  time.	  	  Having	   selectively	   bound	   the	   RNA	   to	   the	   PAXgene	   silica-­‐gel	   membrane	   any	  contaminating	   DNA	   present	   was	   then	   degraded	   by	   incubation	   with	   DNase	   I.	   A	   stock	  solution	   was	   prepared	   by	   dissolving	   solid	   DNase	   I	   (1500	   Kunitz	   units)	   in	   550	   µl	   of	  RNase	  free	  water.	  Ten	  µl	  of	  this	  DNase	  I	  stock	  solution	  was	  added	  to	  70	  µl	  of	  RDD	  buffer	  and	  the	  80	  µl	  pipetted	  into	  the	  centre	  of	  each	  PAXgene	  column	  membrane	  before	  being	  incubated	  for	  20	  minutes	  at	  room	  temperature.	  Any	  remaining	  contaminants	  were	  then	  removed	   in	   three	   efficient	   wash	   steps.	   Following	   each	   wash	   the	   collecting	   tube	  containing	   the	   flow	   through	   was	   discarded	   and	   the	   column	   transferred	   to	   a	   new	  collecting	   tube	   to	   minimize	   the	   risk	   of	   buffer	   carry	   over.	   Following	   the	   DNase	   I	  incubation	  350	  μl	  of	  Buffer	  BR3	  was	  added	  to	  the	  PAXgene	  column	  and	  centrifuged	  for	  1	  minute	   at	   8,000	   g	   then	   500	   μl	   of	   Buffer	   BR4	  was	   added	   to	   the	   PAXgene	   column	   and	  centrifuged	  for	  1	  minute	  at	  8,000	  g.	  Finally	  another	  500	  μl	  of	  Buffer	  BR4	  was	  added	  to	  the	  PAXgene	  column,	  which	  was	  centrifuged	  for	  3	  minutes	  at	  8,000	  g	  to	  dry	  the	  PAXgene	  column	  membrane.	  The	  RNA	  was	  then	  eluted	  into	  a	  fresh	  1.5	  ml	  eppendorf	  tube	  by	  pipetting	  45	  μl	  of	  elution	  buffer	  BR5	  directly	  onto	  the	  PAXgene	  RNA	  spin	  column	  membrane	  and	  centrifuging	  for	  1	  minute	  at	  20,000	  g.	  The	  elution	  was	  labelled	  “Elution	  A”	  and	  was	  used	  for	  all	  further	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RNA	  experiments.	  The	  elution	  was	  then	  repeated	  using	  40	  μl	  elution	  buffer	  BR5	  into	  a	  fresh	  1.5	  ml	  eppendorf	  tube.	  	  The	  supernatant	  obtained	  was	  labelled	  “Elution	  B”.	  	  The	  quantity	  of	  isolated	  RNA	  obtained	  was	  determined	  using	  the	  Nanodrop™	  ND	  1000	  UV-­‐Vis	   spectrophotometer	   (Thermo	  Scientific).	  RNA	  concentration	  was	  given	   in	  ng/μl	  and	  the	  overall	  yield	  obtained	  was	  calculated	  using	  this	  concentration	  multiplied	  by	  the	  elution	  volume.	  The	  quality	  and	  integrity	  of	  the	  isolated	  RNA	  was	  measured	  using	  the	  2100	  Bioanalyzer	  (Agilent).	   RNA	   is	   electrophoretically	   driven	   by	   a	   voltage	   gradient	   through	   a	   polymer	  matrix	   and	   separated	   by	   size.	   Dye	  molecules	   intercalate	   into	   RNA	   strands	   and	   these	  complexes	  are	  detected	  by	  fluorescence.	  Automated	  analysis	  of	  the	  electrophoretic	  trace	  generates	   a	   RNA	   Integrity	   Number	   (RIN)	   score,	   on	   a	   scale	   of	   1-­‐10,	   where	   level	   10	  indicates	   no	   degradation	   and	   that	   	   the	   RNA	   is	   of	   the	   highest	   quality	   possible	   (Figure	  2.10).	   Samples	  with	   a	   RIN	   of	   less	   than	   7	  were	   repeated	   or	   excluded	   from	   expression	  analysis.	  
	  
Figure	  2.10:	  RNA	  electropherograms	  from	  the	  Agilent	  Bioanalyzer.	  Demonstrating	  the	  range	  of	  electropherograms	  from	  completely	  intact	  RNA,	  with	  two	  distinct	  18S	  and	  28S	  peaks,	  to	  strongly	  degraded	  RNA	  with	  a	  RIN	  of	  3.	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2.6.2 Gene	  Expression	  Reticulocytes	  contain	  a	  high	  proportion	  of	  mRNAs	  encoding	  the	  globin	  polypeptides	  and	  can	   reduce	   the	   sensitivity	   of	   microarray	   hybridization	   results,	   potentially	   obscuring	  clinically	  relevant	  information.	  Historically	  to	  avoid	  this	  either	  fractions	  of	  whole	  blood	  (e.g.	   Peripheral	   Blood	   Mononuclear	   Cells	   -­‐	   PBMC)	   were	   isolated	   specifically	   for	  expression	  analysis	  or	  a	  pre-­‐processing	  step	  was	  introduced	  to	  remove	  or	  block	  globin	  RNA	   during	   the	   assay	   (Kam	   et	   al.	   2012).	   These	   methods	   however	   require	   a	   large	  quantity	   of	   RNA,	   introduce	   additional	   processing	   steps	   or	   concentrate	   on	   a	   small	  fraction	   of	   whole	   blood	   and	   therefore	   can	   introduce	   artefacts.	   To	   avoid	   using	   large	  quantities	  of	  RNA	  or	  introducing	  artefacts	  the	  Ovation	  Biotin	  system	  (NuGEN)	  was	  used	  to	   prepare	   amplified	   cDNA	   for	   gene	   expression	   analysis.	   A	   sensitive	   strand-­‐displacement	   amplification	   process	   employing	   DNA/RNA	   chimeric	   primers	   (SPIA®	  primers)	  avoids	  the	  need	  for	  globin	  reduction.	  First	   strand	   cDNA	   is	  prepared	   from	   total	  RNA	  using	   random	  and	  oligo	  dT	  primers	   so	  that	  priming	  occurs	  across	  the	  whole	  transcript.	  Reverse	  transcriptase	  (RT)	  extends	  the	  3	  ́	  DNA	  end	  of	  each	  primer	  generating	   first	  strand	  cDNA	  and	   incorporates	  an	  RNA	  tag	  sequence	  (SPIA	  tag)	  at	  the	  5	  ́	  end	  of	  the	  cDNA.	  Double	  stranded	  cDNA	  is	  then	  generated	  by	  fragmentation	  of	  the	  mRNA	  within	  the	  cDNA/mRNA	  complex	  creating	  priming	  sites	  for	   DNA	   polymerase.	   The	   result	   is	   a	   double-­‐stranded	   cDNA	   with	   a	   DNA/RNA	  heteroduplex	   corresponding	   to	   the	   SPIA	   tag	   at	   one	   end.	   The	   SPIA	   tag	   is	   used	   as	   a	  priming	   site	   for	   the	   SPIA	   amplification	   process.	   The	   amplified	   cDNA	   is	   then	   purified,	  fragmented	  into	  small	  lengths,	  labelled	  and	  hybridized	  to	  the	  microarray.	  Exogenous	  Poly-­‐A	  positive	  controls	  were	  added	  to	  the	  protocol	  to	  monitor	  the	  efficiency	  of	  the	  target	   labelling	  process	  and	  cDNA.	  Each	  array	  contains	  probe	  sets	  for	  several	  B.	  
subtilis	  genes	  that	  are	  absent	  in	  eukaryotic	  samples	  (lys,	  phe,	  thr,	  and	  dap).	  The	  Poly-­‐A	  RNA	   controls	   are	   in	   vitro	   synthesized,	   and	   the	   poly-­‐adenylated	   transcripts	   for	   the	  B.	  
subtilis	  genes	  are	  premixed	  at	  staggered	  concentrations.	  Thirty	  nanograms	  of	  total	  RNA	  was	  used	  to	  synthesise	  double-­‐stranded	  cDNA	  using	  the	  Ovation®	  Pico	  WTA	  System	  V2	  Kit	  (Nugen).	  The	  first	  step	  of	  the	  protocol	  was	  modified	  to	   allow	   the	   addition	   of	   Poly-­‐A	   Controls	   to	   each	   sample	   prior	   to	   the	   First	   Strand	  Synthesis	  step.	  The	  Poly-­‐A	  control	  was	  matched	  to	  the	  amount	  template	  RNA	  (30	  ng)	  by	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performing	   serial	   dilutions	   using	   Poly-­‐A	   Control	   Dilution	   Buffer	   (Affymetrix)	   (Table	  2.5).	  	  
Serial	  dilutions	  
Volume	  of	  4th	  dilution	  
to	  add	  to	  total	  RNA	  1st	  dilution	   2nd	  dilution	   3rd	  dilution	   4th	  dilution	  
1:20	   1:50	   1:50	   1:83	   0.5	  μl	  
Table	  2.5:	  Serial	  dilution	  of	  Poly-­‐A	  RNA	  control	  stock.	  Dilutions	  were	  made	  using	  the	  Poly-­‐A	  Control	  Dilution	  Buffer	  (Affymetrix)	  and	  made	  fresh	  each	  time.	  The	  Ovation®	  Pico	  WTA	  System	  V2	  Kit	  requires	  a	  starting	  substrate	  in	  a	  total	  reaction	  volume	  of	  5	  μl,	  so	  the	  RNA	  stock	  was	  diluted	  and	  re-­‐quantified	  using	  the	  Nanodrop™	  ND	  1000	  UV-­‐Vis	  spectrophotometer	  (Thermo	  Scientific)	   to	  a	  concentration	  of	  between	  10	  and	  15	  ng/μl.	  Thirty	  ng	  of	  this	  dilution	  was	  added	  to	  0.5	  μl	  of	  diluted	  Poly-­‐A	  RNA	  and	  made	   up	   to	   a	   total	   volume	   of	   5	   μl	   with	   Nuclease-­‐free	   Water.	   cDNA	   generation	   and	  subsequent	   purification	   using	   the	   QIAquick	   PCR	   Purification	   kit	   (QIAGEN)	   was	  performed	  according	  to	  the	  manufacturer’s	  protocols.	  The	   quantity	   and	   quality	   of	   the	   purified	   cDNA	   was	   assessed	   by	   measuring	   the	  absorbance	   at	   260,	   280	   and	   320	   nm	   using	   the	   Nanodrop™	   ND	   1000	   UV-­‐Vis	  spectrophotometer	   (Thermo	   Scientific).	   To	   assess	   the	   purity	   the	   adjusted	   (A260-­‐A320)/(A280-­‐A320)	  ratio	  was	  calculated,	  which	  should	  be	  greater	   than	  1.8,	  while	   the	  quantity	  was	  calculated	  by	  assuming	  that	  one	  A260	  unit	  was	  equal	  to	  33	  μg/ml.	  The	  Encore®	  Biotin	  Module	  Kit	   (NuGEN)	  was	  used	   to	   fragment	  2.8	  µg	  of	   the	  purified	  SPIA	   cDNA	   according	   to	   manufacturer’s	   protocols.	   2.8	   μg	   of	   the	   purified	   SPIA	   cDNA,	  made	  up	   to	   a	   volume	  of	   12.5	  μl	  with	  nuclease	   free	  water,	  was	   incubated	  with	  7	  μl	   of	  Fragmentation	   Master	   Mix	   at	   37oC	   for	   30	   minutes	   followed	   by	   2	   minutes	   at	   95oC.	  Immediately	   following	   this	   biotin	   labelling	  was	  performed	  by	   the	   addition	  of	   18	  μl	   of	  Labelling	  Master	  Mix	  and	  incubation	  at	  37oC	  for	  one	  hour	  and	  then	  10	  minutes	  at	  70oC.	  The	  GeneTitan®	  Instrument	  (Affymetrix)	  was	  prepared	   for	   the	  Gene	  1.1	  Sense	  Target	  (ST)	   Array	   Plates	   and	   the	   stain	   trays	   and	   covers	   were	   static	   neutralised.	   The	   stain	  solutions	  and	  array	  holding	  buffer	  were	  placed	   in	   the	  wells	  of	   the	   static-­‐neutral	   trays	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and	  loaded	  into	  the	  GeneTitan®	  according	  to	  the	  manufacturer’s	  protocols,	  along	  with	  the	   polyethylene	   glycol	   (PEG)	   array	   plate,	   Scan	   Tray	   and	   the	   hybridisation	   plate	  containing	  the	  denatured	  hybridisation	  cocktail	  samples.	  The	  array	   layout	  and	  sample	  names	  were	  entered	  into	  the	  control	  portal	  to	  label	  the	  generated	  data.	  At	  all	  stages	  of	  the	  RNA	  processing	  pipeline,	  from	  extraction	  to	  microarray	  processing,	  experiments	  were	  performed	  in	  batches.	  RNA	  extractions	  were	  performed	  in	  batches	  of	  12,	   whilst	   cDNA	   generation,	   labelling	   and	   fragmentation	   were	   done	   as	   one	   step	   in	  batches	   of	   16.	   Samples	   were	   randomised	   across	   extraction	   batches	   and	   then	   re-­‐randomised	  prior	  to	  the	  expression	  work	  to	  ensure	  that	  controls	  and	  IPF	  subjects,	  time	  points	   and	   different	   extraction	   batches	   were	   distributed	   across	   the	   twelve	   16	   PEG	  arrays	   that	  were	   run.	  Additionally,	   all	   these	  batches	  were	   carefully	   recorded	   to	   allow	  detection	   of	   any	   substantial	   batch	   effects	   that	   may	   need	   to	   be	   corrected	   for	   during	  analysis.	  
2.6.3 Data	  Analysis	  
2.6.3.1	   Microarray	  Quality	  Control	  and	  Normalization	  Raw	   intensity	   measurements	   of	   all	   probe	   sets	   were	   corrected	   for	   background	  fluorescence,	   quantile	   normalized,	   median	   polished	   and	   converted	   into	   expression	  measurements	  using	  the	  robust	  multi-­‐array	  averaging	  (RMA)	  algorithm	  as	  implemented	  in	  Affymetrix	   Power	  Tools	   (APT,	   version	   1.12.0).	   Latent	   batch	   effects	   associated	  with	  technical	   variables	   were	   identified	   using	   combating	   batch	   effects	   when	   Combining	  Batches	   of	   gene	   expression	   microarray	   data	   (ComBat)	   (Johnson,	   Li,	   and	   Rabinovic	  2007).	  Factors	  found	  to	  yield	  sample	  clustering	  were	  removed	  prior	  to	  further	  analysis	  to	  increase	  precision	  and	  accuracy	  (Chen	  et	  al.	  2011).	  
2.6.3.2	   Differential	  Expression	  Analysis	  Differential	   expression	   was	   assessed	   through	   linear	   modelling,	   applying	   a	   single	  contrast	   between	   states	   of	   interest,	   i.e.	   IPF	   subjects	   and	   controls,	   IPF	   subjects	   with	  progressive	  disease	  and	  those	  with	  stable	  disease,	  subjects	  who	  survived	  and	  those	  who	  died.	   P-­‐values	   were	   adjusted	   for	   multiple	   testing	   using	   the	   Benjamini	   &	   Hochberg	  (Benjamini,	   Yoav	   and	   Hochberg	   1995)	   method	   for	   the	   control	   of	   the	   expected	   False	  Discovery	   Rate	   (FDR).	   The	   transcript	   clusters	   of	   each	   and	   every	   IPF	   time	   point	  were	  contrasted	  with	  every	  other.	  This	  generated	  a	  T	  statistic	  for	  each	  gene	  which	  was	  used	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to	  generate	  a	  moderated	  F	  statistic,	  and	  subsequently	  P	  value,	  for	  each	  transcript	  cluster	  on	  the	  Gene	  1.1	  ST	  array.	  The	  Gene	  Ontology	  (GO)	  term	  enrichment	  of	  significantly	  differentially	  expressed	  genes	  was	   evaluated	   using	   the	   Database	   for	   Annotation,	   Visualisation,	   and	   Integrated	  Discovery	  (DAVID)	  version	  6.7	  (D.	  W.	  Huang,	  Sherman,	  and	  Lempicki	  2009).	  Transcript	  cluster	  IDs	  represented	  in	  each	  module	  were	  compared	  against	  all	  transcript	  cluster	  IDs	  represented	  on	  the	  full	  HuGene	  1.1	  ST	  array.	  Differential	   expression	   analysis	  was	   conducted	   in	  R	  3.0.2	  using	   the	  Linear	  Models	   for	  Microarray	  Data	  package	  (Limma)	  [Bioconductor	  (www.bioconductor.org)].	  	  
2.6.3.3	   Weighted	  Gene	  Co-­‐expression	  Network	  Analysis	  Weighted	   Gene	   Co-­‐expression	   Network	   Analysis	   (WGCNA)	   was	   used	   to	   describe	  correlation	   patterns	   among	   differentially	   expressed	   genes	   (Langfelder	   and	   Horvath	  2008).	  Groups	  of	  transcript	  clusters	  exhibiting	  high	  topological	  overlap	  (Modules)	  were	  identified.	   A	   minimum	   module	   size	   of	   40	   was	   specified.	   Summary	   gene	   expression	  profiles	   for	   each	   module	   (module	   eigengenes)	   were	   established	   via	   a	   principal	  components	   approach	   (Langfelder	   and	  Horvath	   2007).	  Module	   eigengenes	  were	   then	  correlated	  with	   traits	  of	   interest.	  Genes	   in	  each	  cluster	  were	  analysed	  using	  DAVID	  to	  allow	   functional	   annotation	   clustering	   and	   Gene	   Ontology	   (GO)	   term	   enrichment	  analysis.	   WGCNA	   analysis	   was	   conducted	   in	   R	   3.0.2	   [Bioconductor	  (www.bioconductor.org)].	  
2.7 General	  Statistics	  In	  addition	  to	  the	  analytical	  tools	  already	  outlined	  in	  this	  chapter	  additional	  statistical	  analysis	  was	  performed	  with	   the	  use	   of	   SPSS	   (version	  21)	   and	  R	  3.0.2	   (http://cran.r-­‐project.org/).	  Continuous	  variables	  are	  presented	  as	  means	  (±Standard	  Deviation	  [SD]),	  and	  categorical	  variables	  as	  proportions.	  Testing	  of	  OTUs	  was	  restricted	  to	  those	  with	  a	  differing	  mean	  abundance	  between	  cases	  and	  controls	  of	  more	  than	  1%	  of	  the	  total.	  The	  time-­‐to-­‐event	   curves	   were	   calculated	   using	   the	   Kaplan–Meier	   method	   and	   compared	  with	  the	  use	  of	  the	  log-­‐rank	  test.	  	  The	  numbers	  of	  individuals	  still	  at	  risk	  of	  experiencing	  the	   primary	   endpoint	   are	   indicated	   beneath	   each	   plot.	   Differences	   between	   subject	  groups	  were	  evaluated	  with	  the	  use	  of	  the	  Mann–Whitney	  test	  for	  continuous	  variables	  and	  Fisher's	  exact	   test	   for	  categorical	  variables.	  Spearman's	  rho	  was	  used	   to	  calculate	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correlations	  between	  continuous	  variables.	  The	  statistical	  significance	  of	  association	  of	  variables	   with	   a	   diagnosis	   of	   IPF	   was	   assessed	   with	   the	   use	   of	   stepwise	   logistic	  regression.	  The	  statistical	  significance	  of	  association	  of	  variables	  with	  genotypes	  of	  the	  
MUC5B	  SNP	  rs35705950	  (coded	  0,	  1	  and	  2)	  were	  modeled	  using	  multiple	  permutations	  of	   the	   data	   (bootstrapping).	   A	   two-­‐sided	   P	   value	   of	   less	   than	   0.05	  was	   considered	   to	  indicate	  statistical	  significance.	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Chapter	  3:	  Clinical	  Characteristics	  of	  Study	  Population	  
3.1	   Introduction	  In	   this	   chapter	   the	  demographic	  data	   and	   clinical	   characteristics	  of	   subjects	   recruited	  into	   the	   study	   are	   presented,	   with	   relationships	   between	   them	   described.	   The	  progression	   of	   disease	   within	   the	   cohort	   will	   be	   demonstrated	   and	   interrogated	   for	  associations	  with	  known	  baseline	  predictors	  of	  decline.	  The	  cohort	  will	  then	  be	  used	  to	  assess	   the	   utility	   of	   a	   number	   of	   published,	   but	   not	   yet	   validated,	   composite	   scoring	  systems	  which	   use	   physiological	   and	   radiological	   variables	   in	   order	   to	   provide	   some	  prognostic	  information	  at	  the	  time	  of	  diagnosis.	  Finally	  exploratory	  phenotypic	  analysis	  will	   be	   performed	   aimed	   at	   understanding	   the	   structure	   of	   the	   data	   more	   clearly,	  highlighting	   associations	   between	   traits	   as	   well	   as	   identifying	   potential	   redundant	  variables	  which	  could	  be	  removed	  prior	  to	  downstream	  analyses.	  
3.2 Methods	  Analyses	  were	  conducted	  as	  detailed	  in	  Chapter	  2,	  Section	  2.7.	  
3.3 Results	  
3.3.1 Recruitment	  of	  Subjects	  Patients	   referred	  with	   suspected	   but	   previously	   undiagnosed	   IPF	  were	   consecutively	  recruited	   from	   the	   Interstitial	   Lung	   Disease	   Unit	   at	   the	   Royal	   Brompton	   Hospital,	  London,	  England	  between	  November	  2010	  and	  January	  2013.	  Subjects	  were	  excluded	  if	  the	  suspected	  diagnosis	  had	  been	  made	  over	  one	  year	  prior	   to	  presentation	  or	   if	   they	  met	  any	  of	   the	  predefined	  exclusion	  criteria	   listed	   in	  Chapter	  2,	  Section	  2.1.1.	  Written	  informed	   consent	  was	   obtained	   from	   all	   subjects	   and	   the	   study	  was	   approved	   by	   the	  Local	  Research	  Ethics	  Committee	  (Ref	  10/H0720/12).	  	  Subject	  recruitment	  is	  illustrated	  in	  the	  consort	  diagram,	  Figure	  3.1.	  The	   recruitment	   of	   control	   subjects	   occurred	   separately	   using	   the	   same	   protocols.	  Healthy	  individuals	  (smokers	  and	  non-­‐smokers)	  and	  individuals	  with	  moderate	  (GOLD	  Stage	   II)	   Chronic	   Obstructive	   Pulmonary	   Disease	   (COPD)	   were	   recruited	   through	  respiratory	  clinics	  and	  through	  advertising	  in	  local	  newspapers	  between	  January	  2009	  and	  December	  2012.	  Approval	  was	  obtained	  from	  the	  Local	  Research	  Ethics	  Committee	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(Ref	   00/BA/459E	   and	   07/H0712/138)	   and	   written	   informed	   consent	   was	   obtained	  from	  all	  subjects.	  
	  
Figure	   3.1	   Consort	   diagram	   of	   recruitment	   of	   IPF	   subjects.	  Number	   shown=total	  subjects	  included	  in	  each	  group.	  MDT=Multidisciplinary	  team	  case	  review	  
3.3.2 Exclusion	  and	  Withdrawal	  of	  Study	  Subjects	  During	   the	   study	   period,	   nine	   patients	   with	   suspected	   IPF	   were	   excluded	   from	  enrolment	   as	   they	   reported	   symptoms	   of	   a	   lower	   respiratory	   tract	   infection	   or	  antibiotic	  usage	  in	  the	  preceding	  three	  months.	  For	  those	  subjects	  that	  were	  enrolled,	  a	  final	  diagnosis	  of	  IPF	  was	  made	  following	  multidisciplinary	  team	  discussion.	  Ten	  of	  the	  potential	   IPF	   patients	   who	   had	   passed	   screening	   were	   deemed	   not	   to	   fulfil	   the	   ATS	  diagnostic	  criteria	  for	  IPF	  and	  were	  subsequently	  excluded	  from	  the	  study	  (Raghu	  et	  al.	  2011).	   A	   further	   subject	   withdrew	   due	   to	   the	   duration	   of	   the	   project	   and	   the	   time	  commitment	   required	  but	  no	   subjects	   rescinded	   consent	  post	   screening.	  A	  number	  of	  subjects	   did	   miss	   one	   or	   more	   of	   the	   multiple	   time	   point	   follow-­‐ups	   after	   initial	  recruitment,	  but	  nonetheless	  these	  individuals	  were	  retained	  within	  the	  study.	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3.3.3 Demographics	  of	  IPF	  Subjects	  One	  hundred	  patients	  with	  IPF	  were	  enrolled	  in	  the	  study.	  	  The	  collection	  of	  peripheral	  whole	  blood	  started	  6	  months	  prior	  to	  bronchoscopy	  and	  consequently	  not	  all	  subjects	  underwent	  both	  bronchoscopy	  and	   longitudinal	  gene	  expression	  analysis.	  Twenty-­‐five	  subjects	   underwent	   bronchoscopy	   and	   longitudinal	   gene	   expression	   analysis,	   whilst	  another	   40	   only	   underwent	   bronchoscopy	   and	   a	   further	   35	   only	   gene	   expression	  analysis.	  The	  demographics	  of	  the	  IPF	  subjects	   in	  totality	  are	  presented	  and	  discussed	  below.	  Demographics	  of	   each	   separate	  panel	  of	   subjects	  used	   for	   the	  gene	  expression	  analysis	  and	  microbiota	  analysis	  are	  discussed	  in	  Chapters	  4.3.1	  and	  6.2.1	  respectively	  including	  the	  comparisons	  with	  their	  appropriate	  controls	  groups.	  The	  100	  IPF	  subjects	  were	  predominantly	  male	  (77%)	  with	  a	  mean	  age	  of	  68	  years	  and	  had	   moderately	   severe	   disease	   at	   enrolment	   (Carbon	   Monoxide	   Diffusing	   Capacity	  [DLCO]	   42%	   predicted;	   Forced	   Vital	   Capacity	   [FVC]	   74%	   predicted)	   (Table	   3.1).	   The	  majority	  of	  subjects	  were	  previous	  smokers,	  with	  an	  average	  of	  a	  20	  pack	  year	  history,	  and	  a	  reduced	  6	  minute	  walk	  distance	  reflected	  in	  an	  average	  Medical	  Research	  Council	  (MRC)	   dyspnoea	   score	   of	   3.	   Forty	   two	   percent	   of	   the	   subjects	   reported	   symptoms	   of	  gastro-­‐oesophageal	  reflux.	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Characteristics	   IPF	  (N=100)	  Age	  (yrs)	   68.6	  (±7.8)	  Male	  Sex	  -­‐	  number	  (%)	   77	  (77%)	  Weight	  –	  kg	   81.64	  	  (±16.8)	  Body	  Mass	  Index	  (BMI)	   28.15(±4.4)	  Smoking	  (Ever	  vs	  Never)	  –	  number	  (%)	   69	  	  (69%)	  Pack	  year	  history	  (yrs)	   20.67	  (±26)	  Forced	  Vital	  Capacity	  (FVC)—	  %	   73.49	  (±	  18)	  Forced	  Expiratory	  Volume	  in	  one	  second	  (FEV1)	  —	  %	   74.6	  (±15)	  Ratio	  of	  FEV1	  to	  FVC	   80.0	  (±7)	  DLCO	  -­‐	  %	  of	  predicted	  value	   41.97	  (±13)	  O2	  Saturation—	  %	   95	  (±2)	  6-­‐Minute	  walk	  distance	  –	  m	   377.8	  (±124)	  MRC	  Dyspneoa	  score	   2.99	  (±1.0)	  Immunosuppression	  -­‐	  number	  (%)	   33	  (33%)	  
Table	  3.1.	  Baseline	  Characteristics	  of	  all	  the	  IPF	  subjects.	  Data	  are	  means	  ±Standard	  Deviation.	  DLCO=Carbon	  Monoxide	  Diffusing	  Capacity.	  
3.3.4 Follow	  up	  and	  Disease	  Progression	  Median	  follow-­‐up	  was	  18	  months	  (range,	  3-­‐36)	  and	  29	  patients	  died	  during	  this	  period.	  The	   annual	   rate	   of	   decline	   in	   FVC	   was	   0.18	   litres	   (95%	   CI,	   0.09	   to	   0.26)	   whilst	   the	  annual	  decline	  in	  DLCO	  was	  0.47	  mm/kPa/min	  (95%	  CI,	  0.33	  to	  0.62).	  Neither	  age	  nor	  smoking	  history	  carried	  an	  increased	  risk	  of	  mortality	  in	  the	  cohort	  (P=0.15	  and	  P=0.28	  respectively).	  	  Thirty-­‐three	  patients	  had	  a	  decrease	   in	  FVC	  of	  more	  than	  10%	  in	  12	  months	  and	  they	  were	  at	  higher	  risk	  of	  mortality	  compared	  with	  subjects	  with	  no	  decline	  in	  lung	  function	  (HR	   5.8	   [95%	   CI,	   2.14-­‐16.01],	   P=0.00057)	   (Figure	   3.2).	   Similarly	   individuals	   with	   a	  baseline	  DLCO	  below	  40%	  predicted	  were	  at	  a	  higher	  risk	  of	  mortality	  compared	  with	  subjects	   with	   a	   DLCO	   above	   40%	   predicted	   (HR	   2.6	   [95%	   CI,	   1.12-­‐	   5.80],	   P=0.025)	  (Figure	  3.3).	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Figure	   3.2	   Kaplan-­‐Meier	   curve	   demonstrating	   survival	   in	   subjects	   with	   a	   10%	  
decline	   in	   FVC.	   Subjects	   with	   stable	   disease	   are	   represented	   as	   a	   continuous	   line.	  Subjects	  with	  a	  10%	  decline	  in	  FVC	  over	  12	  months	  are	  represented	  with	  a	  broken	  line.	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Figure	   3.3	   Kaplan-­‐Meier	   curve	   demonstrating	   survival	   in	   subjects	   based	   on	  
Carbon	  Monoxide	  Diffusing	   Capacity	   (DLCO).	   Subjects	  with	  a	  baseline	  DLCO	  below	  40	   are	   represented	   by	   the	   broken	   line.	   	   Subjects	   with	   a	   DLCO	   greater	   than	   40	   are	  represented	  by	  the	  solid	  line.	  
3.3.5 Composite	  End	  Points	  The	  initially	  proposed	  Clinical,	  Radiological	  and	  Physiological	  (CRP)	  scoring	  system	  (T	  E	  King,	  Tooze,	  et	  al.	  2001)	  was	  somewhat	  cumbersome,	  employing	  age,	  smoking	  history;	  clubbing;	   presence	   or	   absence	   of	   pulmonary	   hypertension	   on	   the	   chest	   radiograph;	  Total	  Lung	  Capacity	  (TLC);	  and	  partial	  pressure	  of	  oxygen	  in	  arterial	  blood	  PaO2	  at	  the	  end	  of	  maximal	  exercise	  to	  predict	  outcome.	  Subsequently	  the	  much	  simpler	  Composite	  Physiologic	   Index	   (CPI)	   that	   only	   utilizes	   values	   from	   FEV1,	   FVC,	   and	   DLCO	   was	  proposed	   (Wells	   et	   al.	   2003).	   Despite	   this	   simplified	   system	   it	   has	   not	   been	   widely	  adopted	  and	  a	  more	  recent	  scoring	  system	  has	  been	  developed,	   the	  GAP	   index,	  which	  classifies	  patients	  by	  total	  score	  into	  stages	  which	  can	  then	  be	  used	  to	  predict	  mortality	  (Ley	  et	  al.	  2012).	  	  For	  each	  IPF	  subject,	   the	  CPI	  was	  calculated	  according	  to	   the	   following	   formula	  (91.0-­‐(0.65	   ×	   percent	   predicted	   DLCO)-­‐(0.53	   ×	   percent	   predicted	   FVC)+	   (0.34	   ×	   percent	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predicted	  FEV1)).	   	  The	  mean	  CPI	  was	  49	  (±12)	  with	  an	  average	  annual	  increase	  of	  4.8	  (±7).	  At	  baseline	  the	  CPI	  was	  found	  to	  correlate	  positively	  with	  mortality	  (Spearman’s	  ρ=0.48,	  P=8.0e-­‐25),	  and	  negatively	  with	  length	  of	  survival	  (Spearman’s	  ρ=-­‐0.27,	  P=0.01).	  Although	  there	  is	  no	  formal	  scoring	  system	  to	  predict	  survival	  from	  a	  baseline	  CPI	  score,	  it	  has	  been	  suggested	  that	  individuals	  with	  a	  CPI	  greater	  than	  40	  progress	  more	  rapidly.	  Dichotomizing	   the	  cohort	  at	   this	  point	  demonstrates	   that	   there	  were	  no	  deaths	   in	   the	  panel	  of	  subjects	  who	  had	  a	  baseline	  CPI	  below	  40	  (Figure	  3.4).	  
Figure	  3.4	  Kaplan-­‐Meier	   curve	  demonstrating	   survival	   based	  CPI	   Score.	  Subjects	  with	  a	  baseline	  CPI	  above	  40	  are	  represented	  by	   the	  broken	   line.	   	  Subjects	  with	  a	  CPI	  greater	  than	  40	  are	  represented	  by	  the	  solid	  line.	  The	   GAP	   score	   was	   calculated	   using	   the	   scoring	   system	   in	   Table	   3.2,	   based	   on	   the	  formula	  previously	  described	  (Ley	  et	  al.	  2012).	  The	  total	  point	  score	  classifies	  patients	  as	   Stage	   I	   (0-­‐3	   points),	   Stage	   II	   (4-­‐5	   points),	   or	   Stage	   III	   (6-­‐8	   points).	   The	   higher	   the	  Stage	  (and	  therefore	  total	  point	  score)	  the	  more	  severe	  the	  disease.	  The	  mean	  GAP	  score	  in	  the	  cohort	  was	  4.03	  (±1.5)	  and	  the	  distribution	  of	  the	  subjects	  across	  the	  stages	  is	  given	  in	  Table	  3.3.	  The	  GAP	  stage	  at	  baseline	  was	  found	  to	  correlate	  positively	  with	  mortality	  (Spearman’s	  ρ=0.216,	  P=4.9e-­‐31),	  and	  negatively	  with	   length	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of	   survival	   (Spearman’s	   ρ=-­‐0.13,	   P=1.6e-­‐19).	   Unlike	   the	   CPI,	   the	   GAP	   system	   further	  classifies	  patients	  by	   total	   score	   into	  stages.	  Splitting	   the	   IPF	  cohort	  according	   to	   IPF-­‐GAP	   stage	   we	   see	   that	   mortality	   is	   significantly	   increased	   with	   each	   stage	   (P=0.031)	  (Figure	  3.5).	  
Factor	  
	  
Points	  Gender	   Female	   0	  Male	   1	  Age	   <60	   0	  61-­‐65	   1	  >65	   2	  
Physiology	   FVC	  
>75%	   0	  50-­‐75%	  	   1	  <	  50%	  	   2	  
DLCO	   >55%	   0	  36-­‐55%	  	   1	  <36%	  	   2	  Unable	  to	  Perform	   3	  
Table	  3.2	  The	  GAP	  Index.	  Points	  are	  assigned	  for	  each	  variable	  to	  obtain	  a	  total	  point	  score	   (range,	  0-­‐8).	  The	  score	   is	   then	  used	   to	  classify	  patients	   into	  Stages;	  Stage	   I	   (0-­‐3	  points),	  Stage	  II	  (4-­‐5	  points)	  or	  Stage	  III	  (6-­‐8	  points).	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Patients	   1	  year	   2	  year	   3	  year	  1	   0-­‐3	   35	   8.5	  (5.6)	   17.5	  (10.9)	   17.5	  (16.3)	  2	   4-­‐5	   60	   23	  (16.2)	   30	  (29.9)	   32	  (42.1)	  3	   6-­‐8	   5	   40	  (39.9)	   60	  (62.1)	   60	  (76.8)	  
Table	  3.3	  Observed	  and	  predicted	  cumulative	  mortality	  rates	  based	  upon	  the	  GAP	  
staging	  system.	  Predicted	  cumulative	  mortality	  rates	  shown	  in	  bracket	  to	  compare	  to	  observed	  rates.	  
3.3.6 MUC5B	  Genotype	  As	  discussed	  in	  Chapter	  1,	  the	  strongest	  and	  most	  reproducible	  genetic	  association	  with	  IPF	   to	   date	   is	   that	   of	   the	   Mucin	   5B	   (MUC5B)	   gene.	   The	   minor	   allele	   of	   this	   gene,	  rs35705950,	  confers	  an	  increased	  risk	  for	  idiopathic	  pulmonary	  fibrosis.	  Genotyping	  of	  
	  	   79	  
rs35705950	   of	   DNA	   for	   86	   out	   of	   the	   100	   IPF	   patients	   was	   possible	   through	  collaboration	  (data	  provided	  by	  Dr	  E.	  Murphy).	  The	   frequency	   of	   the	   rs35705950	  MUC5B	   polymorphism	  minor	   allele	   (T)	   among	   the	  cohort	   was	   38%,	   compared	   to	   a	   background	   frequency	   of	   10%	   in	   controls	  (p=2.04×10−17)	  (published	  data	  from	  a	  collaborative	  study	  with	  a	  UK	  cohort)	  (Stock	  et	  al.	  2013).	  
	   GG	  (%)	   GT	  (%)	   TT	  (%)	  IPF	  (N=86)	   34.88	   54.65	   10.47	  UK	  control	  data	  (N=416)	   81.01	   17.07	   1.92	  
Table	  3.4	  MUC5B	  genotype	  frequency	  compared	  to	  published	  UK	  data.	  The	  control	  data	  is	  taken	  from	  Stock	  et	  al.	  2013.	  The	  distribution	  of	  patients	  homozygous	  and	  heterozygous	  for	  the	  minor	  allele	  was	  not	  different	   according	   to	   gender	   (P=0.20),	   age	   (P=0.13),	   baseline	   lung	   function	   (CPI)	  (P=0.32)	  or	  smoking	  history	  (P=0.24)	  (Figure	  3.6).	  
	  
Figure	   3.6	  Distribution	   of	   clinical	   characteristics	   according	   to	  MUC5B	   genotype.	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the	  highest	  and	  lowest	  values.	  (C)	  Distribution	  of	  the	  gender	  according	  to	  the	  genotype.	  (D)	  Distribution	  of	  smoking	  status	  according	  to	  the	  genotype.	  N=86	  IPF	  subjects.	  IPF	  subjects	  heterozygous	  (GT)	  and	  homozygous	  (TT)	  for	  the	  minor	  allele	  were	  found	  to	  have	  a	  lower	  risk	  of	  mortality	  compared	  to	  those	  with	  the	  GG	  genotype	  (hazard	  ratios	  0.37	  [95%	  CI,	  0.16-­‐0.88]	  and	  0.18	  [95%	  CI,	  0.03-­‐1.38],	  respectively;	  P=0.0256)	  (Figure	  3.7).	  
Figure	   3.7	   Kaplan-­‐Meier	   survival	   curve	   by	   MUC5B	   genotype.	   Subjects	   are	   split	  according	   to	   their	  MUC5B	   genotype.	   Individuals	   homozygous	   (large	   dotted	   line)	   and	  heterozygous	  (small	  dotted	  line)	  for	  the	  minor	  allele	  have	  a	  better	  survival	  than	  those	  who	  do	  not	  carry	  the	  minor	  allele	  (solid	  line).	  
3.3.7 BAL	  Volume	  and	  Total	  Cell	  Counts	  Sixty-­‐four	   subjects	   successfully	  underwent	  Bronchoscopic	  Alveolar	  Lavage	   (BAL).	  The	  same	   volume	   of	   saline,	   240	   ml,	   was	   instilled	   during	   each	   bronchoscopy	   performed,	  although	  return	  was	  variable.	  The	  volume	  of	  BAL	  fluid	  recovered	  during	  bronchoscopy	  was	  therefore	  analysed	  to	  evaluate	  between	  or	  within	  group	  differences.	  BAL	  yield	  did	  significantly	   differ	   between	   IPF	   cases	   and	   controls	   with	   larger	   returns	   observed	   for	  cases	  (124.4	  ml	  ±	  31	  vs.	  103.9	  ml	  ±	  39;	  P=0.006).	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The	   IPF	   BAL	   cell	   differential	   predominantly	   consisted	   of	  macrophages	   (62.7%	   ±	   14),	  followed	  by	  lymphocytes	  (17.0%	  ±13),	  neutrophils	  (12.4	  %±12),	  and	  eosinophils	  (5.7%	  ±3).	   In	   contrast	   the	   control	   group	   of	   subjects	   had	   less	   neutrophils	   (2.5%±3)	   and	  eosinophils	  (1.2%±2).	  	  There	  was	  no	  correlation	  between	  any	  of	  the	  BAL	  cell	  differential	  counts	  and	  mortality	  or	  length	  of	  survival	  for	  the	  IPF	  subjects.	  
	  
Figure	  3.9	  BAL	  cell	  differential	  counts.	  Cell	  counts	  are	  represented	  as	  percentage	  of	  total	   cells.	   IPF	   N=65	   Controls	   N=44.	   There	   were	   no	   significant	   differences	   between	  differential	  cell	  counts	  between	  groups.	  
3.3.8 Exploratory	  Analysis	  During	   recruitment	   a	   wealth	   of	   data	   was	   collected	   regarding	   each	   subject.	   To	  understand	   the	   structure	   of	   the	   data	   in	   greater	   depth	   and	   identify	   associations	   and	  correlations	  a	  number	  of	  analyses	  were	  performed.	  Within	   the	   full	   cohort	   of	   100	   IPF	   subjects	   mortality	   correlated	   with	   baseline	   lung	  function	  ([FVC	  Spearman’s	  ρ=-­‐0.43,	  P=3.3e-­‐06]	  [DLCO	  Spearman’s	  ρ=-­‐0.49	  P=1.4e-­‐07])	  and	  CPI	  (Spearman’s	  ρ=0.49	  P=1.8e-­‐07).	  As	  expected	  from	  the	  data	  presented	  in	  Section	  3.3.4,	  mortality	  also	  correlated	  with	  decline	  in	  FVC,	  DLCO	  and	  rise	  in	  CPI,	  and	  markers	  of	   disease	   progression	   including	   FVC	   decline	   >10%	   (Spearman’s	   ρ=0.47,	   P=5.2e-­‐06)	  (Figure	  3.10).	  A	  higher	  MRC	  dyspnoea	  score	  at	  baseline	  was	  associated	  with	  worse	  lung	  function	  and	  lower	   oxygen	   saturations	   (Spearman’s	   ρ=-­‐0.32,	   P=0.01).	   MRC	   dyspnoea	   score	   also	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correlated	   with	   mortality	   (Spearman’s	   ρ=0.4,	   P=3.7e-­‐04)	   and	   interestingly	   was	  associated	  with	  BAL	  culture	  positivity	  (Spearman’s	  ρ=0.37,	  P=0.01).	  	  
Figure	  3.10	  Correlation	  matrix	  of	  the	  phenotypic	  data	  for	  all	  100	  IPF	  subjects.	  The	  strength	  of	   the	  correlation	   is	   indicated	  by	   larger	  circles	  and	  stronger	  colours	  with	  red	  indicating	  a	  negative	  correlation	  and	  blue	  a	  positive	  correlation.	  PaCO2=Arterial	  carbon	  dioxide	   concentration;	   Pa02=Arterial	   oxygen	   concentration;	   DLCO,	   carbon	   monoxide	  diffusing	   capacity;	   FVC,	   forced	   vital	   capacity;	   FEV1,	   forced	   expiratory	   volume	   in	   one	  second;	   CPI=Composite	   Physiological	   Index;	   6MWT=Six	   minute	   walk	   distance;	  BMI=Body	  Mass	  Index;	  Composite	  End	  Point=Death	  of	  10%	  decline	  in	  FVC.	  Next	   clustering	   of	   the	   correlation	   data	  was	   performed	   and	   this	   revealed	   four	   distinct	  large	   clusters	   of	   phenotypic	   variables.	   Cluster	   one	   representing	   markers	   of	   disease	  progression;	   Cluster	   two	   representing	  markers	   of	   baseline	   lung	   function	   and	   disease	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severity;	  Cluster	  three	  consisting	  of	  BAL	  cell	  counts	  and	  Cluster	  four	  representing	  body	  habitus,	   gender	   and	   smoking	   (Figure	   3.11).	   On	   the	   dendrogram	   redundant	   variables	  clearly	   cluster	   together,	   e.g.	   Pa02	   and	   oxygen	   saturations,	   and	   highlight	   phenotypic	  traits	  that	  could	  potentially	  be	  dropped	  from	  downstream	  analysis.	  
	  
Figure	   3.11	   Cluster	   dendrogram	   of	   the	   phenotypic	   data.	   PaCO2=Arterial	   carbon	  dioxide	   concentration;	   Pa02=Arterial	   oxygen	   concentration;	   DLCO,	   carbon	   monoxide	  diffusing	   capacity;	   FVC,	   forced	   vital	   capacity;	   FEV1,	   forced	   expiratory	   volume	   in	   one	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second;	   CPI=Composite	   Physiological	   Index;	   6MWT=Six	   minute	   walk	   distance;	  BMI=Body	  Mass	  Index;	  Composite	  End	  Point=Death	  of	  10%	  decline	  in	  FVC.	  To	   examine	   this	   clustering	   further,	   exploratory	   factor	   analysis	   was	   undertaken	   to	  identify	   how	  many	   phenotypic	   variables	   could	   be	   represented	   by	   a	   smaller	   group	   of	  variables,	   whilst	   accounting	   for	   as	   much	   of	   the	   variability	   in	   the	   data	   as	   possible	  (Williams	  and	  Brown	  2012).	  Principal	  component	  analysis	  (PCA)	  was	  performed,	  with	  oblique	   promax	   rotation	   to	   allow	   for	   the	   presence	   of	   correlated	   factors	   (Costello	   and	  Osborne	  2005).	  	  To	  determine	  the	  number	  of	  components	  to	  retain	  from	  PCA,	  parallel	  analysis	  was	  used	  (Horn	   1965).	   Using	   a	   randomly	   generated	   dataset	   with	   identical	   numbers	   of	  observations	   and	   variables	   a	   correlation	   matrix	   was	   created.	   When	   the	   eigenvalues	  from	   the	   random	  data	  became	   larger	   then	   those	  of	   the	   actual	  PCA,	   it	   implies	   that	   the	  remaining	   components	   are	   random	   noise	   and	   should	   therefore	   be	   discarded.	   Here	  parallel	   analysis	   suggested	   a	   six	   factor	   solution	   (Figure	   3.12).	   This	   resulted	   in	   the	  retention	  of	  factors	  with	  an	  eigenvalue	  greater	  than	  1.0.	  
	  
Figure	  3.12	  Parallel	   analysis.	  Plot	  of	  actual	  (-­‐	  X	  -­‐)	  versus	  randomly	  (…….)	  generated	  eigenvalues.	  A	  six-­‐factor	  solution	  was	  suggested	  by	  the	  intersection	  of	  the	  two	  plots.	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In	   Table	   3.5	   the	   factor	   loadings	   from	   the	   PCA	   analysis	   are	   presented	   for	   each	   item	  showing	  how	  each	   is	   related	   to	   six	  distinct	   factors.	  Only	  phenotypic	   traits	  with	   factor	  loadings	  ≥	  0.4	  or	  ≤	  -­‐0.4	  were	  considered	  as	  strongly	  related	  to	  the	  underlying	  factor.	  The	  first	  factor	  has	  a	  large	  eigenvalue	  (5.59)	  but	  only	  accounts	  for	  approximately	  15%	  of	  the	  variance	  in	  the	  responses	  given	  to	  items.	  In	  total	  the	  six	  factors	  account	  for	  55%	  of	  the	  total	  variance.	  	  Examining	  the	  phenotypic	  traits	  that	  load	  highly	  on	  a	  given	  factor,	  it	  is	  possible	  to	  name	  and	   interpret	   each	   component.	   The	   first	   component	   is	   based	   upon	   baseline	   lung	  function,	   the	   second	  on	  markers	  of	  disease	  progression,	   the	   third	  on	   size	  and	  gender,	  fourth	  on	  BAL	  lymphocytosis	  and	  indices	  of	  dyspnoea,	  the	  fifth	  on	  oxygenation	  and	  the	  final	  component	  on	  BAL	  cell	  counts.	  There	  were	  7	  phenotypic	  variables	  that	  did	  not	  load	  onto	  this	  matrix.	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   PC1	   PC2	   PC3	   PC5	   PC4	   PC6	  Epigene	  Value	   5.59	   5.54	   2.78	   2.27	   2.11	   2.11	  Proportion	  of	  variance	   0.15	   0.15	   0.07	   0.06	   0.06	   0.06	  Cumulative	  variance	   0.15	   0.30	   0.37	   0.43	   0.49	   0.55	  
	   	   	   	   	   	   	  Baseline	  DLCO	  (%	  Predicted)	   -­‐0.92	   	   	   	   	   	  Baseline	  CPI	   0.96	   	   	   	   	   	  Baseline	  DLCO	  <40	   0.89	   	   	   	   	   	  Baseline	  CPI	  <40	   0.82	   	   	   	   	   	  FVC	  (%	  Predicted)	   -­‐0.54	   	   	   	   	   	  GAP	  Score	   0.52	   	   	   	   	   	  GAP	  Stage	   0.44	   	   	   	   	   	  RIP	   0.4	   	   	   	   	   	  FVC	  decline	  (%	  Predicted)	   	   0.91	   	   	   	   	  CPI	  Increase	   	   0.88	   	   	   	   	  FVC	  decline	  >10%	  (Relative)	   	   0.87	   	   	   	   	  FVC	  decline	  >10%	  (Absolute)	   	   0.85	   	   	   	   	  DLCO	  decline	  (%	  Predicted)	   	   0.8	   	   	   	   	  CPI	  rise	  >10	   	   0.79	   	   	   	   	  Composite	  End	  Point	   	   0.78	   	   	   	   	  Weight	   	   	   0.98	   	   	   	  BMI	   	   	   0.89	   	   	   	  FEV1/FVC	  ratio	   0.4	   	   -­‐0.64	   	   	   	  Smoking	  (Ever/Never)	   	   	   	   	   	   	  Gender	   	   	   0.96	   	   	   	  Height	   	   	   0.77	   	   	   	  BAL	  Lymphocyte	  concentration	   	   	   	   0.68	   	   	  6MWT	  desaturation	  to	  less	  than	  88%	   	   	   	   0.63	   	   	  BAL	  Culture	  Positive	   	   	   	   0.57	   	   	  MRC	  Dyspnoea	  score	   	   	   	   0.55	   	   	  Age	   	   	   	   0.44	   	   	  O2	  saturations	   	   	   	   	   0.93	   	  PaO2	   	   	   	   	   0.79	   	  BAL	  Macrophage	  concentration	   	   	   	   -­‐0.4	   	   -­‐0.88	  BAL	  Neutrophil	  concentration	   	   	   	   	   	   0.72	  BAL	  Eosinophil	  concentration	   	   	   	   	   	   0.68	  DLCO	  decline	  >15	  (%	  Predicted)	   	   	   	   	   	   	  Survival	  (Months)	   	   	   	   	   	   	  FEV1	  (%	  Predicted)	   -­‐0.41	   	   	   	   	   	  PaCO2	   	   	   	   	   	   	  
MUC5B	  genotype	   	   	   	   	   	   	  Immunosuppressed	  (Yes/No)	   	   	   	   	   	   	  6MW	  Distance	  covered	  (m)	   	   	   	   	   	   	  
Table	  3.5.	  Factor	  loadings	  from	  exploratory	  principal	  component	  analysis.	  Factor	  loadings	  smaller	  than	  0.4	  have	  not	  been	  presented.	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3.4 Discussion	  
3.4.1 Recruitment	  and	  Demographics	  A	   substantial	   number	   of	   subjects	   were	   screened	   to	   take	   part	   in	   the	   study	   but	   were	  subsequently	  determined	  ineligible.	  The	  majority	  were	  excluded	  on	  screening	  of	  notes	  and	   results,	   predominantly	   due	   to	   the	   strict	   inclusion	   criteria	   and	   the	   recruitment	   of	  only	   incident	   cases.	   Face	   to	   face	   screening	   excluded	   nine	   further	   patients	   with	  suspected	   IPF	   as	   they	   reported	   symptoms	   of	   a	   lower	   respiratory	   tract	   infection	   or	  antibiotic	   usage	   in	   the	   preceding	   three	  months.	   The	   rates	   of	   exclusion	   at	   face	   to	   face	  screening	  was	  so	  low	  because	  prior	  to	  assessment	  at	  the	  interstitial	  lung	  disease	  unit	  all	  patients	   have	   already	   undergone	   High	   Resolution	   Computed	   Tomography	   (HRCT)	  scans,	   Pulmonary	   Function	   Tests	   (PFTs)	   and	   serological	   investigations	   for	   known	  causes	  of	  ILD.	  This	  combined	  with	  detailed	  referral	  letters	  received	  from	  secondary	  care	  centres	   allowed	   screening	   to	   be	   extremely	   effective.	   The	   high	   enrolment	   rates	   reflect	  the	  motivation	   of	   patients	  with	   IPF	   to	   participate	   in	   research,	   and	   as	   this	  was	  not	   an	  interventional	   study,	   there	  was	  very	   little	  other	   commitment	   from	  subjects	  outside	  of	  routine	   clinical	   care.	   This	  was	   reflected	   in	   the	   fact	   that	   only	   one	   subject	   dropped	  out	  during	  the	  course	  of	  the	  study.	  A	  final	  diagnosis	  of	   IPF	  was	  made	  following	  multidisciplinary	  team	  discussion.	   	  Ten	  of	  the	  recruited	  patients,	  who	  did	  not	  fulfil	  the	  ATS	  diagnostic	  criteria	  for	  IPF	  (Raghu	  et	  al.	  2011),	   were	   subsequently	   excluded	   from	   the	   study.	   The	   remaining	   100	   IPF	   subjects	  were	   predominantly	   male	   with	   a	   mean	   age	   of	   68	   years,	   and	   had	   moderately	   severe	  disease	   (Carbon	   Monoxide	   Diffusing	   Capacity	   [DLCO]	   44.7%	   predicted;	   FVC	   76.5%	  predicted).	  This	  cohort	   is	   typical	  of	  a	  referral	  centre	  population,	  with	   the	   IPF	  subjects	  being	  slightly	  younger	  than	  cohorts	  drawn	  from	  primary	  or	  secondary	  practice	  where	  the	  median	  age	  is	  70	  years	  (Wells	  2013).	  The	  cohort	  is	  well	  matched	  to	  all	  the	  large	  IPF	  trial	   populations	   from	  which	   the	  majority	   of	   our	   understanding	   of	   disease	   behaviour	  originates.	  The	  annual	  rate	  of	  decline	  in	  FVC	  was	  0.18	  litres,	  while	  33%	  of	  patients	  had	  a	  decline	  in	  FVC	   of	   more	   than	   10%	   in	   12	   months.	   This	   matches	   the	   rate	   of	   decline	   seen	   in	   the	  placebo	  arms	  of	   the	  pooled	   INPULSIS	   studies	   (0.2	   litres)	  and	   the	  PANTHER-­‐IPF	  study	  (0.19	  litres)	  (Raghu	  et	  al.	  2012;	  Richeldi	  et	  al.	  2014).	  Thirty	  nine	  percent	  of	  the	  placebo	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arm	  in	  INPULSIS	  experienced	  a	  decline	  of	  greater	  than	  10%	  in	  FVC	  (Richeldi	  et	  al.	  2014)	  and	  31%	  of	  the	  placebo	  arm	  in	  the	  combined	  CAPACITY	  suffered	  a	  similar	  decline,	  again	  suggesting	   this	   cohort	   of	   IPF	   patients	   is	  well	  matched	   to	   large	   published	   IPF	   cohorts	  (Richeldi	  et	  al.	  2014;	  Noble	  et	  al.	  2011).	  
3.4.2 Genotype	  The	  observed	  frequency	  of	  the	  MUC5B	  polymorphism	  minor	  allele	  (T)	  among	  the	  cohort	  (38%)	  is	  similar	  to	  previous	  observations	  in	  IPF	  cohorts	  (Peljto	  et	  al.	  2013;	  Stock	  et	  al.	  2013;	  Seibold	  et	  al.	  2011).	  While	  this	  polymorphism,	  in	  the	  promoter	  of	  the	  mucin	  gene,	  confers	  an	   increased	  risk	  of	  developing	   IPF,	   it	  paradoxically	  confers	  a	  survival	  benefit	  amongst	   patients	   with	   IPF	   (Peljto	   et	   al.	   2013).	   In	   the	   cohort	   under	   study	   here,	  heterozygous	  (GT)	  and	  homozygous	  (TT)	  subjects	  were	  also	  at	  significantly	  lower	  risk	  of	   mortality,	   hazard	   ratios	   0.37	   and	   0.18,	   hazards	   ratios	   almost	   identical	   to	   those	  reported	  by	  Peljto	  et	  al.	  (GT	  and	  TT	  genotypes	  HR	  were	  0.39	  and	  0.15	  respectively).	  
3.4.3 Bronchoscopy	  The	  role	  of	  BAL	  in	  IPF	  remains	  controversial	  and	  current	  guidelines	  do	  not	  recommend	  it	  routinely	  (Raghu	  et	  al.	  2011).	  Typical	  findings	  are	  that	  of	  a	  non-­‐specific	  neutrophilia,	  with	  or	  without	  an	  accompanying	  eosinophilia,	  and	  a	  lymphocytosis	  under	  25%	  of	  the	  differential	  cell	   count	   (P	  Spagnolo,	  Richeldi,	  and	  Raghu	  2009;	  Wells	  2010).	  Despite	   its	  critics	   it	   does	   however	   remain	   a	   useful	   tool	   for	   excluding	   other	   causes	   of	   Usual	  Interstitial	   Pneumonia	   (UIP),	   specifically	   chronic	   hypersensitivity	   pneumonitis	   where	  there	  is	  prominent	  lymphocytosis	  (greater	  than	  40%	  of	  total	  cells)	  (Meyer	  et	  al.	  2012).	  The	  differential	  cell	  count	  presented	  here	  with	  both	  a	  neutrophilia	  and	  eosinophilia	   is	  typical	   of	   IPF.	   None	   of	   the	   subjects	   had	   a	   lymphocytosis	   above	   30%	   of	   the	   of	   the	  differential	  cell	  count	  with	  the	  average	  being	  17%.	  Although	  it	  has	  been	  postulated	  that	  a	  marked	  neutrophilia	  is	  indicative	  of	  a	  more	  progressive	  course	  in	  IPF	  (Boomars	  et	  al.	  1995;	  Watters	  et	  al.	  1987)	  no	  correlation	  was	  seen	  between	  any	  of	  the	  cell	  counts	  and	  survival	  or	  mortality.	  
3.4.4 Predicting	  Mortality	  Identifying	  patients	  with	  increased	  risk	  for	  mortality	  is	  important	  to	  allow	  prompt	  and	  timely	  referral	  for	  lung	  transplant	  assessment.	  Neither	  age	  nor	  smoking	  history	  carried	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an	  increased	  risk	  of	  mortality	  in	  this	  cohort,	  fitting	  in	  with	  the	  conflicting	  reports	  of	  the	  association	   of	   both	   of	   these	  with	  mortality	   (Schwartz	   et	   al.	   1994;	   Luckhardt,	   Müller-­‐Quernheim,	  and	  Thannickal	  2012;	  Flaherty	  et	  al.	  2002;	  T	  E	  King,	  Schwarz,	  et	  al.	  2001).	  Baseline	   lung	   function	   in	   general	   has	   not	   proven	   helpful	   in	   predicting	   decline	   in	   IPF	  (Raghu	   et	   al.	   2011)	   and	   again	   in	   this	   current	   study	   absolute	   values	   have	   not	   proven	  effective.	  A	  DLCO	  of	  less	  than	  40%	  predicted	  has	  however	  been	  shown	  to	  be	  associated	  with	  an	  increased	  risk	  of	  death	  (Egan	  et	  al.	  2005).	  This	  prior	  association	  was	  confirmed	  within	   the	   cohort	   of	   this	   study	   with	   individuals	   having	   a	   baseline	   DLCO	   below	   40%	  predicted	   to	   be	   at	   a	   higher	   risk	   of	   mortality	   (HR	   2.6,	   P=0.025).	  Whilst	   baseline	   lung	  function	  has	  not	  allowed	  accurate	  prediction	  of	  mortality,	   longitudinal	  changes	   in	  FVC	  have	  been	  reliably	  associated	  with	  decreased	  survival	  (Richeldi	  et	  al.	  2012;	  Collard	  et	  al.	  2003).	  One	  third	  of	  the	  IPF	  patients	  here	  experienced	  a	  decline	  in	  FVC	  of	  more	  than	  10%	  in	  12	  months.	  This	  carries	  a	  greater	  than	  5	  times	  increased	  risk	  of	  mortality.	  Composite	  scoring	  systems	  performed	  well	  in	  the	  cohort.	  The	  baseline	  CPI	  was	  found	  to	  correlate	   strongly	   with	   mortality	   (Spearman’s	   ρ=0.48,	   P=8.0e-­‐25)	   and	   dichotomizing	  the	   cohort	   above	   and	   below	   a	   CPI	   of	   40	   strikingly	   demonstrated	   that	   there	  were	   no	  deaths	   in	   patients	  with	   a	   CPI	   below	   40.	   The	   GAP	   score	   at	   baseline	  was	  more	  weakly	  correlated	  with	  mortality	   (Spearman’s	  ρ=0.216,	  P=4.9e-­‐31)	  but	   its	   subsequent	  staging	  system	  allowed	  relatively	  accurate	  prediction	  of	  mortality	  in	  the	  cohort.	  	  Note	  however	  that	  the	  two-­‐year	  mortality	  in	  Stage	  one	  subjects	  was	  higher	  than	  predicted.	  
3.4.5 Exploratory	  Analysis	  of	  the	  Phenotypic	  Data	  Comparing	   the	   correlation	   and	   clustering	   of	   phenotypic	   information	   for	   the	   100	   IPF	  subjects,	   a	   number	   of	   patterns	   emerged	   and	   redundant	   entries	   become	   obvious.	  Examining	   the	  phenotypic	   traits	  encompassed	  within	  each	  of	   the	   four	  clusters	  reveals	  the	  first	  cluster	  encompasses	  markers	  of	  disease	  progression,	  the	  second	  body	  habitus,	  gender	  and	  smoking,	  the	  third	  BAL	  cell	  counts	  and	  a	  final	  cluster	  representing	  markers	  of	  baseline	  lung	  function	  and	  disease	  severity.	  Here	  the	  composite	  end	  point	  (death	  or	  decline	  in	  FVC	  >10	  or	  decline	  in	  DLCO	  >15)	  unsurprisingly	  clustered	  with	  mortality	  and	  a	   decline	   in	   CPI	   (reflecting	   changes	   in	   both	   FVC	   and	  DLCO).	   The	   binary	   (FVC	   decline	  >10%	   (Relative	  &	  Absolute))	   and	   continuous	   (FVC	  %	  Decline)	  metrics	   used	   to	   assess	  change	  in	  FVC	  all	  clustered	  together,	  as	  did	  those	  used	  to	  measure	  DLCO.	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Age,	   MRC	   dyspnoea	   score	   and	   desaturation	   during	   6MWT	   all	   grouped	   together.	   An	  increasing	  MRC	  Breathlessness	  score	  reflected	  the	  impact	  of	  breathing	  on	  walking	  and	  daily	  activities	  so	  again	  this	  clustering	  was	  somewhat	  not	  unexpected.	   It	  suggests	  that	  the	   continuous	   MRC	   dyspnoea	   score	   could	   be	   used	   instead	   of	   the	   dichotomous	   and	  arbitrary	   cut	   off	   of	   desaturation	   on	   6MWT.	   The	   markers	   of	   baseline	   disease	   activity	  clustered	  together	  with	  both	  the	  CPI	  and	  GAP	  score	  and	  stage.	  Again	  the	  continuous	  and	  discrete	  variables	  for	  both	  DLCO	  and	  CPI	  correlated	  together.	  Height	   and	   gender	   and	   BMI	   and	   weight	   clustered	   with	   each	   other,	   whilst	   smoking	  history	   was	   found	   to	   cluster	   with	   FEV1/FVC	   ratio	   presumably	   reflecting	   the	   link	  between	   smoking	   and	   emphysema.	   Survival	   clustered	   with	   MUC5B	   genotype	   and	  immunosuppression.	  We	  had	  already	  observed	  the	  impact	  of	  the	  minor	  allele	  of	  MUC5B	  on	  survival	  in	  (Section	  3.3.6)	  and	  recently	  the	  detrimental	  effect	  of	  immunosuppression	  with	  corticosteroids	  has	  been	  demonstrated	  (Raghu	  et	  al.	  2012).	  The	   exploratory	   factor	   analysis	   suggests	   a	   number	   of	   similar	   groupings	   to	   the	  phenotypic	  clustering.	  Six	  components	  account	  for	  55%	  of	  the	  total	  variance	  across	  the	  samples	  and	  a	  number	  of	  components	  represent	  similar	  process	  to	  the	  clustering,	  such	  as	  disease	  progression,	  baseline	  lung	  function	  and	  size	  and	  gender.	  Exploratory	  Factor	  Analysis	   (EFA)	   provides	   a	   statistical	  weight	   to	   each	   factor	   allowing	   assessment	   of	   its	  contribution	  to	  a	  component.	  There	  were	  7	  phenotypic	  variables	  that	  did	  not	  load	  onto	  the	  first	  6	  components	  of	  the	  matrix:	   Smoking	   (Ever/Never),	   DLCO	   decline	   >15	   (%	   Predicted),	   6MWT	   Distance	  covered,	   immunosuppression,	  PaO2,	  MUC5B	   genotype	  and	  survival.	  This	   suggests	   that	  they	   do	   not	   play	   a	   significant	   role	   in	   the	   variance	   of	   the	   cohort,	   although	   it	   does	   not	  mean	  they	  should	  necessarily	  be	  disregarded.	  This	   exploratory	   analysis	   aimed	   to	   better	   understand	   the	   structure	   of	   the	   data	   and	  suggests	   that	   a	   number	   of	   redundant	   variables	   measuring	   similar	   outcomes	   can	   be	  excluded	   when	   conducting	   downstream	   analyses.	   All	   subjects	   have	   a	   measure	   of	  baseline	   oxygen	   saturation	   whilst	   some	   do	   not	   have	   arterial	   readings	   and	   therefore	  PaO2	  will	  not	  be	  used.	  Height	  and	  weight	  are	   likewise	  redundant	  with	  the	   inclusion	  of	  BMI	   and	   will	   therefore	   be	   disregarded.	   Although	   the	   debate	   regarding	   the	   use	   of	   an	  absolute	  or	  relative	  decline	  in	  FVC	  as	  a	  marker	  of	  disease	  progression	  rolls	  on	  (Richeldi	  et	  al.	  2012)	  here	  the	  two	  correlate	  well	  together	  but	  the	  relative	  decline	  carries	  a	  higher	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loading	  in	  the	  EFA	  and	  therefore	  will	  be	  used.	  Decline	  in	  DLCO	  of	  over	  15%	  predicted	  clustered	  with	   other	  markers	   of	   disease	  progression	  but	  was	   found	  not	   to	   contribute	  significantly	   to	   the	   variance	   within	   the	   cohort	   as	   it	   does	   not	   load	   onto	   the	   first	   6	  principal	  components.	  It	  will	  therefore	  not	  be	  used	  in	  downstream	  analyses.	  	  The	  CPI	   correlated	  more	   strongly	  with	   survival	   than	   the	  GAP	   score	   or	   index	   and	  will	  therefore	  be	  used	  in	  subsequent	  analyses	  as	  a	  marker	  of	  progression	  by	  assessing	  for	  a	  rise	  in	  over	  10	  points.	  	  
3.5 Conclusions	  This	  chapter	  demonstrates	  that	  the	  recruited	  IPF	  patients	  are	  comparable	  to	  those	  of	  a	  typical	   IPF	   cohort.	   It	   demonstrates	   the	   poor	   prognosis	   a	   diagnosis	   of	   IPF	   carries	   and	  confirms	  a	  number	  of	  known	  markers	  of	  poor	  prognosis.	  The	   exploratory	   analysis	   suggests	   that	   the	   42	   phenotypic	   traits	   recorded	   can	   be	   cut	  down	   to	   a	   smaller	   list	   of	   32	   for	   further	   analysis	   in	   the	   following	   chapters.	   This	  conservative	   approach	   retains	   a	   number	   of	   variables	   that	   assess	   the	   same	   factor	   in	   a	  continuous	  and	  dichotomous	  manner,	  where	  it	  has	  been	  proven	  a	  certain	  cut	  off	  informs	  prognosis.	  With	  a	   larger	  cohort	  of	  subjects	  true	  phenotypic	  clustering	  in	  IPF	  would	  be	  feasible,	  as	  has	  been	  applied	  to	  a	  number	  of	  respiratory	  diseases.	  	  This	  would	  allow	  one	  to	  attempt	  to	  split	   large	  groups	  of	  subjects	   into	  smaller	  cohorts	  and	  in	  turn	  assess	  the	  individual	  group	  behaviours	  and	  response	  to	  treatments.	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Chapter	  4:	  The	  Respiratory	  Microbiome	  in	  IPF	  
4.1	   Introduction	  Consistent	  clues	  with	  regard	  to	  the	  aetiology	  of	  IPF	  have	  been	  that	  it	  occurs	  primarily	  in	  older	  adults,	  many	  of	  whom	  have	  been	  smokers,	  and	  that	  polymorphisms	  predisposing	  to	  the	  disease	  are	  in	  genes	  related	  to	  epithelial	  integrity	  and	  host	  defence	  (Seibold	  et	  al.	  2011;	   Noth	   et	   al.	   2013;	   Fingerlin	   et	   al.	   2013;	   Peljto	   et	   al.	   2013;	   Lawson,	   Loyd,	   and	  Degryse	   2011).	   Epidemiological	   studies	   have	   highlighted	   occupational	   and	   domestic	  exposures	   associated	   with	   an	   increased	   risk	   of	   developing	   IPF	   (Taskar	   and	   Coultas	  2006),	   suggesting	   that	   environmental	   triggers	  may	   be	   integral	   to	   the	   pathogenesis	   of	  IPF	  in	  genetically	  susceptible	  individuals.	  	  The	  histological	  pattern	  of	   fibrosis	   in	   IPF	   is	   consistent	  with	  multiple	  discrete	  alveolar	  epithelial	  injuries,	  supporting	  a	  model	  of	  repeated	  exposure	  and	  injury.	  Although	  factors	  which	   initiate	   the	   fibrotic	   process	   have	   not	   yet	   been	   identified,	   susceptibility	   to	  infection	  may	  be	  an	  important	  contributor	  to	  disease	  progression	  (I.	  V	  Yang	  et	  al.	  2012).	  While	  viruses	  may	  play	  a	  part	  in	  the	  initiation	  and	  progression	  of	  disease	  as	  well	  as	  be	  responsible	   for	  a	  proportion	  of	   acute	  exacerbations	   (Wootton	  et	   al.	   2011),	   the	   role	  of	  bacteria	   in	   the	  pathogenesis	  and	  progression	  of	   IPF	  has	  as	  yet	   to	  be	  studied	   in	  detail.	  Active	  infection	  in	  IPF	  is	  however	  known	  to	  carry	  a	  high	  morbidity	  and	  mortality	  (Song	  et	  al.	  2011).	  In	  individuals	  with	  IPF	  immunosuppression	  is	  clearly	  deleterious	  (Raghu	  et	  al.	  2012).	  The	   aim	   of	   this	   chapter	   is	   to	   investigate	   the	   role	   of	   bacteria	   in	   the	   pathogenesis	   and	  progression	  of	  IPF	  using	  molecular	  techniques,	  16s	  qPCR	  and	  pyrosequencing,	  and	  BAL	  samples	   from	  IPF	  subjects	  and	  controls.	  As	   IPF	  often	  appears	  against	  a	  background	  of	  smoking-­‐related	   lung	   disease,	   patients	   with	   COPD	   and	  matched	   numbers	   of	   smokers	  were	   included	   in	   the	   control	   groups.	   The	   hypotheses	   examined	   were	   (i)	   that	   the	  microbiome	  and/or	  bacterial	  burden	  differs	  between	  IPF	  patients	  and	  controls,	  and	  (ii)	  that	   within	   the	   IPF	   cohort	   the	   microbiome	   and/or	   bacterial	   burden	   correlates	   with	  disease	  progression.	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4.2	   Materials	  and	  Methods	  
4.2.1	   Study	  Population	  IPF	  patients	  were	  prospectively	  recruited	  from	  the	  Interstitial	  Lung	  Disease	  Unit	  at	  the	  Royal	   Brompton	   Hospital,	   London,	   England	   as	   described	   in	   Chapter	   2,	   Section	   2.1.1.	  Control	   subjects	   included	   non-­‐smokers	   and	   smokers	   with	   normal	   lung	   function	  (referred	   to	   throughout	   as	   healthy	   controls)	   and	   individuals	   with	   moderate	   (GOLD	  Stage	   II)	   Chronic	   Obstructive	   Pulmonary	   Disease	   (COPD)	   were	   recruited	   separately	  using	  the	  same	  protocols	  (Chapter	  2,	  Sections	  2.1.2	  &	  2.1.3).	  
4.2.2	   DNA	  Extraction,	  Quantification	  and	  Quality	  Assessment	  The	  samples	  were	  processed	  at	  the	  time	  of	  collection	  and	  subsequently	  stored	  at	  -­‐80oC.	  The	  samples,	  two	  2	  ml	  aliquots	  of	  BAL,	  were	  thawed	  and	  then	  centrifuged	  at	  20,000	  g	  for	   15	  minutes,	   to	   pellet	   cell	   debris	   and	   bacteria.	   The	   pellets	  were	   re-­‐suspended	   in	   a	  total	  of	  978	  μl	  Sodium	  Phosphate	  Buffer	  and	  122	  μl	  MT	  Buffer	  (MPBIO	  first	  lysis	  buffer	  solution)	  and	  extraction	  performed	  using	   the	  MP	  Bio	  FastDNA®	  SPIN	  Kit	   for	  Soil	   and	  the	  quantity	  and	  quality	  of	  extracted	  genomic	  DNA	  was	  measured	  using	  the	  Nanodrop™	  ND	   1000	   UV-­‐Vis	   spectrophotometer	   (Thermo	   Scientific)	   as	   described	   in	   Chapter	   2,	  Section	  2.3.1.	  DNA	  concentrations	  in	  ng/μl	  and	  purity	  were	  determined	  by	  absorbance	  at	  260nm	  and	  the	  ratio	  of	  absorbance	  at	  260nm	  and	  280nm	  (A260/A280),	  respectively.	  
4.2.3	   16S	  rRNA	  gene	  qPCR	  and	  Pyrosequencing	  The	  V3-­‐V5	  region	  of	  the	  bacterial	  16S	  rRNA	  gene	  was	  amplified	  using	  the	  357F	  forward	  primer	  and	  the	  926R	  reverse	  primer	  for	  both	  16S	  qPCR	  and	  pyrosequencing.	  Triplicate	  10	  µl	  qPCR	  reactions	  were	  set	  up	  containing	  1	  µl	  of	  a	  10-­‐fold	  dilution	  of	  template	  DNA	  as	  described	  in	  Chapter	  2,	  Section	  2.3.3.	  All	  data	  were	  analysed	  using	  the	  Corbett	  Rotor-­‐Gene	  6.1	  software.	  For	   pyrosequencing	   the	   V3-­‐V5	   region	   of	   the	   bacterial	   16S	   rRNA	   gene	   was	   amplified	  using	  the	  standard	  forward	  primer	  357F	  and	  a	  modified	  reverse	  primer	  926R,	  barcoded	  to	   tag	   each	   PCR	   product.	   Quadruplicate	   25	   µl	   PCR	   reactions	   were	   set	   up,	   amplified,	  purified	  and	  prepared	  for	  sequencing.	  Single	  direction	  pyrosequencing	  using	  the	  Lib-­‐L	  kit	  was	  performed	  using	  the	  454	  Life	  Sciences	  GS	  FLX	  (Roche)(Chapter	  2,	  Section	  2.3.2).	  The	  barcoded	  pyrosequence	  reads	  were	  processed	  using	  QIIME	  1.7.0	  with	  poor	  quality	  or	  chimeric	  reads	  discarded	  (Chapter	  2,	  Section	  2.3.2.7).	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4.2.4	   Statistical	  Analysis	  Analyses	  were	  conducted	  as	  detailed	  in	  Chapter	  2,	  Section	  2.3.2.8.	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4.3	   Results	  












Value*	  Age	  (yr)	   60	  (+/-­‐8.5)	   58	  (±17.6)	   	   58.2	  (±8.0)	   68	  (±8.2)	   <	  0.0001	  Female	  Sex	  -­‐	  number	  (%)	   5	  (29%)	   12	  (44%)	   	   17	  (28%)	   17	  (28%)	   NS	  Smoking	   (Ever	   v	   Never)	   -­‐	  number	  (%)	   17	  (100%)	   11	  (40%)	   	   28	  (63%)	   43	  (65%)	   NS	  FVC—	  %	   93.0	  (±13)	   104.4	  (±14)	   	   100	  (±14)	   76.5	  (±	  18)	   <	  0.0001	  FEV1	  —	  %	   69.6	  (±15)	   100.4	  (±12)	   	   88.5	  (±19)	   77	  (±15)	   <	  0.005	  Ratio	  of	  FEV1	  to	  FVC	   59.9	  (±9)	   78.6	  (±5)	   	   71.3	  (±11)	   80.0	  (±7)	   <	  0.0001	  DLCO	  -­‐	  %	   72.3	  (±19)	   84.0	  (±16)	   	   78.8	  (±18)	   44.7	  (±13)	   <	  0.0001	  O2	  Saturation—	  %	   96	  (±6)	   97	  (±2)	   	   97	  (±4)	   95	  (±2)	   NS	  6-­‐Minute	  walk	  distance	  -­‐	  m	   NA	   NA	   	   NA	   377.8	  (±124)	   NA	  Inhaled	  Steroid	  Usage	   0	   0	   	   0	   4	   NS	  
Table	  4.1.	  Baseline	  Characteristics	  of	  the	  Subjects.	  Details	  are	  provided	  for	  IPF	  cases,	  COPD	   subjects,	   Healthy	   subjects	   as	   well	   combined	   controls	   (COPD	   plus	   Healthy	  subjects).	   Data	   are	  means	   ±Standard	  Deviation.	   *	  P-­‐Value	   is	   comparison	   between	   the	  IPF	   and	   combined	   control	   group.	   NA=not	   available;	   NS=not	   significant;	   DLCO,	   carbon	  monoxide	  diffusing	  capacity;	  FVC,	  forced	  vital	  capacity;	  FEV1,	  forced	  expiratory	  volume	  in	  one	  second.	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4.3.2	   DNA	  Extraction	  and	  Quality	  Control	  All	   65	   IPF	   samples	   and	   44	   control	   samples	   yielded	   good	   quality	   DNA,	   with	   an	  A260/A280	   ratio	   of	   1.83	   (±0.21).	   The	   average	   yield	   from	   the	   IPF	   samples	  was	   55.29	  ng/μl	   (±32.31)	   and	   from	   the	   control	   patients	   42.11	   ng/μl	   (±20.10)	   (P=0.38,	   Mann	  Whitney).	   All	   of	   these	   samples	   were	   therefore	   taken	   forward	   for	   16s	   qPCR	   and	  pyrosequencing.	  Quantification	   by	   QuanitIT	   Pico	   green	   of	   the	   amplified	   DNA	   established	   the	   average	  yield	  to	  be	  3.27	  ng/µl,	  therefore	  all	  samples	  were	  pooled,	  purified	  and	  sequenced	  on	  the	  Roche	  454	  FLX	  (Section	  4.1.3).	  The	  Roche	  454	  GS	  FLX+	  was	  used	  as	  it	  allowed	  all	  of	  the	  samples	   to	   be	   incorporated	   into	   a	   single	   sequencing	   run.	   This	   ensured	   the	  standardization	   of	   library	   preparation	   across	   all	   samples	   and	   avoided	   introducing	  unnecessary	  (although	  correctable)	  batch	  effect	  which	  would	  have	  occurred	  if	  the	  454	  GS	  Junior	  platform	  had	  been	  used.	  Library	  preparation	  was	  successful	  with	  the	  optimum	  number	  of	  beads	  being	  deposited	  on	  the	  PTP	  plate	  (raw	  wells	  2,447,018).	  The	  reads	  were	  of	  good	  quality	  and	  had	  a	  mean	  fragment	  length	  of	  550	  bp	  (Figure	  4.1).	  
	  
Figure	  4.1:	  Distribution	  of	  Sample	  Reads	  Length.	  The	  average	  read	  length	  is	  550	  bp	  and	  there	  were	  a	  minimal	  number	  of	  read	  fragments.	  Quality	  control	  steps	  post	  sequencing	  are	  performed	  using	  the	  Roche	  454	  GS	  software	  (Chapter	  2,	  Section	  2.3.2.7).	  The	  raw	  well	  count	  indicates	  the	  total	  number	  of	  reads	  and	  the	   key	   pass	  well	   indicates	   a	  well	   that	   starts	  with	   a	   valid	   sequence	   (either	   library	   or	  control	   DNA)	   that	   should	   be	   carried	   forwards.	   Dot	   and	   Mixed	   filter	   reads	   suggest	  technical	  problems	  within	  the	  raw	  flowgram	  and	  result	  in	  a	  read	  being	  rejected.	  Roche	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suggest	  that	  the	  Dot	  and	  Mixed	  number	  of	  reads	  should	  be	  <20%	  of	  the	  total	  number	  of	  passed	   filter	   wells.	   Further	   reads	   are	   then	   rejected	   if	   they	   are	   far	   shorter	   than	   the	  expected	   fragment	   size.	   Results	   of	   the	  Roche	   454	  GS	   FLX+	  QC	   are	   given	   in	   Table	   4.2.	  Ninety	   six	   %	   of	   the	   raw	   reads	   contained	   a	   valid	   sequence	   but	   of	   those	   19%	   were	  rejected	  on	  flowgram	  criteria	  and	  a	  further	  37.5%	  were	  rejected	  due	  to	  short	  length.	  Raw	  Wells	   2,447,018	  Key	  Wells	   2,355,547	  Dot	  &	  Mixed	   460,107	  (19.5%)	  Short	  reads	   885,328	  (37.6%)	  Total	  Passed	  Filters	   1,004,106	  (42.6%)	  
Table	  4.2.	  Roche	  Quality	  Control	  Metrics.	  Of	  the	  2,355,547	  reads	  that	  started	  with	  a	  valid	  sequence	  42.6%	  passed	  final	  quality	  control.	  The	  remaining	  1,004,106	  reads	  were	  then	  subjected	  to	  denoising,	  chimera	  checking	  and	  singleton	   removal	   in	   QIIME.	   Following	   this	   a	   total	   of	   912,883	   high	   quality	   reads	  remained.	  The	  distribution	  of	   reads	  was	  not	   evenly	   spread	  over	   the	   samples,	   ranging	  from	  796	   to	  12,329	  reads	  per	   sample.	   In	  order	   to	   control	   for	  bias	  of	  per	   sample	   read	  coverage	  the	  sequences	  were	  randomly	  resampled	  (rarefied)	  to	  the	  same	  minimum	  of	  796	  reads	   for	  all	   subjects	   (Figure	  4.2).	   	  This	  ensured	  retention	  of	  as	  many	  samples	  as	  possible	  for	  the	  downstream	  analyses.	  Next,	   sequences	   were	   clustered	   by	   sequence	   similarity	   into	   Operational	   Taxonomic	  Units	   (OTUs),	  which	  are	  approximately	  analogous	   to	  a	  bacterial	   species,	  and	   this	   final	  dataset	  was	  used	  in	  all	  subsequent	  analyses.	  There	  were	  464	  OTUs	  identified	  across	  the	  IPF	   and	   control	   panels	   and	   less	   than	   5%	   of	   the	   sequences	   were	   unclassifiable	   by	  reference	  to	  the	  SILVA	  reference	  database.	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Figure	   4.2:	   Distribution	   of	   Sequencing	   Reads	   across	   Samples.	  The	  distribution	  of	  reads	  as	  can	  be	  seen	  ranged	  from	  796	  to	  12,329	  per	  sample.	  In	  order	  to	  control	  for	  this	  during	   analysis	   rarification	  was	   performed.	   The	   depth	  which	   to	   rarify	  was	   chosen	   in	  order	   to	   retain	   all	   samples	   in	   the	   downstream	   analysis.	   In	   this	   case	   796	   reads	   was	  chosen,	  indicated	  by	  the	  red	  line.	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4.3.3	   Bacterial	  Burden	  
4.3.3.1	   Bacterial	  Burden	  in	  Health	  and	  Disease	  On	  average	  IPF	  subjects	  had	  1.9x108	  copies	  of	  the	  16S	  rRNA	  gene	  per	  ml	  of	  BAL	  which	  was	  more	   than	   two-­‐fold	   higher	   than	   the	   copy	  number	   in	   controls	   (P<0.0001).	  Within	  the	  controls,	  there	  was	  no	  significant	  difference	  in	  bacterial	  load	  between	  subjects	  with	  COPD	   and	   healthy	   controls	   and	   the	   IPF	   patients	   had	   a	   significantly	   higher	   bacterial	  burden	  than	  both	  control	  subgroups	  (P=0.006	  and	  P=0.0007	  respectively)	  (Figure	  4.3).	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Although	  BAL	  yield	  differed	  between	  IPF	  cases	  and	  controls	  (124.4mls	  ±	  31	  vs.	  96ml	  ±	  41;	   P<0.001)	   there	   was	   no	   relationship	   between	   bacterial	   burden	   and	   BAL	   yield	  (Spearman’s	  ρ=-­‐0.027,	  P=0.78)	  (Figure	  4.4).	  	  
	  
Figure	   4.4:	   Correlation	   of	   bacterial	   burden	   and	   BAL	   return.	   There	   was	   no	  relationship	  between	  bacterial	  burden	  and	  BAL	  yield	  (Spearman’s	  ρ=-­‐0.027,	  P=0.78)	  
4.3.3.2	   Bacterial	  Burden	  and	  MUC5B	  Genotype	  Within	   the	   IPF	   subjects	   the	   bacterial	   burden	   associated	   independently	   with	   the	  
rs35705950	   polymorphism	   in	   the	   promoter	   of	   the	   mucin	   gene	   MUC5B	   genotype	  (P=0.01),	   with	   patients	   possessing	   the	   minor	   allele	   having	   a	   lower	   bacterial	   burden	  (Figure	  4.5).	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Figure	  4.5:	  Bacterial	  burden	   in	   IPF	  patients	  based	  on	  MUC5B	   genotype.	  Bacterial	  burden	  associated	   independently	  with	  the	  rs35705950	  polymorphism	  in	   the	  promoter	  of	   the	   mucin	   gene	   MUC5B	   genotype	   (P=0.01).	   The	   box	   signifies	   the	   25th	   and	   75th	  percentiles,	  and	  the	  median	  is	  represented	  by	  a	  line	  within	  the	  box.	  
4.3.3.3	   Bacterial	  Burden	  and	  Baseline	  Disease	  Severity	  There	   was	   no	   correlation	   between	   bacterial	   burden	   and	   baseline	   disease	   severity,	  measured	   by	   either	   FVC	   (Spearman’s	   ρ=-­‐0.11,	   P=0.49),	   total	   lung	   capacity	   (TLC)	  (Spearman’s	  ρ=-­‐0.12,	  P=0.49),	  carbon	  monoxide	  diffusion	  capacity	  (DLCO)	  (Spearman’s	  ρ=-­‐0.20,	  P=0.21)	  or	  the	  composite	  physiologic	  index	  (CPI)	  (Spearman’s	  ρ=0.06,	  P=0.70).	  There	  were	  also	  no	  correlations	  between	  the	  bacterial	  load	  and	  cell	  counts,	  differentials,	  or	  inflammatory	  response	  in	  the	  BAL.	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a	  composite	  of	  either	  a	   relative	  decline	   in	  FVC	  of	  greater	   than	  10%	  or	  death	  before	  6	  months.	   Individuals	   with	   IPF	   whose	   disease	   had	   progressed	   at	   six	   months	   (N=22)	  demonstrated	  a	   significantly	  higher	  BAL	  bacterial	  burden	  when	   compared	   to	   subjects	  with	  stable	  disease	  (2.35x108	  ±1.68x108	  compared	  to	  1.41x108	  ±1.40x108	  copies	  of	   the	  16S	  rRNA	  gene	  per	  ml	  of	  BAL;	  P=0.02).	  	  
	  
Figure	  4.6:	  Bacterial	  burden	  in	  IPF	  patients	  with	  progressive	  and	  stable	  disease.	  IPF	  patients	  who	  experience	  a	  decline	  in	  FVC	  or	  death	  (red)	  (N=22)	  had	  a	  significantly	  higher	  bacterial	  burden	  than	  subjects	  with	  stable	  disease	  (blue)	  (P=0.02).	  To	   investigate	   this	   relationship	   further,	   the	   IPF	   subjects	   were	   separated	   into	   tertiles	  based	  on	  the	  16S	  rRNA	  gene	  copy	  number	  per	  ml	  of	  BAL.	  Individuals	  in	  the	  top	  tertile	  with	   the	   highest	   bacterial	   burden	  were	   at	   a	   substantially	   increased	   risk	   of	   mortality	  compared	  to	  subjects	  in	  the	  bottom	  tertile	  (i.e.	  those	  with	  the	  lowest	  bacterial	  burden)	  (Hazard	  Ratio	  4.59	  (95%	  Confidence	  Interval	  [CI],	  1.05-­‐20,	  P=0.04)	  (Figure	  4.7).	  
	  	   103	  
Figure	  4.7:	  Kaplan–Meier	  Curves	  for	  Time	  until	  Death.	  Subjects	  with	  IPF	  in	  the	  top	  tertile	   with	   the	   highest	   bacterial	   load	   (16S	   copy	   number	   per	   mL	   of	   bronchoalveolar	  lavage)	  (depicted	  by	  the	  large	  dashed	  line)	  were	  at	  increased	  risk	  of	  mortality	  compared	  to	  IPF	  subjects	  in	  the	  tertile	  with	  the	  lowest	  bacterial	  burden	  (depicted	  by	  a	  solid	  line)	  (Hazard	  Ratio	  4.59	  (95%	  Confidence	  Interval	  [CI],	  1.05-­‐20).	  
4.3.4	   Microbiota	  
4.3.4.1	   Microbiota	  in	  Health	  and	  Disease	  
Streptococcus,	  representing	  30%	  of	   total	   reads,	  was	   the	  most	  common	  genus	  detected	  by	  sequencing	  in	  subjects	  with	  IPF.	  Prevotella	  (10.9%)	  and	  Veillonella	  (10.6%)	  were	  the	  second	  and	  third	  most	  prevalent.	  In	  the	  control	  subjects	  this	  order	  was	  preserved	  with	  
Streptococcus	   forming	   the	   most	   common	   genus	   (27.1%	   of	   total	   reads)	   followed	   by	  
Prevotella	   (11.6%)	  and	  Veillonella	   (7.1%).	  There	  were	  no	  significant	  differences	   in	  the	  BAL	   microbiota	   between	   the	   healthy	   controls	   and	   subjects	   with	   COPD.	   The	   baseline	  microbiota	  of	  the	  IPF	  subjects	  did	  however	  differ	  from	  that	  of	  controls	  (Figure	  4.8).	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In	  patients	  compared	  to	  controls,	   there	  was	  a	  3.4	   fold	   increase	   in	  sequence	  reads	  of	  a	  potentially	  pathogenic	  Haemophilus	   sp.	   (OTU	  739)	  (36.0	  ±	  7.5	  vs.	  10.5	  sequences	  ±1.9	  sequences;	  P<0.001);	  a	  2.1	  fold	  increase	  in	  a	  Neisseria	  sp.	  (OTU	  594)	  (57.9	  ±	  9.4	  vs.	  27.5	  ±	  5.5	  sequences;	  P<0.01);	  a	  1.4	  fold	  increase	  in	  a	  Streptococcus	  sp.	  (OTU	  881)	  (113.6	  ±	  11.4	  vs.	  82.2	  ±	  8.9	  sequences;	  P<0.05);	  and	  a	  1.5	  fold	  increase	  in	  a	  Veillonella	  sp.	  (OTU	  271)	  (84.8	  ±	  5.7	  vs.	  56.6	  ±	  4.5	  sequences;	  P<0.001)	  (Figure	  4.9).	   	  Exclusion	  of	  subjects	  with	  COPD	  from	  the	  control	  panel	  did	  not	  change	  the	  differences	  detected.	  
Figure	   4.9	   Differences	   in	   Bacterial	   OTU	   frequencies	   between	   IPF	   and	   control	  
subjects.	  Box	  plots	  showing	  significant	  differences	  (P<0.01)	  in	  OTUs	  between	  controls	  (blue)	   and	  patients	  with	   IPF	   (red).	  Triangles	   represent	  COPD	   subjects,	   circles	  healthy	  controls	  and	  squares	  IPF	  subjects.	  The	  box	  signifies	  the	  25th	  and	  75th	  percentiles,	  and	  the	  median	  is	  represented	  by	  the	  line	  within	  the	  box.	  The	  representative	  sequences	  of	  both	  the	  Neisseria	  sp.	  (OTU	  594)	  and	  Haemophilus	  sp.	  (OTU	  739)	  were	  incorporated	  into	  phylogenetic	  trees	  constructed	  from	  SILVA	  reference	  sequences	   (Molyneaux	   et	   al.	   2013).	   This	   enabled	   the	   confident	   identification	   of	   these	  OTUs	   as	   Haemophilus	   influenzae	   (Figure	   4.10)	   and	  Neisseria	   subflava	   or	  N.	   flavescens	  (Figure	  4.11).	  Streptococcus	  sp.	  (OTU	  881)	  and	  Veillonella	  sp.	  (OTU	  271)	  did	  not	  cluster	  with	  enough	  significance,	  on	  the	  reference	  tree,	  to	  enable	  them	  to	  be	  further	  identified	  with	  any	  confidence.	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Figure	  4.10:	  Phylogenetic	  identification	  of	  Haemophilus	  Sp.	  OTU	  739	  Phylogenetic	  analysis	  of	  the	  representative	  sequence	  of	  OTU	  739	  shows	  there	  is	  strong	  clustering	  of	  this	   bacterium	   within	   the	   Haemophilus	   genus.	   Bootstrapping	   analysis	   provides	   a	  method	  to	  judge	  the	  strength	  of	  confidence	  for	  nodes	  on	  phylogenetic	  trees.	  A	  value	  of	  greater	  than	  95%	  seen	  here	  supports	  confident	  assignment	  of	  this	  OTU	  as	  Haemophilus	  
influenzae.	   The	   scale	   bar	   indicates	   10%	   sequence	   divergence,	   and	   NCBI	   accession	  numbers	   are	   included.	   Out	   Group	   constructed	   with	   sequences	   from	   Morganella	  
morganii,	  Proteus	  mirabilis	  and	  Providencia	  stuartii.	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Figure	  4.11.	  Phylogenetic	  identification	  of	  Neisseria	  OTU	  594.	  Phylogenetic	  analysis	  of	   the	   representative	   sequence	   of	   OTU	   594	   assigned	   taxonomically	   to	   the	   Neisseria	  
subflava	  or	  flavescens	  species.	  Bootstrap	  values	  of	  >	  95%	  are	  shown	  as	  filled	  circles	  and	  those	  between	  75%	  and	  95%	  as	  unfilled	  circles.	  The	  scale	  bar	  indicates	  10%	  sequence	  divergence,	  and	  NCBI	  accession	  numbers	  are	  included.	  The	  tree	  was	  rooted	  with	  a	  near	  neighbor	  Out	  Group	  constructed	  with	  sequences	  from	  Conchiformibius	  spp.	  The	  microbial	  communities	  of	  IPF	  subjects	  were	  less	  diverse	  (Shannon's	  Diversity	  Index	  3.81	  ±	  0.08	  vs.	  4.11	  ±	  0.10;	  P=0.005)	  and	  contained	  fewer	  OTUs	  (44.89	  ±	  1.50	  vs.	  54.33	  ±	  1.86	  OTUs;	  P<0.0001)	  than	  the	  control	  subjects	  (Figure	  4.12).	  
	  
Figure	   4.12:	   Alpha	   diversity	   differences	   between	   IPF	   and	   control	   subjects.	   Box	  plots	   showing	   significant	   differences	   (P<0.01)	   in	   OTUs	   between	   controls	   (blue)	   and	  patients	  with	  IPF	  (red).	  Triangles	  represent	  COPD	  subjects,	  circles	  healthy	  controls	  and	  squares	  IPF	  subjects.	  The	  box	  signifies	  the	  25th	  and	  75th	  percentiles,	  and	  the	  median	  is	  represented	  by	  the	  line	  within	  the	  box.	  
4.3.4.2	   Microbiota	  and	  MUC5B	  Genotype	  For	  patients	  possessing	  the	  minor	  allele	  of	  the	  MUC5B	  gene,	  although	  they	  were	  found	  to	  have	  a	   lower	  bacterial	  burden	   (Chapter	  4.3.3.2)	   there	  was	  no	   significant	  difference	  between	  the	  microbiota	  (at	  Phylum	  or	  Genera	  level)	  based	  on	  genotype	  (Phylum	  level	  data	  shown	  Figure	  4.13).	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Figure	  4.13.	  Phylum	  level	  summary	  of	  the	  microbiota	  based	  on	  MUC5B	  genotype.	  No	  significant	  difference	  in	  the	  microbiota	  between	  subjects	  is	  observed.	  
4.3.4.3	   Microbiota	  and	  Baseline	  Disease	  Severity	  Previously	  at	  baseline	  the	  CPI	  was	  found	  to	  positively	  correlate	  with	  mortality	  (Chapter	  3.3.5)	  and	  a	  baseline	  CPI	  of	  below	  40	  demonstrated	  to	  carry	  a	  poorer	  prognosis.	  Despite	  this	   no	   difference	   in	   the	   baseline	   microbiota	   between	   subjects	   with	   a	   CPI	   above	   or	  below	  40	  was	  observed	  (Figure	  4.14).	  	  
	  
Figure	  4.14.	  Phylum	   level	   summary	  of	   the	  microbiota	  based	  on	  baseline	  CPI.	  As	  can	  be	  seen	  there	  is	  no	  difference	  in	  the	  microbiota	  between	  subjects	  with	  a	  CPI	  above	  or	  below	  40.	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4.3.4.4	   Microbiota	  and	  Disease	  Progression	  There	  were	  no	  demonstrable	  changes	  in	  community	  structure	  or	  composition	  between	  IPF	  patients	  with	  progressive	  or	  stable	  disease,	  as	  determined	  by	  FVC	  decline	   (Figure	  4.15),	  despite	  the	  differences	  in	  overall	  bacterial	  burden	  (Chapter	  4.3.3.4.)	  	  
	  
Figure	  4.15:	  Phylum	  level	  summary	  of	  the	  microbiota	  based	  on	  FVC	  decline.	  As	  can	  be	  seen	  there	  is	  no	  significant	  difference	  in	  the	  microbiota	  between	  subjects	  whose	  FVC	  declined	  by	  10%	  compared	  to	  those	  whose	  FVC	  remained	  stable.	  Similarly	   no	   significant	   differences	   in	   the	  microbiota	  were	   seen	  when	   subjects	   in	   the	  lowest	  versus	  the	  	  highest	  tertiles	  of	  bacterial	  burden	  were	  compared	  (Figure	  4.16).	  
	  
Figure	   4.16.	   Phylum	   level	   summary	   of	   the	  microbiota	   based	   on	   16S	   qPCR	   load.	  There	  is	  no	  significant	  difference	  in	  the	  microbiota	  between	  subjects	  in	  the	  three	  tertiles	  of	  bacterial	  burden.	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4.3.5	   The	  Interaction	  of	  Bacterial	  burden	  and	  the	  Microbiome	  Stepwise	   logistic	   regression	  was	  performed	   to	  examine	  whether	  bacterial	  burden	  and	  the	   relative	  abundance	  of	   the	   four	   significantly	  different	  OTUs	   (Haemophilus	   sp.	   (OTU	  739),	  Neisseria	  sp.	  (OTU	  594),	  Streptococcus	  sp.	  (OTU	  881)	  and	  Veillonella	  sp.	  (OTU	  271)	  were	  associated	  independently	  with	  a	  diagnosis	  of	  IPF.	  Age	  was	  included	  in	  the	  model	  to	  control	  for	  possible	  confounding.	  Total	  bacterial	  burden	  and	  the	  numbers	  of	  three	  of	  the	  four	  specific	  OTUs	  (Veillonella	  sp.	  [OTU	  271],	  Neisseria	  sp.	  [OTU	  594]	  and	  Streptococcus	  sp.	   [OTU	  881])	   all	   remained	   significantly	   associated	  with	   a	  diagnosis	  of	   IPF	   (P=0.001,	  0.007	  and	  0.01	   respectively).	  The	  overall	  R2	  was	  0.66	  with	   age	   in	   the	  model	   and	  was	  0.51	  without	  age.	  The	  abundance	  of	  Haemophilus	  OTU	  739	  was	  strongly	  correlated	  with	  
Neisseria	   OTU	   594	   (Spearman’s	   ρ=0.42).	   Removal	   of	  Neisseria	   from	   the	   model	   made	  
Haemophilus	  OTU	  739	  significant	  (P=0.02;	  β=0.038±0.016)	  with	  minimal	  change	  in	  the	  overall	  multivariate	  R2	  (0.657).	  	  These	   data	   indicate	   that	   total	   bacterial	   load	   and	   abundances	   of	   these	   specific	   OTUs	  provide	  independent	  predictors	  of	  IPF	  case	  status	  and	  suggest	  that	  these	  OTUs	  may	  be	  acting	  synergistically	  within	  a	  context	  of	  increased	  load.	  
	   Beta	   SE	   Z	   P	   95%	  CI	  
Constant	   -­‐34.41	   8.740	   -­‐3.938	   <0.001	   -­‐17.28	   -­‐51.54	  
Age	   0.173	   0.041	   4.255	   <0.001	   0.253	   0.094	  
Veillonella	  sp.	  	  (OTU	  271)	   0.032	   0.009	   3.528	   <0.001	   0.050	   0.014	  
Streptococcus	  sp.	  (OTU	  881)	   0.012	   0.004	   2.712	   0.007	   0.018	   0.003	  
Log10	  Copy	  Number	   2.140	   0.824	   2.596	   0.009	   3.755	   0.524	  
Neisseria	  sp.	  (OTU	  594)	   0.020	   0.008	   2.574	   0.010	   0.035	   0.005	  
Table	   4.4:	   Stepwise	   logistic	   regression	   of	   bacterial	   associations	   to	   Idiopathic	  
Pulmonary	  Fibrosis	  compared	  to	  controls.	  Naglekerke's	  R2=0.66.	  Not	  in	  the	  equation:	  
Haemophilus	  sp.	  (OTU	  739),	  P=0.25	  
4.3.6	   Negative	  Controls	  The	   negative	   control	   samples	   (sterile	   saline	   aspirated	   through	   the	   suction	   channel	   of	  the	   bronchoscope	   and	   then	   processed	   simultaneously	   with	   the	   samples)	   yielded	   a	  bacterial	  burden	  close	  to	  or	  below	  the	  lower	  limit	  of	  qPCR	  quantification	  (1000	  copies	  per	  ml).	  Despite	   their	   low	  16s	   qPCR	  yield	   they	  were	   included	   in	   the	   sequencing	  pool	  (Chapter	  2	  Section	  2.3.2.5)	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Pyrosequencing	  yielded	  read	  numbers	  of	  27,	  55,	  72	  and	  102	  reads	  for	  each	  of	  the	  four	  negative	  controls.	  This	  compares	  to	  the	  average	  number	  of	  reads	  for	  the	  remaining	  IPF	  and	  control	  samples	  that	  was	  5851.	  Over	  50%	  of	  the	  reads	  from	  the	  negative	  controls	  were	   assigned	   to	   the	   Proteobacteria	   phylum,	   while	   a	   further	   25%	   were	   assigned	   as	  Firmicutes.	  Their	  composition	  differs	  dramatically	  from	  that	  of	  both	  the	  control	  and	  IPF	  samples	  (Figure	  4.17).	  	  
	  
Figure	   4.17:	   Phylum	   level	   summary	   of	   the	  Negative	   Controls.	  The	  composition	  of	  the	  negative	  control	  sample	  microbiota	  is	  markedly	  different	  to	  samples	  The	   most	   abundant	   OTUs	   could	   only	   be	   assigned	   at	   the	   order	   level	   and	   represent	  
Pseudomonadales,	  Enterobacteriales	  and	  Clostridiales	  spp.	  None	  of	  the	  OTUs	  identified	  in	  the	  IPF	  or	  control	  subjects	  (Section	  4.1.8.1)	  were	  seen	  in	  the	  negative	  control	  samples.	  The	   significant	   differences	   between	   the	  negative	   control	   and	   the	  BAL	   samples	   can	  be	  seen	  in	  Figure	  4.18	  where	  all	  four	  of	  the	  negative	  controls	  are	  demonstrated	  to	  cluster	  separately.	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Figure	  4.18:	  PCoA	  of	   the	  unweighted	  unifrac	  distance	  between	  negative	  controls	  
and	   samples.	   The	   green	   triangles	   represent	   the	   negative	   controls	   and	   cluster	   in	   the	  upper	  left	  quadrant,	  while	  the	  IPF	  subjects	  (Red)	  and	  controls	  (Blue)	  cluster	  separately.	  
4.3.7	   Bacterial	  Culture	  Standard	  microbial	   culture	   of	   BAL	  was	   positive	   for	   potentially	   pathogenic	   bacteria	   in	  five	  cases	  of	  IPF	  (7.6%)	  but	  none	  of	  the	  controls.	  In	  each	  instance,	  the	  cultured	  bacterial	  species	  were	  also	  identified	  by	  the	  pyrosequencing	  data,	  although	  they	  were	  not	  always	  the	  most	  abundant	  species	  within	  the	  microbiota	  (Table	  4.5).	  
Subject	   Culture	  Result	  1099	   Staphylococcus	  aureus	  1054	   Haemophilus	  influenzae	  Pseudomonas	  aeruginosa	  1053	   Haemophilus	  parainfluenzae	  1038	   Staphylococcus	  aureus	  1031	   Moraxella	  catarrhalis	  Streptococcus	  pneumoniae	  
Table	  4.5:	  BAL	  culture	  results.	  Standard	  microbial	  culture	  of	  BAL	  was	  positive	  in	  5	  
cases	  of	  IPF	  (7.6%).	  Microbial	  culture	  for	  the	  remaining	  subjects	  including	  the	  controls	  was	  negative	  for	  potentially	  pathogenic	  bacteria.	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The	   presence	   of	   bacteria	   in	   BAL	   which	   was	   culture	   negative	   but	   yielded	   16S	   rRNA	  product	   was	   confirmed	   by	   Gram	   staining	   (Figure	   4.19).	   This	   demonstrated	   Gram	  positive	  cocci	  in	  pairs	  and	  one	  short	  chain,	  consistent	  with	  Streptococcous.	  
	  
Figure	  4.19:	  Gram	  stain	  of	   IPF	  BAL.	  Despite	  being	  culture	  negative	  there	  are	  Gram-­‐positive	  cocci	  in	  pairs	  and	  a	  small	  chain.	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4.4	   Discussion	  	  Compared	  to	  controls,	  patients	  with	  IPF	  have	  a	  higher	  bacterial	  load	  in	  broncho-­‐alveolar	  lavage	   fluid	   and	   significant	   differences	   in	   the	   composition	   and	   diversity	   of	   their	  microbiota.	  An	  increased	  bacterial	  load	  at	  the	  time	  of	  diagnosis	  identifies	  patients	  with	  more	  rapidly	  progressive	  IPF	  and	  a	  higher	  risk	  of	  mortality.	  The	   baseline	   bacterial	   communities	   observed	   in	   IPF	   patients	   and	   control	   subjects	  contained	   organisms	   such	   as	   Streptococcus,	  Prevotella,	  Fusobacteria,	   and	  Haemophilus	  which	   are	   commonly	   found	   in	   the	   airways	   of	   healthy	   subjects,	   asthmatics	   and	   COPD	  patients	  (Hilty	  et	  al.	  2010;	  Cardenas	  et	  al.	  2012;	  Y.	   J.	  Huang	  et	  al.	  2010;	  Charlson	  et	  al.	  2010).	  There	  were	  significant	  differences	  in	  specific	  OTUs	  between	  cases	  and	  controls,	  notably	  the	  presence	  of	  more	  Streptococcus,	  Haemophilus,	  Neisseria	  and	  Veillonella	  spp.	  in	   the	   IPF	   patients.	   	   This	   suggests	   that	   potentially	   pathogenic	   OTUs	   may	   be	   acting	  synergistically	   within	   a	   context	   of	   an	   increased	   bacterial	   load.	  Within	   the	   IPF	   cohort	  there	   were	   however	   no	   differences	   in	   the	   microbiome	   between	   subjects	   with	  progressive	   or	   stable	   disease.	   This	   suggests	   that	   following	   development	   of	   IPF	   the	  bacterial	  load	  is	  more	  significant	  in	  driving	  progression.	  The	   rs35705950	  polymorphism	   in	   the	  promoter	  of	   the	  mucin	   gene	  MUC5B	   confers	   an	  increased	   risk	   of	   developing	   IPF	   (Seibold	   et	   al.	   2011)	   but	   paradoxically	   confers	   a	  survival	   benefit	   amongst	   patients	   with	   IPF	   (Peljto	   et	   al.	   2013).	   Bacterial	   burden	  associated	  independently	  with	  rs35705950	  genotype	  (P=0.01),	  with	  patients	  possessing	  the	   minor	   allele	   of	   the	   SNP	   having	   a	   lower	   bacterial	   burden.	   	   This	   suggests	   a	   direct	  relationship	   between	   host	   immunity	   and	   bacterial	   load.	   The	  more	   densely	   populated	  and	   less	   diverse	   bacterial	   communities	   of	   the	   lower	   airways	   in	   IPF	   may	   provide	  persistent	  stimuli	  for	  repetitive	  alveolar	  injury.	  The	  temporal	  and	  spatial	  heterogeneity	  observed	   in	  usual	   interstitial	   pneumonia	   (the	  histological	   lesion	  of	   IPF)	   speaks	   to	   the	  likely	  importance	  of	  repetitive	  injury	  as	  a	  major	  factor	  in	  the	  pathogenesis	  of	  the	  disease	  (Talmadge	   E	  King,	   Pardo,	   and	   Selman	   2011).	   The	   bacterial	   communities	   of	   the	   lower	  airways	   are	   a	   plausible	   candidate	   for	   this	   trigger	   and	   regional	   differences	   in	   the	  bacterial	  microbiome	  (Erb-­‐Downward	  et	  al.	  2011)	  may	  help	  explain	  the	  distribution	  of	  the	  fibrotic	  lesions	  within	  the	  lungs.	  From	  the	  work	  conducted	  here,	  no	  conclusions	  can	  be	  drawn	  regarding	  the	  causal	  nature,	  or	  not,	  of	  this	  altered	  respiratory	  microbiome	  in	  IPF.	  Trials	  of	  antibiotic	  therapy	  may	  help	  elucidate	  this.	  There	  has	  recently	  been	  a	  large	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placebo	   controlled	   multi-­‐centre	   study	   evaluating	   the	   use	   of	   septrin	   in	   the	   broader	  category	   of	   fibrotic	   idiopathic	   interstitial	   pneumonias	   (Shulgina	   et	   al.	   2013).	   This	  treatment	  was	  not	  well	  tolerated,	  with	  a	  large	  number	  of	  drop-­‐out,	  and	  ultimately	  there	  was	  no	  detectable	  difference	  in	  the	  primary	  endpoint	  of	  change	  in	  vital	  capacity.	  Despite	  this,	   in	  subjects	  who	  tolerated	  septrin	  therapy	  there	  was	  a	  reduction	  in	   infections	  and	  subsequent	  mortality.	  Shulgina	  et	  al.	  hypothesized	  that	  this	  observation	  may	  be	  a	  result	  of	   septrin’s	   antimicrobial	   effects,	   but	   it	   is	   difficult	   to	   draw	   conclusions	   because	   of	   its	  concurrent	   anti-­‐inflammatory	   actions.	   Combined	  with	   the	  data	   presented	  here	   in	   this	  chapter	  and	  the	  high	  mortality	  associated	  with	  bacterial	  respiratory	  tract	   infections	  in	  IPF,	  it	  would	  however	  suggest	  that	  a	  more	  targeted	  and	  well	  tolerated	  antibiotic	  should	  be	  trialled	  in	  an	  IPF	  cohort.	  	  
4.4.1	   Comparison	  to	  the	  Known	  Literature	  There	  is	  a	  wide	  variation	  in	  the	  reported	  qPCR	  values	  for	  bacterial	  load	  in	  BAL,	  and	  the	  absolute	  quantification	   is	  dependent	  on	  multiple	   factors	   from	  sampling	   to	  processing,	  hindering	   comparisons	   between	   studies	   with	   differing	   primers	   and	   qPCR	   conditions.	  The	   bacterial	   loads	   reported	   here	   are	   comparable	  with	   other	   studies	   (Charlson	   et	   al.	  2012;	   Erb-­‐Downward	   et	   al.	   2011)	   and	   crucially	   conclusions	   are	   based	   upon	   relative	  values	   between	   cases	   and	   controls	   and	   those	   with	   stable	   or	   progressive	   disease.	  Sampling	   controls	   (sterile	   saline	   aspirated	   through	   the	   suction	   channel	   of	   the	  bronchoscope)	  were	  also	  included	  and	  yielded	  a	  bacterial	  burden	  close	  to	  or	  below	  the	  lower	  limit	  of	  qPCR	  quantification	  (1000	  copies	  per	  ml).	  Not	  only	  is	  this	  consistent	  with	  the	   findings	   of	   other	   studies	   it	   demonstrates	   that	   the	   qPCR	   results	   are	   not	   simply	  artefact	  from	  a	  sampling	  or	  processing	  error	  (Charlson	  et	  al.	  2012).	  There	  was	  no	  difference	   in	   the	  bacterial	   load	  or	   the	  microbiome	  between	   the	  healthy	  controls	   and	   the	   moderate	   GOLD	   Stage	   II	   COPD	   subjects.	   This	   finding	   has	   been	   a	  consistent	  in	  studies	  involving	  BAL	  (Erb-­‐Downward	  et	  al.	  2011),	   lung	  tissue	  (Sze	  et	  al.	  2012)	  and	  sputum	  (Molyneaux	  et	  al.	  2013)	  where	  the	  bacterial	  load	  in	  mild	  to	  moderate	  COPD	  to	  healthy	  controls	  has	  been	  compared.	  Han	  and	   colleagues	  have	   recently	  presented	  data	   for	   the	  microbiota	  of	  55	   individuals	  with	   idiopathic	   pulmonary	   fibrosis	   (Han	   et	   al.	   2014).	   The	  most	   commonly	   identified	  bacteria	   in	  the	   lungs	  of	   individuals	  with	   idiopathic	  pulmonary	  fibrosis	  were	  Prevotella	  sp,	  Veillonella	  sp,	  and	  Escherichia	  sp.	  All	  three	  species	  are	  well	  known	  inhabitants	  of	  the	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healthy	  respiratory	  microbiome	  and	  seen	  in	  this	  cohort.	  Han	  et	  al.	  however	  performed	  no	   bacterial	   load	   quantification.	   The	   authors	   found	   that	   the	   presence	   of	   a	   specific	  
Streptococcus	   sp.	   or	   Staphylococcus	   sp.	   above	   a	   statistically	   modelled	   threshold	   was	  strongly	   associated	   with	   disease	   progression,	   defined	   as	   a	   composite	   of	   death,	   acute	  exacerbation,	   lung	   transplant,	   or	   relative	   drop	   in	   forced	   vital	   capacity	   FVC	   or	   DLCO.	  Despite	   demonstrating	   this	   statistical	   association	   only	   23	   (42%)	   of	   55	   patients	   had	  either	  of	  these	  bacteria	  in	  levels	  greater	  than	  the	  threshold,	  suggesting	  neither	  can	  fully	  explain	  disease	  pathogenesis	  or	  progression	  (Molyneaux	  and	  Maher	  2014).	  	  Also	  of	   importance	   is	   the	   fact	   that	   the	  study	  by	  Han	  et	  al.	  was	   retrospective,	  meaning	  there	  was	  a	  failure	  to	  standardise	  operating	  procedures	  for	  the	  bronchoscopic	  collection	  of	   samples,	   with	   varying	   endoscopic	   approaches	   (nasal	   vs.	   oral)	   and	   different	   lavage	  locations	   (right	   middle	   lobe	   vs	   lingual).	   Additionally	   there	   were	   a	   number	   of	  methodological	  differences	  between	   this	   current	   study	   (Chapter	  4)	   and	   theirs,	   so	   it	   is	  therefore	   not	   surprising	   that	   such	   small	   changes	   reported	   by	   Han	   et	   al.	   were	   not	  replicated	   here.	   Here	   there	   is	   no	   association	   between	   specific	   microbes	   and	   disease	  progression.	  An	  additional	  benefit	  of	  this	  current	  study	  was	  the	  longer	  follow	  up	  period	  allowing	  investigation	  for	  associations	  between	  the	  microbiome	  and	  survival.	  Although	  there	  are	  clear	  differences	  in	  the	  IPF	  microbiome	  compared	  to	  healthy	  individuals	  it	  is	  the	  bacterial	  load	  which	  effects	  survival.	  
4.4.2	   Limitations	  This	  work	  has	  a	  number	  of	  limitations.	  IPF	  is	  a	  disease	  of	  the	  lung	  parenchyma	  whereas	  BAL	  fluid	  was	  utilized	  to	  sample	  the	  distal	  airways.	  Direct	  sequencing	  of	  lung	  tissue	  may	  provide	   further	   information	  on	   the	  pulmonary	  microbiome	   (Sze	  et	  al.	  2012),	  but	   lung	  biopsies	  are	  undertaken	  infrequently	  in	  IPF	  and	  gathering	  true	  healthy	  control	  samples	  would	   be	   extremely	   difficult.	   The	   oropharnygeal	   route	   was	   used	   to	   pass	   a	  bronchcoscope	   into	   the	   lungs	   and	   some	   secretions	   from	   the	   upper	   airways	  will	   have	  been	   carried	   on	   the	   tip	   of	   the	   bronchoscope.	   Any	   carry	   over	   however	  will	   have	   been	  heavily	  diluted	  by	  the	  240ml	  of	  BAL	  fluid	   instilled.	  The	  high	  percentage	  of	  BAL	  return	  and	   an	   absence	   of	   ciliated	   epithelial	   cells	   in	   BAL	   fluid	   (indicative	   of	   large	   airway	  contamination)	   provided	   confidence	   that	   BAL	   return	  was	   primarily	   derived	   from	   the	  distal	   airspace.	   Importantly	   there	   are	   strong	   similarities	   between	   the	   microbiota	  identified	   from	   BAL	   fluid	   and	   from	   surgically	   removed	   lung	   tissue	   in	   which	   upper	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airway	  contamination	  was	  not	  an	   issue	   (Erb-­‐Downward	  et	   al.	   2011).	  Crucially,	   in	   this	  present	  study	  the	  same	  protocols	  and	  procedures	  were	  used	  for	  cases	  and	  controls,	  so	  if	  perchance	   any	   contamination	   has	   occurred,	   it	   would	   have	   been	   consistent	   across	   all	  samples	  and	  therefore	  will	  not	  have	  influenced	  the	  results.	  Although	  there	  is	  currently	  no	   universally	   adopted	   approach	   to	  minimize	   potential	   upper	   airways	   carry	   over	   the	  use	  of	  protected	  BAL	  fluid,	  pro-­‐BAL	  catheters	  or	  protected	  catheter	  brushes	  could	  help	  avoid	  contamination.	  	  While	   the	   combination	   of	   16S	   rRNA	   PCR	  with	   next-­‐generation	   sequencing	   allows	   the	  parallel	   sequencing	   of	   large	   number	   of	   samples	   at	   relatively	   low	   cost	   there	   are	  limitations	   to	   the	   technique.	  The	  most	  significant	  are	   the	  biases	   introduced	  by	  primer	  design,	   which	  may	   select	   for	   or	   against	   particular	   bacteria	   (Sim	   et	   al.	   2012;	  Metzker	  2010),	   resulting	   in	   some	   bacterial	   species	   not	   being	   detected	   by	   the	   PCR	   primers.	   A	  further	   limitation	   of	   this	   present	   study	   is	   that	   that	   there	   was	   no	   assessment	   for	   the	  presence	   or	   absence	   of	   other	   potential	   non-­‐bacterial	   lung	   pathogens.	   Although	   a	  substantial	  study	  found	  no	  evidence	  of	  detectable	  viruses	  by	  PCR	  of	  BAL	  fluid	  from	  40	  stable	   IPF	   patients	   (Wootton	   et	   al.	   2011)	   it	   is	   conceivable	   that	   some	   differences	   in	  progression	  could	  be	  due	  to	  the	  presence	  of	  respiratory	  viruses	  in	  this	  current	  set	  of	  IPF	  patients.	  
4.5	   Conclusions	  	  An	  increased	  bacterial	  load	  at	  the	  time	  of	  diagnosis	  identifies	  patients	  with	  more	  rapidly	  progressive	  IPF	  and	  a	  higher	  risk	  of	  mortality.	  It	  is	  not	  possible	  to	  conclude	  whether	  the	  presence	   of	   an	   altered	  microbiome	   is	   the	   cause	   or	   a	   result	   of	   the	   destruction	   of	   the	  normal	   lung	   architecture.	   Whilst	   requiring	   further	   validation	   in	   larger	   prospective	  cohorts,	   these	   findings	   provide	   a	   strong	   rationale	   for	   trials	   of	   antimicrobial	   therapy	  which	  will	   help	   determine	   the	   aetiological	   role	   of	   bacteria	  while	   at	   the	   same	   time	   as	  investigating	  a	  novel	  potential	  treatment.	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Chapter	  5:	  Exacerbations	  of	  IPF	  
5.1 Introduction	  During	   the	   course	   of	   their	   disease,	   IPF	   patients	   will	   often	   experience	   episodes	   of	  increasing	   dyspnoea	   and	   deterioration	   in	   pulmonary	   function	   tests.	   	   This	   results	   in	  substantial	  morbidity	  and	  mortality	  (Raghu	  et	  al.	  2011;	  Collard	  et	  al.	  2007;	  Song	  et	  al.	  2011).	  Pneumonia,	  heart	  failure	  and	  pulmonary	  thromboembolic	  disease	  are	  often	  the	  trigger.	   However,	   the	   cause	   for	   many	   remains	   unknown.	   These	   idiopathic	   episodes,	  termed	   acute	   exacerbations	   of	   IPF	   (AE-­‐IPF),	   have	   been	   formally	   defined	   as	   clinically	  significant	  deteriorations	  of	  unidentifiable	  cause	  in	  patients	  with	  underlying	  IPF	  within	  the	   prior	   30	   days	   (Collard	   et	   al.	   2007).	   A	   true	   AE-­‐IPF	   needs	   to	   meet	   a	   number	   of	  diagnostic	   criteria:	   worsening	   or	   development	   of	   dyspnoea	   within	   30	  days;	   new	  bilateral	   infiltrates	   on	   CT	   scan;	   exclusion	   of	   infection	   by	   endotracheal	   or	  bronchoalveolar	   lavage;	   and	   the	   exclusion	   of	   alternative	   causes,	   including	   left	   heart	  failure	  and	  pulmonary	  embolism.	  This	  classification	  specifically	  requires	   the	  exclusion	  of	  any	  infective	  trigger,	  suggesting	  that	  there	  is	  no	  role	  for	  infection	  in	  the	  aetiology	  of	  exacerbations.	  The	  exact	  pathogenesis,	  however,	   remains	  unknown	  and	   it	   is	   currently	  unclear	   if	   they	   represent	   an	   accelerated	   phase	   or	   flare	   of	   the	   underlying	  fibroproliferative	  process	  or	  are	  due	  to	  unidentified	  infection	  or	  micro-­‐emboli	  (Toby	  M	  Maher	  2008).	  Given	   the	   lack	   of	   sensitivity	   encountered	   with	   current	   culture-­‐dependant	   clinical	  microbiology	  techniques	  and	  the	  limited	  repertoire	  of	  tools	  available	  to	  diagnose	  acute	  viral	   infections,	   it	   is	   plausible	   to	   hypothesise	   that	   many	   episodes	   of	   apparent	   acute	  exacerbations	  simply	  represent	  the	  sequelae	  of	  infection.	  Indeed	  there	  is	  some	  evidence	  to	  support	  this.	  Seasonal	  patterns	  to	  AE-­‐IPF	  exist	  with	   increased	  exacerbations	  during	  the	   winter	   months	   (Olson	   et	   al.	   2009).	   In	   addition	   respiratory	   tract	   infections	   in	  individuals	  with	  IPF	  confer	  a	  mortality	  risk	  indistinguishable	  from	  that	  seen	  with	  acute	  exacerbations	  (Song	  et	  al.	  2011)	  and	  Post	  mortem	  examination	  in	  such	  cases	  frequently	  discloses	  associated	  diffuse	  alveolar	  damage	  identical	  to	  that	  seen	  during	  an	  AE-­‐IPF.	  In	  animal	  models	  viral	   infection	  can	  exacerbate	  established	   fibrosis	  and	   in	   so	  doing	  give	  rise	  to	  a	  lesion	  resembling	  DAD	  (McMillan	  et	  al.	  2008).	  In	  humans,	  however,	  the	  largest	  clinical	   study	   to	   date	   looking	   at	   the	   role	   of	   viruses	   in	   exacerbations	   was	   essentially	  negative	  (Wootton	  et	  al.	  2011).	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Unfortunately	   the	   very	   definition	   of	   an	   AE-­‐IPF	   means	   that	   if	   they	   are	   triggered	   by	  infection	   we	   would	   struggle	   to	   detect	   it.	   Unlike	   other	   respiratory	   conditions	   where	  exacerbations	   are	   acute	   events,	   the	   onset	   in	   IPF	   is	   more	   insidious	   with	   a	   gradual	  worsening	   over	  weeks	   to	  months.	   	   Consequently	   by	   the	   time	   of	   presentation	   viruses	  may	  no	  longer	  be	  detectable	  (Beasley	  et	  al.	  2012).	  While	  the	  role	  of	  viruses	  in	  IPF	  has	  been	  extensively	  investigated	  there	  has	  been	  little	  focus	  on	  a	  potential	  role	  for	  bacteria	  and	   to	  date	   there	  has	  been	  no	  assessment	  of	   the	  role	  of	   the	  respiratory	  microbiota	   in	  exacerbations	  of	  IPF.	  In	  this	  chapter	  in	  order	  to	  explore	  the	  effect	  of	  an	  exacerbation	  on	  the	  respiratory	  microbiota	  16S	  qPCR	  and	  pyrosequencing	  has	  been	  performed	  on	  both	  stable	  and	  exacerbation	  samples	  in	  subjects	  with	  IPF.	  
5.2 Materials	  and	  Methods	  
5.2.1 Study	  population	  The	   research	   protocol	   implemented	   had	   planned	   to	   capture	   acute	   exacerbations	   that	  occurred	   in	   patients	  who	   had	   undergone	   baseline	   bronchoscopy.	   Based	   on	   estimates	  from	  other	  studies	  it	  was	  anticipated	  3	  to	  10	  patients	  would	  experience	  an	  exacerbation	  during	  the	  study	  period.	  Four	  of	  the	  cohort	  did	  indeed	  experience	  an	  exacerbation,	  but	  unfortunately	  all	  were	  too	  unwell	   to	  undergo	  bronchoscopy	  at	   the	  time.	  Consequently	  sampling	  of	   the	  microbiome	  during	  an	  exacerbation	  was	  not	   feasible	   for	   the	  PROFILE	  cohort.	   Fortuitously	   due	   to	   a	   collaboration	  with	   a	   South	  Korean	   IPF	   centre	   it	   became	  feasible	  to	  investigate	  the	  key	  hypothesis	  using	  an	  independent	  cohort	  of	  IPF	  patients,	  granted	   not	   white	   Caucasian	   in	   terms	   of	   ethnicity.	   As	   little	   is	   known	   about	   the	  geographical	  variation	   in	   the	  respiratory	  microbiota	  a	  number	  of	   stable	  South	  Korean	  IPF	  patients	  were	  also	  sampled	  to	  provide	  a	  reference	  for	  comparison.	  
5.2.2 DNA	  Extraction,	  Quantification	  and	  Quality	  Assessment	  The	  samples	  were	  processed	  at	  the	  time	  of	  collection	  and	  subsequently	  stored	  at	  -­‐80oC	  as	   separate	   cell	   pellets	   and	   supernatants.	   The	   samples,	   one	   2	   ml	   aliquot	   of	   BAL	  supernatant	   and	   one	   BAL	   pellet	   including	   supernatant,	   were	   thawed	   and	   then	  centrifuged	   at	   20,000	   g	   for	   15	  minutes,	   to	   pellet	   cell	   debris	   and	   bacteria.	   The	   pellets	  were	   then	   re-­‐suspended	   in	   978	   μl	   Sodium	   Phosphate	   Buffer	   and	   122	   μl	   MT	   Buffer	  (MPBIO	   first	   lysis	   buffer	   solution)	   and	   extraction	   performed	   using	   the	   MP	   Bio	  FastDNA®	   SPIN	   Kit	   for	   Soil	   (http://www.mpbio.com)	   (Chapter	   2,	   Section	   2.3.1).	   The	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quantity	  and	  quality	  of	  extracted	  genomic	  DNA	  was	  measured	  using	  the	  Nanodrop™	  ND	  1000	  UV-­‐Vis	  spectrophotometer	  (Thermo	  Scientific).	  DNA	  concentrations	  in	  ng/μl	  and	  purity	  were	  determined	  by	  absorbance	  at	  260nm	  and	  the	  ratio	  of	  absorbance	  at	  260nm	  and	  280nm,	  (A260/A280	  with	  a	  ratio	  of	  ~1.8	  considered	  pure	  DNA),	  respectively	  
5.2.3 16S	  rRNA	  Gene	  qPCR	  and	  Pyrosequencing	  The	  V3-­‐V5	  region	  of	  the	  bacterial	  16S	  rRNA	  gene	  was	  amplified	  using	  the	  357F	  forward	  primer	  and	  the	  926R	  reverse	  primer	  for	  both	  16S	  qPCR	  and	  pyrosequencing.	  Triplicate	  10	  µl	  qPCR	  reactions	  were	  set	  up	  containing	  1	  µl	  of	  a	  10-­‐fold	  dilution	  of	  template	  DNA	  as	  described	  in	  Chapter	  2,	  Section	  2.3.3.	  All	  data	  were	  analysed	  using	  the	  Corbett	  rotor-­‐gene	  6.1	  software.	  For	   pyrosequencing	   the	   V3-­‐V5	   region	   of	   the	   bacterial	   16S	   rRNA	   gene	   was	   amplified	  using	  the	  standard	  forward	  primer	  357F	  and	  a	  modified	  reverse	  primer	  926R,	  barcoded	  to	   tag	   each	   PCR	   product.	   Quadruplicate	   25	   µl	   PCR	   reactions	   were	   set	   up,	   amplified,	  purified	   and	   prepared	   for	   sequencing	   (Chapter	   2,	   Section	   2.3.2).	   Single	   direction	  pyrosequencing	  using	  the	  Lib-­‐L	  kit	  was	  performed	  using	  the	  454	  Life	  Sciences	  GS	  Junior	  (Roche)	   (Chapter	  2,	   Section	  2.3.2).	  The	  barcoded	  pyrosequence	   reads	  were	  processed	  using	   QIIME	   1.7.0	   with	   poor	   quality	   or	   chimeric	   reads	   discarded	   (Chapter	   2,	   Section	  2.3.2.8).	  
5.2.4 Statistical	  Analysis	  Analyses	  were	  conducted	  as	  detailed	  in	  Chapter	  2,	  Section	  2.3.2.8.	  
5.3 Results	  
5.3.1 Subjects	  and	  Sampling	  Twenty	   patients	   with	   acute	   exacerbations	   of	   IPF	   undergoing	   bronchoscopy	   were	  enrolled	  at	  the	  University	  of	  Ulsan	  in	  Korea	  between	  2007	  and	  2009.	  A	  diagnosis	  of	  an	  acute	  exacerbation	  of	  IPF	  was	  made	  based	  on	  established	  criteria	  (Collard	  et	  al.	  2007).	  All	   acute	   exacerbation	   patients	   had	   negative	   clinical	   evaluation	   for	   infectious	   causes	  including	   respiratory	   syncytial	   virus	   (RSV),	   influenza	   A	   and	   B,	   human	   parainfluenza	  viruses,	  adenovirus,	  human	  cytomegalovirus,	  herpes	  simplex	  and	  varicella-­‐zoster	  virus.	  Fifteen	   matched	   control	   patients	   with	   stable	   IPF	   (defined	   by	   the	   absence	   of	   acute	  exacerbation)	  underwent	  bronchoscopy	  at	   the	   time	  of	  diagnosis.	  None	  of	   the	   subjects	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had	  received	  antibiotics	  prior	  to	  sampling.	  There	  was	  no	  difference	  between	  steroid	  and	  immunosuppression	  usage	  between	  the	  stable	  and	  acute	  exacerbation	  subjects.	  	  	   Stable	  IPF	  (N=15)	   AE-­‐IPF	  (N=20)	   P	  Value	  Age	  (yr)	   66.7	  (±6.4)	   66.3	  (±6.7)	   NS	  Female	  Sex	  -­‐	  number	  (%)	   3	  (20%)	   5	  (25%)	   NS	  Smoking	  (Ever	  v	  Never)	  -­‐	  number	  (%)	   11	  (73%)	   15	  (75%)	   NS	  FVC—	  %	   79.0	  (±21)	   80.0	  (±19)	   NS	  DLCO	  -­‐	  %	   69.0	  (±14)	   66.0	  (±16)	   NS	  
Table	   5.1.	   Baseline	   Characteristics	   of	   the	   Subjects.	  Details	   are	  provided	   for	   stable	  IPF	   and	   AE-­‐IPF	   cases.	   Data	   are	  means±Standard	   Deviation.	   NS=not	   significant.	   DLCO,	  carbon	  monoxide	  diffusion	  capacity;	  FVC,	  forced	  vital	  capacity.	  
5.3.2 DNA	  Extraction	  and	  Quality	  Control	  All	  35	  samples	  yielded	  genomic	  DNA.	  The	  average	  yield	  from	  the	  exacerbation	  samples	  was	   55.29	   ng/μl	   (±32.31)	   and	   from	   the	   stable	   IPF	   patients	   42.11	   ng/μl	   (±20.10)	  (P=0.38,	   Mann	   Whitney),	   with	   an	   A260/A280	   ratio	   of	   1.81	   (±0.18)	   indicting	   good	  quality	   DNA.	   All	   of	   these	   samples	   were	   therefore	   taken	   forward	   for	   16s	   qPCR	   and	  pyrosequencing.	   Quantification	   of	   the	   amplified	   DNA	   demonstrated	   the	   average	   yield	  was	   3.27	   ng/µl.	   Three	   of	   the	   samples	   (2	   exacerbations	   and	   1	   stable	   sample)	   yielded	  insufficient	   16S	   product	   to	   take	   forward	   with	   pyrosequencing	   and	   were	   therefore	  excluded.	  The	  remaining	  32	  samples	  were	  sequenced	  on	  the	  Roche	  454	  GS	  Junior.	  The	  sequencing	  run	  generated	  105,316	  high	  quality	  reads,	  which	  have	  a	  mean	  fragment	  length	  of	   550bp.	   It	  was	  noted	   that	   the	   run	  was	   somewhat	  under	   enriched	   (raw	  wells	  only	  112,129	  with	  a	  target	  of	  250,000)	  suggesting	  there	  was	  under	  enrichment	  during	  the	   emulsion	   PCR	   (Chapter	   2.3.2.6).	   The	   Roche	   454	   GS	   Junior	   software	   performs	   a	  number	  of	  quality	  control	  steps	  post	  sequencing.	  The	  raw	  well	  count	  indicates	  the	  total	  number	  of	  reads	  and	  the	  key	  pass	  well	  indicates	  a	  well	  that	  starts	  with	  a	  valid	  sequence	  (either	   library	   or	   control	   DNA)	   and	   should	   be	   carried	   forwards.	   Dot	   and	  Mixed	   filter	  reads	   suggest	   technical	   problems	   with	   the	   raw	   flowgram	   and	   result	   in	   a	   read	   being	  rejected,	  Roche	  suggest	  this	  number	  should	  be	  <20%	  of	  the	  total	  number	  of	  passed	  filter	  wells.	  Further	  reads	  are	  rejected	  if	  they	  are	  far	  shorter	  than	  expected	  fragment.	  Here	  it	  can	  been	  seen	  that	  although	  the	  run	  was	  under-­‐enriched	  the	  quality	  of	  the	  run	  was	  not	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affected	   and	   the	   sequences	   therefore	   robust	   and	   suitable	   for	   downstream	   processing	  (Figure	  5.1).	  
	  
Figure	   5.1:	   Distribution	   of	   sample	   reads	   length.	   Although	   the	   run	   was	   under-­‐enriched	  (only	  112,129	  out	  of	  a	  potential	  250,000	  raw	  wells)	   the	  average	  read	   length	  was	   good	   and	   there	   were	   very	   few	   short	   read	   fragments,	   highlight	   by	   the	   fact	   that	  105,316	  reads	  passed	  initial	  quality	  control.	  Denoising,	  chimera	  checking	  and	  singleton	  removal	  was	  performed	  in	  QIIME.	  Following	  this	   a	   total	   of	   83,187	   high	   quality	   reads	   remained.	   The	   distribution	   of	   reads	  was	   not	  evenly	  spread	  over	  the	  samples,	  ranging	  from	  116	  to	  9681	  reads	  per	  sample.	  In	  order	  to	  control	   for	  bias	  of	  per	  sample	  read	  coverage	  the	  sequences	  were	  randomly	  resampled	  (rarefied)	  to	  the	  same	  minimum	  of	  543	  reads	  for	  all	  subjects	  (Fig	  5.2).	  This	  maximised	  sample	   retention	   and	   sequence	   reads	   per	   sample	   but	   resulted	   in	   the	   loss	   of	   two	  exacerbation	  samples	  from	  the	  downstream	  analysis.	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Figure	  5.2:	  The	  distribution	  of	  sequencing	  reads	  across	  samples.	  The	  distribution	  of	  reads	  as	  can	  be	  seen	  ranged	  from	  116	  to	  9681	  per	  sample.	  In	  order	  to	  control	  for	  this	  during	   analysis	   rarification	  was	   performed.	   The	   depth	  which	   to	   rarify	  was	   chosen	   to	  maximise	   sample	   retention	   and	   sample	   reads.	   In	   this	   case	   543	   reads	   was	   chosen,	  indicated	  by	  the	  red	  line.	  
5.3.3 Bacterial	  Load	  Acute	  Exacerbations	  of	  IPF	  (AE-­‐IPF)	  subjects	  had	  on	  average	  1.4x109	  copies	  of	  the	  16S	  rRNA	  gene	  per	  ml	  of	  BAL	  which	  was	  more	  than	  four	  times	  higher	  than	  the	  copy	  number	  in	   the	   Stable	   IPF	   subjects	   (3.1x108)	   	   (P=0.012)	   (Figure	   5.3).	   There	   was	   a	   strong	  correlation	  between	  bacterial	  burden	  and	  disease	  state	  (Spearman’s	  ρ=0.45,	  P=0.008),	  indicating	   that	   total	   bacterial	   load	   is	   an	   independent	   predictor	   of	   AE-­‐IPF.	   Bacterial	  burden	  remained	  significantly	  associated	  with	  a	  diagnosis	  of	  AE-­‐IPF,	  using	  a	  stepwise	  logistic	  regression	  (P=0.029,	  R2	  0.51).	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Figure	   5.3:	   Bacterial	   burden	   in	   stable	   IPF	   compared	   to	   AE-­‐IPF.	   AE-­‐IPF	   patients	  (red)	   (N=18)	   had	   a	   significantly	   higher	   bacterial	   burden	   than	   stable	   subjects	   (blue)	  (N=14)	   (P=0.012).	  The	  box	   signifies	   the	  25th	  and	  75th	  percentiles,	   and	   the	  median	   is	  represented	  by	  the	  line	  within	  the	  box.	  
5.3.4 Microbiota	  At	   phylum	   level	   the	  microbiota	   of	   the	   stable	   Korean	   IPF	   subjects	   was	   dominated	   by	  Firmicutes	   (34%)	   and	   Proteobacteria	   (32%),	   with	   large	   numbers	   of	   Bacteroidetes	  (16%)	  and	  Actinobacteria	  (10%)	  also	  present.	  Although	  the	  same	  phyla	  predominated	  in	  the	  AE-­‐IPF	  subjects,	  Proteobacteria	  accounted	  for	  over	  40%	  of	  the	  total	  reads,	  with	  the	   percentage	   of	   reads	   assigned	   to	   Firmicutes	   (29%),	   Bacteroidetes	   14%,	   and	  Actinobacteria	   (6%)	   dropping	   compared	   to	   the	   stable	   subjects	   (Figure	   5.4).	   The	  differences	   in	   the	  overall	  percentage	  abundance	  at	   the	  phylum	   level	  between	   the	   two	  groups	  was	  not	   statistically	   significant	   (Metastats).	  Within	   the	  Proteobacteria	  phylum	  however	  there	  was	  a	  higher	  relative	  abundance	  of	  two	  potentially	  pathogenic	  OTUs	  in	  the	   AE-­‐IPF	   samples;	   Campylobacter	   sp.	   (OTU108)	   (P=0.02)	   and	   Stenotrophomonas	   sp.	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(OTU261)	   (P=0.03).	   This	   was	   accompanied	   by	   significantly	   higher	   numbers	   of	   a	  
Veillonella	  sp.	  (OTU692)	  (P<0.01)	  in	  the	  stable	  IPF	  samples.	  
	  
Figure	  5.4:	  Abundance	  of	   the	   top	  5	  phyla	   in	   stable	  disease	   compared	   to	  AE-­‐IPF.	  Proteobacterial	   sequence	   numbers	   were	   present	   in	   a	   greater	   abundance	   in	   AE-­‐IPF	  patients	  (red)	  compared	  to	  stable	  subjects	  (blue).	  Ralstonia	   was	   the	   most	   common	   genus	   in	   both	   the	   stable	   and	   AE-­‐IPF	   subjects,	  accounting	  for	  16.5%	  and	  24.1%	  of	  total	  reads	  respectively,	  followed	  by	  Streptococcus	  (11.7%	  and	  9.8%)	  and	  then	  Prevotella	  (6.8%	  and	  7.05%)	  (Figure	  5.5).	   	  Although	  there	  were	  over	  50	  OTUs	  significantly	  different	  between	  the	  stable	  and	  AE-­‐IPF	  panels,	  they	  all	  had	  a	  differing	  mean	  abundance	  of	  less	  than	  0.5%	  of	  the	  total,	  and	  are	  therefore	  likely	  of	  minimal	  biological	  significance.	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Figure	   5.5	   Phylogenetic	   tree	   and	   heatmap	   of	   bacterial	   16S	   rRNA	   sequences	  
grouped	   into	   stable	   IPF	   and	   AE-­‐IPF.	   This	   depicts	   the	   top	   50	   OTUs	   organised	  phylogenetically	   by	   tree	   with	   abundance	   indicated	   by	   the	   colour	   (Darker	   Blue	   more	  abundant	  to	  white	  not	  present).	  There	   were	   no	   differences	   in	   the	   richness,	   diversity	   or	   evenness	   of	   the	   microbial	  populations	   between	   stable	   IPF	   and	   AE-­‐IPF	   samples	   as	   determined	   by	   the	   Shannon	  index,	  Inverse	  Simpson	  index,	  species	  richness	  as	  well	  as	  Pielous	  evenness	  (Figure	  5.6).	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Figure	  5.6	  Richness	  and	  diversity	  indices	  in	  stable	  and	  AE-­‐IPF	  subjects.	  Box	  plots	  demonstrating	  that	  no	  difference	  in	  the	  Shannon	  index,	  Inverse	  Simpson	  index,	  species	  richness	  or	  Pielous	  evenness	  is	  observed	  between	  stable	  IPF	  subjects	  (blue)	  and	  those	  with	   AE-­‐IPF	   (red).	   The	   box	   signifies	   the	   25th	   and	   75th	   percentiles	   with	   the	   median	  represented	  by	  the	  line	  within	  the	  box.	  To	  evaluate	  for	  similarities	  between	  samples,	  Principal	  Coordinate	  Analysis	  (PCoA)	  was	  performed	  using	   the	  UniFrac	  and	  Bray-­‐Curtis	  distance	  matrices.	  No	  distinct	  clustering	  patterns	  between	  the	  two	  groups	  were	  observed	  (Figure	  5.7).	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Figure	   5.7:	   Weighted	   UniFrac	   Principal	   Coordinate	   Analysis	   (PCoA)	   plot	  
comparing	   presence/absence	   metrics	   and	   abundance.	   There	   is	   no	   obvious	  clustering	  of	  either	  stable	  IPF	  or	  AE-­‐IPF	  samples.	  Nonmetric	   Multidimensional	   Scaling	   (NMDS)	   is	   a	   non-­‐metric	   alternative	   to	   PCoA	  analysis	   used	   to	   compare	   groups	   of	   samples	   based	   on	   phylogenetic	   or	   count-­‐based	  distance	  metric.	  The	  NMDS	  was	  performed	  using	  the	  weighted	  UniFrac	  and	  Bray-­‐Curtis	  distance	  matrices	  and	  again	  revealed	  no	  distinct	  clustering	  by	  sample	  type	  (Figure	  5.8).	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Figure	  5.8:	  Nonmetric	  multidimensional	  scaling	  plot	  based	  upon	  the	  Bray-­‐Curtis	  
distance	   matrix.	   No	   obvious	   clustering	   of	   either	   stable	   IPF	   or	   AE-­‐IPF	   samples	   is	  observed.	  To	   confirm	   whether	   or	   not	   the	   AE-­‐IPF	   and	   stable	   IPF	   samples	   were	   significantly	  different	   ADONIS	   and	   ANOSIM	   were	   employed.	   Both	   ADONIS	   and	   ANOSIM	   are	  nonparametric	   statistical	   techniques	  which	   take	  a	  distance	  matrix	   file,	   a	  mapping	   file,	  and	   a	   category	   in	   the	   mapping	   file	   to	   determine	   sample	   grouping.	   Employing	   the	  UniFrac,	   weighted	   UniFrac,	   Bray	   Curtis	   and	   Canberra	   distance	   matrices	   ADONIS	   and	  ANOSIM	  detected	  no	  difference	  between	  the	  groups	  (P=0.19	  and	  P=0.32	  respectively).	  Pearson	   correlation	   demonstrated	   that	   there	   were	   no	   OTUs	   whose	   members	   were	  differentially	  represented	  across	  stable	  and	  exacerbating	  samples.	  Nearest	  Taxon	  Index	  (NTI)	  and	  Net	  Relatedness	  Index	  (NRI)	  indicate	  whether	  a	  group	  of	  samples	  are	  phylogenetically	  clustered	  or	  over-­‐dispersed.	  	  Clustering	  indicates	  samples	  are	  under	  more	  selective	  pressure	  and	  identifies	  coexistence	  of	  closely	  related	  species.	  NTI	  indicates	  clustering	  or	  over-­‐dispersion	  at	  the	  tips	  of	  the	  tree,	  whereas	  NRI	  is	  a	  Tree-­‐
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wide	  clustering	  metric.	  Both	  metrics	  demonstrated	  no	  significant	  differences	  between	  the	  clustering	  of	  the	  stable	  or	  AE-­‐IPF	  samples	  (NTI	  P=0.41,	  NRI	  P=0.20).	  	  
5.3.5 Paired	  Samples	  For	  two	  of	  the	  individuals	  within	  the	  cohort	  there	  was	  both	  a	  stable	  sample	  as	  well	  as	  an	  exacerbation	   sample.	   Comparing	   the	   microbiota	   of	   the	   two	   stable	   samples	   of	   these	  individuals	   revealed	   that	   they	   were	   dramatically	   different	   from	   each	   other.	   	   This	  highlights	  why	  grouping	  individuals	  together	  and	  examining	  for	  change	  between	  states	  may	   both	   highlight	   as	   well	   as	   mask	   major	   changes	   in	   the	   microbiome.	   There	   were	  however	  clear	  changes	   in	  each	   individual’s	  microbiota	  during	  an	  exacerbation	  (Figure	  5.9).	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In	   the	   case	   of	   the	   second	   individual,	   their	   stable	   microbiome	   was	   dominated	   by	  Proteobacteria	   accounting	   for	   over	   70%	   of	   the	   total	   reads.	   During	   an	   exacerbation	  however	   the	   microbiome	   again	   changed	   dramatically,	   with	   a	   large	   increase	   in	   the	  Firmicutes	  and	  Bacteroidetes	  phyla.	  This	  was	  due	  to	  a	  38%	  increase	  in	  abundance	  of	  a	  
Streptococcus	   sp.	   and	   an	   18%	   increase	   in	   a	   Prevotella	   sp.,	   with	   a	   consequent	   fall	   in	  abundance	  of	  43%	  in	  a	  Ralstonia	  sp..	  
5.4 Discussion	  AE-­‐IPF	   is	   associated	  with	   an	   increased	  BAL	   bacterial	   burden	   compared	   to	   stable	   IPF.	  The	   bacterial	   communities	   of	   the	   stable	   Korean	   IPF	   subjects	   were	   found	   to	   contain	  
Streptococcus,	   Prevotella,	   Veillonella,	   Haemophilus	   and	   Pseudomonas	   which	   have	  previously	   been	   reported	   in	   the	   airways	   of	   healthy	   individuals,	   asthmatics	   and	   COPD	  patients.	  During	  an	  AE-­‐IPF	  the	  microbiome	  was	  observed	  to	  change	  with	  an	  increase	  in	  two	  potentially	  pathogenic	  Proteobacterial	  OTUs	  in	  the	  AE-­‐IPF	  samples,	  Campylobacter	  
sp.	  and	  Stenotrophomonas	  sp.,	  and	  a	  drop	  in	  Veillonella	  sp..	  
Campylobacter,	   although	   best	   known	   as	   a	   gastrointestinal	   pathogen,	   has	   previously	  been	   identified	   in	   the	   respiratory	   microbiome	   of	   individuals	   with	   severe	   COPD	  (Pragman	  et	  al.	  2012).	  Its	  presence	  in	  the	  respiratory	  microbiome	  is	  likely	  to	  arise	  from	  silent	  microaspiration	  of	  gastric	  contents,	  indeed	  it	  has	  previously	  been	  identified	  in	  an	  empyema	   following	   aspiration	   (Behl,	   Manchanda,	   and	   Thomas	   2008).	   Aspiration	   of	  gastric	  contents	   is	  probably	  a	  cause	  of	  AE-­‐IPF	   in	  a	  subgroup	  of	  patients	   (J	  S	  Lee	  et	  al.	  2012).	   The	   demonstration	   of	   an	   increase	   in	   Campylobacter	   sp.	   during	   an	   AE-­‐IPF	  strengthens	   this	   already	   identified	   association	   of	   reflux	   and	   aspiration	   with	   acute	  exacerbations.	   It	   is	   not	   possible	   however	   to	   conclude	   whether	   the	   increase	   in	  
Campylobacter	  sp.	  is	  a	  simply	  a	  biomarker	  for	  aspiration	  or	  the	  responsible	  trigger.	  
Stenotrophomonas,	   a	   Gram-­‐negative	   bacterium,	   is	   known	   to	   colonise	   the	   respiratory	  tract	  of	  patients	  with	  chronic	   lung	  disease	  (Pathmanathan	  and	  Waterer	  2005).	   Indeed	  Erb-­‐Downward	   and	   colleagues	   have	   previously	   identified	   Stentrophomonas	   sp.	   in	   the	  respiratory	   microbiome	   of	   subjects	   with	   severe	   COPD.	   It	   is	   a	   potential	   respiratory	  pathogen	   and	   although	   most	   commonly	   associated	   with	   intubated	   and	   ventilated	  patients,	   it	   is	   responsible	   for	   respiratory	   infections	   in	   CF	   patients	   and	   patients	   with	  chronic	  health	  conditions	  (Aisenberg	  et	  al.	  2007).	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Veillonella	  has	  been	  identified	  as	  part	  of	  the	  healthy	  respiratory	  microbiome	  and	  loss	  of	  these	  organisms	  is	  often	  associated	  with	  a	  disease	  state.	  Cardenas	  et	  al.	  demonstrated	  a	  loss	   of	   these	   potentially	   ‘protective’	   Veillonella	   from	   the	   respiratory	   microbiome	   in	  infants	  with	  wheezing	  compared	  to	  controls.	  They	  suggest	  alteration	  in	  the	  normal	  flora	  weakens	  host	  resistance	  to	  pathogen	  colonization	  in	  a	  similar	  manner	  as	  has	  been	  seen	  in	  the	  gastrointestinal	  tract	  (Artis	  2008).	  Despite	  differences	   in	  bacterial	  burden	  and	  microbiome	  community	  abundances	   there	  were	  no	   significant	  differences	   in	   the	   structure	  of	   the	  microbiome,	  highlighted	  by	   the	  lack	   of	   distinct	   clustering	   patterns	   between	   the	   two	   groups.	   There	   were	   also	   no	  differences	  in	  the	  richness,	  diversity	  or	  evenness	  of	  the	  microbial	  populations	  between	  stable	  and	  AE-­‐IPF.	  The	  comparison	  of	  the	  paired	  samples	  provides	  some	  indication	  as	  to	  why	  this	  may	  be.	  Both	  individuals	  have	  distinct	  stable	  microbiomes	  and	  although	  there	  were	   changes	   in	   both	   during	   exacerbation,	   different	   bacteria	   were	   involved.	   This	  suggests	   that	   if	   an	   exacerbation	   is	   a	   result	   of	   changes	   in	   the	  microbiome,	   the	   causal	  bacteria	  may	  be	  specific	  to	  an	  individual	  subject.	  A	  plausible	  concept	  considering	  not	  all	  community	   acquired	   pneumonias	   in	   healthy	   individuals	   are	   caused	   by	   the	   same	  bacteria.	  	  
5.4.1 Comparisons	  to	  UK	  IPF	  Data	  There	  have	  not	  been	  any	  studies	  of	  geographical	  differences	  in	  the	  healthy	  respiratory	  microbiome,	  let	  alone	  in	  disease.	  There	  are	  a	  number	  of	  clear	  differences	  between	  both	  the	  bacterial	  load	  and	  microbiome	  between	  the	  stable	  Korean	  and	  UK	  IPF	  subjects.	  The	  collection	  and	  storage	  of	  these	  BAL	  samples	  was,	  however,	  completely	  different	  to	  the	  UK	   study.	   For	   example	   Korean	   samples	   were	   split	   into	   pellets	   and	   supernatant	   and	  stored	  at	  -­‐80oC	  for	  a	  substantially	  longer	  period	  of	  time.	   	  In	  relation	  to	  the	  latter	  point	  longitudinal	  data	  with	  regard	  to	  sample	  storage	  for	  the	  molecular	  biological	  approach	  to	  analyse	  the	  microbiota	  present	  have	  as	  yet	  to	  be	  conducted.	  	  Prior	  experience	  within	  the	  Genomic	  Medicine	   department	  with	   regard	   to	   handling	   and	   processing	   such	   samples	  has	   highlighted	   the	   importance	   of	   maintaining	   extraction	   protocols	   and	   time	   to	  extraction	   as	   consistently	   as	   possible.	   	   The	   variability	   between	   the	   Korean	   and	   UK	  sampling	   does	   unfortunately	   render	   any	   baseline	   comparisons	   un-­‐interpretable.	   It	   is	  important	  to	  note	  that	  the	  same	  protocols	  and	  procedures	  were	  employed	  for	  all	  Korean	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stable	   and	   AE-­‐IPF	   samples,	   so	   there	   are	   no	   technical	   differences	   that	   would	   have	  influenced	  the	  results	  contained	  in	  this	  chapter.	  
5.4.2 Limitations	  Unlike	  exacerbations	  of	  other	  respiratory	  conditions	  which	  are	   truly	  acute	  events,	   the	  onset	  of	  an	  exacerbation	  in	  IPF	  is	  more	  insidious.	  This	  therefore	  means	  that	  by	  the	  time	  of	  presentation	  any	  triggering	  viruses	  may	  no	  longer	  be	  detectable,	  despite	  exhaustive	  searching.	  Although	  the	  samples	  were	  collected	  prospectively	  the	  microbiome	  work	  was	  all	   retrospective	   in	   nature,	   so	   the	   sampling	   protocols	  were	   not	   optimised.	   This	  work	  suffers	   from	  the	  same	   limitations	  discussed	   in	  Chapter	  4,	  again	   IPF	   is	  a	  disease	  of	   the	  lung	  parenchyma	  whereas	  BAL	  fluid	  was	  utilised	  here	  to	  sample	  the	  distal	  airways	  and	  no	  oropharyngeal	  sampling	  occurred.	  
5.5 Conclusions	  In	  conclusion	  AE-­‐IPF	  is	  associated	  with	  an	  increased	  BAL	  bacterial	  burden	  compared	  to	  stable	  disease.	  In	  this	  study	  this	  was	  associated	  with	  changes	  in	  the	  microbiome	  with	  an	  increase	   in	  Campylobacter	   sp.	   and	   Stenotrophomonas	   sp.,	   and	   a	   drop	   in	  Veillonella	   sp..	  Although	   paired	   sample	   analysis	   highlights	   the	   heterogeneity	   in	   the	   respiratory	  microbiome	   it	   notably	   shows	   that	   there	   are	  detectable	   changes	   in	   the	   composition	   of	  the	   respiratory	  microbiome	  during	  an	  AE-­‐IPF,	   an	  event	   that	   current	  guidelines	  would	  lead	   us	   to	   believe	   is	   non-­‐infective.	   It	   is	   not	   possible	   to	   conclude	   if	   the	   presence	   of	   a	  higher	  bacterial	  load	  and	  altered	  microbiome	  during	  an	  exacerbation	  reflects	  an	  active	  infection,	  increased	  aspiration	  or	  is	  simply	  a	  result	  of	  widespread	  DAD.	  Analysis	  of	  the	  bacterial	   load	   in	  non	   IPF	  ALI	   subjects	  or	   longitudinal	   sampling	  during	  an	  AE-­‐IPF	  may	  allow	  us	  to	  determine	  this.	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Chapter	  6:	  Gene	  Expression	  in	  IPF	  
6.1	   Introduction	  The	  word	  transcriptome	  encompasses	  the	  complete	  set	  of	  RNA	  transcripts	  encoded	  by	  the	   genome	   under	   specific	   circumstances	   or	   in	   a	   specific	   cell	   type.	   Comparison	   of	  transcriptomes	   generated	   in	   healthy	   and	   disease	   states	   or	   in	   response	   to	   different	  disease	   treatments	   can	   enable	   the	   identification	   of	   differentially	   expressed	   genes	  thereby	   improving	  our	  understanding	  of	   the	  aetiology	  of	  different	  diseases.	  There	  are	  three	  main	  techniques	  that	  can	  be	  used	  that	  allow	  the	  cataloguing	  and	  quantification	  of	  RNA	  transcripts:	   real-­‐time	  quantitative	  PCR	  (qPCR),	  microarrays	  and	  RNA-­‐Sequencing	  (RNA-­‐Seq).	  Real-­‐time	   quantitative	   PCR	   (qPCR)	   simultaneously	   amplifies	   and	   quantifies	   cDNA	  generated	  from	  RNA	  isolated	  from	  a	  sample	  of	  interest.	  It	  is	  a	  highly	  sensitive	  technique,	  in	  which	  transcripts	  are	  identified	  and	  specific	  primers	  designed	  in	  a	  hypothesis	  driven	  approach.	  Due	  to	  the	  quantity	  of	  RNA	  required	  and	  cost	  implications	  it	  invariably	  only	  allows	   a	   small	   number	   of	   genes	   to	   be	   studied.	   Thus	   qPCR	   is	   generally	   reserved	   for	  interrogating	  a	   relatively	   small	  number	  of	   transcripts	   in	   a	   large	   set	  of	   samples	   and	   is	  often	  used	  to	  validate	  findings	  from	  gene	  expression	  studies.	  Microarrays	  are	  a	  hypothesis	  neutral	   technology	   that	  allow	   the	   comparison	  of	   tens	  of	  thousands	   of	   genes	   between	   samples	   (Gresham,	   Dunham,	   and	   Botstein	   2008).	   The	  technique	  relies	  on	  complimentary	  binding	  of	   target	  cDNA	  to	  probes	  on	  a	  microarray.	  The	   labelling	   of	   target	   cDNA	   allows	   hybridisation	   to	   be	   detected	   and	   quantified	   by	  fluorescence,	   generating	   a	   snapshot	   of	   the	   transcriptome	   on	   a	   single	  microarray	   chip	  (DeRisi	   et	   al.	   1996).	   Microarrays	   are	   relatively	   cheap	   and	   the	   automation	   of	   the	  hybridisation,	  washing	  and	  detection	  of	   fluorescence	  allows	  not	  only	  high-­‐throughput	  processing	  of	  multiple	  samples	  but	  minimisation	  of	  potential	  operator	  effects.	  	  Microarrays	  can	  only	  detect	  sequences	  homologous	  to	  known	  transcripts	  present	  on	  the	  array.	  In	  contrast,	  RNA-­‐Seq	  is	  completely	  unbiased	  technique	  that	  is	  not	  reliant	  on	  prior	  probe	   selection	   and	   avoids	   biases	   introduced	   during	   hybridization	   of	   microarrays.	  Direct	  sequencing	  of	  transcripts	  by	  next	  generation	  sequencing	  technologies	  offers	  the	  potential	   to	   discover	   novel	   transcripts	   and	   determine	   gene	   structure	   and	   sequence.	  Recent	  comparisons	  of	  RNA-­‐Seq	  and	  expression	  arrays	  have	  demonstrated	  high	   levels	  of	  correlation	  between	  expression	  profiles	  using	  identical	  samples	  (S.	  Zhao	  et	  al.	  2014).	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Zhao	  et	  al.	  also	  demonstrated	  RNA-­‐Seq	  to	  be	  superior	  in	  the	  	  detection	  of	  low	  abundance	  transcripts	  thereby	  allowing	  the	  detection	  of	  more	  differentially	  expressed	  genes	  with	  higher	   fold-­‐change.	   Despite	   these	   potential	   advantages	   RNA-­‐Seq	   currently	   requires	  substantial	   amounts	   of	   RNA,	   is	   very	   costly	   and	   due	   to	   the	   vast	   quantity	   of	   data	  generated	   it	   at	   present	   lacks	   the	   well-­‐established	   and	   robust	   analysis	   pipelines	  currently	  available	  for	  the	  microarray	  technology.	  	  The	  work	  presented	  in	  this	  chapter	  commenced	  four	  years	  ago	  when	  RNA-­‐Seq	  was	  in	  its	  infancy	  and	   the	   issues	   surrounding	   the	  processing	  and	  analysis	  of	   the	  data	  generated	  were	   even	   more	   pronounced.	   	   Consequently	   microarray	   technology	   was	   chosen	   to	  conduct	  global	  gene	  expression	  and	  thereby	  study	  the	  peripheral	  blood	  transcriptome	  in	  IPF.	  
6.2	   Materials	  and	  Methods	  
6.2.1	   Study	  Population	  IPF	  patients	  were	  prospectively	  recruited	  from	  the	  Interstitial	  Lung	  Disease	  Unit	  at	  the	  Royal	   Brompton	   Hospital,	   London,	   England	   as	   described	   in	   Chapter	   2,	   Section	   2.1.1.	  Control	   subjects,	   including	   non-­‐smokers	   and	   smokers	   with	   normal	   lung	   function	  (referred	  to	  throughout	  as	  healthy	  controls),	  were	  recruited	  separately	  using	  the	  same	  protocols	  (Chapter	  2,	  Section	  2.1.2).	  
6.2.2	   RNA	  Extraction,	  Quantification	  and	  Quality	  Assessment	  The	   PAXgeneTM	   Blood	   RNA	  Kit	   (QIAGEN)	  was	   used	   to	   isolate	   RNA	   from	  whole	   blood	  collected	   in	   PAXgene	   tubes	   as	   described	   in	   Chapter	   2,	   Section	   2.6.1.	   The	   quantity	   of	  isolated	   RNA	   obtained	   was	   determined	   using	   the	   Nanodrop™	   ND	   1000	   UV-­‐Vis	  spectrophotometer	   (Thermo	   Scientific)	   and	   the	   quality	   and	   integrity	   was	   measured	  using	  the	  2100	  Bioanalyzer	  (Agilent).	  (Chapter	  2,	  Section	  2.6.1)	  	  
6.2.3 Gene	  Expression	  	  Thirty	   nanograms	   of	   each	   RNA	   sample	   was	   used	   to	   synthesise	   double-­‐stranded	   (ds)	  cDNA	  using	   the	  Ovation®	  Pico	  WTA	  System	  V2	  Kit	   (Nugen)(Chapter	  2,	  Section	  2.6.2).	  Exogenous	  Poly-­‐A	  positive	  controls	  were	  added	  at	  this	  stage	  to	  monitor	  the	  efficiency	  of	  the	  synthesis	  of	   the	  ds	  cDNA	  and	   target	   labelling	  process.	  The	  quantity	  and	  quality	  of	  the	  purified	  cDNA	  was	  assessed	  by	  measuring	  the	  absorbance	  at	  260,	  280	  and	  320	  nm	  using	   the	   Nanodrop™	   ND	   1000	   UV-­‐Vis	   spectrophotometer	   (Thermo	   Scientific).	   The	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Encore®	  Biotin	  Module	  Kit	  (NuGEN)	  was	  used	  to	  fragment	  2.8	  µg	  of	  the	  purified	  cDNA	  	  which	  was	  then	  hybridised,	  washed	  and	  scanned	  on	  the	  GeneTitan®	  (Affymetrix)	  using	  the	  Gene	  1.1	  Sense	  Target	  (ST)	  Array	  Plates	  (Chapter	  2,	  Section	  2.6.2).	  
6.2.4 Gene	  Expression	  and	  Statistical	  analysis	  Raw	   expression	   data	   were	   background	   adjusted,	   quantile	   normalised	   and	   median	  polished	   using	   the	   RMA	   algorithm	   as	   implemented	   in	   the	   Affymetrix	   Power	   Tools	  software	   suite	   (APT,	   version	   1.12.0)	   (Chapter	   2,	   Section	   2.6.3.1).	   Linear	   Models	   for	  Microarray	  Data	  (LIMMA)	  was	  used	  to	  identify	  differentially	  expressed	  genes	  between	  each	   pair	   of	   sample	   groups	   (Chapter	   2,	   Section	   2.6.3.2).	   P-­‐values	   were	   adjusted	   for	  multiple	  testing	  using	  the	  Benjamini	  &	  Hochberg	  method	  for	  the	  control	  of	  the	  expected	  False	   Discovery	   Rate	   (FDR).	   Genes	   with	   significant	   differential	   expression	   were	   then	  selected	  by	  use	  of	  a	  cut-­‐off	  of	  an	  FDR-­‐adjusted	  P	  value	  and	   fold	  change	   in	   the	   level	  of	  expression.	  
6.3	   Results	  
6.3.1	   Subjects	  and	  Sampling	  Sixty	  patients	  with	   IPF	  and	  20	  controls	  were	   included	   in	   the	  gene	  expression	  analysis	  (Table	  6.1).	  The	  60	   IPF	   subjects	  were	  predominantly	  male	   (65%)	  with	  a	  mean	  age	  of	  67.8	   years	   and	   had	   moderately	   severe	   disease	   (Carbon	   Monoxide	   Diffusing	   Capacity	  [DLCO]	  40.9%	  predicted;	  FVC	  73.4%	  predicted).	  The	  20	  controls	  were	  matched	  for	  age,	  sex	  and	  smoking	  history.	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   IPF	  (N=60)	   Controls	  (N=20)	   P-­‐value	  Age	  (yr)	   67.8	  (±8)	   66.0(±10.0)	   NS	  Female	  Sex	  -­‐	  number	  (%)	   21	  (35%)	   8	  (40%)	   NS	  Smoking	  (Ever)	  -­‐	  number	  (%)	   41	  (68%)	   12	  (60%)	   NS	  FVC—	  %	   73.4	  (±	  21)	   NR	   	  FEV1	  —	  %	   74.3	  (±19)	   NR	   	  Ratio	  of	  FEV1	  to	  FVC	   81.2	  (±7)	   NR	   	  DLCO	  -­‐	  %	   40.9	  (±16)	   NR	   	  O2	  Saturation—	  %	   95	  (±2)	   97	  (±4)	   NS	  6-­‐Minute	  walk	  distance	  -­‐	  m	   321	  (±134)	   NR	   	  
Table	   6.1.	   Baseline	   characteristics	   of	   the	   subjects	   in	   the	   gene	   expression	   study.	  Details	   are	   provided	   for	   IPF	   cases	   and	   healthy	   controls.	   Data	   are	   means	   ±Standard	  Deviation.	   NA=not	   available;	   NS=not	   significant;	   DLCO,	   carbon	   monoxide	   diffusing	  capacity;	  FVC,	  forced	  vital	  capacity;	  FEV1,	  forced	  expiratory	  volume	  in	  one	  second.	  There	  were	   190	   Arrays	   in	   total	   including	   60	   IPF	   subjects	   at	   baseline	   and	   20	   healthy	  controls.	  Longitudinal	  samples	  were	  also	  collected	  from	  the	  IPF	  subjects.	  Thirty	  subjects	  were	   sampled	   at	   time	   point	   1	   (1	   month),	   29	   subsequently	   sampled	   at	   time	   point	   2	  (3months),	   the	   full	   30	   sampled	   at	   time	   point	   3	   (6	  months)	   with	   21	   of	   the	   30	   finally	  sampled	  at	  time	  point	  4	  (1	  year	  sample).	  
6.3.2	   RNA	  Extraction	  and	  Quality	  Control	  All	  170	  IPF	  samples	  and	  20	  control	  samples	  yielded	  good	  quality	  RNA,	  with	  a	  RIN	  of	  8.3	  (±0.89).	  The	  average	  yield	  from	  the	  IPF	  samples	  was	  154.1	  ng/μl	  (±72.35)	  and	  from	  the	  control	   patients	   162.6	   ng/μl	   (±67.36).	   All	   of	   the	   samples	   were	   taken	   forward	   for	  expression	  analysis.	  Normalisation	  between	  arrays	  was	  required	  to	  compensate	  for	  the	  systematic	  technical	  differences	  in	  measurement	  between	  the	  16	  array	  plates	  that	  were	  run	  separately.	  The	  raw	   intensity	   measurements	   of	   all	   probe	   sets	   were	   corrected	   for	   background	  fluorescence,	   quantile	   normalized,	   median	   polished	   and	   converted	   into	   expression	  measurements	  using	  the	  robust	  multi-­‐array	  averaging	  (RMA)	  algorithm	  as	  implemented	  in	   Affymetrix	   Power	   Tools	   (APT,	   version	   1.12.0).	   Log	   transformation	   was	   also	  implemented	  to	  remove	  skew	  within	  the	  distributions	  and	  makes	  relative	  changes	  less	  sensible	   to	   errors.	   The	   Affymetrix	   Expression	   Console	   was	   used	   to	   interrogate	   the	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bacterial	   and	   poly-­‐A	   spike	   control	   probe	   sets.	   The	   poly-­‐A	   controls	   are	   a	   set	   of	   poly-­‐adenylated	   RNA	   spikes	   that	   are	   used	   to	   identify	   any	   bias	   that	   occurs	   during	   reverse	  transcription.	   Figure	   6.1	   demonstrates	   that	   the	   poly-­‐A	   spikes	   displayed	   the	   expected	  descending	  rank	  order	  (Dap,	  Thr,	  Phe	  and	  Lys)	  confirming	  that	  there	  were	  no	  problems	  with	  either	  the	  RNA	  sample	  or	  target	  preparation.	  
	  
Figure	  6.1	  RNA	  sample	  and	   target	  preparation	  controls.	  The	  poly-­‐A	  spikes	  display	  the	   expected	   descending	   order	   of	   Thr,	   Dap,	   Phe	   and	   Lys	   (red,	   green,	   pink,	   blue),	  indicating	  there	  were	  no	  issues	  with	  either	  RNA	  sample	  or	  target	  preparation.	  Affymetrix	   arrays	   include	   spike-­‐in	   hybridization	   controls	   that	   do	   not	   cross-­‐hybridise	  with	  non-­‐bacterial	   or	  non-­‐viral	   samples.	   Consequently	  hybridization	   efficiency	   can	  be	  assessed	  using	  biotinylated	  target	  bacterial	  spike-­‐in	  controls	  (BioB,	  BioC,	  BioD	  and	  CRE)	  that	  are	  added	  before	  the	  labelling	  process	  in	  different	  concentrations.	  	  Examination	  of	  the	   signal	   values	   for	   the	   bacterial	   spikes	   for	   the	   current	   set	   of	   arrays	   revealed	   the	  expected	  rank	  orders,	  confirming	  that	   there	  had	  been	  no	  problems	  with	  hybridisation	  (Figure	  6.2).	  
	  
Figure	   6.2	   Hybridisation	   controls.	   The	   bacterial	   spikes	   display	   the	   expected	  descending	  order	  of	  Cre,	  BioD,	  BioC,	  BioB	  (red,	  blue,	  pink,	  green)	  indicating	  there	  were	  no	  problems	  with	  the	  hybridization	  and/or	  array.	  All	  190	  arrays	  passed	   the	  absolute	  quality	  metrics.	  Next	   relative	  quality	  metrics	  were	  used	  to	  compare	  each	  array's	  intensities	  against	  those	  of	  other	  arrays	  within	  the	  dataset	  to	   establish	  whether	   any	   outliers	   existed.	  Outliers	   are	   generally	   arrays	   of	   low	  quality	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that	   add	   noise	   and	   impair	   the	   statistical	   and	   biological	   signal	   detected.	   The	  bioconductor	   package	   arrayQualityMetrics	   (Kauffmann,	   Gentleman,	   and	   Huber	   2009)	  was	  used	  to	  generate	  an	  MA-­‐plot,	  boxplot	  of	  the	  Relative	  Log	  Expression	  (RLE)	  values	  and	   a	   heatmap	   plot	   of	   the	   distance	   between	   arrays.	   The	   MA	   plot	   allows	   pair-­‐wise	  comparisons	  of	  the	  log-­‐intensity	  of	  each	  array	  to	  the	  median	  array	  and	  identification	  of	  intensity-­‐dependent	  biases.	  The	  RLE	  values	  calculate	  the	  ratio	  between	  the	  expression	  of	   a	   probe-­‐set	   and	   the	   median	   expression	   of	   the	   probe-­‐set	   across	   all	   arrays.	   As	   the	  majority	  of	  probe-­‐sets	  are	  unchanged	  across	  arrays	  these	  ratios	  should	  be	  around	  0	  on	  a	  log	   scale	   and	   have	   a	   similar	   spread	   on	   a	   box	   plot.	   Sixteen	   arrays	   were	   identified	   as	  outliers	  by	  two	  or	  more	  of	  the	  metrics,	  suggesting	  they	  were	  of	  low	  quality.	  These	  were	  subsequently	   visualised	   on	   a	   principal	   components	   plot	   (Figure	   6.3)	   prior	   to	   being	  excluded.	  Downstream	  analyses	  therefore	  focused	  on	  the	  remaining	  174	  arrays.	  
	  
Figure	  6.3	   Identification	  of	   outliers.	  Principal	  components	  analysis	  (PCA)	  of	  all	  190	  arrays.	   	   Arrays	   identified	   as	   outliers	   by	  quality	   control	  metrics	   are	   highlighted	   in	   red	  and	  were	  excluded	  from	  subsequent	  analyses.	  At	  all	  stages	  of	  the	  RNA	  processing	  pipeline,	  from	  extraction	  to	  microarray	  processing,	  experiments	  were	   performed	   in	   batches	   (Chapter	   2.6.2).	   Twelve	   16	   PEG	   arrays	  were	  run	   and	   during	   this	   time	   essential	   maintenance	   to	   the	   GeneTitan®	   (Affymetrix)	  occurred	  and	   the	  scanner	  was	  replaced	   in	  order	   to	  correct	  an	  equipment	  design	   flaw.	  This	   together	  with	  other	  potential	   sources	  of	  batch	  effects	  were	   carefully	   recorded	   to	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allow	   detection	   of	   any	   substantial	   latent	   batch	   effects	   associated	   with	   technical	  variables.	  Principal	  Variance	  Component	  Analysis	  (PVCA)	  (Scherer	  2009)	  was	  used	  as	  a	  screening	   tool	   to	   determine	  which	   sources	   of	   variability	  were	  most	   prominent	   in	   the	  data	  set	  (Figure	  6.4).	  
	  
Figure	   6.4:	   Identification	   of	   batch	   effects.	   Principal	   Variance	   Component	   Analysis	  (PVCA)	  quantifies	  the	  proportion	  of	  variation	  of	  each	  effect.	  While	  phenotype	  accounts	  for	  over	  10%	  of	  the	  variance	  a	  more	  substantial	  proportion	  (21%)	  is	  attributable	  to	  the	  change	  in	  the	  GeneTitan®	  scanner.	  PVCA	   suggested	   that	   phenotype	   accounts	   for	   over	   10%	   of	   the	   variance	   within	   the	  arrays,	  however,	  a	  more	  substantial	  proportion	  (21%)	  was	  attributable	  to	  the	  change	  in	  GeneTitan®	  scanner	  which	  was	  used	  to	  process	  the	  arrays.	  	  This	  can	  also	  be	  seen	  on	  the	  PCA	   plot	   (Figure	   6.5).	   This	   batch	   effect	  was	   therefore	   corrected	   for	   using	   Combining	  Batches	  of	  Gene	  Expression	  Microarray	  Data	  (Combat)	  prior	  to	  undertaking	  any	  further	  analyses	  (Johnson,	  Li,	  and	  Rabinovic	  2007).	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Figure	   6.5	   Batch	   effect	   due	   to	   scanner.	   Principal	   components	   analysis	   (PCA)	  demonstrating	   the	   clustering	  of	   samples	  based	  on	   the	  use	  of	   the	  original	  GeneTitan®	  scanner	  (Red)	  or	  the	  updated	  replacement	  scanner	  (Blue).	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6.3.3 Differential	  Expression	  Analysis	  
6.3.3.1 Baseline	  IPF	  versus	  Controls	  A	  total	  of	  1,358	  transcript	  clusters	  were	  differentially	  expressed	  between	  IPF	  samples	  and	   healthy	   controls	   at	   baseline,	   employing	   a	   1%	   False	   Discovery	   Rate	   (FDR).	   Five	  hundred	  and	  30	  transcript	  clusters	  (39%)	  demonstrated	  an	  increased	  abundance	  in	  IPF	  relative	   to	   healthy	   controls	   with	   the	   remaining	   828	   (61%)	   demonstrating	   a	   relative	  decrease	  (Figure	  6.6).	  	  
	  
Figure	   6.6	   Volcano	   plot	   of	   differential	   expression	   between	   IPF	   and	   control	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For	   the	   1,358	   transcript	   clusters	   (1%	   FDR),	   331	   met	   or	   exceeded	   an	   absolute	   fold	  change	  criterion	  of	  1.4	  with	  238	  of	  the	  transcript	  clusters	  up-­‐regulated	  in	  IPF	  with	  the	  remaining	  93	  being	  down-­‐regulated	  in	  IPF	  (Table	  6.2).	  	  
Transcript	  
Cluster	  ID	   Ave	  Expr	   t	  statistic	   P	  Value	   B-­‐H	  adjusted	  P	  Value	   Gene	  Name	   Absolute	  Fold	  Change	  8163185	   7.80	   8.80	   1.96E-­‐13	   2.75E-­‐09	   TXN	   2.22	  8082058	   8.41	   8.48	   8.27E-­‐13	   5.81E-­‐09	   CSTA	   2.06	  7996313	   6.91	   8.15	   3.81E-­‐12	   1.78E-­‐08	   CMTM2	   1.72	  7920238	   9.81	   7.73	   2.49E-­‐11	   8.75E-­‐08	   S100A12	   1.94	  7897522	   7.74	   7.06	   5.16E-­‐10	   1.45E-­‐06	   RBP7	   1.86	  8169659	   8.97	   6.70	   2.58E-­‐09	   3.61E-­‐06	   NDUFA1	  	   1.50	  8050695	   7.82	   6.68	   2.72E-­‐09	   3.61E-­‐06	   SF3B14	   1.70	  8157446	   5.56	   6.68	   2.79E-­‐09	   3.61E-­‐06	   ORM1	   3.62	  7997520	   7.33	   6.66	   3.09E-­‐09	   3.61E-­‐06	   HSBP1	   1.41	  7961440	   8.91	   6.61	   3.76E-­‐09	   4.06E-­‐06	   PLBD1	   1.57	  8006573	   8.41	   -­‐6.50	   6.01E-­‐09	   5.28E-­‐06	   TAF15	   -­‐1.47	  7920244	   10.50	   6.52	   5.68E-­‐09	   5.28E-­‐06	   S100A8	   1.56	  8004175	   5.32	   6.38	   1.04E-­‐08	   8.56E-­‐06	   TXNDC17	   1.54	  8067288	   9.42	   6.19	   2.36E-­‐08	   1.44E-­‐05	   ATP5E	   1.55	  7968270	   7.96	   6.15	   2.77E-­‐08	   1.62E-­‐05	   ATP5EP2	   1.43	  7956013	   7.93	   6.13	   2.99E-­‐08	   1.62E-­‐05	   BLOC1S1-­‐RDH5	   1.47	  8122554	   6.24	   6.13	   2.97E-­‐08	   1.62E-­‐05	   RAB32	   1.52	  8160587	   6.58	   6.09	   3.54E-­‐08	   1.77E-­‐05	   NDUFB6	  	   1.41	  8098762	   8.68	   6.10	   3.48E-­‐08	   1.77E-­‐05	   	  ATP5I	   1.70	  7990818	   6.50	   6.03	   4.58E-­‐08	   2.01E-­‐05	   BCL2A1	   2.19	  
Table	   6.2:	   The	   top	   20	   transcript	   clusters	   significant	   at	   1%	   FDR	   threshold	  
accompanied	  by	  a	  fold	  change	  ≥	  1.4.	  Ave	  Expr	  is	  the	  average	  log2-­‐expression	  level	  for	  that	  gene	  across	  all	  the	  arrays.	  As	   can	   be	   seen	   from	   Table	   6.2,	   the	   five	   top	   differentially	   expressed	   genes	   are	  thioredoxin	  (TXN,	  Fold	  Change	  [FC]	  2.2,	  P=2.75E-­‐09),	  Cystatin	  A	  (CSTA,	  FC	  2.1,	  p=5.81e-­‐09),	   Chemokine-­‐Like	   Factor	   Superfamily	  Member	   (CMTM2,	   FC	   1.7,	   p=1.78e-­‐08),	   S100	  calcium	   binding	   protein	   A12	   (S100A12,	   FC	   1.94,	   p=8.75e-­‐08),	   and	   retinol	   binding	  protein	  7	  (RBP7,	  FC	  1.86,	  p=1.45e-­‐06).	  Table	  6.3	  shows	  the	  top	  differentially	  expressed	  genes	  (1%	  FDR)	  organised	  by	  fold	  change,	  the	  highest	  fold	  change	  seen	  being	  3.62	  for	  
ORM1.	  The	  ORM1	  gene	  encodes	  an	  acute	  phase	  plasma	  protein.	  BCLA2A1,	  which	  shows	  a	  2.19	   fold	   increase	   in	   expression,	   is	   a	   direct	   transcription	   target	   of	   NF-­‐kappa	   B	   in	  response	   to	   inflammatory	  mediators.	   It	   is	   also	   interest	   to	   note	   that	   tumour	   necrosis	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factor-­‐inducible	   gene	   6	   (TNFAIP6)	   expression	   is	   increased	   (fold	   change	   2.15	   adjusted	  
P=0.0003).	   Expression	   levels	   of	   this	   gene	   have	   previously	   been	   associated	   with	   skin	  fibrosis	  (Gardet,	  Zheng,	  and	  Viney	  2013).	  
Transcript	  
Cluster	  ID	   Ave	  Expr	   t	  statistic	   P	  Value	   B-­‐H	  adjusted	  P	  Value	   Gene	  Name	   Absolute	  Fold	  Change	  8157446	   5.56	   6.68	   2.79E-­‐09	   3.61E-­‐06	   ORM1	   3.62	  8149109	   6.62	   3.69	   0.0004	   0.0051	   DEFA4	   3.04	  8029280	   5.66	   4.63	   1.39E-­‐05	   0.0006	   CD177	   2.52	  8122058	   5.09	   4.02	   0.0001	   0.0027	   ARG1	   2.29	  8066493	   7.69	   5.56	   3.41E-­‐07	   7.05E-­‐05	   SLPI	   2.29	  8063115	   7.75	   4.79	   7.42E-­‐06	   0.0004	   MMP9	   2.28	  7973105	   6.49	   4.17	   7.61E-­‐05	   0.0019	   RNASE3	   2.26	  8163185	   7.80	   8.80	   1.96E-­‐13	   2.75E-­‐09	   TXN	   2.22	  7990818	   6.50	   6.03	   4.58E-­‐08	   2.01E-­‐05	   BCL2A1	   2.19	  8045688	   6.85	   4.93	   4.37E-­‐06	   0.0003	   TNFAIP6	   2.15	  7981943	   4.68	   -­‐4.86	   5.57E-­‐06	   0.0003	   SNORD64	   -­‐2.11	  8095986	   7.23	   5.38	   7.12E-­‐07	   0.0001	   ANXA3	   2.11	  8079590	   7.24	   4.78	   7.82E-­‐06	   0.0004	   CAMP	   2.11	  8082058	   8.41	   8.48	   8.27E-­‐13	   5.81E-­‐09	   CSTA	   2.06	  7997188	   5.51	   4.11	   9.29E-­‐05	   0.0021	   HP	   2.05	  7953749	   5.87	   5.18	   1.58E-­‐06	   0.0001	   CLEC4D	   2.02	  8104738	   7.32	   5.37	   7.23E-­‐07	   0.0001	   SUB1	   2.01	  7969288	   4.80	   2.88	   0.005	   0.0301	   OLFM4	   2.00	  8037742	   7.64	   5.72	   1.71E-­‐07	   4.54E-­‐05	   PGLYRP1	   1.99	  8012469	   8.92	   5.64	   2.42E-­‐07	   5.66E-­‐05	   RPL26	   1.97	  
Table	  6.3:	  The	  top	  20	  transcript	  clusters	  significant	  at	  a	  1%	  FDR	  ordered	  by	  fold	  
change.	  Highest	  fold	  change	  in	  complete	  set	  of	  differentially	  expressed	  genes	  (N=1,358)	  was	   3.62.	   Ave	   Expr	   is	   the	   average	   log2-­‐expression	   level	   for	   that	   gene	   across	   all	   the	  arrays.	  The	  genes	  encoding	  two	  antimicrobial	  peptides	  were	  also	  observed	  to	  be	  up	  regulated	  with	   a	   large	   fold	   change,	   secretory	   leukocyte	   peptidase	   inhibitor	   (SLPI	   –	   fold	   change	  2.29)	  and	  Cathelicidin	  Antimicrobial	  Peptide	  (CAMP	  –	   fold	  change	  2.11).	  Up	  regulation	  of	  two	  genes	  previously	  associated	  with	  IPF,	  MMP-­‐9	  and	  DEFA4	  was	  also	  found.	  When	   looking	   at	   those	   genes	   differentially	   expressed	   with	   an	   FDR	   of	   1%	   and	   a	   fold	  change	  over	  1.4,	   the	  top	  enriched	  GO	  biological	  processes	  were	   found	  to	  be	  related	  to	  host	  defence	  and	  stress	  (Table	  6.4).	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   GO	  Term	   P	  Value	   B-­‐H	  adjusted	  P	  Value	  GO:0002376	   Immune	  system	  process	   6.36E-­‐06	   0.0093	  GO:0006952	   Defence	  response	   9.08E-­‐06	   0.0066	  GO:0006955	   Immune	  response	   1.75E-­‐05	   0.0085	  GO:0006119	   Oxidative	  phosphorylation	   3.14E-­‐05	   0.0115	  GO:0009617	   Response	  to	  bacterium	   3.18E-­‐05	   0.0093	  GO:0009605	   Response	  to	  external	  stimulus	   7.21E-­‐05	   0.0175	  GO:0006091	   Generation	  of	  metabolites	  and	  energy	   1.61E-­‐04	   0.0332	  GO:0009607	   Response	  to	  biotic	  stimulus	   3.47E-­‐04	   0.0616	  GO:0042981	   Regulation	  of	  apoptosis	   4.64E-­‐04	   0.0728	  GO:0042742	   Defence	  response	  to	  bacterium	   5.19E-­‐04	   0.0733	  
Table	  6.4:	  GO	  biological	  processes	  of	  genes	  differentially	  expressed	  with	  an	  FDR	  
of	  1%	  and	  a	  fold	  change	  over	  1.4.	  	  
6.3.3.2 Weighted	  Gene	  Co-­‐expression	  Network	  Analysis	  Network	   analysis	   identifies	   genes	   which	   are	   correlated	   in	   their	   expression	   profiles.	  Understanding	  co-­‐ordinated	  gene	  function	  and	  the	  underlying	  transcriptional	  network	  structure	  may	   allow	   the	   identification	   of	   potential	   therapeutic	   targets.	   In	   this	   section	  Weighted	   Gene	   Co-­‐expression	   Network	   Analysis	   (WGCNA)	   was	   performed	   using	   the	  differential	  gene	  expression	  data	  generated	  in	  Section	  6.3.3.1.	  WGCNA	   describes	   correlation	   patterns	   among	   genes	   across	   microarray	   samples.	   It	  quantifies	   not	   only	   the	   correlations	   between	   individual	   pairs	   of	   genes,	   but	   also	   the	  extent	   to	   which	   genes	   share	   the	   same	   neighbours.	   The	   resulting	   gene	   co-­‐expression	  network	   is	   then	   used	   to	   cluster	   similarly	   expressed	   genes	   into	  modules	   (clusters)	   of	  highly	   correlated	   genes	   (B.	   Zhang	   and	   Horvath	   2005).	   Relationships	   between	  phenotypic	  traits	  of	  interest	  and	  modules	  can	  be	  compared,	  allowing	  correlation	  with	  a	  handful	  of	  modules	  rather	   than	  thousands	  of	   individual	  genes,	  alleviating	  the	  multiple	  testing	  problems	  faced	  when	  correlating	  large	  data	  sets.	  Modules	  of	  interest	  can	  then	  be	  interrogated	  further	  to	  understand	  their	  biological	  functions	  and	  gene	  membership.	  To	  generate	   the	  co-­‐expression	  network	  a	  Pearson	  correlation	  matrix	  was	  constructed,	  providing	   pairwise	   comparisons	   between	   all	   transcript	   clusters.	   WGCNA’s	   soft-­‐thresholding	   strategy	   keeps	   all	   possible	   links	   within	   the	   co-­‐expression	   network,	   but	  requires	   the	   network	   to	   be	   raised	   to	   the	   power	   'beta'	   so	   that	   high	   correlation	   are	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emphasized	   at	   the	   expense	   of	   low	   correlations.	   The	   power	   value	  was	   determined	   by	  sequential	  assessment	  of	  model	  fit	  to	  a	  scale	  free	  topology	  (Figure	  6.7).	  There	  is	  a	  trade-­‐off	  between	  maximising	  scale	   free	  topology	  while	  maintaining	  a	  high	  mean	  number	  of	  connections.	  Mean	  connectivity	  is	  therefore	  also	  taken	  into	  account	  when	  choosing	  the	  value	  of	  beta.	  A	  power	  of	  10	  was	  selected	  as	   this	   represented	   the	   first	  value	  at	  which	  scale	  free	  topology	  was	  approximated.	  
	  
Figure	  6.7	  A	  scale-­‐free	  topology	  plot.	  	  The	  left	  panel	  shows	  the	  scale-­‐free	  fit	  index	  (y-­‐axis)	  as	  a	  function	  of	  the	  soft-­‐thresholding	  power	  (x-­‐axis).	  The	  right	  panel	  displays	  the	  mean	  connectivity	  (degree,	  y-­‐axis)	  as	  a	  function	  of	  the	  soft-­‐thresholding	  power	  (x-­‐axis)	  All	  1,358	  differentially	  expressed	  transcript	  clusters	  significant	  at	  a	  1%	  FDR	  threshold	  were	   included	   in	  a	  signed	  weighted	  gene	  co-­‐expression	  network	  analysis.	  All	  modules	  with	   genes	   that	   were	   highly	   co-­‐expressed	   or	   contained	   fewer	   than	   30	   genes	   were	  merged.	  A	  total	  of	  5	  modules	  were	  identified	  (Figure	  6.8).	  Each	  module	  was	  assigned	  a	  unique	   colour	   identifier;	   turquoise	   (containing	   690	   members),	   blue	   (289	   members),	  brown	   (186	  members),	   yellow	   (131	  members)	   and	   green	   (54	  members).	   A	   total	   of	   8	  transcript	  clusters	  remained	  unassigned	  (grey	  module).	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Figure	   6.9:	   Module	   eigengene	   dendrogram	   and	   adjacency	   heatmap.	   The	  module	  eigengene	  network	  shown	  as	  a	  dendrogram	  and	  heatmap.	   	   Incorporated	   into	  both	  are	  phenotype,	  survival	  and	  death.	  The	  turquoise	  and	  yellow	  modules	  are	  highly	  related,	  as	  evidenced	  by	  their	  low	  merging	  height,	  and	  both	  associate	  with	  survival.	  The	  brown	  module	  associates	  closely	  with	  the	  phenotype.	  The	  classification	  of	  alive	  or	  dead	  (RIP)	  associated	  with	  three	  of	  the	  modules	  blue,	  green	  and	  brown.	   In	  order	   to	  explore	   further	   the	  specific	  clinical	  contribution	  of	  each	  module,	  correlations	  were	  sough	  between	  the	  module	  epigenes	  and	  the	  remaining	  phenotypic	  data	  (Figure	  6.10).	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The	  brown,	  blue	  and	  green	  modules	  showed	  the	  highest	  positive	  correlation	  with	  an	  IPF	  phenotype	   whilst	   the	   turquoise	   and	   yellow	   modules	   had	   the	   highest	   negative	  correlation.	   In	   addition	   to	   its	   relationship	  with	   phenotype	   the	   turquoise	  module	  was	  found	   to	   have	   a	   strong	   positive	   correlation	   (P=2e-­‐04)	   with	   survival	   and	   a	   negative	  correlation	  with	  decline	  in	  FVC	  (P=3e−04),	  DLCO	  (P=0.03)	  or	  CPI	  (P=2e-­‐04)	  and	  death	  (P=0.001).	  As	  such,	   increased	  expression	  of	   the	   turquoise	  module	  appears	   to	  co-­‐occur	  with	   longer	   survival,	   less	  decline	   in	   lung	   function	  and	   fewer	  deaths.	   Interestingly	   this	  module	   was	   also	   associated	   with	   significantly	   lower	   BAL	   (P=9e−04)	   and	   blood	  neutrophilia	  (P=1e−05)	  and	  a	  higher	  BAL	  lymphocytosis	  (P=3e−04).	  The	  yellow	  module	  demonstrated	  a	  very	  similar	  pattern	  of	  correlation,	  as	  would	  be	  predicted	  from	  Figure	  6.9.	  The	  module	  was	  also	  positively	  correlated	  with	  baseline	  Pa02	  (P=0.06).	  The	  blue	  module	  showed	  the	  strongest	  negative	  correlation	  with	  survival	  (P=5e-­‐04)	  the	  latter	  appearing	  to	  be	  driven	  by	  a	  decline	  in	  lung	  function	  since	  the	  module	  is	  positively	  correlated	  with	   declines	   in	   FVC	   (P=0.001),	   DLCO	   (P=0.02)	  and	   CPI	   (P=5e-­‐04).	   This	   is	  also	  reflected	  in	  the	  strong	  positive	  correlation	  of	  the	  module	  with	  death	  (RIP	  P=0.001).	  The	   blue	   module	   was	   also	   positively	   correlated	   with	   increased	   BAL	   (P=9e−04)	   and	  blood	   neutrophilia	   (P=2e−07)	   as	   well	   as	   a	   higher	   BAL	   bacterial	   load	   (P=0.04).	   As	  predicted	  by	  hierarchical	  clustering	  (Figure	  6.9)	  the	  green	  module	  demonstrated	  a	  very	  similar	   pattern	   of	   correlations	   to	   that	   seen	   for	   blue	   module.	   The	   brown	   module	  demonstrated	  similar	  associations	  with	  decline	  in	  lung	  function,	  survival	  and	  death,	  but	  did	  not	  associate	  with	  BAL	  neutrophilia.	  The	  brown	  module	  did	  however	  show	  positive	  correlation	  with	  baseline	  MRC	  dyspnoea	  score	  (P=0.02).	  In	   summary	   increased	  expression	  of	   the	  blue	  and	  green	  modules	   appears	   to	   co-­‐occur	  with	  declining	  lung	  function,	  with	  increased	  neutrophilia	  and	  BAL	  bacterial	  load,	  while	  increased	  expression	  of	  the	  turquoise	  module	  conversely	  co-­‐occurs	  with	  improved	  lung	  function,	  decreased	  BAL	  neutrophilia	  and	  BAL	  bacterial	  load.	  To	   determine	   whether	   specific	   modules	   were	   enriched	   for	   novel	   gene	   categories	   or	  pathways,	  DAVID	  analysis	  was	   repeated	   for	  each	  module.	  The	   top	   three	  GO	  biological	  processes	  most	  enriched	  within	  the	  blue	  module	  were	  GO:0006952	  (defence	  response,	  
P=3.5e-­‐4),	   GO:0009617	   (response	   to	   bacterium	   P=0.001)	   and	   GO:0006955	   (immune	  response,	   P=0.003).	   Consistent	   with	   these	   enrichments	   genes	   in	   the	   blue	   module	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included	   ALOX5	   (P=2.37E-­‐31),	   NLRC4	   (P=5.97E-­‐26),	   IL1R1	   (P=7.03E-­‐25),	   PGLYRP1	  (P=8.32E-­‐25)	  and	  CEBPB	  (P=5.56E-­‐24).	  The	   top	   GO	   biological	   process	   associated	   with	   the	   green	   module	   was	   cell	   death	  (GO:0008219).	  The	  most	  highly	  connected	  genes	  (hubs)	  within	  the	  green	  module	  were	  
ZNF267	  (P=6.76E-­‐30),	  CD58	  (P=8.11E-­‐30),	  NMI	  (P=3.17E-­‐28)	  and	  BCL2A1	  (P=3.69E-­‐28).	  For	   the	   brown	   module	   the	   GO	   terms	   associated	   with	   it	   were	   all	   related	   to	   cellular	  metabolism;	   GO:0006091	   (generation	   of	   precursor	   metabolites,	   P=7.2e-­‐13);	  GO:0006119	   (oxidative	   phosphorylation,	   P=2.1e-­‐11)	   and	   GO:0022900	   (electron	  transport	  chain,	  P=2.2e-­‐9).	  The	   turquoise	   (690	   members)	   and	   yellow	   (131	   members)	   modules	   were	   both	  negatively	  correlated	  with	  the	  IPF	  phenotype.	  In	  addition	  they	  both	  showed	  association	  with	   more	   stable	   lung	   function	   and	   better	   survival.	   The	   top	   three	   GO	   biological	  processes	  most	  enriched	  within	   the	   turquoise	  module	  were	  GO:0006139	   (nucleobase,	  nucleoside,	   nucleotide	   and	   nucleic	   acid	   metabolic	   process,	   P=5.5e-­‐11),	   GO:0044260	  (cellular	   macromolecule	   metabolic	   process,	   P=7.0e-­‐11)	   and	   GO:0016070	   (RNA	  metabolic	   process,	   P=1.1e-­‐9).	   Processes	   involved	   in	   chromosome	   and	   chromatin	  organisation	   were	   enriched	   for	   the	   yellow	  module,	   but	   there	   were	   no	   significant	   GO	  functional	  annotation	  clusters.	  WGCNA	   generates	   a	   gene	   significance	   score	   for	   each	   transcript	   that	   reflects	   its	  biological	   significance	   to	   the	   trait	   of	   interest,	   in	   this	   case	   phenotype.	   Combining	   this	  with	  the	  module	  membership	  score,	  a	  measure	  of	  how	  tightly	  a	  particular	  gene	  fits	  into	  its	  module,	  allows	   identification	  of	  genes	  that	  are	  strongly	  associated	  with	  modules	  of	  interest	  and	  have	  a	  high	  significance	  for	  IPF	  (Figure	  6.11).	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The	  mean	  MM	  ±	  SEM	  ranged	   from	  0.60	  ±	  0.01	   (yellow	  module)	   to	  0.82	  ±	  0.01	   (green	  module),	   indicating	   that	  modules	  consisted	  of	  genes	  sharing	  highly	  similar	  expression	  patterns.	  Next	  genes	  with	  the	  highest	  module	  membership	  and	  gene	  significance	  were	  selected	  and	  networks	  constructed.	   	  This	  allowed	  the	  identification	  of	  important	  (hub)	  genes,	   visualisation	   of	   their	   interactions	   within	   the	   module	   and	   consequently	   the	  identification	  of	  potential	  candidate	  driver	  genes.	  Within	  the	  turquoise	  module	  the	  most	  highly	  connected	  genes	  were	  NLC,	  MYCBP2,	  KDM4C	  and	  FUBP1	  (Figure	  6.12).	  COMMD6	  was	  the	  most	  highly	  connected	  transcript	  in	  the	  brown	  module	  (Figure	  6.12),	  whilst	  for	  the	  blue	  module	  one	  of	  the	  most	  highly	  connected	  genes	  was	  NLRC4	  (Figure	  6.12).	  	   	  
	  	   154	  
	  
	  	  	   	  
Figure	  6.12:	  Visualisation	  of	  the	  most	  highly	  connected	  nodes	  in	  the	  (A)	  Blue	  (B)	  
Turquoise	  and	   (C)	  Brown	  modules.	  For	  improved	  clarity,	  only	  those	  nodes	  with	  the	  highest	  module	  memberships	  are	  considered	  (up	  to	  a	  maximum	  of	  40),	  and	  only	  those	  connections	  with	  a	  topological	  overlap	  >0.025	  are	  shown.	   	  
	  	   155	  
6.3.3.3 All	  IPF	  Samples	  versus	  Controls	  Following	  baseline	  analysis	  of	   IPF	  versus	  controls	  next	  all	   IPF	  samples	   irrespective	  of	  time	  point	  were	  combined	  into	  one	  cohort.	  This	  allowed	  the	  comparison	  of	  IPF	  (n=154)	  v	   controls	   (n=20)	   factoring	   in	   multiple	   time	   points	   from	   each	   individual	   (Smyth,	  Michaud,	  and	  Scott	  2005).	  There	  were	  2,898	  genes	  differentially	  expressed	  in	  the	  data	  set	  at	  an	  FDR	  of	  1%.	  	  Using	  a	  more	   stringent	   FDR	   of	   0.01%	  1,375	   genes	  were	   differentially	   expressed	   between	   IPF	  and	  controls.	  The	  top	  three	  differentially	  expressed	  genes	  were	  identical	  to	  those	  seen	  for	   the	  baseline	   comparisons	   (Section	  6.3.3.1);	   thioredoxin	   (TXN,	   FC	  2.3,	  P=1.79e-­‐18),	  Cystatin	   A	   (CSTA,	   FC	   2.25,	   P=2.26e-­‐20)	   and	   a	   Chemokine-­‐Like	   Factor	   Superfamily	  Member	  (CMTM2,	  FC	  1.7,	  P=1.88e-­‐15).	  Taking	   the	   2,898	   differentially	   expressed	   transcripts	   (FDR	   of	   1%)	   WGCN	   analysis	  resulted	  in	  10	  modules	  being	  generated.	  	  The	  relationship	  between	  these	  modules	  was	  again	  explored	  via	  the	  generation	  of	  an	  eigengene	  network	  with	  phenotype,	  death	  and	  survival	  data	  incorporated	  (Figure	  6.13).	  Phenotype	  was	  found	  to	  closely	  associate	  with	  both	  the	  green	  and	  brown	  modules.	  The	  classification	  of	  alive	  or	  dead	  (RIP)	  associated	  with	  the	  blue,	  green	  and	  brown	  modules.	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Figure	  6.13:	  Module	  eigengene	  dendrogram	  and	  adjacency	  heatmap.	  The	  module	  eigengene	   network	   shown	   as	   a	   dendrogram	   and	   heatmap,	   incorporating	   into	   both	  phenotype,	  survival	  and	  death.	  The	  turquoise	  and	  yellow	  modules	  are	  highly	  related,	  as	  evidenced	  by	  their	  low	  merging	  height,	  and	  both	  associate	  with	  survival.	  The	  brown	  module	  associated	  closely	  with	  the	  phenotype.	  The	  classification	  of	  alive	  or	  dead	  (RIP)	  associated	  with	  the	  black,	  turquoise,	  green	   and	   brown	  modules.	  While	   survival	   associated	  with	   the	   pink,	   yellow,	   blue	   and	  purple	  modules.	   In	   order	   to	   further	   explore	   the	   specific	   clinical	   contribution	   of	   each	  module,	  the	  module	  epigenes	  were	  then	  correlated	  with	  the	  remaining	  phenotypic	  data	  (Figure	  6.14).	   	  
	  	   157	  




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































	  	   158	  
The	  highest	  positive	  correlations	  with	  the	  IPF	  phenotype	  were	  seen	  with	  the	  magenta,	  red,	  brown,	  green,	  black	  and	  turquoise	  modules	  with	  the	  highest	  negative	  correlations	  being	  with	  the	  pink,	  yellow,	  blue	  and	  purple	  modules.	  The	  pink,	  yellow,	  blue	  and	  purple	  modules	   demonstrated	   a	   strong	   positive	   correlation	   with	   survival	   and	   a	   negative	  correlation	  with	  decline	  in	  FVC,	  DLCO	  or	  CPI	  and	  death.	  As	  such,	  increased	  expression	  of	  these	  modules	   appears	   to	   co-­‐occur	  with	   longer	   survival,	   less	   decline	   in	   lung	   function	  and	   fewer	  deaths.	  All	   of	   the	  modules	  were	   associated	  with	   lower	  BAL	  and	  peripheral	  blood	  neutrophil	  counts	  and	  a	  BAL	  lymphocytosis	  (Figure	  6.14).	  The	  blue	  module	  was	  also	  associated	  with	  higher	  oxygen	  saturations	  (P=9e−08).	  The	  green	  module	  demonstrated	  the	  strongest	  negative	  correlation	  with	  survival	  (P=2e-­‐08)	  appearing	  to	  be	  driven	  by	  a	  decline	  in	  lung	  function,	  since	  the	  module	  is	  positively	  correlated	  with	  declines	   in	  FVC	  (P=1e-­‐04),	  DLCO	  (P=1e-­‐05)	  and	  CPI	  (P=5e-­‐06).	  This	   is	  also	  reflected	  in	  its	  strong	  positive	  correlation	  with	  death	  (P=5e-­‐06).	  The	  magenta	  and	  red	  modules	  associated	  with	  an	  increased	  MRC	  dyspnoea	  score	  (P=6e−04	  and	  P=0.002	  respectively).	  The	   green	  and	   turquoise	  modules	  were	   strongly	   correlated	  with	  both	   a	  BAL	   and	   peripheral	   blood	   neutrophilia.	   In	   addition	   to	   this	   relationship	   the	   turquoise	  module	  was	   also	   found	   to	   be	   associated	  with	   significantly	   higher	  BAL	  16S	   qPCR	   load	  (P=6e−07).	  In	   summary	   increased	   expression	   of	   the	   brown,	   green,	   black	   and	   turquoise	  modules	  appears	  to	  co-­‐occur	  with	  declining	  lung	  function,	  increased	  neutrophilia	  and	  increased	  BAL	   bacterial	   load,	   while	   increased	   expression	   of	   the	   blue	   and	   purple	   modules	  conversely	   co-­‐occurs	   with	   improved	   lung	   function,	   decreased	   BAL	   neutrophilia	   and	  decreased	  bacterial	  load.	  DAVID	   analysis	   revealed	   the	   top	   GO	   biological	   processes	   associated	   with	   the	   blue	  module	   to	   be	   related	   to	   mRNA	   and	   RNA	   metabolic	   processes.	   Consistent	   with	   these	  observations	   the	   two	   most	   highly	   connected	   genes	   within	   the	   blue	   module	   were	  
HNRNPA2B1	   (heterogeneous	   nuclear	   ribonucleoprotein	   A2/B1)	   and	   SFRS5	  (serine/arginine-­‐rich	  splicing	  factor	  5).	  The	  purple	  module	  was	  found	  to	  be	  enriched	  for	  processes	   involved	   in	   chromosome	   and	   chromatin	   organisation,	   but	   no	   significant	  functional	  GO	  annotation	  clusters	  were	  found.	  The	   green	  module	  had	   the	  most	   significant	   association	  with	  both	  BAL	  and	  peripheral	  blood	  neutrophilia	  and	  the	  top	  GO	  biological	  processes	  associated	  with	  the	  module	  were	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found	  to	  be	  GO:0009607	  (response	  to	  biotic	  stimulus,	  P=0.008),	  GO:0006952	  (defense	  response,	   P=0.018),	   GO:0009617	   (response	   to	   bacterium,	   P=0.009),	   GO:0042742	  (defense	   response	   to	   bacterium,	  P=0.006)	   and	  GO:0002376	   (immune	   system	  process,	  
P=0.006).	   The	   most	   highly	   connected	   genes	   within	   the	   green	   module	   are	   CMTM1	  (P=1.24e-­‐52),	   LCK	   (P=8.46e-­‐51),	   EVL	   (P=1.29e-­‐50)	   and	   RNF130	   (P=1.34e-­‐50).	   The	  brown	  module	  was	  enriched	  for	  processes	   involved	  in	  the	  regulation	  of	  apoptosis	  and	  programmed	  cell	  death,	  but	  produced	  no	  significant	  functional	  GO	  annotation	  clusters.	  The	   black	   and	   turquoise	   modules	   similarly	   did	   not	   produce	   any	   significant	   GO	  annotation	  clusters.	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6.3.4	   Comparisons	  within	  the	  IPF	  cohort	  
6.3.4.1	   Baseline	  Gene	  Expression	  The	   IPF	  cohort	  was	  split	   into	   those	  with	  stable	  and	  progressive	  disease	   to	   investigate	  for	   any	   differentially	   expressed	   genes	   between	   patients	   with	   differing	   disease	  behaviours.	   Only	   one	   gene	   TST	   was	   significantly	   differentially	   expressed	   when	  comparing	  the	  baseline	  expression	  profiles	  of	  subjects	  who	  died	  during	  the	  study	  versus	  those	  who	   survived	   (Table	   6.5).	   Employing	   a	   composite	   end	   point	   of	   decline	   in	   lung	  function	   (FVC	   decline	   >10%)	   or	   death	   to	   categorise	   the	   IPF	   subjects	   into	   those	  with	  progressive	  and	  stable	  disease	  did	  not	  result	  in	  any	  significantly	  differentially	  expressed	  genes	  (1%	  FDR)	  being	  identified.	  
Transcript	  
Cluster	  ID	   Ave	  Expr	   t	  statistic	   P	  Value	   B-­‐H	  adjusted	  P	  Value	   Gene	  Name	   Absolute	  Fold	  Change	  8075857	   6.70	   -­‐5.20	   2.48E-­‐06	   0.034	   TST	   -­‐1.38	  8066493	   8.00	   -­‐4.02	   0.00016	   0.327	   SLPI	   -­‐1.80	  8018428	   5.04	   -­‐3.98	   0.00018	   0.327	   GALK1	   -­‐1.28	  7985099	   6.61	   -­‐3.98	   0.00019	   0.327	   PSTPIP1	   -­‐1.19	  7921462	   3.52	   -­‐3.96	   0.00019	   0.327	   VSIG8	   -­‐1.24	  
Table	  6.5:	  The	  top	  5	  transcript	  clusters	  differentially	  expressed	  between	  subjects	  
who	  died	  during	  the	  study	  and	  those	  who	  remained	  alive.	  Ave	  Expr	  is	  the	  average	  log2-­‐expression	  level	  for	  that	  gene	  across	  all	  the	  arrays.	  Chapter	  3,	  Section	  3.3.4	  demonstrated	   that	  subjects	  with	  a	  baseline	  DLCO	  of	   less	   than	  40%	   had	  more	   than	   a	   2.5	   fold	   risk	   of	   death	   compared	   to	   those	  with	   a	   higher	   DLCO.	  There	   were	   however,	   no	   significantly	   differentially	   expressed	   genes	   when	   the	   IPF	  subjects	  were	  categorised	  into	  two	  groups	  those	  with	  a	  DLCO	  ≤	  40%	  versus	  those	  with	  a	  DLCO	  ≥	  40%.	  	  The	  baseline	  CPI	  had	  also	  been	  seen	  to	  correlate	  strongly	  (Chapter	  3,	  Section	  3.3.5)	  with	  mortality	   and	   dichotomizing	   the	   cohort	   above	   and	   below	   a	   CPI	   of	   40	   had	   strikingly	  revealed	   a	   lack	   of	   deaths	   in	   patients	   with	   a	   CPI	   below	   40.	   Consideration	   of	   this	  phenotype	  however	  also	  revealed	  no	  significantly	  differentially	  expressed	  genes.	  Although	  a	  decline	  in	  FVC	  of	  more	  than	  10%	  in	  12	  months	  carries	  a	  greater	  than	  5	  times	  increased	   risk	   mortality	   (Chapter	   3,	   Section	   3.3.4)	   there	   were	   no	   significantly	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differentially	  expressed	  genes	  at	  a	  1%	  false	  discovery	  threshold	  between	  subjects	  with	  and	  without	  a	  10%	  decline	  in	  FVC.	  
6.3.4.2 Survival	  The	   baseline	   expression	   profiles	   of	   IPF	   subjects	   were	   then	   examined	   for	   differences	  based	   upon	   survival.	   The	   significance	   analysis	   of	   microarrays	   algorithm	   (Tusher,	  Tibshirani,	  and	  Chu	  2001)	  was	  used	  to	  generate	  a	  Cox	  score	  for	  each	  gene	  (Figure	  6.15).	  A	  positive	  Cox	  score	  indicates	  that	  higher	  expression	  correlates	  with	  higher	  risk,	  in	  this	  case,	   increased	   expression	   corresponds	   to	   shorter	   survival.	   The	   reverse	   is	   true	   for	  negative	   scores:	   a	  negative	   score	  means	  higher	  expression	   correlates	  with	   lower	   risk,	  i.e.	  longer	  survival.	  
	  
Figure	   6.15	   Significance	   of	   microarray	   (SAM)	   analysis	   of	   survival.	   Plotted	   are	  expected	   SAM	   score	   (x-­‐axis)	   vs.	   observed	   SAM	   score	   (y-­‐axis)	   showing	   significant	  deviation	   (FDR	   <1%)	   from	   expected	   for	   both	   up-­‐regulated	   (red)	   and	   down-­‐regulated	  (green)	  genes.	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Increased	   expression	   of	   five	   genes	   (genes	   with	   a	   Cox	   score	   ≥2.5)	   and	   decreased	  expression	  of	   twenty-­‐nine	  genes	   (genes	  with	  a	  Cox	  score	  ≤−2.5)	  were	  correlated	  with	  survival	  (FDR	  <1%)	  (Table	  6.6).	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Gene	  
Symbol	   Gene	  Name	  
Cox	  
Score	  
TST	   Thiosulfate	  sulfurtransferase	  (rhodanase)	  	   3.55	  
SLPI	   Secretory	  leukocyte	  peptidase	  inhibitor	  	   3.05	  
GALK1	   Galactokinase	  1	  	   3.02	  
PVALB	   Parvalbumin	  	   3.00	  
GALNT14	   Polypeptide	  N-­‐	  acetylgalactosaminyltransferase	  14	   2.99	  
CD247	   CD247	  molecule	  	   -­‐3.26	  
PRKCH	   Protein	  kinase	  C,	  eta	  	   -­‐3.13	  
SNORD78	   Small	  nucleolar	  RNA,	  C	   -­‐3.02	  
CYP4V2	   Cytochrome	  P450,	  family	  4,	  subfamily	  V2	   -­‐2.99	  
LCK	   Lymphocyte-­‐specific	  protein	  tyrosine	  kinase	  	   -­‐2.96	  
GPR171	   G	  protein-­‐coupled	  receptor	  171	  	   -­‐2.95	  
ZNF570	   Zinc	  finger	  protein	  570	  	   -­‐2.89	  
FBXO31	   F-­‐box	  protein	  31	  	   -­‐2.85	  
SNORA14A	   Small	  nucleolar	  RNA,	  H	   -­‐2.74	  
SCARNA17	   Small	  Cajal	  body-­‐specific	  RNA	  17	  	   -­‐2.74	  
POMGNT1	   Protein	  O-­‐linked	  mannose-­‐N-­‐acetylglucosaminyltransferase	  	   -­‐2.67	  
STAT4	   Signal	  transducer	  and	  activator	  of	  transcription	  4	  	   -­‐2.62	  
CAMK4	   Calcium/calmodulin-­‐dependent	  protein	  kinase	  IV	   -­‐2.62	  
CCDC43	   Coiled-­‐coil	  domain	  containing	  43	  	   -­‐2.61	  
TBC1D19	   TBC1	  domain	  family,	  member	  19	  	   -­‐2.61	  
SNORD45C	   Small	  nucleolar	  RNA,	  C	   -­‐2.59	  
LOC541473	   FK506	  binding	  protein	  6,	  36kDa	  pseudogene	  	   -­‐2.58	  
OR2A42	   Olfactory	  receptor,	  family	  2,	  subfamily	  A,	  member	  42	  	   -­‐2.55	  
MYBL1	   V-­‐myb	  myeloblastosis	  viral	  oncogene-­‐like	  1	  	   -­‐2.55	  
WDR89	   WD	  repeat	  domain	  89	  	   -­‐2.55	  
SLFN5	   Schlafen	  family	  member	  5	  	   -­‐2.55	  
IFFO2	   Intermediate	  filament	  family	  orphan	  2	  	   -­‐2.54	  
ATG5	   Autophagy	  related	  5	  	   -­‐2.53	  
TRIM59	   Tripartite	  motif	  containing	  59	  	   -­‐2.53	  
CD2	   CD2	  molecule	  	   -­‐2.52	  
CHORDC1	   Cysteine	  and	  histidine-­‐rich	  domain	  (CHORD)	  containing	  1	  	   -­‐2.52	  
MTX3	   Metaxin	  3	  	   -­‐2.51	  
GVINP1	   GTPase,	  very	  large	  interferon	  inducible	  pseudogene	  1	  	   -­‐2.51	  
TC2N	   Tandem	  C2	  domains,	  nuclear	   -­‐2.50	  
Table	  6.6:	  Expression	  data	  for	  genes	  with	  a	  Cox	  score	  ≥2.5	  and	  ≤−2.5	  (FDR	  <1%).	  A	  positive	   Cox	   score	   indicates	   that	   higher	   expression	   correlates	   with	   shorter	   survival,	  whereas	   a	   negative	   score	   indicates	   that	   higher	   expression	   correlates	   with	   longer	  survival	   time.	  So	   in	   the	   IPF	  cohort	  higher	  expression	  of	  TST,	  SLPI,	  GALK1,	  PVALB	  and	  GALNT14	   all	   correlate	   with	   a	   decreased	   survival,	   while	   higher	   expression	   of	   twenty	  nine	  genes	  including	  CD247,	  PRKCH,	  SNORD78	  correlate	  with	  a	  longer	  survival	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So	   in	   the	   IPF	   cohort	   higher	   expression	   of	  TST,	   SLPI,	  GALK1,	   PVALB	   and	  GALNT14	   all	  correlate	   with	   a	   decreased	   survival,	   while	   higher	   expression	   of	   twenty	   nine	   genes	  including	  CD247,	  PRKCH,	  SNORD78	  correlate	  with	  a	  longer	  survival.	  
6.3.4.3	   Longitudinal	  Gene	  Expression	  The	  baseline	  analysis	  of	  subjects	  with	  IPF	  versus	  healthy	  individuals	  (Chapter	  6,	  Section	  6.3.3.1)	   identified	   a	   number	   of	   differentially	   expressed	   genes	   (Table	   6.2).	   Analysis	   of	  survival	  (Chapter	  6,	  Section	  6.3.4.2)	  and	  expansion	  of	  the	  IPF	  cohort	  (by	  inclusion	  of	  the	  multiple	   time	   point	   samples	   –	   Chapter	   6,	   Section	   6.3.3.3)	   resulted	   in	   further	  identification	   of	   differentially	   expressed	   genes	   and	   genes	   associated	   with	   survival	  within	   the	   IPF	   cohort.	   Longitudinal	   expression	   profiles	   over	   12	   months	   were	  constructed	   for	   theses	   genes	   (N=74,	   Appendix	   1)	   to	   investigate	   how	   their	   expression	  changed	  over	  time	  within	  the	  IPF	  subjects	  (Figure	  6.16).	  
	  
Figure	   6.16:	   Expression	   values	   over	   time	   in	   genes	   of	   interest.	  The	   expression	  of	  
MMP9,	  TXN,	  CSTA,	  CMTM2,	  ORM1	  and	  S100A12	  increased	  significantly	  over	   time,	  while	  
LCK	   expression	   decreased.	   There	  was	   no	   significant	   change	   in	   the	   expression	   of	  SLPI	  and	  STAT4	  was	  seen	  over	  the	  12-­‐month	  period.	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The	  rate	  of	  gene	  expression	  change	  (Δ)	  over	  12	  months	  demonstrated	  that	  expression	  of	  MMP9,	  TXN,	  CSTA,	  CMTM2	  and	  S100A12	   all	   increased	   in	   the	   IPF	   cohort	   as	   a	  whole.	  The	   most	   significant	   increases	   were	   seen	   in	  MMP9	   expression	   levels	   (Δ=0.65),	   with	  substantial	  increases	  in	  expression	  also	  observed	  for	  ORM1	  (Δ=0.41)	  TXN	  (Δ=0.39)	  and	  
CSTA	  (Δ=0.38).	  No	  major	  changes	  in	  expression	  values	  from	  baseline	  to	  1	  month	  were	  seen	  for	  any	  of	  the	  transcripts	  studied.	  The	  expression	  levels	  of	  LCK	  dropped	  in	  the	  IPF	  cohort	  over	  12	  months	  (Δ=-­‐0.31)	  whilst	  those	  of	  SLPI	  and	  STAT4	  remained	  stable.	  	  Next	   the	   IPF	   subjects	   were	   split	   into	   two	   groups	   –	   progressive	   (defined	   as	   6	   month	  decline	   in	  FVD	  of	  >10%	  or	  death)	  versus	  stable	  disease	  –	  and	   longitudinal	  expression	  profiles	  again	  constructed	  for	  the	  nine	  genes	  (Figure	  6.17).	  
	  
Figure	   6.17:	   Expression	   values	   over	   time	   in	   genes	   of	   interest	   in	   stable	   and	  
progressive	  IPF.	  The	  trend	  of	  change	  is	  the	  same	  in	  progressive	  and	  stable	  disease,	  but	  the	  absolute	  expression	  levels	  vary	  depending	  on	  disease	  state.	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The	  direction	  of	  gene	  expression	  change	  (Δ)	   in	  all	  of	   the	  genes	  was	  the	  same	  for	  both	  stable	  and	  progressive	  IPF	  (defined	  as	  6	  month	  decline	  in	  FVC	  of	  >10%	  of	  death).	  The	  absolute	   expression	   levels,	   however,	   vary	   depending	   on	   the	   nature	   of	   the	   disease.	   As	  can	   be	   seen	   from	   the	   figure	   the	   expression	   levels	   of	   LCK	   (P=0.0159)	   and	   STAT4	  (P=0.0079)	  are	  higher	   in	  stable	   IPF	  at	  all	   time	  points.	  The	  MMP9	  and	  SLPI	  expression	  levels	   are	   increased	   at	   all	   time	   points	   in	   progressive	   disease	   compared	   to	   stable	  (P=0.050	  and	  P=0.0079	  respectively).	  
6.4 Discussion	  
6.4.1 Differential	  Gene	  Expression	  One	   thousand,	   three	   hundred	   and	   fifty	   eight	   transcript	   clusters	   were	   differentially	  expressed	  between	  IPF	  samples	  and	  healthy	  controls,	  employing	  a	  1%	  FDR.	  The	  top	  5	  differentially	   expressed	   genes	   between	   baseline	   IPF	   and	   controls	   were	   TXN,	   CSTA,	  
CMTM2,	  S100A12	  and	  RBP7	  (Table	  6.2).	  These	  genes	  have	  roles	  in	  apoptosis,	  oxidative	  stress,	   angiogenesis	   and	   cellular	   inflammation	   and	   some	   have	   previously	   been	  associated	  with	  IPF	  or	  other	  fibrotic	  conditions.	  	  
TXN	   encodes	   thioredoxin,	   a	   protein	   which	   demonstrates	   a	   cytoprotective	   activity	  against	   oxidative	   stress-­‐induced	   apoptosis	   (Nakamura,	   Nakamura,	   &	   Yodoi,	   1997).	  There	   are	   two	   thioredoxins,	   cytosolic	   and	   mitochondrial,	   and	   their	   expression	   is	  induced	  by	  viral	  infection,	  ischemic	  insult	  and	  exposure	  to	  UV	  light	  or	  X-­‐rays	  (Nakamura	  et	  al.	  2005;	  Hoshino	  et	  al.	  2008).	  Elevated	  cytosolic	  thioredoxin	  levels	  have	  been	  seen	  in	  sera	   and	   BAL	   fluid	   in	   patients	   with	   acute	   respiratory	   distress	   syndrome	   (ARDS)	  (Callister	   et	   al.	   2006)	   and	   in	  BAL	   in	   sarcoid	  patients	   (Koura	  2000).	  Elevated	   levels	   of	  thioredoxin	  have	  been	  seen	  in	  the	  lungs	  and	  serum	  in	  IPF	  and	  NSIP	  (Iwata	  et	  al.,	  2010).	  This	   is	   however	   the	   first	   time	   elevated	   peripheral	   blood	   expression	   of	  TXN	   has	   been	  observed	  in	  IPF	  patients.	  
CSTA	   encodes	   Cystatin	   A	   which	   has	   been	   implicated	   in	   the	   regulation	   of	   apoptosis	  (Kuopio	   et	   al.,	   1998).	   It	   acts	   to	   counter-­‐balance	   the	   excessive	   activity	   of	   cysteine	  cathepsins	   the	   latter	   being	   associated	   with	   matrix	   remodelling.	   Lung	   matrix	  homeostasis	   depends	   on	   a	   fine	   regulation	   of	   proteolytic	   activities.	   Cathepsin	   B	  participates	  in	  this	  process	  by	  triggering	  the	  TGF-­‐β1/Smad	  pathway	  which	  leads	  to	  up-­‐	  regulation	  of	   the	  secretion	  of	   cystatin	  C	  resulting	   in	   inhibition	  of	  extracellular	  matrix-­‐degrading	  cathepsins	  (Kasabova	  et	  al.,	  2014).	  It	  has	  therefore	  been	  suggested	  that	  both	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cathepsin	  B	  and	  cystatin	  C	  could	  play	  a	  crucial	  role	  in	  fibrosis	  by	  favouring	  accumulation	  of	   ECM.	   Bronchoalveolar	   lavage	   cystatin	   C	   has	   even	   been	   suggested	   as	   a	   potential	  biomarker	  of	  IPF	  (Kasabova	  et	  al.	  2014).	  Cystatin	  A	  (also	  known	  as	  stefin	  A)	  could	  play	  a	  role	   in	   this	   lung	   matrix	   homeostasis	   pathway	   as	   it	   is	   an	   inhibitor	   of	   the	   cysteine	  protease	  cathepsin	  B	  (Strojnik	  et	  al.	  2000).	  Here	  transcript	  levels	  of	  CSTA	  were	  elevated	  in	  IPF	  subjects	  compared	  to	  healthy	  controls.	  	  The	  S100A12	  gene	  encodes	  a	  member	  of	  the	  S100	  family,	  and	  has	  been	  associated	  with	  a	  number	  of	  inflammatory	  conditions	  (Meijer,	  Gearry,	  &	  Day,	  2012).	  S100A12	  is	  elevated	  in	   BAL	   in	   acute	   respiratory	   distress	   syndrome	   (ARDS)	   (Lorenz	   et	   al.,	   2008).	  	  Interestingly	   another	   member	   of	   the	   S100	   family,	   MRP14,	   stimulates	   fibroblast	  proliferation	   in	   vitro	   and	   elevated	   levels	   have	   been	   detected	   in	   BAL	   in	   both	   IPF	   and	  sarcoidosis	  (Korthagen	  et	  al.,	  2010).	  	  Retinol	   binding	   protein	   7	   is	   an	   adipocytokine	   encoded	   by	  RBP7,	   which	   is	   potentially	  associated	   with	   fibrosis	   and	   angiogenesis.	   Decreased	   serum	   RBP4	   levels	   have	   been	  associated	   with	   the	   severity	   of	   interstitial	   lung	   disease	   in	   diffuse	   systemic	   sclerosis	  (Toyama	  et	  al.,	  2013).	  Of	   the	   top	  differentially	  expressed	  genes	   there	  are	  a	  number	  with	  a	   large	   fold	  change	  (Table	  6.3).	  Among	  these	  genes	  are	  ORM1	  that	  encodes	  an	  acute	  phase	  plasma	  protein	  and	  BCL2A1,	  which	  is	  a	  direct	  transcription	  target	  of	  NF-­‐kappa	  B	  and	  Tumour	  necrosis	  factor-­‐inducible	  gene	  6	  (TNFAIP6),	  which	  has	  been	  associated	  with	  skin	  fibrosis	  (Gardet,	  Zheng,	   &	   Viney,	   2013).	   Interestingly	  ANXA3	   is	   also	   over-­‐expressed	   in	   the	   IPF	   cohort.	  
ANXA3	   encodes	   a	   protein	   involved	   in	   cell	   proliferation,	   motility,	   invasiveness	   and	  signalling	  pathways	  and	  is	  up-­‐regulated	  in	  and	  potentially	  involved	  in	  the	  pathogenesis	  of	  Pulmonary	  Langerhans	  Cell	  Histiocytosis	  (PLCH)	  (Landi	  et	  al.,	  2011).	  DAVID	  analysis	  of	  the	  complete	  dataset	  revealed	  the	  top	  three	  GO	  biological	  processes	  most	  enriched	  within	   the	  differentially	  expressed	  genes	   (N=1,358)	  are	   related	   to	  host	  defence,	   immune	   response	   and	   response	   to	  bacterium.	  Consistent	  with	   this	   the	   genes	  encoding	   two	   antimicrobial	   peptides	  were	   found	   to	   be	   up	   regulated	  with	   a	   large	   fold	  change,	   secretory	   leukocyte	   peptidase	   inhibitor	   (SLPI)	   and	   Cathelicidin	   Antimicrobial	  Peptide	  (CAMP).	  SLPI	  is	  a	  serine	  protease	  inhibitor	  with	  anti-­‐microbial	  properties	  found	  in	   mucosal	   fluids.	   SLPI	   has	   been	   shown	   to	   regulate	   intracellular	   enzyme	   synthesis,	  suppress	   matrix	   metalloproteinase	   production	   and	   activity,	   mediate	   normal	   wound	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healing	  and	  prevent	  scar	  formation	  (Ashcroft	  et	  al.	  2000).	  As	  highlighted	  above,	  TGF-­‐β	  activation	   by	   serine	   proteases	   is	   a	   possible	   pathogenic	   mechanism	   in	   IPF	   and	   SLPI	  tightly	  regulates	   these	  protease	   inhibitors.	   In	  a	  bleomycin-­‐induced	  pulmonary	   fibrosis	  model,	   SLPI	   knockout	   mice	   demonstrate	   altered	   collagen	   deposition	   (Habgood	   et	   al.,	  2014).	   Cathelicidin	   Antimicrobial	   Peptide	   is	   a	   protein	   that	   has	   several	   functions	   in	  addition	   to	   antimicrobial	   activity,	   including	   cell	   chemotaxis,	   immune	   mediator	  induction	   and	   inflammatory	   response	   regulation.	   CAMP	   gene	   expression	   has	   already	  been	   demonstrated	   to	   be	   up	   regulated	   in	   peripheral	   blood	   in	   “severe”	   compared	   to	  “mild”	  IPF	  subjects	  (Yang	  et	  al.,	  2012).	  	  
RNASE3	  is	  also	  overexpressed	  in	  IPF	  subjects	  compared	  to	  controls	  (Table	  6.3)	  and	  the	  protein	   encoded	   by	   this	   gene	   also	   displays	   a	   wide	   range	   of	   anti-­‐pathogen	   activities.	  RNASE3	   is	   released	   by	   leukocytes	   and	   epithelial	   cells	   and	   contributes	   to	   tissue	  protection	  (Pulido	  et	  al.	  2013).	  Overexpression	  within	   the	   IPF	   cohort	  of	   two	  genes	  previously	  widely	  associated	  with	  IPF,	  MMP9	  and	  DEFA4	  was	  also	  observed.	  There	  was	  a	  three-­‐fold	  increase	  in	  expression	  of	  Defensin	  alpha	  4	  in	  IPF	  subjects	  compared	  to	  healthy	  controls.	  Defensins	  are	  a	  family	  of	  microbiocidal	  and	  cytotoxic	  peptides	  involved	  in	  host	  defence.	  They	  are	  abundant	  in	  the	   granules	   of	   neutrophils	   and	   found	   in	   the	   bronchial	   epithelium.	   IPF	   subjects	   are	  known	  to	  have	  significantly	   increased	  concentrations	  of	  α-­‐defensins	  in	  plasma	  but	  not	  in	   BAL.	   Indeed	   the	   plasma	   the	   levels	   of	   α-­‐defensins	   have	   been	   shown	   to	   correlate	  inversely	   with	   Pao2,	   FVC,	   FEV1	   and	   DLCO	   in	   patients	   with	   IPF	   (Mukae	   et	   al.	   2002).	  Plasma	   levels	   of	   alpha-­‐defensins	   have	   also	   been	   demonstrated	   to	   be	   elevated	   in	  (Konishi	  et	  al.	  2009),	  and	  correlate	  with,	  the	  clinical	  course	  of	  acute	  exacerbations	  in	  IPF	  (Mukae	   et	   al.,	   2002).	   Alpha	   defensins	   role	   in	   fibrosis	   is	   further	   confirmed	   in	   patients	  with	   chronic	   hepatitis	   C,	   where	   the	   alpha-­‐defensin	   levels	   and	   anti-­‐bacterial	   activity	  correlate	  directly	  with	  the	  liver	  fibrosis	  (Aceti	  et	  al.	  2006).	  The	  dysregulated	  action	  of	  metalloproteinases	  implicated	  in	  IPF	  may	  play	  a	  central	  role	  in	   its	   pathogenesis	   (Dancer,	   Wood,	   &	   Thickett,	   2011).	   Although	   the	   majority	   of	   the	  association	   between	   IPF	   and	   matrix	   metalloproteinase	   involves	   MMP-­‐1	   and	   MMP-­‐7	  (Toby	  M	  Maher	   2013)	   here	   levels	   of	   the	   gene	  MMP9	   were	   overexpressed	   in	   the	   IPF	  subjects	  when	  compared	  to	  controls	  (2.23	  fold	  difference).	  Matrix	  metalloproteinase	  are	  present	  in	  low	  quantities	  in	  the	  healthy	  adult	  lung,	  but	  much	  more	  abundant	  in	  asthma,	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IPF	  and	  COPD	  (Atkinson	  and	  Senior	  2003).	  Levels	  of	  MMP-­‐9	  in	  BALF	  and	  MMP-­‐9	  activity	  are	  greatest	  in	  samples	  from	  rapidly	  progressive	  IPF	  cases	  (McKeown,	  Richter,	  O’Kane,	  McAuley,	   &	   Thickett,	   2009).	   It	   remains	   unclear	   however,	   whether	   this	   elevation	   is	  simply	  a	  marker	  of	  activated	  neutrophils	  or	  whether	  MMP-­‐9	  is	  actively	  involved	  in	  the	  alveolar	  damage.	  
6.4.2	   Network	  Analysis	  Weighted	  gene	  co-­‐expression	  network	  analysis	  (WGCNA)	  was	  employed	  to	  identify	  co-­‐ordinated	   gene	   function;	   highly	   connected	   genes	   (hubs);	   previously	   unknown	  interactions	   and	   potentially	   identify	   suitable	   points	   for	   therapeutic	   intervention.	  WGCNA	  analysis	   of	   the	  1,358	   transcript	   clusters	   differentially	   expressed	  between	   IPF	  and	  controls	  at	  a	  1%	  FDR	  threshold	  identified	  five	  modules	  of	  co-­‐expressed	  genes.	  Increased	   expression	   of	   the	   blue	   and	   green	   modules	   correlated	   with	   declining	   lung	  function	   and	   with	   increased	   BAL	   and	   peripheral	   blood	   neutrophilia	   as	   well	   as	   BAL	  bacterial	  load.	  Reflecting	  these	  associations	  the	  top	  three	  GO	  biological	  processes	  most	  enriched	   within	   the	   blue	   module	   were	   found	   to	   be	   GO:0006952	   (defence	   response,	  
P=3.5e-­‐4),	   GO:0009617	   (response	   to	   bacterium	   P=0.001)	   and	   GO:0006955	   (immune	  response,	  P=0.003).	  The	  most	  highly	  connected	  gene	  (hub)	  within	  this	  module	  (Figure	  6.12)	  was	  found	  to	  be	  NLRC4.	  NLRC4	  encodes	  a	  key	  component	  of	  inflammasomes,	  the	  latter	  playing	  a	  crucial	   role	   in	   the	  host	   response	   to	  proteins	   from	  pathogenic	  bacteria	  and	  fungi	  (Y.	  Zhao	  et	  al.	  2011).	  	  Interrogating	   the	  blue	  module	   further	   identified	   a	   number	   of	   other	   genes	   involved	   in	  the	   host	   response.	   ALOX5	   encodes	   a	   member	   of	   the	   lipoxygenase	   gene	   family	   which	  catalyzes	   two	   steps	   in	   the	   biosynthesis	   of	   leukotrienes	   from	   arachidonic	   acid,	  leukotrienes	   being	   a	   group	   of	   lipid	   mediators	   of	   inflammation	   (Rådmark	   and	  Samuelsson	   2009).	   Activation	   of	   the	   5-­‐lipoxygenase	   pathway	   inhibits	   apoptosis	   and	  interferes	   with	   the	   initiation	   of	   T	   cell	   immunity	   and	   has	   been	   implicated	   in	   the	  pathogenesis	   of	   tuberculosis	   (Divangahi	   et	   al.	   2010).	   Another	   gene	   in	   the	   module,	  
PGLYRP1	  encodes	  a	  novel	  antimicrobial	  protein	  which	  not	  only	  binds	  to,	  but	  possesses	  bactericidal	   activity	   against	   Gram-­‐positive	   bacteria	   (Cho	   et	   al.	   2005).	   It	   is	   highly	  expressed	  in	  the	  cornea	  where	  it	  protects	  the	  ocular	  surface	  from	  bacterial	  infections.	  In	  Pglyrp1	  knockout	  mice	  there	  is	  delayed	  healing	  and	  poor	  clearing	  of	  bacterial	  keratitis	  (Ghosh	  et	  al.	  2009).	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The	  green	  and	  brown	  modules	  were	  also	  associated	  with	  the	  IPF	  phenotype.	  The	  top	  GO	  biological	  process	  associated	  with	  the	  Green	  module	  was	  cell	  death	  (GO:0008219).	  The	  most	  highly	  connected	  genes	  (hubs)	  within	  the	  green	  module	  were	  ZNF267,	  CD58,	  NMI	  and	  BCL2A1.	   CD58	   encodes	   a	   protein	   ligand	   of	   the	   T	   lymphocyte	   CD2	   protein,	   which	  plays	   a	   role	   in	   adhesion	   and	   activation	   of	   T	   lymphocytes.	   It	   has	   been	   suggested	   that	  CD58	  plays	   a	   role	   in	   some	  host-­‐tumour	   interactions	   (Altomonte	   et	   al.	   1993).	   ZNF267	  represses	  MMP-­‐10	   gene	   expression	   (Schnabl	   et	   al.	   2005)	   acting	   as	   a	   transcriptional	  repressor.	  NMI	  encodes	  a	  protein	  that	  interacts	  with	  NMYC	  and	  CMYC	  (two	  members	  of	  the	  oncogene	  Myc	   family).	   It	   is	  highly	  expressed	  among	   several	   cancer	   cell	   lines	   (Bao	  and	  Zervos	  1996).	  The	  protein	  encoded	  by	  BCL2A1	  is	  able	  to	  reduce	  the	  release	  of	  pro-­‐apoptotic	  cytochrome	  c	  from	  mitochondria	  and	  block	  caspase	  activation.	  This	  gene	  is	  a	  direct	   transcription	   target	   of	  NF-­‐kappa	  B	   in	   response	   to	   inflammatory	  mediators	   and	  has	  been	  implicated	  in	  the	  mechanism	  regulating	  inhibition	  of	  pre-­‐T	  cell	  death	  (Mandal	  et	  al.	  2005).	  In	   addition	   to	   its	   relationship	   with	   an	   IPF	   phenotype,	   the	   brown	   module	   was	   also	  positively	  correlated	  with	  baseline	  MRC	  dyspnoea	  score.	  The	  GO	  terms	  associated	  with	  this	  module	  were	  all	  related	  to	  cellular	  metabolism.	  The	  network	  structure	  of	  the	  brown	  module	  revealed	  COMMD6	   to	  be	  the	  most	  highly	  connected	  transcript	  (hub).	  COMMD6	  down-­‐regulates	   the	   activation	   of	   NF-­‐Κβ.	   NF-­‐Κβ	   regulates	   a	   large	   number	   of	   genes	  involved	  in	  cell	  survival,	  differentiation,	  proliferation,	  apoptosis	  and	  inflammation	  (Ma	  et	   al.	   2009).	   It	   is	   a	   key	   transcriptional	   regulator	   of	   the	   inflammatory	   response	   (Karin	  and	  Ben-­‐Neriah	  2000)	  and	  mediates	   the	  activity	  of	  TNFa.	  From	  data	  generated	   in	   the	  bleomycin	  mouse	  model	  of	  fibrosis	  it	   is	  believed	  that	  NF-­‐Κβ	  plays	  a	  central	  role	  in	  the	  pathogenesis	  of	  lung	  injury	  and	  fibrosis	  (Gurujeyalakshmi,	  Wang,	  and	  Giri	  2000).	  In	  the	  gamma	  herpes	  virus-­‐associated	  pulmonary	   fibrosis	  mouse	  model	   the	   inhibition	  of	  NF-­‐Κβ	   signalling	   in	   the	   infected	   lung	   cells	   of	   IFN	   gamma	   R	   (-­‐/-­‐)	   mice	   reduces	   virus	  persistence	   and	   ameliorates	   pro-­‐fibrotic	   events	   (Krug	   et	   al.	   2010).	  Additionally	   it	   has	  been	  suggested	  that	  hepatic	  activation	  of	  NF-­‐Κβ	  is	  sufficient	  to	  induce	  liver	  fibrosis	  by	  way	  of	  macrophage-­‐mediated	  chronic	  inflammation	  (Sunami	  et	  al.	  2012).	  The	  turquoise	  and	  yellow	  modules	  demonstrated	  almost	  entirely	  opposing	  patterns	  of	  correlations	   to	   the	   brown,	   green	   and	   blue	  modules.	   They	  were	   associated	  with	  more	  stable	  lung	  function	  and	  better	  survival.	  The	  yellow	  module	  was	  enriched	  for	  processes	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involved	   in	   chromosome	   and	   chromatin	   organisation,	   but	   produced	  no	   significant	  GO	  functional	  annotation	  clusters.	  Within	  the	  turquoise	  module	  the	  most	  highly	  connected	  gene	  was	  NCL.	  NCL	  encodes	  Nucleolin	  which	  is	  the	  major	  nucleolar	  protein	  of	  growing	  eukaryotic	   cells,	   involved	   in	   the	   synthesis	   and	   maturation	   of	   ribosomes.	   Nucleolin	  interacts	   with	   human	   telomerase	   reverse	   transcriptase	   subunit	   (hTERT),	   playing	   a	  crucial	  role	  in	  the	  dynamic	  intracellular	  localization	  of	  the	  telomerase	  complex	  (Khurts	  et	  al.	  2004).	  A	  number	  of	  hTERT	  mutations	  have	  been	  identified	  in	  a	  IPF	  patients,	  who	  exhibited	  shorter	   telomeres	  compared	  with	  age-­‐matched	  controls	   (Tsang	  et	  al.	  2012).	  The	  finding	  of	  decreased	  NCL	  transcript	  expression	  in	  the	  IPF	  population	  is	  therefore	  of	  great	   interest.	   Unfortunately,	   none	   of	   the	   IPF	   subjects	   were	   characterised	   for	   hTERT	  mutations	  but	  this	  would	  be	  worthwhile	  doing.	  
6.4.3	   IPF	  Severity,	  Survival	  and	  Longitudinal	  Changes	  Only	  one	  gene,	  TST,	  demonstrated	  any	  difference	  when	  comparing	  expression	  profiles	  from	   those	  with	   stable	  and	  progressive	  disease.	  Dichotomising	   the	   IPF	  patients	  based	  on	   FVC	   decline,	   baseline	   lung	   function	   and	   composite	   scores	   did	   not	   generate	   any	  significant	  differentially	  expressed	  genes.	  Survival	  analysis	  however	  did	  identify	  that	  in	  the	  IPF	  cohort	  higher	  expression	  of	  TST,	  
SLPI,	  GALK1,	  PVALB	  and	  GALNT14	   all	   correlated	  with	  a	  decreased	  survival.	  Conversely	  higher	  expression	  of	  TC2N,	  STAT4,	  CD247,	  PRKCH,	  SNORD78,	  CYP4V2,	  LCK	  and	  22	  other	  genes	  all	  correlated	  with	  an	   improved	  survival.	  These	   findings	  were	  supported	  by	   the	  longitudinal	  gene	  expression	  profiles	  	  (Figures	  6.16	  and	  6.17).	  Expression	   of	   secretory	   leukocyte	   protease	   inhibitor	   (SLPI)	   has	   already	   been	  demonstrated	  to	  be	  up-­‐regulated	  in	  IPF	  subjects	  compared	  to	  controls.	  Here,	  however,	  
SLPI	  expression	  was	  found	  to	  be	  related	  to	  survival	  with	  expression	  levels	  increased	  at	  all-­‐time	  points	  (over	  a	  12	  month	  period)	  in	  patients	  with	  progressive	  disease	  compared	  to	  stable	  disease.	  Of	   the	  remaining	  genes	  which	  were	   found	   to	  correlate	  with	   increased	  survival	  STAT4,	  
TC2N	   and	   LCK	   have	   also	   previously	   been	   shown	   to	   correlate	   with	   transplant	   free	  survival	   time	   in	   IPF	   (Herazo-­‐Maya	   et	   al.	   2013).	   STAT4	   is	   essential	   for	   mediating	  responses	   to	   IL12	   in	   lymphocytes	  as	  well	   as	   regulating	   the	  differentiation	  of	  T-­‐helper	  cells.	   The	   rs7574865	   mutation	   in	   the	   gene	   has	   been	   reported	   to	   associate	   with	   the	  scleroderma	  interstitial	  lung	  disease	  (ILD)	  phenotype	  (Borie	  et	  al.	  2013).	  Kaminski	  and	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colleagues	   showed	   that	   STAT4	   carried	   a	  Cox	   score	  of	   −2.67	   in	   IPF	   for	   transplant	   free	  survival,	  which	   is	   almost	   identical	   to	   the	   -­‐2.62	   that	   is	   seen	  here	   for	   survival	   (Herazo-­‐Maya	  et	  al.	  2013).	  Interestingly	  the	  expression	  levels	  of	  STAT4	  remained	  static	  over	  12	  months	  follow	  up,	  however,	  the	  expression	  levels	  were	  higher	  in	  stable	  IPF	  at	  all-­‐time	  points.	  
LCK	  encodes	  a	  protein	  that	  is	  a	  key	  signalling	  molecule	  in	  the	  selection	  and	  maturation	  of	   developing	  T-­‐cells.	   IPF	   patients	  with	   higher	   levels	   of	   peripheral	  LCK	   have	   a	   longer	  survival	   time	   to	   transplant	   (Herazo-­‐Maya	   et	   al.	   2013).	   Consistent	   with	   this	   the	   data	  presented	  in	  this	  chapter	  demonstrates	  that	  although	  expression	  levels	  of	  LCK	  dropped	  in	   the	   IPF	   cohort	   as	   a	  whole	   over	   the	   12	  month	   period,	   the	   expression	   levels	   of	  LCK	  were	  higher	  in	  stable	  IPF	  subjects	  at	  all	  time	  points.	  Although	  not	  associated	  with	  survival	  longitudinally	  the	  greatest	  increase	  in	  expression	  values	  were	  seen	  for	  MMP9	  expression	  levels,	  again	  with	  higher	  expression	  levels	  at	  all-­‐time	  points	  in	  progressive	  disease	  compared	  to	  stable.	  
6.4.4	   Comparison	  to	  Known	  Literature	  Since	  the	  work	  presented	  was	  commenced	  there	  have	  been	  two	  studies	  examining	  the	  peripheral	  blood	   transcriptome	   in	   IPF,	  both	  of	  which	  have	  been	  referred	   to	   in	  section	  6.4	  above(Herazo-­‐Maya	  et	  al.	  2013;	  I.	  V	  Yang	  et	  al.	  2012).	  Yang	   and	   colleagues	   hypothesised	   that	   peripheral	   blood	   transcriptional	   profiles	   from	  patients	  with	  IPF	  could	  distinguish	  patients	  with	  IPF	  from	  controls,	  and	  mild	  from	  more	  advanced	   stages	   of	   the	   disease	   (I.	   V	   Yang	   et	   al.	   2012).	   Expression	   profiles	   were	  generated	  for	  123	  IPF	  subjects	  (53	  sporadic	  cases	  of	  IPF,	  and	  70	  samples	  familial	  IPF)	  and	   27	   controls.	   Despite	   these	   relatively	   large	   numbers	   of	   IPF	   subjects	   all	   the	  subsequent	  analyses	  were	  performed	  on	  sub	  groups	  of	  their	  cohort.	  Comparing	  mild	  IPF	  (n=16)	  to	  controls	  Yang	  et	  al.	  found	  1,428	  genes	  were	  differentially	  expressed,	  while	  the	  comparison	   between	   severe	   (n=15)	   and	   controls	   identified	   2,790	   differentially	  expressed	   transcripts.	   Employing	   a	   5%	   FDR	   Yang	   et	   al.	   were	   able	   to	   identify	   13	  differentially	  expressed	  transcripts	  between	  mild	  and	  severe	  IPF.	  These	  included	  CAMP,	  
CEACAM6,	  CTSG,	  DEFA3	  and	  A4,	  OLFM4,	  HLTF,	  PACSIN1,	  GABBR1	   and	  IGHM.	   In	  support	  of	   these	   findings	   the	   experiments	   conducted	   in	   this	   current	   study	   (Section	   6.3.3.1)	  found	  CAMP,	  DEFA4	   and	  OLFM4	   all	   to	  be	  over	   expressed	   in	   IPF	   subjects	   compared	   to	  healthy	   controls.	   Due	   to	   this	   current	   study	   involving	   a	   larger	   cohort	   as	   well	   as	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longitudinal	   follow	   up	   it	   was	   possible	   to	   dichotomise	   the	   IPF	   subjects	   based	   on	  progressive	  or	  stable	  disease,	  in	  contrast	  to	  the	  one	  off	  measure	  of	  lung	  function	  used	  by	  Yang	  et	  al.	  Consequently	  the	  present	  study	  has	  not	  shown	  any	  of	  the	  remaining	  genes	  to	  be	  differentially	  expressed.	  Herazo-­‐Maya	  and	  collegues	  generated	  peripheral	  blood	  mononuclear	  cell	  (PBMC)	  gene	  expression	   profiles	   with	   the	   aim	   of	   identifying	   a	   signature	   which	   could	   predict	  outcomes	   in	   IPF	   (Herazo-­‐Maya	   et	   al.	   2013).	   Microarray	   analyses	   identified	   52	   genes	  associated	   with	   transplant-­‐free	   survival	   (TFS)	   and	   the	   signature	   was	   validated	   in	   a	  second	  cohort.	  Pathway	  analysis	  of	  the	  52	  genes	  highlighted	  CD28,	  ICOS,	  LCK	  and	  ITK	  as	  specific	  genes	  of	  interest.	  Splitting	  the	  validation	  cohort	  in	  half	  around	  the	  median	  qRT-­‐PCR	   levels	   of	   the	   genes	   demonstrated	   a	   worse	   survival	   for	   subjects	   with	   lower	  expression	  values	  of	  all	  four	  genes.	  In	  the	  present	  study	  presented	  here	  in	  this	  chapter,	  WGCNA	   highlights	   LCK	   as	   one	   of	   the	   most	   connected	   genes	   in	   the	   green	   module,	   a	  module	  associated	  with	  the	  IPF	  phenotype	  and	  declining	  lung	  function	  (Section	  6.3.3.2,	  Figure	  6.10).	  Survival	  analysis	  showed	  that	  LCK	  has	  a	  negative	  Cox	  score	  similar	  to	  that	  identified	   by	   Herazo-­‐Maya	   et	   al.	   The	   expression	   levels	   of	   LCK	   in	   the	   present	   study	  dropped	  in	  the	  IPF	  cohort	  as	  a	  whole	  over	  a	  12-­‐month	  period	  and	  were	  higher	  in	  stable	  IPF	  patients	  at	  all-­‐time	  points	  supporting	  the	  association	  of	  a	  lower	  expression	  level	  and	  worse	  survival.	  Of	  note	  Herazo-­‐Maya	  et	  al.	  found	  STAT4	  and	  TC2N	  to	  also	  be	  correlated	  with	  transplant	  free	  survival	  and	  in	  the	  present	  study	  both	  genes	  	  were	  similarly	  found	  to	  correlate	  with	  survival	  too.	  
6.4.5	   Limitations	  The	  main	   limitation	   of	   the	  work	   presented	   in	   this	   chapter	   is	   the	   lack	   of	   longitudinal	  healthy	   control	   samples.	   Without	   these	   comparisons	   in	   longitudinal	   change	   between	  IPF	  and	  health	  subjects	  are	  not	  possible.	  Although	  comparisons	  can	  be	  made	  between	  subsets	  of	  the	  IPF	  subjects	  it	  would	  be	  interesting	  to	  compare	  the	  longitudinal	  changes	  in	   healthy	   subjects	   in	   some	   of	   the	   transcripts	   of	   interest,	   such	   as	   MMP9	   and	   LCK.	  Secondly	   the	   findings	  here	  have	  not	  been	  validated	  either	   in	   a	   second	  cohort,	   using	  a	  second	   technique	   such	   as	   qPCR	   or	   at	   the	   protein	   level.	   The	   longitudinal	   samples	   do	  nonetheless	  help	  provide	  further	  supporting	  evidence	  and	  previously	  published	  studies	  confirm	  a	  number	  of	  the	  findings	  described	  here.	  	  The	  next	  steps	  for	  the	  present	  study	  however	  will	  include	  formal	  validation	  of	  the	  findings.	  Following	  this,	  larger	  studies	  on	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more	  ethnically	  diverse	  populations	  will	  be	  of	  great	  interest	  to	  establish	  the	  relevance	  of	  the	  findings	  in	  general	  IPF	  populations.	  	  Finally,	  and	  most	  importantly	  it	  cannot	  be	  concluded	  whether	  gene	  expression	  changes	  in	   the	   peripheral	   blood	   are	   a	   direct	   reflection	   of	   changes	   in	   the	   lung	   parenchyma	   or	  simply	   surrogate	   biomarkers.	   Consequently	   validation	   in	   lung	   biopsy	   samples	  will	   be	  required	  to	  answer	  this	  outstanding	  question.	  	  
6.5 Conclusions	  The	  peripheral	  blood	  transcriptome	  has	  the	  potential	  to	  distinguish	  normal	  individuals	  from	  patients	  with	  IPF	  and	  offers	  potential	  mechanistic	  insights	  to	  the	  pathogenesis	  of	  IPF.	  Apoptosis,	   oxidative	   stress,	   angiogenesis,	   cellular	   inflammation	   and	   antimicrobial	  processes	  have	  all	  been	  implicated	  by	  this	  work.	  Novel	  potential	  interactions	  with	  well	  established	  putative	   fibrotic	  pathways	  have	  also	  been	   identified,	  with	   the	   interactions	  between	  TGF-­‐β	  pathways	  and	  Cystatin	  A	  and	  SLPI	  particularly	  intriguing.	  Validation	  of	  these	  findings	  at	  the	  protein	  level	  needs	  to	  occur,	  followed	  by	  functional	  studies.	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Chapter	  7:	  General	  Discussion	  
7.1	   General	  Discussion	  The	   exact	   triggers	   that	   initiate	   the	   fibrotic	   processes	   in	   idiopathic	   pulmonary	   fibrosis	  continue	  to	  remain	  unknown.	  Infectious	  agents,	  including	  viruses	  and	  bacteria,	  have	  the	  capacity	   to	   cause	   alveolar-­‐epithelial	   injury	   and	   therefore	   they	   may	   potentially	   be	  important	   triggers.	   Despite	   this	   relatively	   few	   studies	   have	   examined	   the	   role	   of	  infection	  in	  IPF,	  and	  those	  that	  have,	  have	  focused	  on	  the	  role	  of	  viruses.	  The	  part	  that	  bacteria	  have	  to	  play	  in	  the	  pathogenesis	  and	  progression	  of	  IPF	  had	  not	  been	  studied	  in	  detail	  when	  the	  work	  detailed	  within	  this	  thesis	  commenced.	  	  One	  hundred	  patients	  with	  IPF	  and	  64	  control	  subjects	  were	  recruited	  and	  followed	  up	  over	   a	   three-­‐year	   period.	   The	   IPF	   patients	  were	   comparable	   to	   those	   of	   a	   typical	   IPF	  cohort	   (Talmadge	  E	  King	  et	  al.	  2014;	  Richeldi	  et	  al.	  2014)	  and	  had	  moderately	  severe	  disease.	  Twenty-­‐nine	  patients	  died	  during	   follow-­‐up	  highlighting	  the	  poor	  prognosis	  a	  diagnosis	  of	   IPF	  carries.	  The	  median	  survival	   for	  patients	  with	   IPF	   is	   three	  years	  post	  diagnosis	  (Ley	  et	  al.	  2010)	  and	  the	  clinical	  course	  of	  individual	  patients	  is	  variable	  and	  unpredictable.	   This	   present	   study	   confirmed	   a	   number	   of	   known	   predictors	   of	   poor	  prognosis	  including	  a	  baseline	  DLCO	  of	  less	  than	  40%	  predicted	  or	  a	  decline	  in	  FVC	  of	  >10%	  predicted	  over	  6	  months	  (Chapter	  3,	  Section	  3.3.4).	  This	  work	  also	  demonstrated	  that	   composite	   scoring	   systems	   in	   IPF	   can	   perform	   well	   in	   predicting	   disease	  progression.	   For	   the	   first	   time	   it	   was	   demonstrated	   that	   a	   baseline	   composite	  physiological	   index	   score	   of	   over	   40	   carries	   a	   poor	   prognosis.	   	   If	   validated	   this	   could	  translate	  into	  an	  important	  tool	  for	  use	  in	  clinical	  practice.	  The	   application	   of	   molecular	   techniques	   to	   the	   field	   of	   bacteriology	   has	   produced	  fascinating	   insights	   into	   disease	   pathogenesis	   (The	   Human	   Microbiome	   Project	  Consortium	   2012).	   Hilty	   et	  al.	   employed	   these	   techniques	   to	   clearly	   demonstrate	   the	  presence	  of	  a	  wide	  variety	  of	  bacteria	   in	  the	  airways	  of	  healthy	  non-­‐smoking	  subjects,	  establishing	   the	   very	   existence	   of	   a	   healthy	   respiratory	   microbiome	   and	   detailing	  differences	  in	  disease	  (Hilty	  et	  al.	  2010).	  Since	  then	  the	  combination	  of	  these	  molecular	  techniques	   with	   next	   generation	   sequencing	   by	   a	   number	   of	   studies	   has	   resulted	   in	  validation	  of	  the	  original	  findings	  of	  Hilty	  et	  al.,	  with	  many	  suggesting	  that	  alterations	  in	  the	  lung	  microbiome	  are	  associated	  with	  disease	  and	  influence	  disease	  behaviour.	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In	   this	   present	   study,	   characterization	   of	   the	   respiratory	   microbiota	   clearly	  demonstrated	   that	   patients	   with	   IPF	   have	   a	   higher	   bacterial	   load	   and	   significant	  differences	  in	  the	  composition	  and	  diversity	  compared	  to	  controls	  (Chapter	  4,	  Sections	  4.3.3	  &	   4.3.4)	  While	   there	  was	   no	   association	   between	   specific	  microbes	   and	   disease	  progression	  within	  the	  IPF	  cohort,	  an	   increased	  bacterial	   load	  at	  the	  time	  of	  diagnosis	  did	   identify	  patients	  with	  more	  rapidly	  progressive	   IPF	  and	  subsequent	  higher	  risk	  of	  mortality.	   In	   isolation	   this	   finding	   cannot	   determine	   whether	   this	   is	   aetiological	   or	  secondary	   to	   loss	  of	   the	  normal	   lung	  architecture.	  The	   lack	  of	  an	  association	  between	  baseline	  disease	  severity	  and	  bacterial	   load	  (Chapter	  4,	  Section	  4.3.3.3)	  does	  however	  suggest	  that	  it	  may	  not	  be	  a	  simple	  consequence	  of	  disease	  extent	  but	  bacterial	  load	  may	  in	  some	  way	  contribute	  to	  disease	  progression.	  The	   independent	  association	  of	  bacterial	   load	  with	   the	  minor	  allele	  of	   the	  rs35705950	  polymorphism	   in	   the	   promoter	   of	   the	  mucin	   gene	  MUC5B	  provides	   a	   tantalizing	   link	  between	   host	   immunity	   and	   the	   respiratory	   microbiome	   (Chapter	   4,	   Section	   4.3.3.2)	  Current	   evidence	   suggests	   that	   the	   minor	   allele	   predisposes	   to	   a	   milder	   form	   of	   IPF	  associated	  with	  a	  longer	  survival	  (Peljto	  et	  al.	  2013).	  	  The	  work	  conducted	  in	  this	  thesis	  is	   supportive	  of	   the	  Peljto	  et	  al.	   finding	   since	   IPF	   subjects	  possessing	   the	  minor	  allele	  were	  found	  to	  have	  the	  lowest	  bacterial	  burden	  and	  the	  longest	  survival.	  If	  the	  bacterial	  communities	  of	  the	  lower	  airways	  are	  acting	  as	  persistent	  stimuli	  for	  repetitive	  alveolar	  injury	  then	  higher	  bacterial	  burdens	  could	  conceivably	  accelerate	  this	  process.	  Regional	  differences	  in	  the	  bacterial	  microbiome	  (Sze	  et	  al.	  2012)	  could	  also	  provide	  a	  plausible	  explanation	   for	   the	   temporal	   and	   spatial	   heterogeneity	   observed	   in	   usual	   interstitial	  pneumonia,	  the	  histological	  correlate	  of	  IPF.	  In	   the	   present	   study	   the	   bacterial	   communities	   observed	   in	   IPF	   patients	   and	   control	  subjects	   contained	   organisms	   such	   as	   Streptococcus,	   Prevotella,	   Fusobacterium	   and	  
Haemophilus	  (Chapter	  4,	  Section	  4.3.4).	  All	  of	   these	  organisms	  are	  commonly	   found	   in	  the	   airways	   of	   healthy	   subjects,	   asthmatics	   and	   COPD	   patients	   (Sze	   et	   al.	   2012;	  Molyneaux	  et	  al.	  2013;	  J.	  Zhao	  et	  al.	  2012;	  Charlson	  et	  al.	  2010;	  Hilty	  et	  al.	  2010).	  There	  were	   specific	   differences	   between	   the	   microbiome	   in	   IPF	   subjects	   versus	   healthy	  subjects,	   notably	  Streptococcus,	  Haemophilus,	  Neisseria	   and	  Veillonella	   spp.	  were	  more	  abundant	  in	  the	  IPF	  patients	  (Chapter	  4,	  Section	  4.3.4.1).	  These	  differences	  in	  addition	  to	   the	   finding	   of	   a	   consistently	   higher	   bacterial	   burden	   in	   IPF	   patients,	   raises	   the	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possibility	  that	  they	  may	  be	  acting	  synergistically	  to	  drive	  the	  repetitive	  alveolar	  injury.	  A	   potential	   therapeutic	   intervention	   could	   therefore	   target	   these	   bacterial	   phyla	  specifically,	  avoiding	  a	  blanket	  attack	  on	  the	  whole	  microbiome.	  Having	  characterized	  the	  microbiome	  in	  stable	  IPF	  at	  the	  time	  of	  diagnosis	  the	  next	  aim	  of	   the	   thesis	   was	   to	   establish	   if	   and	   how	   the	   microbiome	   changed	   during	   an	   IPF	  exacerbation.	   Data	   from	   the	   control	   arms	   of	   larger	   randomized	   control	   IPF	   studies	  suggests	  that	  4-­‐15%	  of	  individuals	  with	  IPF	  will	  experience	  an	  acute	  exacerbation	  every	  year	   (Noble	   et	   al.	   2011;	   Raghu	   et	   al.	   2012).	   In	   keeping	   with	   this	   observation	   four	  patients	   within	   the	   cohort	   did	   unfortunately	   experience	   an	   exacerbation.	   	   It	   was	  however	   impossible	   to	   obtain	   samples	   for	   these	   patients	   as	   they	  were	   too	   unwell	   to	  undergo	  bronchoscopy.	  	  Collaboration	  with	  a	  South	  Korean	   IPF	  Centre	  however	  did	  allow	  some	  exploration	  of	  changes	  in	  the	  microbiome	  during	  an	  acute	  exacerbation	  (AE-­‐IPF).	  Little	  is	  known	  about	  the	  geographical	  variation	  in	  the	  respiratory	  microbiome	  and	  therefore	  the	  microbiome	  of	  stable	  South	  Korean	  IPF	  patients	  was	  initially	  characterised	  (Chapter	  5,	  Section	  5.3.4)	  as	  a	  baseline	  prior	  to	  examining	  for	  change	  during	  an	  exacerbation.	  Using	  16S	  qPCR	  it	  was	  found	  that	  there	  is	  a	  higher	  bacterial	  load	  detectable	  during	  an	  AE-­‐IPF.	  Within	  the	  cohort	   as	   a	  whole	   an	   increase	   in	  Campylobacter	   spp.	   and	   Stenotrophomonas	   spp.,	  was	  observed	   whilst	   a	   notable	   decrease	   in	   Veillonella	   spp.	   occurred.	   These	   findings	  contradict	   current	   guidelines	   that	   suggest	   AE-­‐IPF	   is	   non-­‐infective	   event.	   The	   changes	  were	   heterogeneous	   across	   the	   cohort	   as	   highlighted	   by	   the	   paired	   sample	   analysis	  (Chapter	  5,	  Section	  5.3.5).	  Although	  there	  were	  detectable	  changes	  in	  the	  composition	  of	  the	   respiratory	   microbiota	   between	   stable	   disease	   and	   acute	   exacerbation,	   if	   an	  exacerbation	   is	   a	   result	   of	   changes	   in	   the	   microbiome,	   the	   causal	   bacteria	   may	   be	  specific	  to	  an	  individual	  subject.	  	  This	   work	   therefore	   does	   not	   allow	   at	   present	   conclusions	   to	   be	   drawn	   regarding	  whether	   the	   presence	   of	   a	   higher	   bacterial	   load	   and	   altered	   microbiome	   during	   an	  exacerbation	   reflects	   an	   active	   infection,	   increased	   aspiration	   or	   is	   simply	   a	   result	   of	  widespread	   diffuse	   alveolar	   damage	   (DAD).	   Analysis	   of	   the	   bacterial	   load	   and	  microbiota	  in	  subjects	  with	  a	  non-­‐IPF	  acute	  lung	  injury	  or	  longitudinal	  sampling	  during	  an	  AE-­‐IPF	  may	  allow	  further	  conclusions	  to	  be	  drawn	  (Molyneaux	  et	  al.	  2013).	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To	   explore	   the	   link	   between	   the	   microbiome	   and	   the	   host	   response	   longitudinal	  peripheral	  blood	  global	  gene	  expression	  was	  analysed	  (Chapter	  6).	  Investigation	  of	  the	  differential	   gene	   expression	   profiles	   between	   IPF	   and	   healthy	   individuals	   has	   yielded	  some	  fascinating	  results.	  Key	  is	  the	  finding	  that	  the	  peripheral	  blood	  transcriptome	  has	  the	   potential	   to	   distinguish	   normal	   individuals	   from	  patients	  with	   IPF	   and	   this	   offers	  potential	  mechanistic	   insights	   to	   the	   pathogenesis	   of	   IPF.	   Apoptosis,	   oxidative	   stress,	  angiogenesis,	   cellular	   inflammation	   and	   antimicrobial	   processes	   have	   all	   been	  implicated.	   Novel	   potential	   interactions	   with	   well-­‐established	   putative	   fibrotic	  pathways	  have	  also	  been	  identified,	  with	  the	  interactions	  between	  TGF-­‐β	  pathways	  and	  Cystatin	   A	   and	   SLPI	   particularly	   intriguing	   (Chapter	   6,	   Section	   6.3).	   Up-­‐regulated	  expression	   of	   CSTA,	   CAMP,	   DEFA4	   and	   OLFM4	   in	   IPF	   has	   now	   been	   highlighted	   in	  multiple	  studies	  using	  a	  variety	  of	  platforms.	  The	  case	  for	  Lymphocyte-­‐specific	  protein	  tyrosine	  kinase	  (LCK)	  as	  a	  potential	  prognostic	  biomarker	  is	  considerably	  strengthened	  by	  the	  findings	  of	  this	  current	  study.	  	  Weighted	  gene	  co-­‐expression	  network	  analysis	  (WGCNA)	  was	  employed	  to	  identify	  co-­‐ordinated	   gene	   function;	   highly	   connected	   genes	   (hubs);	   previously	   unknown	  interactions	   and	   potentially	   identify	   suitable	   points	   for	   therapeutic	   intervention.	  WGCNA	  analysis	   of	   the	  1,358	   transcript	   clusters	   differentially	   expressed	  between	   IPF	  and	   controls	   at	   a	   1%	   FDR	   threshold	   identified	   five	   modules	   of	   co-­‐expressed	   genes.	  Interrogation	  of	  these	  highlighted	  a	  number	  of	  novel	  findings	  and	  associations.	  Two	  of	  the	  three	  modules	  strongly	  associated	  with	  a	  diagnosis	  of	  IPF	  were	  also	  correlated	  with	  increased	  lavage	  and	  peripheral	  blood	  neutrophilia	  as	  well	  as	  BAL	  bacterial	  load.	  Genes	  within	  these	  modules	  were	  strongly	  associated	  with	  these	  modules	  were	  involved	  in	  the	  host	   defence	   response	   and	   included	   NLRC4	   which	   encodes	   a	   key	   component	   of	  inflammasomes	  (Y.	  Zhao	  et	  al.	  2011)	  and	  PGLYRP1	  which	  encodes	  a	  novel	  antimicrobial	  protein	   with	   bactericidal	   activity	   against	   Gram-­‐positive	   bacteria	   (Cho	   et	   al.	   2005).	  WGCNA	   analysis	   also	   highlighted	   potential	   associations	   between	   a	   number	   of	   T	  lymphocyte	  signals	  and	  the	  IPF	  phenotype,	  with	  potential	  interactions	  with	  NF-­‐kappa	  B	  (Chapter	  6,	  Section	  6.3.3.2).	  The	   remaining	   modules	   (turquoise	   and	   yellow)	   were	   associated	   with	   the	   healthy	  phenotype,	   more	   stable	   lung	   function	   and	   better	   survival.	   The	   yellow	   module	   was	  enriched	  for	  processes	   involved	   in	  chromosome	  and	  chromatin	  organisation,	  whilst	   in	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the	  turquoise	  module	  the	  most	  highly	  connected	  gene	  was	  NLC,	  which	  encodes	  for	  the	  major	  nuclear	  protein	  of	  growing	  eukaryotic	  cells.	  Longitudinal	   follow	   up	   allowed	   the	   interrogation	   of	   expression	   profiles	   for	   an	  association	   with	   survival,	   rather	   than	   composite	   end	   points,	   and	   for	   the	   first	   time	  demonstrated	   longitudinal	   expression	   changes	   in	   IPF	   subjects.	   Survival	   analysis	  demonstrated	  that	  in	  the	  IPF	  cohort	  higher	  expression	  of	  TST,	  SLPI,	  GALK1,	  PVALB	  and	  
GALNT14	  all	  correlated	  with	  a	  decreased	  survival.	  	  While	  expression	  of	  SLPI	  was	  already	  demonstrated	   to	   be	   up-­‐regulated	   in	   IPF	   subjects	   compared	   to	   controls	   (Chapter	   6,	  Section	  6.3.4.2),	  expression	  levels	  were	  found	  to	  be	  related	  to	  survival	  and	  significantly	  increased	   at	   all-­‐time	   points	   (over	   a	   12	   month	   period)	   in	   patients	   with	   progressive	  disease	   compared	   to	   stable	   disease.	   These	   longitudinal	   changes	   help	   support	   the	  differential	  expression	  findings,	  although	  they	  now	  require	  validation	  either	  in	  a	  second	  cohort	  or	  in	  lung	  tissue	  itself.	  
7.2	   Future	  Work	  The	  findings	  of	  this	  thesis	  require	  further	  validation	  in	  larger	  cohorts.	  	  Nonetheless	  the	  findings	   do	   provide	   a	   strong	   rationale	   for	   trials	   of	   antimicrobial	   therapy	   in	   IPF.	  Combined	  validation	  and	  intervention	  trials	  will	  assist	  in	  furthering	  our	  understanding	  of	  the	  aetiological	  role	  of	  bacteria	  in	  the	  progression	  of	  IPF.	  At	  the	  same	  time	  they	  will	  allow	   the	   investigation	   of	   a	   novel	   treatment	   approach	   for	   what	   is	   currently	   an	  intractable	  and	  fatal	  disease.	  In	   addition	   to	   recruiting	   larger	   patient	   numbers	   across	   multiple	   centres	   there	   are	   a	  number	  of	  ways	  in	  which	  the	  current	  study	  could	  be	  expanded.	  Here	  the	  upper	  airways	  were	   traversed	   to	   access	   the	   respiratory	   tract	   and	   there	   will	   always	   remains	   some	  concern	   that	   the	   lung	  microbial	   signature	  may	   be	   contaminated	   by	  microbiota	   of	   the	  upper	  respiratory	  tract.	  Although	  there	  is	  currently	  no	  universally	  adopted	  approach	  to	  minimize	  potential	  upper	  airways	  carry	  over,	  the	  use	  of	  pro-­‐BAL	  catheters	  or	  protected	  catheter	   brushes	   could	   help	   minimise	   the	   risk	   of	   potential	   contamination.	   Likewise	  direct	   sampling	   of	   lung	   parynchyma	   would	   remove	   upper	   airways	   carry	   over	  completely	  although	  such	  a	  procedure	  clearly	  carries	  a	  considerable	  risk	  of	  morbidity.	  Simultaneous	   longitudinal	   non-­‐invasive	   sampling	   of	   the	   microbiome	   would	   gather	   a	  wealth	   of	   data	   and	   facilitate	   larger	   studies	   as	   one	   would	   be	   able	   to	   recruit	   patients	  unable	   to	  undergo	  bronchoscopy.	   In	   addition	   it	  would	  provide	   a	  baseline	   for	  patients	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who	  when	  experiencing	  an	  exacerbation	  could	  then	  be	  sampled	  non-­‐invasively	  during	  any	   acute	   deteriorations.	   Sze	   and	   colleagues	   have	   previously	   demonstrated	   regional	  differences	   in	   the	   microbiome	   throughout	   the	   lung	   (Sze	   et	   al.	   2012).	   Assessing	   this	  variation	  across	  the	  respiratory	  tract	  in	  IPF	  would	  allow	  correlation	  with	  the	  extent	  of	  fibrosis.	  This	  could	  further	  help	  in	  elucidating	  the	  role	  of	  specific	  microbes	  or	  bacterial	  burden	  in	  driving	  the	  fibrotic	  process.	  To	  build	  upon	  the	  findings	  of	  the	  expression	  work	  that	  has	  been	  conducted	  (Chapter	  6)	  the	  next	  crucial	  step	  is	  validation	  of	  the	  transcriptome	  findings	  at	  the	  protein	  level	  and	  subsequently	   functional	   studies.	   Following	   this	   larger	   studies	   on	   more	   ethnically	  diverse	  populations	  will	  be	  required	  to	  validate	  the	  findings	  in	  general	  IPF	  populations.	  This	  work	   cannot	   conclude	  whether	   gene	   expression	   changes	   in	   the	  peripheral	   blood	  are	   a	   direct	   reflection	   of	   changes	   in	   the	   lung	   parenchyma	   or	   simply	   surrogate	  biomarkers.	  Validation	  in	  lung	  biopsy	  samples	  will	  therefore	  be	  required	  to	  answer	  this	  outstanding	   question.	   This	   would	   provide	   a	   unique	   opportunity	   to	   simultaneously	  sample	   the	   microbiome	   and	   perform	   expression	   analysis	   potentially	   allowing	   direct	  correlations	  to	  be	  drawn.	  The	   work	   conducted	   in	   this	   thesis	   has	   improved	   the	   understanding	   of	   the	   disease	  mechanisms	   of	   IPF,	   identified	   further	   avenues	   of	   research	   that	   can	   be	   conducted	   and	  may	  hopefully	  one	  day	  help	  improve	  the	  outcomes	  in	  this	  devastating	  disease.	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Reference	  8098762	   ATP5I	   6.3.3.1	   8160587	   NDUFB6	   6.3.3.1	  8095986	   ANXA3	   6.3.3.1	   7969288	   OLFM4	   6.3.3.2	  8122058	   ARG1	   6.3.3.1	   8136985	   OR2A42	   6.3.4.2	  8128592	   ATG5	   6.3.4.2	   8157446	   ORM1	   6.3.4.2	  8067288	   ATP5E	   6.3.3.1	   8037742	   PGLYRP1	   6.3.4.2	  7968270	   ATP5EP2	   6.3.3.1	   7961440	   PLBD1	   6.3.4.2	  8037018	   B9D2	   6.3.3.1	   7915801	   POMGNT1	   6.3.4.2	  7990818	   BCL2A1	   6.3.3.1	   7974835	   PRKCH	   6.3.4.2	  7956013	   BLOC1S1	   6.3.3.1	   8075838	   PVALB	   6.3.4.2	  8107307	   CAMK4	   6.3.4.2	   8001030	   PYCARD	   6.3.3.1	  8079590	   CAMP	   6.3.3.2	   8122554	   RAB32	   6.3.3.1	  8016088	   CCDC43	   6.3.4.2	   7897522	   RBP7	   6.3.3.1	  8029280	   CD177	   6.3.3.1	   7973105	   RNASE3	   6.3.3.1	  7904287	   CD2	   6.3.4.2	   8012469	   RPL26	   6.3.3.1	  7922040	   CD247	   6.3.4.2	   7920238	   S100A12	   6.3.3.1	  7950983	   CHORDC1	   6.3.4.2	   7920244	   S100A8	   6.3.3.1	  7953749	   CLEC4D	   6.3.3.1	   8021183	   SCARNA17	   6.3.4.2	  7996313	   CMTM2	   6.3.3.1	   8050695	   SF3B14	   6.3.3.1	  8082058	   CSTA	   6.3.3.1	   8068361	   SLC5A3	   6.3.3.1	  8098637	   CYP4V2	   6.3.4.2	   8006531	   SLFN5	   6.3.4.2	  7964460	   DDIT3	   6.3.3.1	   8066493	   SLPI	   6.3.4.2	  8149109	   DEFA4	   6.3.3.1	   8133688	   SNORA14A	   6.3.4.2	  8003249	   FBXO31	   6.3.4.2	   7902396	   SNORD45C	   6.3.4.2	  8018428	   GALK1	   6.3.4.2	   7981943	   SNORD64	   6.3.3.1	  8051298	   GALNT14	   6.3.4.2	   7922408	   SNORD78	   6.3.4.2	  8091503	   GPR171	   6.3.4.2	   8057771	   STAT4	   6.3.4.2	  7946275	   GVINP1	   6.3.4.2	   8104738	   SUB1	   6.3.3.1	  7997188	   HP	   6.3.3.2	   8006573	   TAF15	   6.3.3.1	  7997520	   HSBP1	   6.3.3.1	   8094476	   TBC1D19	   6.3.4.2	  7912994	   IFFO2	   6.3.4.2	   7980891	   TC2N	   6.3.4.2	  8173269	   LAS1L	   6.3.3.1	   8045688	   TNFAIP6	   6.3.3.1	  7899753	   LCK	   6.3.4.2	   8091757	   TRIM59	   6.3.4.2	  8140291	   LOC54147	   6.3.4.2	   8075857	   TST	   6.3.4.2	  8063115	   MMP9	   6.3.3.1	   8163185	   TXN	   6.3.3.1	  8112857	   MTX3	   6.3.4.2	   8004175	   TXNDC17	   6.3.3.1	  8151101	   MYBL1	   6.3.4.2	   7979565	   WDR89	   6.3.4.2	  8169659	   NDUFA1	   6.3.3.1	   8028248	   ZNF570	   6.3.4.2	  	  
